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Chapter 1 
 
General Introduction 
 
Hepatitis E virus (HEV) infection 
HEV is a single-stranded positive-sense RNA virus that was first discovered in 1983. HEV belongs to 
the Orthohepevirus genus within the Hepeviridae family and at least four genotypes can provoke 
human infections. It is the most common causative agent for acute viral hepatitis worldwide with an 
estimated 20 million infections annually and around 56,000 related deaths (1). HEV genotypes 1 and 
2 are indigenous predominantly in countries of the developing world, especially in Asia and Africa. 
They are transmitted via a fecal-oral route through contaminated water sources in conjunction with 
poor sanitary conditions, thus these genotypes responsible for many water-borne outbreaks of 
hepatitis E (2). In contrast, HEV genotypes 3 and 4 infect humans and animals and are transmitted 
from animal reservoirs (like pigs) to humans. They are reported mainly in developed countries (3). In 
general, HEV causes a self-limiting infection with low mortality. However, fulminant hepatitis may 
develop and a high mortality rate (as high as 20%–30%) is reported in the population of pregnant 
women. Chronic HEV infections are increasingly documented in immunocompromised patients, and 
provoke liver fibrosis and cirrhosis in some cases (4). As thus, HEV constitutes an important threat to 
global health. 
Molecular virology of HEV  
Knowledge as to the molecular mechanism employed by HEV to prey on the human may hold clues 
to better treatment and prevention of disease. HEV contains a single positive-stranded RNA genome 
of approximately 7.2-kb in size. The whole genome composes of three open reading frames (ORFs) 
with 7-methylguanylate (m7G) capped at the 5’ end and a poly-A tail at the 3’ end. ORF1 encodes a 
nonstructural multi-functional protein essential for viral replication. ORF2 encodes the viral capsid 
protein. And ORF3 is a small functional protein involved in viral secretion step (5) Recently, a novel 
ORF4 was also defined (6). 
ORF1 translates into a polyprotein with a molecular mass of 186 kDa. Its main putative 
functional domains include a methyltransferase (MeT), a Y domain (Y), a papain-like cysteine 
protease (PCP), a proline-rich hinge domain, a X domain, an RNA helicase (Hel) domain, an RNA-
dependent RNA polymerase (RdRp) domain (7). The enzymatic function of the methyltransferase 
domain has been experimentally verified. It can catalyze both guanine-7-methyltransferase and 
guanylyl-transferase activities required for capping of HEV mRNAs (8). The function of the putative 
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PCP domain during HEV replication is still controversial. Generally, positive-strand RNA virus express 
proteases for processing viral polyproteins or host proteins in turn facilitating viral infection. In 
apparent agreement, some studies indicate that HEV PCP also processes the ORF1 polyprotein (9, 10). 
However, an absence of processing activity by PCP has also been reported (11, 12). Further studies 
are still needed for a clear understanding of the functionality of this domain. Hel domain is a 
nucleoside triphosphate (NTPase) with the ability to unwind RNA duplexes into the 5'-to-3' direction. 
It also possesses the ability to mediate the first step of 5’ cap synthesis (13, 14). The RdRp domain 
can specifically bind to the 3’ end of the HEV RNA with poly (A) stretch, which then acts as the 
template to synthesize RNA (15). Of note, recent reports indicated that HEV mutations emerged in 
this domain is associated with altered viral fitness and ribavirin sensitivity (16, 17) and thus this part 
of the virus is subject to evolutionary pressure emanating from human strategies to combat the virus. 
ORF2, the second largest ORF, encodes the major viral capsid protein and constitutes of 660 
AA and is as thus the major target for HEV-evoked antibody responses. Structural analysis revealed 
three domains: the shell domain (S), the middle domain (M), and protruding domain (P). These 
studies postulated that the neutralizing epitope(s) interacting with human immunity locate to the P 
domain of ORF2. Also functional analyses indicated that the P domain is involved in the binding to 
cells susceptible to HEV infection and contains epitopes mediating antibody-dependent 
neutralization of viral activity (18, 19). ORF2 contains 3 putative N-glycosylation sites (Asn 132, Asn 
310 and Asn 562), but the biological function of such potential post-translational modifications is still 
unclear (20). It was also reported that ORF2 can specifically bind to the HEV genome RNA via a 76-
nucleotide (nt) region at the 5' end of the HEV genome and plays an essential role in virus assembly 
process (21). As the capsid protein, ORF2 not only protects the integrity of the viral genome but is 
also involved in many important regulatory activities. One od these appears to be interfering with 
host responses to viral infection. The activation of general immune response activating transcription 
factor NF-κB requires the phosphorylation and degradation of I-kβ, which unmasks a nuclear 
localization signal and thus allows translocation of NF-κB dimmer to the nucleus. ORF2 can block the 
degradation of Ikβ, and, as a result, NF-kB activity is inhibited in HEV-infected human hematoma cells 
(22). 
The ORF3 is the smallest among the canonical ORFs of HEV. It partially overlaps with ORF2 in 
a different reading frame, and encodes a protein product of 13 kD (VP13). VP13 contains two 
hydrophobic domains in its N-terminal and two proline-rich domains in its C-terminal part. A 
phosphorylation site (Ser71) was identified in the first proline-rich domain and this site can be 
phosphorylated by MAP kinase (23). Studies have suggested that VP13 plays multiple roles during 
HEV infection. VP13 is dispensable for viral replication in cultured cells, however it is indispensable 
for both virus release and infection (24, 25). The ORF3 protein was also reported to interact with HEV 
viral proteins such as Hel, PCP, Met and RDRP domains, suggesting its potential roles during HEV 
replication and viron formation (26). However, elucidating the full function of HEV ORF3 protein still 
needs further investigations.  In conjunction these viral constituents exploit host cell machinery for 
viral reproduction but also provide opportunities for host defense through both innate and adaptive 
immunity. In this thesis I focus on cell-autonomous element of former to create enhanced 
understanding of HEV biology and to uncover potential novel avenues for rational treatment of 
disease.  
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Interferon-stimulated genes 
Interferon-stimulated genes (ISGs) are a group of gene products that coordinately combat pathogen 
invasions, in particular viral infections. Classically, upon IFN binding to its cognate cell-surface 
receptors, a signal is transmitted through the membrane into the cell via the JAK–STAT pathway, 
leading to rapid transcriptional activation of ISGs. There are hundreds of ISGs that are thought to be 
the ultimate antiviral effectors (27). Some ISGs control pathogen infection by directly targeting 
pathways and functions required during pathogen life cycle, whereas others have potent activity 
against a broad spectrum of pathogens. They are thought to enhance further IFN production, in turn 
inducing strong and broad induction of ISGs capable of combating infection, also through other 
positive feedback loops. Some ISGs act as negative regulators in these processes apparently to 
constrain and maintain the expression of ISGs at a certain stable levels, and appear essential for 
balancing beneficial antiviral versus detrimental pro-inflammatory effects of this signaling system. 
Thus, ISGs constitute a complex web of host defense machinery (28). Importantly, how this web 
interacts with HEV to mount defensive responses against this virus remains only partly understood. 
Treatment of HEV infection 
In general, the vast majority cases of acute hepatitis E are either asymptomatic or the illness is mild 
and self-limiting, not necessitating special treatment. However, patients with underlying chronic liver 
disease or those immunosuppressed patients who develop acute HEV display high mortality, and 
treatment should be considered (29). Chronic HEV infection was mainly described in 
immunosuppressed patients. Around one-third of those patients chronically infected with HEV will 
clear the virus when the level of immunosuppressive therapy is diminished. Hence, a reduction of 
immunosuppressive therapy is generally considered the first step in the treatment of chronic HEV 
infection. In those of whom this strategy fails, the use of an antiviral therapy is required (30). 
Pegylated interferon α (PegIFN-α) or ribavirin monotherapy or a combination of both have been used 
in this respect. PegIFN-α has achieved success in a small number of liver transplant patients. 
However, interferon has an immunostimulatory effect that sometimes lead to graft rejection and 
thus should be used with care in transplantation patients. Therefore, ribavirin as monotherapy is the 
most widely used therapy, although both antiviral treatments obtain strong antiviral response (31). 
Ribavirin monotherapy is effective for treating chronic HEV, with sustained virological responses 
(SVRs) of 85–90%. For patients who relapse, retreatment with ribavirin for a longer period achieves 
viral clearance in some but not all patients. Indeed, a few cases of ribavirin-treatment failure have 
been reported (16, 32). Currently, still no alternative treatment to ribavirin exists. In one study, it has 
been shown that sofosbuvir may inhibit HEV replication and may display enhanced antiviral effects 
when combined with ribavirin (33). However, the in-vitro efficacy of sofosbuvir against HEV reported 
in this study is modest (even at high concentrations). Other both in-vitro and in-vivo studies showed 
that sofosbuvir appears not very effective with respect to HEV, neither in monoinfection nor in HCV–
HEV co-infection (34-36). Therefore, sofosbuvir is unlikely to develop into the drug of choice for 
patients who fail to ribavirin therapy. Further studies are urgently needed to identify novel antiviral 
agents in treating HEV infected patients. 
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Virus-host interaction 
Virus infection universally elicits dynamic interactions between the virus and host. Host cells are 
equipped with mechanisms that rapidly detect and respond to virus invasion. These defense 
mechanisms largely rely on receptors that monitor the cytosol for the presence of atypical nucleic 
acids from the virus. For example, Toll-like receptor 3 (TLR3) can recognize ds-RNA (double-stranded 
RNA ) in the endosome (37). Retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation 
associated protein 5 (MDA5) detect viral RNA through the unique signatures of the RNA involved, in 
the cytoplasm (38). For DNA viruses, their viral DNA can be recognized by cyclic GMP-AMP synthase 
(cGAS). Upon the detection of virus by these PRRs, downstream pathways will be activated, 
ultimately leading to the production of anti-viral cytokines (e.g. type I IFNs) (39). Once secreted, IFNs 
bind to their corresponding cell surface receptor complexes. This leads to the phosphorylation and 
activation of STAT (signal transducers and activators of transcription) 1 and 2. The phosphorylated 
STAT1, STAT2 together with IRF9 will form a transcriptional complex, denominated as IFN-stimulated 
gene factor 3 (ISGF3). This complex will translocate to the nucleus and bind to IFN-stimulated 
response elements (ISRE) and finally leading to the transcriptional activation of more than 300 IFN-
stimulated genes (ISGs). The products of these genes are the ultimate antiviral effectors to constrain 
virus replication (27). Until now, there are still very limited studies on the cellular innate immune 
response following HEV infection. For instance, it remains unknown whether the HEV RNA genome 
can be efficiently recognized by the host and evoke antiviral response. There is thus an urgent need 
for fundamental studies elucidating the interaction of cell-autonomous innate immunity and HEV. 
Nevertheless, it has become clear that such mechanisms are important as the virus has 
evolved strategies to combat host innate immune response. One study has identified an antagonistic 
activity to IFN-signaling exerted by the HEV ORF1 polyprotein, suppressing poly (I:C)-initiated IFN-β 
expression and IFN-related innate immune response (40). Similarly, the ORF3 protein of HEV also 
inhibits IFN-α-induced phosphorylation of STAT1, provoking downregulation of ISGs (41). In apparent 
contrast, however, another study indicated that ORF3 could stimulate the poly (I·C)-initiated IFN 
response through the activation of retinoic acid-inducible gene I (RIG-) (42). Besides IFN-related 
pathways, other immune response may also be modulated by the HEV infection, for instance, TNF-α 
induced NF-κB signaling activity (43). However, it is fair to say that the mechanisms that HEV on one 
hand and the cell-autonomous immune system on the other hand exploit to combat each other 
remain obscure at best and require further study. 
Aim of this thesis 
Based on the former, I try in this thesis to address three important issues relating to the molecular 
mechanisms that the HEV virus and the cell-autonomous innate immune system employ to exert 
their effects or that relate to the development of novel therapy. The main aims of this thesis are: (1) 
to investigate the regulatory mechanisms of IFN-stimulated genes and the resulting antiviral effects 
against HEV (Part I, Chapter 3-7), (2) to evaluate the effects of direct-acting antiviral drugs or 
compounds for HEV (Part II, Chapter 8-11), (3) to dissect virus-host interactions between HEV and 
host cells (Part III, Chapter 12-15). As will become evident, these efforts have yielded progress and 
novel insights in all three of these issues and thus may help develop novel relational therapeutic 
avenues of dealing with HEV infection. 
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Abstract 
Hepatitis E virus (HEV) is responsible for repeated water-borne outbreaks since the past century, 
representing an emerging issue in public health. However, the global burden of HEV outbreak has not 
been comprehensively described. We performed a systematic review of confirmed HEV outbreaks 
based on published literatures. HEV outbreaks have mainly been reported from Asian and African 
countries, and only a few from European and American countries. India represents a country with 
the highest number of reported HEV outbreaks. HEV genotypes 1 and 2 were responsible for most of 
the large outbreaks in developing countries. During the outbreaks in developing countries, a 
significantly higher case fatality rate was observed in pregnant women. In fact, outbreaks have 
occurred both in open and closed populations. The control measures mainly depend upon 
improvement of sanitation and hygiene. This study highlights that HEV outbreak is not new, yet it is a 
continuous global health problem. 
 
Keyword: global burden, hepatitis E, outbreaks 
 
Key Points 
• India represents a country with the highest number of reported HEV outbreaks. 
• The number of reported HEV outbreaks is most likely underestimation of the actual burden 
of HEV outbreaks globally. 
• In recent years, the burden of HEV outbreaks come from refugee camps in African countries. 
• The availability of HEV vaccine should contribute to better control of HEV disease. 
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Introduction 
Hepatitis E virus (HEV) infection is a major cause of outbreaks and acute sporadic hepatitis worldwide. 
HEV infecting humans consists of four different genotypes (genotype 1–4), with several sub 
genotypes exist in each. However, only one single HEV serotype was recognized.[1, 2] HEV genotypes 
1 and 2 are found mainly in developing countries. They are transmitted via faecal-oral route through 
a contaminated water source, exclusively infect humans, and are thus responsible for many water-
borne outbreaks. In contrast, HEV genotypes 3 and 4 infect humans and animals. They are found 
mainly in developed countries and are responsible for sporadic cases seen in the western world.[3, 4] 
In 2005, it was estimated that HEV genotypes 1 and 2 were responsible for about 20.1 million 
incidents of HEV infections, 3.4 million symptomatic cases, 70,000 fatalities, and 3000 stillbirths.[5] In 
general, HEV causes a self-limiting infection and does not need specific treatment. The mortality rate 
is low. However, fulminant hepatitis may develop and a high mortality rate (as high as 20%–30%) is 
reported in the population of pregnant women after infection with genotype 1.[1] 
HEV is a spherical, non-enveloped, single-stranded positive sense ribonucleic acid (RNA) virus 
that mainly infects the hepatocyte.[6] HEV genome was first entirely cloned in 1991.[7, 8] Historically, 
HEV was suggested as a causative agent during jaundice outbreaks with a high attack rate among 
young adults and resulted in a high mortality rate among pregnant women.[9] Many large, water-
borne, jaundice outbreaks in the past were described as non-A, non-B (NANB) hepatitis outbreaks 
due to failure in identifying hepatitis A (HAV) and hepatitis B virus (HBV) as the responsible agent of 
the outbreaks.[10, 11] The existence of HEV was already suggested in 1980 during the investigation 
of the causative agent of a NANB hepatitis outbreak in Kashmir Valley, India.[12] 
Since the discovery of HEV, many archived samples obtained during NANB hepatitis 
outbreaks were tested for the presence of HEV.[13] The first retrospectively identified HEV outbreak 
was a large jaundice outbreaks in New Delhi, India, in 1955–1956 with more than 29,000 suspected 
cases.[13, 14] Along with the development of serology- and reverse transcription-polymerase chain 
reaction (RT-PCR)-based diagnostic methods, many HEV outbreaks were then identified (confirmed), 
both in the past (NANB hepatitis outbreaks) and in the recent years. Understanding the global 
distribution of confirmed HEV outbreaks could heighten our awareness of this under-recognized and 
under-reported human pathogen and improve HEV surveillance. 
Therefore, we comprehensively reviewed the confirmed HEV outbreaks in the literature. 
More specifically, we described the global geographical distribution of (confirmed) HEV outbreaks, 
the severity (case-fatality rates), outbreak settings and modes of transmission, control measures, and 
the distribution of HEV genotype responsible for the outbreaks. 
Materials and Methods 
Literature search 
A systematic search of available literature (conducted on 10 March 2015) was performed using the 
electronic database Embase.com, Medline (Ovid), the Cochrane library, Web of Science, Scopus, and 
Cinahl (EBSCOhost). Additional references were retrieved from unindexed references from PubMed, 
Lilacs, Scielo and Google Scholar. Additional references were sought by reviewing the reference list 
of selected studies. The search terms were designed by an experienced information specialist (WB). 
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The search was executed without any restrictions of publication date or language. The search terms 
were consisted of two main elements: hepatitis E virus (HEV) and outbreak. For each element, 
multiple synonyms were searched in title and/or abstract, and when available thesaurus terms 
(Mesh for medline, Emtree for embase and CINAHL headings for CINAHL). The search strategies for 
all databases are available in Table S1. 
Study selection, inclusion and exclusion criteria 
After removing the duplicates, we screened the articles based on the title and abstract. The full-text 
copies of included studies based on title and abstract screening were then assessed for eligibility. The 
inclusion criteria include: (i) Original research articles or reports, informing an outbreak of hepatitis E. 
An outbreak was identified by: (a) reporting an attack rates; (b) clearly demonstrated the 
epidemiological curve; (c) reporting large scale, affect several hundred to several thousands of 
people; (d) specify the time course, either short (few weeks) or long period (few months until year[s]); 
(ii) This study used PCR-based and/or serology-based diagnostics (IgM and IgG anti-HEV antibody to 
confirm the presence of HEV as a responsible agent for the outbreak; (iii) Studies showing NANB 
hepatitis outbreak that was confirmed later by another study showing that the outbreak was due to 
HEV; (iv) Any studies that confirmed previous NANB hepatitis outbreak as an HEV outbreak; (v) Any 
studies reported sequencing analysis of HEV strains derived from the outbreak. The following 
exclusion criteria were used for full-text screening: (i) full-text not available; (ii) language other than 
English; (iii) not primary study during the outbreak; (iv) not sufficient information. The selection 
procedure was performed by two independent investigators (M.S.H. and W.W.). Disagreements were 
resolved by discussion. 
Data extraction 
M.S.H. extracted the data with help of W.W. Data were extracted from the full-text papers of the 
included studies. The following items were extracted: author, year of publication, country, specific 
region (if available), the time of the outbreak (month and year), number of suspected cases, attack 
rate in general population, diagnosis used (serology, RT-PCR, sequencing), number of sample tested, 
number of confirmed cases, case fatality rates (CFR) both in general population and pregnant women, 
outbreak settings, risk factors (modes of transmission), control measures, and HEV genotype. Attack 
rate was defined as the number of suspected cases divided by the number of exposed population 
times 100. CFR was defined as the number of deaths divided by the number of suspected cases times 
100. Our procedures accorded with the PRISMA guidelines for reporting systematic review and/or 
meta-analysis (Table S5). 
Results 
Description of the included studies 
Using our search strategy, we identified potentially relevant 3776 articles. After removal of 
duplicates, 1653 articles were recorded for title and abstract screening. Of these, 191 articles met 
the eligibility criteria based on full-text and abstract screening and 10 articles identified from manual 
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search. After assessing 201 full-text articles, we ultimately included 98 articles in this systematic 
review (Fig.1). 
Since we did not restrict the publication date and considering the fact that HEV has caused 
NANB hepatitis outbreak far before its identification, the publication dates of the included studies 
ranged from 1978 to 2015. Most of these studies describe the incident of HEV outbreaks in Asian and 
African countries, and only five studies describe HEV outbreaks in American and European countries. 
Interestingly, a large number of the included studies describing HEV outbreaks occurred in one 
country, India. 
 
Figure 1. Flow diagram showing literature search and selection results. 
Confirmed HEV outbreak and overall attack rate 
Asia 
HEV outbreaks have been reported from 12 countries: Indonesia,[15-17] Myanmar,[18] Vietnam,[19] 
Japan,[20] China,[21] Bangladesh,[22, 23] Pakistan,[24-29] Nepal,[30] Iraq,[31] Uzbekistan,[32] 
Turkmenistan,[33] and India [12-14, 34-65] (Fig.2 and Table S2 and S3). The first confirmed HEV 
outbreaks occurred in New Delhi, India in 1955.[13] During this outbreak, about 29,000 suspected 
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cases were reported, with an attack rate 2.05%. Retrospective analysis of archived serum samples 
from 28 patients successfully detected IgM anti-HEV antibodies in all samples (100%) to confirm that 
HEV was responsible for this large historical outbreak.[13] After this large outbreak, India has 
repeatedly reported large HEV epidemics, affecting hundreds to thousands of people (Fig.3). The 
largest HEV outbreak in India was reported in Kanpur, India during December 1990–April 1991. 
About 79,000 suspected cases (jaundice patients) were reported, with an attack rate of 3.76%. 
Analysis of 41 serum samples showed evidence of NANB hepatitis outbreak.[43] Analysis of stool 
samples from this epidemic demonstrated the evidence of HEV RNA in six of 10 samples analysed 
(60%), confirming that HEV was the aetiologic agent of this NANB hepatitis outbreak.[42] Another 
large HEV outbreak was reported from Nellore (south India) with 23,915 suspected cases.[62] From 
1975 to 1994, India experienced 21 HEV outbreaks, 13 of them (62%) reported more than 1000 of 
suspected cases. The most recent epidemic in India was reported from Lalkuan (Nainital District, 
Uttarakahand) with approximately 240 suspected cases.[65] The attack rate ranged from 0.34%[37] 
to 8.61%.[65] There were only three outbreaks that reported attack rate of more than 10%, i.e. 
Saharanpur, 1992–1993 (14%);[45] Nainital district, Uttarakhand, July 2005 (16%);[56] and Baramulla 
district, Kashmir, 2007–2008 (21.6%).[60] These data suggest that India is highly endemic for 
hepatitis E. 
 
 
Figure 2. The Global HEV outbreak distribution. (Note: Sudan and South Sudan are regarded as one country). 
 
There were four HEV outbreak reported from Pakistan.[24-28] The first reported HEV 
outbreak was Sargodha outbreak which occurred during March–April 1987.[24, 25] A large water-
borne outbreak was reported from the city of Islamabad, affecting 3827 people, with 10.4% attack 
rate.[27] A localized HEV outbreak was occurred in the military unit of Abbottabad (August–
September 1988), in which more than 100 suspected cases were recorded.[26] In all these outbreaks, 
the reported attack rates were more than 10%, ranging from 10.4%[27] to 20%.[24] 
Bangladesh reported only two HEV outbreaks.[22, 23] An outbreak with more than 4000 
cases was reported from Arichpur, an urban area near Dhaka, with 4% attack rate.[22] From south-
east Asian countries, Indonesia reported two HEV outbreaks, in East Java [17] and Kalimantan 
island.[15, 16] Other south-east Asian countries, such as Myanmar and Vietnam only reported one 
outbreak.[18, 19] 
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In east Asia, the largest reported outbreak in the world so far was reported from Xinjiang, 
China. A huge number of 120,000 suspected cases was reported during prolonged outbreak that 
lasted from September 1986–April 1988, with an overall attack rate of 3.0%.[21] In the middle-east 
region, HEV outbreak was only reported from Baghdad, Iraq at 2005, after the Iraq war. More than 
250 suspected cases were reported during this outbreak.[31] From central Asia, a large HEV outbreak 
occurred in the Dashoguz province of Turkmenistan, with more than 16,000 cases were reported.[33] 
 
 
Figure 3. The Epidemic history of large HEV outbreak in India with more than 1,000 suspected cases. 
Africa 
HEV outbreaks have been reported from 14 countries: Egypt,[66] Kenya,[67, 68] Sudan and South 
Sudan,[69-76] Central African Republic (CAR),[77-79] Uganda,[80-84] Chad,[73, 76, 85-89] Republic of 
Djibouti,[90] Algeria,[85, 86, 89, 91] Namibia,[92, 93] Morocco,[94, 95] Somalia,[96, 97] Ethiopia,[98] 
South Africa,[99] and Cameroon[100] (Fig.2 and Table S2). The first, large, laboratory-confirmed HEV 
outbreak involved more than 140 villages in Somalia on early 1988 – late 1989. There were more 
than 11,000 suspected cases reported with an overall attack rate of 4.6%.[96, 97] A large HEV 
outbreak was also reported from Kitgum district, Uganda. More than 10,000 suspected cases from 
October 2007–June 2009 were reported with an overall attack rate of 25.1%.[80-82] During the 
investigation, the outbreak was still ongoing and therefore, the number of suspected cases might be 
increasing. In the last decade, outbreaks of hepatitis E have been reported from several area with 
warfare and conflict, causing human displacement. Several large HEV outbreaks, involving hundreds 
to thousands cases, were reported from refugee camps in Kenya (1702 cases);[67] South Sudan 
(>5000 cases);[75] Darfur, Sudan (2621 cases);[70, 71] and Chad (>900 cases).[73, 87] 
America and Europe 
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Only few outbreaks were reported from European and American countries. In Europe, a confirmed 
HEV outbreak probably related to shellfish exposition and involving genotype 3 was reported on 
cruise ship returning to UK after a world cruise. Thirty-three of 789 passengers (4%) who provided 
blood samples were IgM anti-HEV positive, confirming a recent acute HEV infection.[101] A small 
HEV outbreak was reported from Lazio, Italy. Five suspected cases were reported and all of them 
were HEV positive (genotype 4).[102] In America, HEV outbreak was first reported from two villages, 
Huitzililla and Telixtac, Mexico in 1986, with more than 200 suspected cases. The overall attack rate 
was 5%–6%.[103-105] No HEV outbreak was reported from Mexico thereafter. Another country, 
Cuba, reported two HEV outbreaks.[106] 
Case fatality rate (CFR) 
The CFRs were reported in 38 studies (Table S4). In overall population, CFRs were relatively low, 
between 1% and 3%. The highest reported CFR of overall population was 3.6%, in the Kashmir valley 
outbreak, India, in 1978–1979, involving 275 suspected cases.[12] One study reported an overall CFR 
of 33% (six fatalities out of 18 cases).[28] This outbreak occurred among patients in neurosurgery 
ward in the hospital. Therefore, the underlying disease and condition might be important factors 
influencing this high CFR. 
Compared with overall population, fatalities are higher in pregnant woman. The CFR among 
pregnant woman ranging from 5.1% in Rajasthan, India during February 2006[58] to 31.1% in refugee 
camp, Darfur, Sudan during July–December 2004.[70, 71] From 15 studies which reported CFR of 
both overall and pregnant women population, we found a significantly higher CFR in pregnant 
women compared to overall population (Fig.4). One study specifically compared the CFR among non-
pregnant and pregnant females population. It was shown that the CFR of pregnant females was 
significantly higher than non-pregnant females (11% vs 1.5%, P<.01).[96] 
 
Figure 4. Case Fatality Rates (CFR) of overall population and pregnant women. 
In addition to a high CFR among pregnant woman, HEV infection during pregnancy may lead 
to worse outcome. In HEV outbreak setting, several studies descriptively reported worse pregnancy 
outcomes such as postpartum haemorrhage, premature delivery, stillbirth, miscarriage and neonatal 
death.[22, 74, 78] Since these were descriptive studies, the relative contributions of HEV infection to 
pregnancy-related outcome could not be determined. Gurley ES et al.[22] reported that pregnancies 
complicated by acute jaundice had an increased risk for miscarriage, stillbirth and neonatal death, as 
compared to pregnancy without jaundice (OR 2.7; 95% CI 1.2–6.1). 
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Outbreak settings 
Most HEV outbreaks occurred in community-based settings, such as village (rural area), city (urban 
area) or affecting a large area (one province) (Table 1). Several outbreaks occurred in a more-
restricted (closed) settings, such as military units,[18, 26, 30, 49, 51, 98] college,[24] prison,[47] and 
factory.[106] In recent years, several outbreaks were also reported from refugee camps with a big 
number of suspected cases.[67, 68, 70, 75, 92] Interestingly, one study reported an HEV outbreak 
that occurred on a cruise ship.[101] 
 
Table 1. HEV outbreak settings and underlying cause of HEV outbreaks 
Outbreak settings  and underlying cause 
(modes of transmission) 
References 
Outbreak settings 
City (urban area) [22]; [23]; [27]; [31]; [37]; [38]; [43]; [45]; [46]; [48]; [52-55]; [57]; [59]; 
[61]; [62]; [65]; [78]; [79]; [93]; [106]5 
Village (rural area) [12, 36]3; [17]4; [19]4; [40]; [56]; [58]; [60]; [64]; [66]; [91]; [96]4; [100]; 
[104, 105]3 
Affect large area (district or province) [33]2; [41]; [50]1; [80-82]3; [84] 
Refugee camps [67]; [68]; [70, 71]3; [75]; [83]; [92] 
Military units or military camps [18]; [26]; [30]; [49]; [51]; [98] 
Hospital [28]; [99] 
Cruise ship [101] 
Prison [47] 
Factory [106]5 
College [24] 
Modes of transmission 
Contamination of drinking water  
eakage of water pipeline (broken, poor construction) [18]; [22]; [31]; [38]; [41]; [45]; [49]; [51]; [53]; [54]; [57-59]; [61]; 
[64]; [65] 
Failure of water treatment [24]; [27]; [40]; [43]; [45]; [52]; [60]; [70] 
Use of untreated water from river, spring [12]; [17]; [56]; [91]; [96] 
Flooding, heavy rainfall [19]; [31]; [69]; [75] 
Leakage of sewage pipelines [38]; [55] 
Food contamination [101] 
1 Two district affected. 2 One province affected. 3 Refer to one outbreak. 4 Situated along the river. 5 Two outbreaks 
reported in one study 
Risk factors and modes of transmission 
Several risk factors were reported as the underlying cause of the outbreak (Table 1). The main mode 
of transmission reported was water-borne transmission. Leakage of water pipeline due to broken or 
poor construction was the most reported cause underlying the outbreak. The broken water pipelines 
lead to faecal or sewage contamination of the drinking water supply. Another underlying cause of 
the outbreak was failure of water treatment (such as filtration or chlorination). This failure led to the 
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supply of grossly contaminated drinking water to the household. The use of untreated water from 
river and spring was also reported as the underlying cause of the outbreak. Several HEV outbreaks 
occurred following flooding or heavy rainfall,[19, 31, 69, 75] facilitating contamination of water 
supplies with faeces. One study reported food contamination as the likely cause of the outbreak of 
HEV aboard a cruise ship.[101] 
Role of person-to-person transmission 
Several studies investigated the occurrence of person-to-person transmission during HEV 
outbreaks.[26, 40, 43-45, 58, 63, 81, 94, 104] Most of the studies suggest that there was no or 
minimal evidence of person-to-person transmission during HEV outbreak. However, there were 
variations between studies to determine the occurrence of person-to-person transmission. Only one 
study suggested that person-to-person transmission might be responsible for HEV outbreak in a large 
and prolonged HEV outbreak in Uganda.[81] This conclusion was supported by several observations: 
(i) prolonged outbreak, which occurred about 2 years; (ii) HEV was undetectable from the 
environment (water sources) and the zoonotic sources (pig); (iii) improvement of hygiene (such as 
chlorination) could not stop the epidemic and (iv) evidence of close contact and time interval 
between index and secondary cases within household.[81] However, some inquiries have been 
questioned to argue against the evidence.[107, 108] The relative contribution of person-to-person 
transmission therefore deserves further investigation, especially in the large and prolonged 
outbreaks. As HEV transmission occur via faecal-oral route, person-to-person transmission might be 
possible. 
 
Table 2. Control measures of HEV outbreak 
No Intervention References 
1 Chlorination of the water supply [26]; [37]; [38]; [40]; [44]; [45]; [54]; [63]; 
[65]; [77]; [83] 
2 Repair of water pipelines [26]; [45]; [46]; [49]; [53]; [57]; [59]; [61]; 
[62]; [65] 
3 Improving general hygienic precautions (handwashing, boiling 
water) 
[26]; [38]; [65]; [68]; [75]; [83] 
4 Provision of alternate water supply [27]; [30]; [65] 
5 Hastening latrine construction. [68]; [83] 
6 Surveillance for additional cases (active case finding) [26]; [75] 
7 Simultaneous closure of of the water supply [24]; [27] 
8 Improving safe drinking water availability [75] 
9 Training of health care workers [68] 
10 Increasing community awareness [68] 
Control measures 
To cope with the outbreak, control measures should be taken to prevent more additional cases. 
However, not all studies described specifically the control measures taken during the outbreaks 
(Table 2). Chlorination of the water supply was the most reported control measures during HEV 
outbreaks, followed by repairing of the broken water pipeline. Improving general hygienic precaution 
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(such as hand washing and boiling of drinking water) is a simple and low cost intervention to prevent 
HEV transmission during outbreak. Provision of an alternatively safe water supply (such as providing 
containers of safe drinking water) was reported. Lack of proper facilities for disposal of human faeces 
is one of the underlying factors responsible for outbreaks, especially in refugee camps. Therefore, 
hastening of latrine construction was reported as a control measure during HEV outbreaks in the 
refugee camps. 
Table 3. HEV genotype responsible for the outbreak. 
Country Year HEV Region sequenced HEV Genotype Reference 
Asia     
India 
 
2008 RNA-dependent RNA polymerase 
(RdRp gene) 
Genotype 1, subtype A 
 
[62] 
India 2010 ORF1 Genotype 1, subtype A [63] 
India 1981 RNA polymerase Genotype 1, subtype A [109] 
India 1975 - 1976 RNA polymerase Genotype 1, subtype B [109] 
India 1984 RNA polymerase Genotype 1, subtype A [109] 
India 1990 RNA polymerase Genotype 1, subtype A [109] 
India 1991 RNA polymerase Genotype 1, subtype D [109] 
Kyrgyzstan 1987 - 1989 ORF 2 (nt 5972-6319) and ORF 1 (nt 71-
353) 
Genotype 1 [114] 
Bangladesh 2010 ORF2 Genotype 1, subtype A [23] 
Turkmenistan 1985 ORF2 Genotype 1 [33] 
Pakistan 1987 Full genome (7195 nt) Genotype 1, subtype B [29]; [109] 
China  1986 - 1988 Full genome Genotype 1, subtype B [21] 
Japan 2005 ORF1 Genotype 3 [20] 
Africa     
Morocco 1994 nt 5,014 - 7,186 (the 3’-terminal region 
of ORF1, full length ORF2 and ORF3, 
and a portion of the 3’-noncoding 
region) 
Genotype 1 [95] 
Central African 
Republic 
2002 NS Genotype 1 and 2 [77] 
Sudan and Chad 2004 ORF 2 nucleotides 6,653-7,100 Genotype 1 
 
[76] 
 
Chad  1983 - 1984 ORF2 and ORF3 Genotype 1, subtype C [89]; [109]  
Uganda 2007 - 2009 
 
ORF2 Genotype 1 
 
[80] 
Algeria 1986 - 1987 ORF2 Genotype 1 
 
[91] 
 
Algeria 1979 - 1980 ORF2 and ORF3 Genotype 1, subtype C [89]; [109] 
Namibia 1995 - 1996 451 bp region of a subgenomic 
fragment from the 3’ end of the 
genome in ORF2 
Genotype 2 [93] 
Europe     
United Kingdom 2008 NS Genotype 3 [101] 
Italy 2011 ORF1 and ORF2 Genotype 4 [102] 
America     
Cuba 1999 and 
2005 
ORF1 Genotype 1 [106] 
Mexico  1986 Nearly complete genome (7185 nt) Genotype 2 [109]; [110]  
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Figure 5. HEV genotype distribution responsible for the outbreaks. (Note: Sudan and South Sudan are 
regarded as one country.) 
HEV genotypes responsible for the outbreak 
Data on the genotype responsible for HEV outbreak were available only from limited number of 
studies (as summarized in Table 3 and shown in Fig.5). The open reading fragment 2 (ORF2) region 
was the most frequently region sequenced to determine the HEV genotype, followed by ORF 1 region 
(including RNA polymerase region). In accordance with the global distribution of the HEV genotypes, 
genotype 1 and 2 were mainly responsible for the outbreaks occurred in developing countries (Asia 
and Africa), while genotype 3 and 4 were responsible for small outbreaks in the western world 
(Europe), i.e. UK [101] and Italy.[102] Genotype 2 was responsible for outbreaks in CAR,[77] 
Namibia,[93] and Mexico.[109, 110] In Asia, all but one outbreak were due to genotype 1. In Asia and 
Africa, it seems that genotype 1 was more responsible than genotype 2 as the causative agent of HEV 
outbreaks. Moreover, genotype 1 was also responsible for several large HEV outbreaks, such as in 
China (1986–1988, with 120,000 suspected cases);[21] India (2008, with 23,915 suspected cases);[62] 
Turkmenistan (1985, with 16,175 suspected cases);[33] and Uganda (2007–2009, with >10,000 
suspected cases).[80] No large HEV outbreaks so far were reported due to genotype 3 and 4. 
Discussion 
Historically, epidemic of jaundice and hepatitis with high attack rates in young adults and 
predominant or exclusive deaths among pregnant women was believed to be due to HEV.[9] The first 
laboratory-confirmed HEV outbreak is Delhi outbreak (1955–1956).[111] Since then, many HEV 
outbreaks were reported in the literature, especially after the availability of HEV diagnostic assay 
(HEV serology and RT-PCR). Our data suggest that HEV outbreak occurred repeatedly up to the 
recent years in many different countries, especially in Asian and African countries. It indicates that 
HEV outbreak is not new, yet it is a continuous health problem in developing countries. It is highly 
possible that our data only represent a tip of the iceberg. A higher percentage of HEV outbreaks that 
have occurred in many (other) countries might be not reported and not well-documented, mainly 
due to the absence of a surveillance system of HEV infection or lack of serology and PCR confirmation. 
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For example, about 33 outbreaks of acute viral hepatitis in Cuba were not well-reported and 
therefore excluded from our analysis.[112] Similarly, reports from 10 different Asian and African 
countries were not well-documented.[113] We also found a report of an HEV sequence derived from 
a Kyrgyztan outbreak, but we could not find the outbreak description.[114] Consequently, the actual 
number of HEV outbreaks should be much higher than what we present in this study. Therefore, the 
problem of HEV infection should not be underestimated by national and international health 
agencies. 
HEV represents a significant health problem, especially in the developing countries. Acute 
sporadic form of HEV disease is the most frequent cause of acute viral hepatitis globally.[2] 
Epidemics of HEV, either in a small or large scale, occur periodically up to this moment, as reported 
from India.[115, 116] Many large outbreaks of hepatitis E have been reported especially from west 
and north part of India and thus represent a major health problem in the country (Fig.3). Several 
outbreaks have also been reported from neighbouring countries such as Bangladesh, Pakistan and 
Nepal (Fig.2). The Indian subcontinent, therefore, could be the best representation of areas with high 
endemicity of HEV infection. 
In recent years, several large HEV outbreaks reported from refugee settlements. As a result 
of warfare and conflict in some African countries, displaced populations occupy refugee settlements 
and this has led to a new epidemic setting for HEV.[67, 68, 70, 75, 92] As the disease is mainly 
transmitted by faecal contamination of drinking water, the density of the resident population, a 
limited access to a good quality of drinking water, lack of adequate sanitation and personal hygiene, 
may predispose to the occurrence of HEV outbreaks in refugee camps.[117] Currently, increasing 
number of refugee population, resulted from wars, persecution, conflict and human rights violations, 
imposes one of the most pressing global challenges. This led to a complex humanitarian crisis, partly 
due to lack access of health service.[118] The most common causes of death in this population are 
communicable diseases, such as diarrhoeal diseases, measles and malaria.[119] These refugee camps 
are potential risk settings for water-borne outbreaks including HEV, cholera, hepatitis A virus (HAV), 
and rotavirus,[120-123] and they deserve the access of more timely, appropriate and quality 
healthcare services. 
Although our data showed a limited number of reported HEV outbreaks in European and 
American countries, we cannot fully exclude the possibility that HEV could be the future threat in the 
region. HEV was considered as one of the emerging zoonotic swine pathogens.[124] Autochthonous 
HEV infection was reported from several countries in Europe, with evidence of zoonotic transmission 
from pigs.[125] A recent study has reported a small outbreak in China, which is caused by the 
zoonotic genotype 4 HEV and is related to the food in the company's cafeteria.[126] Therefore, it is 
highly possible that HEV genotypes 3 and 4 could be the potential cause of small-scale outbreaks in 
the developed countries in the near future, especially with the lack of transmission route 
identification and the lack of effective intervention strategies. 
During HEV infection, the risk of progression towards fulminant hepatitis is higher among 
pregnant women as compared to men and non-pregnant women.[127, 128] Several studies during 
HEV outbreaks demonstrated that HEV infection could result in worse maternal and fetal 
outcome.[22, 74, 78] Similarly, studies of pregnant women presenting with jaundice due to acute 
viral hepatitis in hospital-based setting showed that FHF and mortality rate was greater in HEV-
infected women than in non-HEV-infected women.[128] HEV-infected pregnant women have also a 
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significantly higher risk of developing obstetric complications, intrauterine fetal death, preterm 
delivery and stillbirth as compared to non-HEV-infected pregnant women.[128] It is estimated that 
HEV is responsible for ~9.8% of pregnancy-associated deaths in Bangladesh and about 10500 of 
annual maternal death in southern Asia.[129] Some immunological and hormonal factors have been 
associated with high mortality rate in HEV-infected pregnant women.[130-132] Interventions to 
prevent the occurrence of HEV infections in this high-risk population are therefore urgently 
required.[129] 
Most studies reported faecal contamination of drinking water as the major route of 
transmission during HEV outbreak. The most commonly reported underlying cause of this 
contamination is leakage of water pipeline distribution system, either due to damaged or poor 
construction. As the water pipelines located close to drain or sewerage system, the damaged 
facilitate mixing of sewage materials and drinking water supplied to the household, causing water-
borne outbreaks such as HEV, HAV, shigellosis and cholera.[133-135] A water-borne outbreak of 
pesticide poisoning was also reported due to damage of water pipeline distribution system.[136] 
Therefore, this kind of outbreak could be prevented by proper construction of water pipelines, 
keeping them away from the drain system, and also by monitoring of pipelines for damage. 
Since HEV outbreak is mainly due to contaminated-drinking water, its control would depend 
upon improved hygiene and sanitation, such as increased access to safe water, provision of soap and 
chlorine tablets to improve personal hygiene, and proper sewage disposal. During outbreak, it is 
pivotal to intensively investigate the suspected underlying cause and then initiate targeted 
intervention to control and stop the outbreak.[83] Mass vaccination of HEV could be another 
effective strategy to control the outbreaks. Currently, an HEV vaccine has already been licensed for 
use in China[137] and give an insight that HEV is a vaccine-preventable disease.[111] Comparing the 
experience with HAV vaccination as an effective measure to control HAV outbreaks, the HEV vaccine 
holds promises to control large outbreaks. However, it is not known whether the current vaccine 
works fast enough to effectively protect the exposed population for clinical disease during an HEV 
outbreak and how long the protection will be afforded. Moreover, it is also not known whether the 
vaccine is safe and effective in pregnant women, the population in which a high fatality rate was seen 
during the outbreak.[129] In fact, there is disagreement among the HEV experts whether the current 
licensed vaccine is necessary to prevent outbreak following the recent earthquake in Nepal.[138-140] 
Limitation of the published literature 
There are some limitations in the published literature of HEV outbreaks. Firstly, the studies used 
different criteria to define suspected cases during HEV outbreak. Some studies only used physical 
symptoms of acute hepatitis (such as jaundice);[27] whereas other studies included laboratory 
criteria such as liver enzyme (aspartate and alanine aminotransferase).[47, 62] The differences in the 
criteria may then influences the different calculations of the attack rate. Secondly, the studies on 
HEV outbreak used different assays and diagnostic methods to confirm the presence of HEV as the 
causative agent of outbreak. Therefore, it is difficult to compare the validity of the reports. Thirdly, 
the outbreaks studied varied in the proportion of suspected cases to be tested for HEV. Consequently, 
the proportion of confirmed HEV cases differs markedly between outbreaks. Moreover, these data 
also suggest that some of these outbreaks might have been caused not only by a single agent (HEV), 
but also another agent that may also spread by faecal-oral route, especially HAV. Finally, the 
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outbreak studies used different epidemiological methods to investigate the outbreaks. Some of 
those outbreaks were investigated thoroughly, but some of them were not. The full versions of 
epidemiological investigations of several Indian epidemics were not available, although the 
outbreaks involved a large scale, in which thousands of people were affected.[13] 
Conclusions 
The available data suggest that HEV outbreaks occur repeatedly in many developing countries, 
especially in India and become a significant health problem in Asian and African continent, even 
before its identification. These outbreaks were mainly due to HEV genotype 1 and 2. Prevention of 
HEV outbreak in the future is therefore required to reduce the burden of HEV disease. The HEV 
vaccine, which has been licensed in China, could be potentially used in the control of HEV infection in 
the future. However, its safety (especially in pregnant women) and efficacy during the outbreak 
require further investigation. Meanwhile, the preventive measures of HEV outbreak would mainly 
depend upon improved sanitation and hygiene. 
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Abstract 
Interferon-stimulated genes (ISGs) are a group of gene products that coordinately combat pathogen 
invasions, in particular viral infections. Transcription of ISGs rapidly occurs upon pathogen invasion, 
and this is classically provoked via activation of the Janus kinase/signal transducer and activator of 
transcription (JAK-STAT) pathway, mainly by interferons (IFNs). However, plethoras of recent studies 
have reported a variety of non-canonical mechanisms regulating ISG transcription. These new studies 
are extremely important for understanding the quantitative and temporal differences in ISG 
transcription under specific circumstances. Because these canonical and non-canonical regulatory 
mechanisms are essential for defining the nature of host defense and associated detrimental pro-
inflammatory effects, we comprehensively review the state of this rapidly evolving field and the 
clinical implications of recently acquired knowledge in this respect. 
Outstanding Questions 
• Although signaling through the same receptor, there are many type I IFNs in the genome. 
How the cells dynamically control the production of the particular members of these type I 
IFNs? 
• Upon IFNλ binding, which types of modification (e.g. phosphorylation, acetylation) happened 
to IFNλRs to kick off ISG transcription? 
• Generally, HAT activity transforms chromatin into a more relaxed structure, while HDAC 
activity organizes chromatin into higher order nucleosomes. Counterintuitively, HDAC activity 
has been reported to be required for ISG transcription. How this mechanistically works? 
• How exactly the nucleotide synthesis pathways mediate ISG transcription? 
• Will ISG-based antiviral strategy circumvent the issue of side effects caused by IFN treatment, 
but retain the therapeutic potency in patients?  
Trends Box 
• Transcriptional regulation of interferon-stimulated genes (ISGs) defines the state of host anti-
pathogen defense. 
• In light of the recently identified regulatory elements and mechanisms of the IFN-JAK-STAT 
pathway, new insights have been gained into this classical cascade in regulating ISG 
transcription. 
• A variety of non-canonical mechanisms have been recently revealed that coordinately 
regulate ISG transcription. 
• With regards to the adverse effects of IFNs in clinic, ISG-based antiviral strategy could be the 
next promising frontier in drug discovery. 
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Host antiviral defense 
IFN-mediated innate immune response forms a forward line of cell-autonomous defense against 
pathogens. Virus invasion (e.g. the presence of single-stranded RNA in endosomes or cytosolic 
double-stranded RNA) triggers the host cells to recognize the infection through pattern recognition 
receptors, that in turn mediates production of IFNs [1]. The thus-released IFN molecules bind to cell 
surface receptors and initiate signal transduction prominently involving the Janus kinase signal 
transducer and activator of transcription (JAK-STAT) pathway. This activates the transcription of 
hundreds of so-called IFN-stimulated genes (ISGs) that are the effectors of cell-autonomous antiviral 
defense. The representative well-studied ISG members in this respect with specific or broad antiviral 
activities include RIG-I, MDA5, MX2, IRF1, IRF3, IRF7, IRF9, IFITM3, ISG15 and OASL [2]. ISGs act at 
different stages of the viral life cycle, from entry, replication, assembly to release. This leads to a 
remarkable antiviral state that provides adequate cellular immunity against positive-, negative-, and 
double-stranded RNA viruses, DNA viruses, and even intracellular bacteria and parasites. 
Although the JAK-STAT pathway plays key roles in regulating ISG transcription, a far more 
complex cell signaling network with both canonical and non-canonical mechanisms is involved [3]. The 
signaling strength, kinetics and specificity of regulatory pathways on ISG transcription are modulated 
at various levels by distinct mechanisms in conjunction. Understanding the different mechanisms of 
ISG transcription and how their mode-of-action relates to clinically used antiviral medications will 
reveal new insights of virus-host interactions and provide novel avenues for antiviral drug 
development. Therefore, we aim to comprehensively review the classical and non-classical 
mechanisms in regulating ISG transcription and to emphasize their clinical implications.  
Classical mechanisms of regulating ISG transcription: the IFN-JAK-
STAT pathway 
Upon IFN binding to its cognate cell surface receptors, a signal is transmitted through the membrane 
into the cell via the JAK-STAT pathway, leading to rapid transcriptional activation of ISGs [4]. Decades 
of dedicated efforts have elucidated this classical regulatory network, as we have outlined here 
(Figure 1). 
IFNs and their receptors-dependent regulation  
Genes encoding IFNs and their receptors have been duplicated extensively throughout vertebrate 
evolution, indicating substantial evolutionary pressure on this system in combating pathogens [5]. Up 
to now, more than twenty distinct IFN genes/proteins have been identified. Based on the type of 
receptor through which they signal, the multitude of different IFNs in mammalian genome are 
classified into three major types: Type I, II and III. In humans, type I IFNs include IFN-α (which can be 
further subdivided into 13 different subtypes), IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-ζ and IFN-ω1-3. All type 
I IFNs bind to a common cell-surface receptor, the type I IFN heterodimeric receptor complexes 
comprising two subunits: IFN-α receptor 1 (IFNAR1) and IFN-α receptor 2 (IFNAR2). Unlike type I IFNs, 
there is only one type II IFN, IFN-γ. It has no marked structural homology with type I IFNs. IFN-γ 
binds to a different cell surface receptor comprised of two subunits: IFNGR1 and IFNGR2. 
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Figure 1. The classical IFN signaling pathways in regulating ISG transcription. The three different classes of 
IFNs signal through their corresponding receptor complexes, leading to the phosphorylation of preassociated 
Janus kinases. For type I and III IFNs, the phosphorylated Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) in 
turn phosphorylate the receptors at specific intracellular tyrosine residues. This leads to the recruitment and 
phosphorylation of signal transducers and activators of transcription 1 and 2 (STAT1 and STAT2) at specific 
tyrosine residues. Then, STAT1 and 2 recruits IRF9 to form the IFN-stimulated gene factor 3 (ISGF3). For type II 
IFNs, the phosphorylated JAK1 and JAK2 tyrosine kinases phosphorylate the receptor chains, leading to tyrosine 
phosphorylation and homodimerization of STAT1. Both ISGF3 and STAT1 homodimer translocate to the nucleus 
to get further phosphorylation at specific serine residues of STAT1, achieving fully activation. Consequently, 
IFN-stimulated genes (ISGs) are transcriptionally activated upon the binding of ISGF3 and STAT1 homodimer to 
IFN-stimulated response elements (ISRE) and gamma-activated sequence (GAS) promoter elements, 
respectively. Conversely, the specific phosphatases in the nucleus dephosphorylate STAT1 and STAT2 to avoid 
excessive and detrimental responses. 
 
Type III IFN family is composed of four genes: IFNλ1 (IL29), IFNλ2 (IL28A), IFNλ3 (IL28B) and IFNλ4 
(frameshift variant of IL28B). They signal through the IFNλ receptor (IFNλR) which is composed of 
two subunits: IFNλR1 (IL28Rα) and IL10Rβ.  
Type II IFN signaling leads to STAT1 phosphorylation, followed by homodimerization, nuclear 
translocation, and DNA binding at gamma-activated sequence (GAS) elements located within 
promoter regions of IFN-γ-induced genes. While both type I and III IFN signaling activate similar 
intracellular JAK-STAT pathway forming the transcription complex, ISGF3, to transcribe ISGs, 
although they utilize distinct receptor complexes for signaling [6]. However, IFNAR is ubiquitously 
expressed in all nucleated cells; whereas IFNλR1 is only expressed on specific tissues/cells of 
epithelial origin [7], suggesting a selectivity of type III IFNs compared with type I IFNs.  
For optimal activation, signaling through the IFN receptor complex depends on tyrosine 
phosphorylation, serine phosphorylation and acetylation on IFN receptors (Table 1) [8-10]. 
Nevertheless, negative regulation is also essential for balancing its beneficial antiviral versus 
detrimental pro-inflammatory effects. Primarily, this is achieved by (i) phosphorylation induced IFN 
receptor ubiquitination and degradation [11]; (ii) blocking the interaction between IFNAR and 
downstream signaling elements, such as the function of USP18, ISG15 and SOCS1 [12-16]; (iii) receptor-
mediated ligand internalization/degradation [17]; and (iv) modulating cell surface IFN receptor level [18, 
19].  
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JAK kinases (JAKs)-dependent regulation  
The JAKs comprises 4 members, three of them (JAK1, JAK2 and TYK2) function in IFN signaling and 
are ubiquitously expressed [20]. They are pre-associated with the corresponding IFN receptor. Upon 
IFN binding to receptor, they become activated through close proximity trans-phosphorylation (JAK1: 
Tyr1022,1023, JAK2: Tyr1007,1008 and TYK2: Tyr1054,1055). Subsequently, activated JAKs phosphorylate the 
cytoplasmic regions of the receptor, generating docking sites for SH2-domain containing proteins, in 
particular STAT1 and STAT2 [21]. Activation of JAK enzymatic activity also triggers negative feedback 
on antiviral immunity. Phosphatases, including T cell protein tyrosine phosphatase (TCPTP), protein 
tyrosine phosphatases (PTP) 1B and CD45, are the most important negative regulators [22-25]. The 
SOCS-1 protein also negatively regulates this process through phosphorylation mediated 
proteasomal degradation of JAK [26]. The critical function of JAKs in cell signaling has made them ideal 
targets for controlling a range of autoimmune diseases. Several JAK inhibitors have been approved 
by the FDA or are in clinical trials for the treatment of rheumatoid arthritis, psoriasis, inflammatory 
bowel disease and ankylosing spondylitis [27].  
Table 1. Classical modification of the IFN-JAK-STAT pathway 
 Modification site Modification typea Signal transduction References 
IFNAR1 Tyr466 Phosphorylation Activation [28] 
IFNAR1 Tyr512 and Tyr337 Phosphorylation Activation [29] 
IFNAR1 Ser535, Ser539 Phosphorylation Inactivation [11] 
IFNAR1 Lys501, Lys525 and Lys526 Ubiquitination Inactivation [11] 
IFNAR2 Ser364, Ser384 Phosphorylation Activation [9] 
IFNAR2 Lys399 Acetylation Activation [9] 
IFNGR1 Pro267 ND Activation [30] 
IFNGR1 Tyr440 Phosphorylation Activation [31] 
IFNGR1 270LI271 ND Inactivation [17] 
IFNGR1 Tyr441 Phosphorylation Inactivation [16, 31] 
IFNGR2 263PPSIP267 and 270IEEYL274 ND Activation [10] 
JAK1 Tyr1022,1023 Phosphorylation Activation [21] 
JAK2 Tyr1007,1008 Phosphorylation Activation [21] 
TYK2 Tyr1054,1055 Phosphorylation Activation [21] 
STAT1 Tyr701 Phosphorylation Activation [32] 
STAT1 Ser727 Phosphorylation Activation [32] 
STAT1 Ser708 Phosphorylation Activation [33] 
STAT1 Lys703 SUMO-1 Binding Inactivation [34] 
STAT2 Tys690 Phosphorylation Activation [35] 
STAT2 Ser287 Phosphorylation Inactivation [35] 
aND, not determined. 
STAT-dependent regulation 
There are seven STAT members in mammals, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and 
STAT6. STAT1 and STAT2 are the most important STATs with respect to IFN signaling [2]. In response 
to IFNs, STAT1 is phosphorylated on Tyr701, Ser708 and Ser727. These sites are all positively related to 
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signaling transduction [33, 36]. STAT2 acquires transcriptional activation upon tyrosine phosphorylation 
(Tyr690). Conversely, serine phosphorylation (Ser287) in STAT2 negatively regulates IFN response [21, 35]. 
Although JAKs play key role in STAT1 phosphorylation and activation, nevertheless, other cellular 
factors are also required. Tyrosine kinase non-receptor 1 (TNK1) and retinoic acid-inducible gene I 
(RIG-I) potentiate dual phosphorylation of STAT1 at Tyr701 and Ser727 positions [37-39]; Nuclear cyclin-
dependent kinase 8 (CDK8) phosphorylates Ser727 of STAT1 [40, 41]. Protein kinase C family members, 
PKC-δ or PKC-ε mediates phosphorylation of STAT1 on Ser727 (no effect on STAT1 tyrosine 
phosphorylation) via its upstream phosphatidylinositol 3-kinase (PI3K)-AKT pathway [42-45]. 
Interestingly, stress signals can also induce phosphorylation of STAT1 (Ser727) via the p38-MAPK 
pathway [46]. As p38-MAP kinase inhibitors are well tolerated and safe for humans, it is thus tempting 
to speculate that such inhibitors may be used to mitigate pro-inflammatory effects following IFN-γ-
therapy [47].  
Evidently, phosphatase-dependent STAT1 dephosphorylation constitutes an important 
negative-regulatory event that is central in titrating the IFN response. The functional phosphatases 
include SHP-2 [48, 49], the nuclear isoform of TCPTP, TC45 [50] and SHPTP1 [51]. Phosphatase 
dysregulation has been reported in cancers and autoimmune disorders, thus representing potential 
therapeutic targets [52]. A small ubiquitin-related modifier 1 (SUMO-1) was also reported to conjugate 
at Lys703 of STAT1 to inhibit signaling transduction [34]. Thus, a plethora of molecular mechanisms can 
balance the IFN response through acting on STAT1. 
IRF9 is a main DNA binding component of the ISGF3 complex. IRF9 alone binds to DNA and 
recognizes the specific promotor elements denoted as interferon-stimulated response elements 
(ISRE), but has no transcriptional activity. Upon its DNA binding, IRF9 provides specific protein-DNA 
interaction sites for STAT1 and STAT2. Activated STAT1 and STAT2 bind to the ISRE region together 
with IRF9 to exert strong pro-transcriptional activity [53 ]. Theoretically, IRF9 (as part of the ISGF3 
complex) only involves in type I and III IFN signaling to regulate ISG transcription. However, IFNγ 
induced ISG activation and antiviral state were severely impaired in the absence of IRF9, indicating 
that IRF9 may also be involved in type II IFN signaling [54, 55]. More interestingly, IFNγ pretreatment 
induces high levels of IRF9, which serves as an important subunit of latent precursor to ISGF3. In this 
way, IFN-α and IFN-γ synergize to induce the formation of ISGF3 complex, leading to much stronger 
ISG transcription [56].  
Regulation of ISGs at the transcriptional level 
In the case of type I and III IFNs, ISGF3 works as the predominant transcriptional factor binding to 
ISREs within the promoter region of ISGs; whereas for type II IFN, the homodimers or heterodimers 
of STATs are the determinant binding to GAS elements. However, this is a simplified model and other 
regulatory elements are also involved (Figure 2).  
Chromatin modulators. Histone octamers bind to DNA and organize chromatin into higher 
order nucleosomes, prohibiting transcription factor binding and gene expression [57]. As a 
consequence, the induction of ISGs by IFNs requires chromatin remodeling. The condensed 
chromatin needs to be transformed into a more relaxed structure. In humans, the nucleosome 
remodeling complex BAF and PBAF prime ISG promoters by utilizing ATP-derived energy to maintain 
chromatin in a constitutively open conformation, allowing fast and potent induction of ISGs after IFN 
exposure [58-61]. Histone acetylation and deacetylation are also essential in chromatin modulation. 
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These reactions are typically catalyzed by enzymes with histone acetyltransferase (HAT) or histone 
deacetylase (HDAC) activity. HAT activity transforms chromatin into a more relaxed structure, while 
HDAC activity organizes chromatin into higher order nucleosomes. Therefore, the HAT family 
members, including p300/CBP and GCN5, are essential for transcriptional activation of ISGs [62, 63]. 
HATs are positive regulators of transcription in general. However, HDAC activity is also essential for 
transcriptional induction of ISGs [64-69]. HDAC activity has been reported to be required for recruiting 
RNA polymerase II to the promoters of ISGs [70], although how HDACs regulate transcriptional 
activation of ISG remains unclear. In addition, FOXO3 and PI3K/AKT pathway coordinate in chromatin 
modulation. FOXO3 together with the nuclear co-repressor 2 (NCOR2) and HDAC3 forms a ternary 
complex to facilitate a closed chromatin structure to limit ISG transcription under basal conditions. 
However, type I IFN can activate the PI3K/AKT pathway, which in turn leads to FOXO3 degradation 
and ISG transcription [71]. 
Co-activators and co-repressors. Particular co-activators or co-repressors mediate the 
transcription of ISGs via the interaction with ISGF3 or STAT1 homodimers. The co-activators, such as 
MCM5 (minichromosome maintenance) and MCM3 protein complex [72, 73], N-Myc interactor (NMi) [74] 
and DRIP150 [75], facilitate the transcriptional activation of ISGs. Conversely, co-repressors, such as 
TAF-1 [76] and the protein inhibitor of activated STAT proteins (PIAS1 and PIASγ [77, 78], negatively 
suppress the formation of transcription complex on the ISG promoter to limit transcription. Recently, 
four previously unrecognized regulatory factors (ETV6, ATF3, LYN and TBK1) of ISG transcription have 
been identified [79]. These efforts have led to a more comprehensive understanding of ISG 
transcription. 
 
Figure 2. The transcriptional regulation of IFN-stimulated genes (ISGs) involves chromatin remodeling and 
various co-activators and co-repressors. Upon IFN stimulation, the IFN-stimulated gene factor 3 (ISGF3) or 
STAT1 homodimer binds to ISG promoter regions, recruiting various chromatin remodeling factors and 
transcriptional co-activators. These factors include the nucleosome remodeling complex BAF and PBAF, 
p300/CBP and GCN5 histone acetyltransferase (HAT), histone deacetylase (HDAC), minichromosome 
maintenance 3 and 5 (MCM3 and MCM5), N-Myc interactor (NMi), DRIP150 (a subunit of the multimeric 
mediator coactivator complex). Consequently, the condensed chromatin transforms into a more relaxed 
structure to facilitate the transcription of ISGs. Conversely, the co-repressor factors could inhibit ISG 
transcription either via the facilitation of a closed chromatin or interference with the recruitment of STAT1 or 
ISGF3 to the ISG promoter. 
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Non-canonical regulation of ISG transcription  
All three types of IFNs signal through the JAK-STAT pathway to elicit antiviral activity. Yet, type II IFN 
is thought to do so only through STAT1 homodimers; whereas type I and III IFNs activate both STAT1 
and STAT2 to form ISGF3 together with IRF9. However, accumulating evidence highlights a far more 
complex process of activation and function beyond this classical theory. The heterogeneity of the 
regulatory mechanisms of ISG transcription has been recently highlighted. A substantial fraction of 
these cascades have little or no link to STAT1/2 and ISGF3, paralleling the existence of non-canonical 
mechanisms outside of the JAK-STAT axis [79]. Here, we review both JAK-STAT axis dependent and 
independent non-canonical mechanisms of ISG transcription (Figure 3). 
 
Figure 3. Non-canonical mechanisms in regulating ISG transcription. Non-canonical mechanisms both within 
and outside of the IFN-JAK-STAT axis were summarized. Together with canonical mechanisms, they 
coordinately regulate ISG transcription, thus defining the cellular defense status against pathogen invasion. 
Non-canonical ISGF3 complex. 
Up to date, three different forms of non-canonical ISGF3 complexes have been identified, including 
ISGF3II, the STAT2-IRF9 complex and unphosphorylated ISGF3 (U-ISGF3). IFN-γ treatment has been 
reported to induce the formation of a new manifestation of ISGF3 (ISGF3II) containing 
phosphorylated STAT1, unphosphorylated STAT2 and IRF9 [80]. In the absence of STAT1, STAT2 was 
found to interact with IRF9 to form an ISGF3-like complex to mediate specific ISG transcription [81]. 
Finally, continuous exposure to a low level of exogenous IFNs, U-ISGF3 formed by IFN induced IRF9 
and unphosphorylated STAT1 and STAT2, can lead to increased expression of a subset of ISGs [82, 83].  
STAT5-CrkL complex.  
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Apart from STAT1 and STAT2, STAT5 is also involved in type I IFN induced ISG transcription. STAT5 
interacts constitutively with IFN receptor-associated TYK-2. Upon type I IFN stimulation, STAT5 is 
phosphorylated on both tyrosine and serine sites, thus acting as a docking site for the SH2 domain of 
CrkL. CrkL and STAT5 then form a complex that translocates to the nucleus and binds to GAS 
elements to activate type I IFN-dependent gene transcription [3, 84].  
IRFs. 
IRF1 has been shown to function as a transcription factor. The DNA sequences (IRF-E site) recognized 
by IRF1 overlap with the ISRE, and in this way IRF1 induces a subset of ISGs. IRF1 can also enhance 
the levels of both total and phosphorylated STAT1 to amplify ISG transcription via JAK-STAT pathway 
[85]. Conversely, IRF2 binds to the same IRF-E site to repress IRF1 induced transcription [86, 87]. Upon 
virus infection, IRF3 is activated and cooperates with NF-κB and ATF-2/c-Jun to form a 
transcriptionally active enhanceosome complex on the IFN-β promoter. Newly synthesized IFN binds 
to cognate receptors to activate ISG transcription via the JAK-STAT pathway. Importantly, IRF3 was 
also been reported to directly induce a subset of ISGs in an IFN-independent manner through the 
ISREs element on their promoters [88, 89]. 
Cross-regulation between TNF and IFN signaling.  
It is well documented that when combined with TNF-α, type I or II IFN works cooperatively on 
antiviral ISG induction and exerts synergistic antiviral effects [90-93]. TNF-α has been reported to inhibit 
hepatitis C virus (HCV) infection-caused degradation of IFNAR2, thus maintaining IFN signaling and 
ISG expression [93]. TNF-α alone can already moderately induce the transcription of a subset of ISGs 
[90, 91]. This is mainly through NF-κB protein complex, a key downstream element of the TNF-α 
signaling. This may explain the antiviral activity of TNF-α on different virus as documented [92, 94-96]. 
Rac1/p38 pathway.  
Rac1/p38 Map kinase signaling regulates IFN induced ISG transcription. Type I IFN treatment results 
in activation of Rac1 and its downstream effectors including MAP kinase kinase 3 (MKK3), MAP 
kinase kinase 6 (MKK6) [97, 98] and cytosolic phospholipase A2 [99, 100]. In turn, these events provoke 
phosphorylation and activation of the p38 MAP kinase, an important mediator of the inflammatory 
response [101]. p38 MAP kinase activation leads to downstream MapKapK-2 and MapKapK-3 
activation, contributing to type I IFN-dependent transcriptional regulation of ISGs. However, 
Rac1/p38 Map kinase signaling is not required for IFN-dependent phosphorylation of STAT1 on both 
sites (Ser727 and Tyr701) and has no impact on the formation of ISGF3 complex [102, 103]. Histone 
phosphorylation and chromatin remodeling are possible mechanisms employed by this cascade [102]. 
Many immune-relevant gene products are subject to post-transcriptional regulation by this signaling 
[104], but ISGs have not been investigated in this respect. 
IFN-γ-activated response element (GATE).  
In response to IFN-γ, two factors bind to a unique IFN-γ-activated response element called GATE, the 
CCAAT/enhancer binding protein C/EBP-β and the GATE binding factor GBF-1. MEK1, ERK1 and ERK2 
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are the upstream kinases needed to activate C/EBP-β in response to IFN-γ [105]. This novel IFN-γ-
activated pathway promotes ISG expression in STAT1-, but not JAK1-dependent manner.  
Nucleotide synthesis inhibitor.  
Purine and pyrimidine nucleotides are the major cellular energy carriers and constitute subunits of 
nucleic acids. Nucleotides can be synthesized de novo through a series of enzymatic reactions or 
recycled through salvage pathways. Interestingly, purine and pyrimidine synthesis inhibitors (such as 
ribavirin, mycophenolic acid and brequinar) can efficiently induce ISG expression and exert strong 
and broad antiviral responses [106-108]. However, this process is independent of the classical JAK-STAT 
cascade, suggesting a non-canonical mechanism that is independent of IFNs [109]. Ribavirin, an 
inhibitor of the IMPDH enzyme, was shown to reset a subset of ISG promoters to a “ready to be 
activated” status, thus potentiating ISG activation [110]. However, the crosstalk of nucleotide synthesis 
and innate immune response remains to be further elucidated. 
Retinoic acid.  
Retinoic acid (RA) is a metabolite of vitamin A that mediates the functions of vitamin A required for 
growth and development. RA activates transcriptional status via retinoic acid receptors (RAR) and 
retinoid X receptors (RXR) heterodimer, which binds to regions in promoters called retinoic acid 
response elements (RAREs). Numerous studies have reported antiviral activities of RA against a 
variety of pathogens [111, 112]. Interestingly, intracellular RA increases ISG expression at basal levels 
and augments ISG induction in response to IFNs [113]. This is consistent with the clinical observation 
that RA enhances the response to IFN-based antiviral therapy [112, 114]. Strikingly, a bioinformatics 
study showed that most ISGs regulatory regions contain RARE sequence [113]. This indicates that RA 
can induce transcriptional activation of these ISGs containing RAREs, facilitating the binding of 
additional transcription factors to the promoters of these ISGs. Consequently, RA initiates and works 
synergistically with IFNs to induce ISG expression.  
IFNs and ISGs: clinical implications and future perspective 
IFNs have been used in various clinical settings to counteract pathogen-related diseases. Because of 
its robust and broad antiviral activity, IFN-α represents the standard treatment for chronic hepatitis B 
virus (HBV) or HCV infections for decades. Its application also extends to other virus infections as off-
label treatment, e.g. hepatitis E virus [115] and severe acute respiratory syndrome [116]. IFN-λ has been 
shown to play a crucial role in cancer, autoimmune disease and viral infections [117]. The antitumor 
and anti-infection activities of IFN-γ have been comprehensively evaluated and used in a variety of 
clinical indications. It has been approved by FDA to treat chronic granulomatous disease and 
osteopetrosis and is experimentally used for the treatment of idiopathic pulmonary fibrosis and 
Friedreich's ataxia [118]. But it is unsuccessful for treating viral infections [119, 120]. IFN-λ has been shown 
specific antiviral activity in both chronic HBV and HCV patients, not superior as compared to IFN-α 
therapy but with limited side effects [121, 122]. This is because of the fact that IFNλR1 has a more 
restricted tissue-specific pattern of expression. IFN-λ has also been shown to determine the intestinal 
epithelial antiviral host defense against rotavirus infection. It acts synergistically with IL-22 for the 
induction of ISGs and eventually controls rotavirus infection in animal models [123, 124]. Thus, IFN-λ 
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might be an attractive option for the treatment of many viral infections. Although the clinical 
application of IFNs, in particular for HCV, will be limited because of the recent launch of direct-acting 
antiviral agents, it may extend to other devastating viral diseases such as Ebola, Zika or Dengue virus 
infections.  
Mechanistically, for all three different types of IFNs, ISGs are the ultimate antiviral effectors. 
Recent studies on the function of individual ISG indicate that different viruses are targeted by unique 
sets of ISGs. Some ISGs possess broad antiviral but others have specific antiviral effects [125]. Thus, 
characterization of individual ISG with respect to their antiviral spectrum or specificity provides new 
avenues for improving current antiviral therapies. Interestingly, several ISGs have been reported to 
paradoxically enhance the replication of certain viruses, illustrating the complexity of the network of 
mutual interaction between ISGs and viruses [125]. In pre-clinical or clinical studies, the expression 
pattern of some specific ISGs have been identified as bio-makers to predict treatment responses, 
disease progression or outcomes in both infectious (e.g. HCV and HIV infections) [126-128] and non-
infectious human diseases (e.g. Aicardi-Goutieres syndrome and systemic lupus erythematosus) [129, 
130]. Some ISGs (e.g. TLR3, TLR7, RIG-I and MDA5) belong to pattern recognition receptors (PRRs). 
Attributing to their key roles in innate immune responses, there is a growing interest in targeting 
PRRs for the prevention and treatment of cancer, autoimmune diseases and infections. Their specific 
activators are now undergoing preclinical and clinical evaluation for safety and efficacy [131]. With 
regards to the adverse effects of IFNs in clinic, ISG-based antiviral strategies could be the next 
promising frontier in drug discovery. 
Concluding Remarks  
Decades of research has shaped up a picture of the complex network in regulating ISG transcription. 
This includes both canonical and non-canonical mechanisms within and outside of the IFN-JAK-STAT 
axis, coordinately defining the cellular defense status against pathogen invasion. We expect that the 
spectrum of new elements involved in both canonical and non-canonical regulation of ISG 
transcription will continue to grow and their mechanism-of-actions will be further clarified (see 
Outstanding Questions). Because of their importance in clinical implication, this knowledge is highly 
relevant in guiding the development of new therapies that promote the eradication of severe 
pathogen infections, but avoiding autoimmune diseases and toxic effects to the host. 
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Type I interferons (IFNs) have broad antiviral activities through the induction of interferon-stimulated 
genes (ISGs). It is considered to constitute the first line of antiviral defense, but excessive exposure to 
IFNs provokes tissue damage and other pathological events. In addition to type I IFNs, however, the 
body has other innate antiviral defenses as well, which were commandingly reviewed by dr. Paludan 
in a recent issue of Trends in Immunology [1]. The article highlights that type I IFN-independent 
antiviral mechanisms, including alternative antiviral cytokines (e.g. IFN-λ or interleukin 22), or the 
basal expression of particular ISGs that all can mediate early antiviral defenses without evoking the 
inflammatory damage associated with production of type I IFNs. However, we feel that, while the 
constitutively expressed IFN regulatory factors (IRFs) and pattern recognition receptors (PRRs) have 
been largely examined in the context of the scaling of IFN responses, they also mediate important 
antiviral mechanisms that are independent of IFN induction and, thus, should also be emphasized.  
There are hundreds of ISGs that are usually induced by IFNs. Although they are thought to be 
the ultimate antiviral effectors, only a small subset of ISGs actually have potent antiviral activity as 
recently demonstrated by a screening of over 380 human ISGs for their antiviral effects [2, 3]. Some 
ISGs appear to act on specific viruses; whereas others have potent antiviral activity against a broad 
spectrum of viruses, especially IRFs (e.g. IRF1 and IRF2) and PRRs (e.g. cGAS, RIG-I and MDA5) [2, 3]. 
Classically, the induction or/and activation of these broad antiviral ISGs by viruses or IFNs are 
thought to enhance further IFN production, in turn inducing strong and broad induction of ISGs 
capable of combating viral infection through positive feedback loop. However, constitutive 
expression of particular ISGs may provide necessary antiviral defense without the need for IFN 
production. Especially the observation that, several ISGs have general antiviral effects in human 
STAT1 deficient fibroblasts, which are deficient in IFN signal transduction, in our view strongly 
supports this notion [2]. 
IRFs are transcription factors that indeed can bind to promoter regions of specific IFN genes 
to drive their transcription. PRRs can recognize specific components of the viral nucleic acid and 
trigger IFN production through downstream elements including IRF3 and IRF7 [4]. Thus, IFNs are 
important mediators of their antiviral action. However, accumulating evidence suggest that these 
broad antiviral ISGs simultaneously function through IFN-independent pathways, as they are capable 
of inducing transcription of many ISGs independent of IFN production or signaling [2]. For instance, 
IRF1 inhibits hepatitis E virus infection through activation of STAT1 transcription and phosphorylation 
without concomitant IFN production [5]. cGAS can induce a large number of ISGs via a STING-
dependent, IRF3-mediated process but functions independent of the canonical IFN signaling [3]. RIG-I 
has also been demonstrated to induce ISGs by augmenting STAT1 activation but independent of the 
classical IFN pathway [6]. It has been reported to strengthen STAT1 activation by disruption of the 
binding of STAT1 to its negative regulator SHP1 [7].  
We feel that this idea is further bolstered by the definition of at least some of the other 
molecular mechanisms that execute type I IFN-independent antiviral defense. RIG-I can directly 
inhibit viral replication by blocking the binding of viral polymerase to viral RNA [8, 9]. During hepatitis B 
virus (HBV) infection, RIG-I recognizes and binds the 5’-ε region of the pregenomic viral RNA (pgRNA). 
It thus prevents the interaction of HBV polymerase with this 5’-ε region, leading to suppression of 
HBV replication [8]. During influenza A virus infection, RIG-I binds to the nucleocapsids of cytoplasm-
invading viruses, resulting in destabilization of the nucleocapsids that hampers viral propagation [9]. 
Furthermore, RIG-I and MDA5 exert their direct antiviral functions that require intact ATPase activity 
Chapter 4 
48 | P a g e  
and involves displacing viral proteins from their pre-bound positions on dsRNA [10]. In response, 
viruses have also developed sophisticated strategies to counteract host antiviral defense. For 
instance, herpesvirus can hijack activated RIG-I to avoid antiviral cytokine production [11]. Hepatitis C 
virus can prevent physical interaction between viral RNA and host PRRs like RIG-I and MDA5 [12]. 
Nevertheless, constitutive expression of RIG-I and MDA5 can be expected to provide protection 
against a variety of viruses. 
In line with the review by Paludan highlighting the essential role of IFN-independent antiviral 
response, we now have extended and emphasized the importance of possible IFN-independent 
mechanisms of these broad antiviral ISGs. However, these non-canonical antiviral mechanisms are 
largely elusive, thus deserving further investigation, although the IFN-dependent mechanisms also 
require further clarification (Figure 1). We would thus call upon the scientific community to devote 
more attention to this under-investigated subject as it appears to constitute a vital component of the 
defense of the body against viral challenges. 
 
 
Figure 1. Interferon (IFN)-Dependent and Independent Antiviral Mechanisms of IFN-Stimulated Genes (ISGs).  
Classically, Type I IFN induces gene expression via the Janus kinase-signal transducer and activator of 
transcription (JAK-STAT) pathway, resulting in expression of a range of ISGs that can be mainly divided into 
antiviral effectors and positive regulators. Some positive regulators, such as retinoic-acid inducible gene I (RIG-
I), melanoma differentiation associated protein 5 (MDA5), and cyclic GMP-AMP synthase (cGAS), can recognize 
viral nucleic acid, triggering expression of IFNs through the IFN regulatory factors IRF3 and IRF7. Many of these 
positive regulators can activate the transcription of ISGs independently of IFN production. In particular, cGAS 
can induce ISG expression via a stimulator of IFN genes (STING)-dependent, IRF3-mediated process. RIG-I can 
induce ISG expression by augmenting STAT1 activation. IRF1 can activate ISG expression via STAT1 activation. 
Of note, RIG-I and MDA5 also directly inhibit viral propagation. Abbreviations: IFNAR1/2, IFN-α receptor 1/2; 
ISRE, IFN-stimulated response element. The red line with a blunt end indicates antiviral activity. 
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Abstract 
IFN-α has been used for decades to treat chronic hepatitis B and C, and as an off-label treatment for 
some cases of hepatitis E virus (HEV) infection. TNF-α is another important cytokine involved in 
inflammatory disease, which can interact with interferon signaling. Because interferon-stimulated 
genes (ISGs) are the ultimate antiviral effectors of the interferon signaling, this study aimed to 
understand the regulation of ISG transcription and the antiviral activity by IFN-α and TNF-α. In this 
study, treatment of TNF-α inhibited replication of HCV by 71  ±  2.4% and HEV by 41  ±  4.9%. 
Interestingly, TNF-α induced the expression of a panel of antiviral ISGs (2-11 fold). Blocking the TNF-α 
signaling by Humira abrogated ISG induction and its antiviral activity. Chip-seq data analysis and 
mutagenesis assay further revealed that the NF-κB protein complex, a key downstream element of 
TNF-α signaling, directly binds to the ISRE motif in the ISG promoters and thereby drives their 
transcription. This process is independent of interferons and JAK-STAT cascade. Importantly, when 
combined with IFN-α, TNF-α works cooperatively on ISG induction, explaining their additive antiviral 
effects. Thus, our study reveals a novel mechanism of convergent transcription of ISGs by TNF-α and 
IFN-α, which augments their antiviral activity against HCV and HEV. 
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Introduction 
Cytokines orchestrate cellular communication in an autocrine, juxtacrine, or paracrine fashion 
through binding to distinct families of receptors, triggering specific immune responses against 
invading pathogens. The interferon (IFN)-mediated innate immune response is probably the most 
prominent response and provides a robust first defense line. Among different types of interferons, 
IFN-α (a type I member) has been used for decades to treat chronic hepatitis B or C infection in the 
clinic [1]. When stimulated by its cognate ligand, interferon receptors respond by the activation of 
kinases of the Janus family (JAKs), which in turn phosphorylate tyrosine residues in the intracellular 
tail of the interferon receptors. These phosphotyrosines serve as docking sites for recruitment and 
phosphorylation of the Signal Transducers and Activators of Transcription (STAT) family, which 
provokes STAT1 and STAT2 dimerization and subsequent binding to interferon regulatory factor 9 
(IRF9) to form the IFN-stimulated gene factor 3 (ISGF3) complex. The ISGF3 complex translocates into 
the nucleus, and binds to specific promotor elements denoted as interferon signaling response 
elements (ISREs) and thus mediate the transcription of so-called interferon-stimulated genes (ISGs). 
ISGs are the ultimate antiviral effectors of the interferon signaling. 
It is generally believed that ISGs are predominantly induced by interferons. However, ISGs 
are still up-regulated in embryonic fibroblasts from IFN alpha/beta receptor knockout mouse upon 
infection of West Nile virus [2]. These observations suggest the existence of alternative mechanisms 
of regulating ISG transcription. But these non-canonical mechanisms remain largely unknown. 
Tumor necrosis factor alpha (TNF-α) is another important cytokine that mediates host 
response to infections. TNF-α/TNFR interactions can play decisive roles in the outcome of a number 
of viral infections, contributing to virus control or immune mediated pathology [3]. Deregulation of 
TNF-α is associated with many pathological conditions, including various types of arthritis and 
inflammatory bowel disease (IBD) [4]. TNF-α inhibitors have been successfully used in the clinic to 
treat these chronic immune-mediated diseases [5]. However, patients receiving TNF-α inhibitors are 
often at high risk of viral infections [6]. Treatment with TNF-α inhibitors have been reported to 
increase reactivation of concurrent chronic hepatitis B and potentially increase hepatitis C virus (HCV) 
replication [7], further supporting the importance of TNF-α in defending the human body against viral 
infections. Interestingly, several previous studies reported crosstalk between TNF-α and the antiviral 
interferon signaling and ISG expression in the setting of vesicular stomatitis virus [8], hepatitis C virus 
(HCV) [9], respiratory virus [10] and poxvirus infections [11]. 
However, the exact antiviral mechanisms of TNF-α and how it cooperates with the interferon 
signaling remain largely elusive, thus prompting us to explore their molecular basis. Here we report 
that TNF-α alone was sufficient to induce the expression of ISGs and to exert antiviral activity against 
HCV and hepatitis E virus (HEV). This is through the activation of the NF-κB signaling but independent 
of the canonical interferon pathway. Surprisingly, we found a consensus DNA binding sequence 
between the NF-κB and ISRE motif with bioinformatics analysis. Functional assays revealed that the 
NF-κB complex is able to bind to the ISRE motif and directly activates the transcription of antiviral 
ISGs. Combination of TNF-α with IFN-α further boosts the induction of ISGs and results in augmented 
antiviral activity against HCV and HEV. Thus, this study identified a non-canonical mechanism of 
driving antiviral ISG transcription, which provides the molecular basis for the antiviral action of TNF-α 
and its additive antiviral effect with interferon. 
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Results 
TNF-α activates ISG transcription and exerts antiviral activity against HCV and 
HEV 
TNF-α is involved in host responses to a variety of pathogen invasions, including HCV and HEV 
infections [9, 12]. To assess the direct effects of TNF-α on HCV and HEV replication, we employed a 
human hepatocyte cell line, i.e. Huh7, transfected with a HCV or HEV replicon luciferase as reporters. 
In parallel, Huh7 cells constitutively expressing a non-secreted firefly luciferase under control of the 
human phosphoglycerate kinase (PGK) promoter (LV-PGK-Luc) were also used for normalization of 
nonspecific effects on luciferase signals. Both HCV and HEV replicon luciferase activity were 
significantly inhibited by treatment of cells with TNF-α (Fig. 1A, B). For instance, 100  ng/mL TNF-α 
inhibited HCV to 29  ±  2.4% (n  =  5, P  <  0.001), HEV to 59  ±  4.9% (n =  5, P  <  0.01) at 72 hrs. 
 
Figure 1. TNF-α activates ISG transcription and exerts antiviral activity against HCV and HEV. (A) In 
the Huh7 cell-based subgenomic HCV replicon, treatment with recombinant human TNF-α 
(100 ng/mL) inhibited HCV replication-related luciferase activity as measured at 3 different time 
points (n  =  5). (B) Same as (A) for the Huh7 cell-based subgenomic HEV replicon model. (C) In the 
Huh7 cell-based ISRE luciferase reporter cells, treatment with IFN-α resulted in a dose-dependent 
induction of ISRE-related luciferase activity (n  =  3 independent experiments with 2 - 3 replicates 
each). (D) Same as (C) for TNF-α. (E) Expression profile of 20 antiviral ISGs in Huh7 cells as measured 
by qRT-PCR. Most ISGs were highly up-regulated with TNF-α treatment (n  =  5). Data presented as 
mean  ±  SD (*P  <  0.05; **P  <  0.01; ***P  <  0.001). 
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Since TNF-α has been reported to interacts with interferon signaling and ISGs are the 
ultimate antiviral effectors of the interferon cascade, we thus attempted to investigate whether TNF-
α alone has any effect on ISG transcription. Based on the knowledge that interferon induces ISG 
expression via the activation of the ISRE motifs within the promoters of ISGs, a Huh7 cell line stably 
harboring a ISRE-driven luciferase reporter was used [13]. As expected, IFN-α treatment induced a 
strong transactivation of ISRE-driven luciferase value (Fig. 1C). Surprisingly, TNF-α stimulation also 
provoked a strong transactivation of the ISRE transcription elements (Fig. 1D). This interesting result 
prompted us to investigate the relative expression level of a panel of well-studied antiviral ISGs by 
qRT-PCR. Consistently, treatment of TNF-α provoked the induction of most tested ISGs, ranging from 
1.7 to 11.3 fold increase (Fig. 1E). These data demonstrate that TNF-α transactivates the ISRE motif, 
resulting in the induction of ISGs, which in turn mediate the antiviral effects of TNF-α against HCV 
and HEV. 
Activation of ISRE transcription by TNF-α does not require interferon 
production 
The fact that TNF-α can induce ISGs inspired us to investigate the straightforward possibility that 
TNF-α merely triggers the production of interferons. Interferon regulatory factor 1 (IRF1) was 
demonstrated to be important in a TNF-α triggered IFN-β autocrine loop in primary macrophage cells 
[14]. To dissect whether a similar mechanism exist in our experiment system, we first studied the 
potential involvement of IRF1. Lentiviral vector was used to overexpress IRF1 in Huh7 based ISRE-
driven luciferase reporter cells and the successful overexpression of IRF1 was confirmed at both 
mRNA and protein levels (Fig. 2A, B). IRF1 overexpression significantly increased ISRE-regulated 
luciferase activity (Fig. 2C). Surprisingly, the combination of IRF1 overexpression and TNF-α induced a 
strong additive ISRE activation (Fig. 2C). Furthermore, stable IRF1 knockdown by lentiviral RNAi (Fig. 
2D, E) had no significant effect on TNF-α induced ISRE activation (Fig. 2F). In addition, the 
involvement of another interferon regulatory factor, IRF7, was also examined via loss-of-function 
assay. TNF-α induced ISRE activation was not affected even upon the efficient IRF7 knockdown 
(Supplementary Figure 1A-C). These results suggest that TNF-α triggered ISRE activation is 
independent of IRF1 and IRF7. 
We next investigated the effects of TNF-α on gene expression of type I interferons. As 
determined by qRT-PCR, the constitutive expression levels of IFN-α and β1 in Huh7 cells are rather 
low, compared to the reference genes GAPDH and RP2 (Fig. 2G). Moreover, TNF-α treatment did not 
significantly increase IFN-α and IFN-β1 mRNA levels (Fig. 2H). This is consistent with a previous study 
showing that the Huh7 cell line responds to interferon but does not produce interferon [15]. These 
data collectively indicate that activation of ISRE transcription by TNF-α does not require interferon 
production in our model system. 
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Figure 2: Activation 
of ISRE transcription 
by TNF-α does not 
require interferon 
production and the 
JAK-STAT signaling. 
(A) qRT-PCR analysis of 
IRF1 overexpression by 
lentiviral vectors in the 
Huh7 based ISRE 
luciferase reporter 
cells. Compared to the 
control vector 
transduced cells, the 
IRF1 lentiviral vector 
showed strong IRF1 
induction on RNA level. 
(B) Western blot 
analysis confirmed the 
successful 
overexpression of IRF1 
by lentiviral vectors in 
the Huh7 based ISRE 
luciferase reporter 
cells. (C) In the Huh7 
cell-based ISRE 
luciferase reporter 
cells, the combination 
of IRF1 overexpression 
and TNF-α induced a strong additive ISRE activation as measured at 3 different time points (n  =  5). (D) qRT-
PCR analysis of IRF1 knockdown by lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. 
Compared to the control vector transduced cells, the IRF1 shRNA treated clones showed strong reduction of 
IRF1 RNA levels. (E) Western blot analysis confirmed the successful knockdown of IRF1 by lentiviral shRNA 
vectors in the Huh7 based ISRE luciferase reporter cells. (F) Knockdown of IRF1 in Huh7 based ISRE luciferase 
reporter cells did not block TNF-α induced ISRE-related luciferase activation (n  =  4). (G) The relative IFN-α and 
β1 expression levels in Huh7 cells were determined by qRT-PCR. GAPDH and RP2 served as internal reference 
genes. (H) IFN-α and β1 expression levels in Huh7 cells were not up-regulated upon TNF-α treatment as 
measured by qRT-PCR (n  =  6). (I) JAK inhibitor I (5 μM) did not abrogate TNF-α induced ISRE-related luciferase 
activation (n  =  3 independent experiments with 2 - 3 replicates each). Data presented as mean  ±  SD (*P  < 
 0.05; **P  <  0.01; ***P  <  0.001; ns, not significant). 
TNF-α induced ISRE activation is independent of the JAK-STAT signaling 
Classically, ISGs are induced by interferons via the JAK-STAT signaling. Following receptor activation 
by interferons, JAK1 phosphorylates STAT1 and Tyrosine kinase 2 (TYK2) phosphorylates STAT2. This 
provokes STAT1 and STAT2 dimerization and subsequent binding to IRF9 to form the ISGF3 complex. 
The ISGF3 complex translocates into the nucleus, binds to the ISRE motif [5′-CAGTTTCACTTTCC-3′] 
and drives the transcription of ISGs (Supplementary Figure 2A). To test whether activation of ISRE by 
TNF-α require JAK-STAT signaling, we first examined the role of JAKs. Strikingly, neither JAK inhibitor 
(an inhibitor of JAK1, JAK2, JAK3 and TYK2) nor Bayer-18 (a selective TYK2 inhibitor) abrogated TNF-α 
induced ISRE activation (Fig. 2I and Supplementary Figure 2B). Consistently, TNF-α induced ISG 
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expression was not affected by the treatment of JAK inhibitor I (Supplementary Figure 2D). In 
contrast, both IFN-α induce ISRE activation and ISG expression were largely blocked by JAK inhibitor I 
(Supplementary Figures 2C and 3A). Interestingly, the selective TYK2 inhibitor, Bayer-18, did not 
significantly affect IFN-α induced ISRE activation (Supplementary Figure 2C). This is consistent with a 
previous study, showing that TYK2 plays a restricted role in IFN-α signaling [16]. 
Furthermore, to see if TNF-α treatment has any effect on STATs activation and translocation, 
we examined the phosphorylation status of STAT1 at amino acid 701 (Y701P) and STAT2 at amino 
acid 690 (Y690), which are indispensable signature of STAT1 and STAT2 activation, respectively. WB 
results showed TNF-α treatment had no effects on the phosphorylation of both STAT1 and STAT2 at 
indicated sites (Fig. 3A, B). Confocal microscopy analysis also confirmed that IFN-α induced the 
activation and nuclear translocation of STAT1 and STAT2 via the phosphorylation at indicated sites, 
while TNF-α had no effects (Fig. 3C, D). To further exclude a role of STAT1 in TNF-α induced ISRE 
activation, lentiviral RNAi was used to knockdown STAT1. The stable STAT1 knockdown (Fig. 3E, F) 
had no effect on both TNF-α induced ISRE activation and ISG expression (Fig. 3G, H). Collectively, 
TNF-α triggered ISRE activation is totally independent of STAT1.  
In addition, the role of IRF9 was also verified, which is a key downstream element of 
interferon pathway. IRF9 was up-regulated and translocated into cell nucleus upon IFN-α stimulation, 
whereas TNF-α stimulation did not induce the translocation of IRF9 into cell nucleus (Supplementary 
Figure 3B). These results collectively demonstrate that TNF-α induced ISRE activation is independent 
of the JAK-STAT signaling. 
TNF-α activates ISRE via TNF receptor 1 
TNF receptor (TNFR) is the important upstream component in TNF-α induced signaling transduction. 
TNF acts through two receptors, TNFR1 and TNFR2. TNFR1 is the major signaling receptor for TNF-α 
and is expressed by all human tissues, while TNFR2 is mostly expressed in immune cells and mediates 
limited biological responses [17]. In light of the fact that TNF-α is capable of activating ISG 
transcription, we sought to determine whether this action of TNF-α was mediated via TNFR. For this, 
the ISRE reporter cell line was transduced with integrating lentiviral RNAi vectors to silence TNFR1, 
resulting in a profound down-regulation of TNFR1 expression (Fig. 4A). As expected, IFN-α induced 
ISRE activation was not influenced (Fig. 4B), but TNF-α induced ISRE luciferase activity was largely 
abrogated in TNFR1 knockdown cells when compared to control cells (Fig. 4C). Consistently, the 
induction of ISGs by TNF-α was also blocked by TNFR1 knockdown (Supplementary Figure 4A). 
To further confirm these results, the clinically widely used drug for rheumatoid arthritis 
patients and Crohn’s disease, Humira (adalimumab), was used. Humira binds specifically to TNF-α 
and blocks its interaction with TNF receptors. As expected, Humira effectively blocks TNF-α induced 
activation of NF-κB luciferase activity (Fig. 5A), NF-κB activity being a well-known downstream effect 
of TNF-α receptor ligation. Importantly, both TNF-α induced ISRE luciferase activity and ISG 
expression were also abrogated by Humira treatment (Fig. 5B, C). This effect was not limited to Huh7 
cells, but also observed in a human lung cell line, A549 (Supplementary Figure 4B). More relevantly, 
Humira totally abolished TNF-α mediated antiviral effect against HCV and HEV (Fig. 5D, E), providing 
a possible explanation for the high risk of infection in patients treated with TNF-α inhibitors. Next, we 
collected serum samples from anti-TNF-α treatment naive Crohn’s disease patients and measured 
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the serum TNF-α levels by ELISA. 3 serum samples with high TNF-α levels were selected to treat Huh7 
based ISRE-driven luciferase reporter cells (Fig. 5F). Consistently, all 3 serum samples exerted higher 
ISRE activity compared to control serum sample (Fig. 5F, right). Furthermore, Humira decreased the 
serum induced ISRE activity (Supplementary Figure 4C). More interestingly, serum samples with 
higher TNF-α levels inhibited HCV-related luciferase activity compared to control serum sample 
(Supplementary Figure 4D). Collectively, these results demonstrate that TNF-α acts via its receptor to 
activate ISG transcription and exerts antiviral activity, which can be blocked by clinically used TNF-α 
inhibitor. 
 
 
 
 
 
 
 
 
 
Figure 3: TNF-α activates ISRE in a STAT1 independent manner. (A) Western blot analysis of total STAT1 and 
phosphorylated STAT1 (Y701P) protein levels under the treatment of TNF-α (100 ng/mL), IFN-α (1000 IU/mL). 
(B) Same as (A) for the detection of total STAT2 and phosphorylated STAT2 (Y690P) protein levels under the 
treatment of TNF-α, IFN-α. (C) Confocal microscopy analysis of phosphorylated STAT1 (Y701P) localization in 
Huh7 cells treated with IFN-α or TNF-α. STAT1 was phosphorylated and translocated to the nucleus upon IFN-α, 
but not TNF-α treatment. Phosphorylated STAT1 (Y701P) antibody (green). Nuclei were visualized by DAPI 
(blue). (D) Same as (C) for the detection and localization of phosphorylated STAT2 (Y690P). (E) qRT-PCR 
confirmed the successful STAT1 knockdown by lentiviral shRNA vectors in the Huh7 based ISRE luciferase 
reporter cells. (F) Western blot analysis confirmed the successful knockdown of STAT1 by lentiviral shRNA 
vectors in the Huh7 based ISRE luciferase reporter cells. (G) STAT1 knockdown had no significant influence on 
TNF-α induced ISRE-related luciferase activation as measured at 3 different time points (n  =  3 independent 
experiments with 2 -3 replicates each). (H) STAT1 knockdown exerts no effect on TNF-α induced ISG expression 
as measured by qRT-PCR (n  =  3). 
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Figure 4: TNF-α 
activates ISRE via TNF 
receptor I. 
(A) qRT-PCR analysis of 
TNFR1 knockdown by 
lentiviral shRNA 
vectors in the Huh7 
based ISRE luciferase 
reporter cells. 
Compared to the 
control vector 
transduced cells, the 
two shRNA treated 
clones (sh-02 and sh-
03) showed strong 
reduction of TNFR1 
RNA levels. (B) TNFR1 
knockdown had no 
significant influence on 
IFN-α induced ISRE-
related luciferase 
activation as measured 
at 3 different time points (n  =  3 independent experiments with 2 - 3 replicates each). (C) TNFR1 knockdown 
blocked TNF-α induced ISRE-related luciferase activation as measured at 3 different time points (n  =  3 
independent experiments with 2 - 3 replicates each). 
TNF-α mediates the activation of ISRE through NF-κB signaling 
Activation of NF-κB signaling is one of the most important canonical responses to the stimulation of 
TNF-α. Following TNF receptor activation by TNF-α, inhibitor of kappa B (IκB) proteins undergo 
phosphorylation dependent ubiquitination and degradation, resulting in the activation and 
translocation of NF-κB dimers into the cell nucleus. In the cell nucleus, NF-κB dimers bind to the 
specific NF-κB motifs, [5′-GGGAA/CTTTCC-3′], within the promoter regions driving the expression of 
NF-κB target genes (Supplementary Figure 5A). Because some studies have reported that TNF-α can 
also increase the transcriptional activity of activator protein-1 (AP-1) in some specific cell types [18, 19], 
we thus created Huh7 based stable NF-κB or AP-1 driven luciferase reporter cell lines, respectively. 
As shown in Supplementary Figure 5B, stimulation with TNF-α led to strong activation of NF-κB 
luciferase activity, but no significant effect on AP-1 activity. Therefore, we only focused on NF-κB 
signaling for the following investigation. 
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Figure 5: Both TNF-α induced ISG expression and antiviral activity against HCV and HEV were 
abrogated by its inhibitor Humira. (A) In the Huh7 cell-based NF-κB luciferase reporter cells, the 
TNF-α inhibitor, Humira, abrogated TNF-α induced NF-κB-related luciferase activation as measured at 
3 different time points (n  =  3 independent experiments with 2 - 3 replicates each). (B) Same as (A) 
for the Huh7 cell-based ISRE luciferase reporter cells. (C) In Huh7 cells, the TNF-α inhibitor, Humira, 
abrogated TNF-α induced ISG expression as measured by qRT-PCR (n  =  4). (D) In the Huh7 cell-based 
subgenomic HCV replicon, Humira abrogated the TNF-α induced anti-HCV effect as measured at 3 
different time points (n  =  3 independent experiments with 2 - 3 replicates each). (E) Same as (D) for 
Huh7 cell-based subgenomic HEV replicon. (F) TNF-α levels in serum samples collected from anti-
TNF-α treatment naive Crohn’s disease patients were measured by ELISA kit (left). Serum samples 
with higher TNF-α levels showed stronger ISRE-related luciferase activity compared with control 
serum as measured at 3 different time points. Data presented as mean  ±  SD. (*P  <  0.05; **P  < 
 0.01; ***P  <  0.001; ns, not significant). 
 
The NF-κB complex is the endpoint of its signal transduction, which comprises the 
heterodimeric RelA (P65)-P50 complex. Indeed, unstimulated cells display little nuclear RelA, but the 
RelA protein level in the cell nucleus was substantially elevated following TNF-α stimulation (Fig. 6A). 
Thus, to dissect the role of the RelA (P65)-P50 complex in TNF-α induced ISRE activation, the Huh7 
ISRE reporter cell line was transduced with integrating lentiviral RNAi vectors to silence RelA (P65), 
resulting in profound down-regulation of RelA expression (Fig. 6B). Consistently, TNF-α induced ISRE 
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luciferase activity and ISG expression was largely demolished in RelA knockdown cells when 
compared with control cells (Fig. 6C, D). On the contrary, IFN-α induced ISRE activation was not 
affected (Fig. 6E). Thus, NF-κB signaling appears to be essential for TNF-α mediated ISRE activation. 
 
 
 
 
Figure 6: TNF-α mediates the induction of ISRE 
by activation of the NF-κB signaling. (A) 
Confocal microscopy analysis of RelA induction 
and localization in Huh7 cells treated with TNF-
α. RelA was induced and translocated to the 
nucleus upon TNF-α treatment. RelA antibody 
(green). Nuclei were visualized by DAPI (blue). 
(B) Western blot analysis confirmed the 
successful knockdown of RelA by lentiviral 
shRNA vectors in the Huh7 based ISRE luciferase 
reporter cells. (C) RelA knockdown largely 
blocked TNF-α induced ISRE-related luciferase 
activation as measured at 3 different time 
points (n =  3 independent experiments with 2 - 
3 replicates each). (D) RelA knockdown largely 
blocked TNF-α induced ISG expression as 
measured by qRT-PCR (n  =  4). (E) RelA 
knockdown has no significant influence on IFN-α 
induced ISRE-related luciferase activation as 
measured at 3 different time points (n  =  3 
independent experiments with 2 - 3 replicates 
each). Data presented as mean  ±  SD (*P  < 
 0.05; **P  <  0.01; ***P  <  0.001; ns, not 
significant). 
 
 
 
 
 
 
 
 
The NF-κB complex directly binds to ISRE and drives its transcriptional activity 
Upon TNF-α stimulation and signaling activation, the transcription factor complex, NF-κB, can directly 
bind to a sequence specific motif [5’-GGGAA/CTTTCC-3’] to promote target gene transcription [13, 20-
22]. The puzzling role of NF-κB in the transactivation of ISRE led us to perform an in silico analysis 
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comparing the ISRE motif and the NF-κB DNA binding site. Surprisingly, we identified a partial 
consensus sequence region in common within these two motifs (Fig. 7A). We thus hypothesized that 
NF-κB might bind to this consensus sequence within the ISRE motif to drive transcription of 
corresponding ISGs. To test this hypothesis, we retrieved genome wide RelA and STAT1 (positive 
control) ChIP-seq data from the ENCODE ChIP-seq Experiment Matrix database. ChIP-seq datasets 
were processed and analyzed. Confirming our hypothesis, we found that RelA showed a similar 
genome-wide binding pattern with STAT1. For a large cohort of genes, RelA overlapped with STAT1 in 
their gene binding site (Fig. 7B, left). To be more specifically, we further analyzed the RelA and STAT1 
binding sites that were within 1 kb of a transcription start site. This region is frequently located at the 
site of the promoter. Consistently, RelA still overlaps with STAT1 in the specific binding sites near 
gene transcription start sites. Since most genes bound and regulated by STAT1 are ISGs, this indicates 
that RelA also possesses the ability to bind and regulate a large cohort of ISGs. Then we analyzed 
RelA binding on a list of well-established antiviral ISGs. Convincingly, RelA shows strong and specific 
binding on the promoters of indicated ISGs, while the rabbit-IgG (negative control) shows no 
significant binding (Fig. 7C). To further confirm that NF-κB binds to the consensus sequence within 
the ISRE motif to drive corresponding ISG transcription, we mutated the consensus nucleotide 
sequence within the ISRE motif based on the lentiviral transcriptional reporter vector expressing the 
firefly luciferase gene driven by multiple ISREs. In theory, RelA will not be able to bind to this mutant 
ISRE sequence (Supplementary Figure 6). Huh7 cells were transduced with this vector to create a 
stable reporter cell line. As expected, TNF-α failed to activate this mutated ISRE (Fig. 7D). Hence, NF-
κB can directly bind to the ISRE motif and activate its transcriptional activity. 
Figure 7: The NF-κB complex directly binds to ISRE 
and drives its transcriptional activity. (A) NF-κB and 
ISRE sequence specific binding regions. Their 
consensus nucleotides are labeled in red color, and 
the consensus region is enclosed by the rectangular 
box. (B) Heatmaps display the normalized ChIP-seq 
reads representing the binding intensity of STAT1 and 
RelA. Displayed are 8 kb regions centered on the 
summits of significant STAT1 and/or RelA binding sites. 
The heatmap are clustered for the STAT1 and RelA 
binding signal based on the central 0.5 kb of the 
heatmap. left) Heatmaps of all significant STAT1 and 
RelA binding sites (n  =  13367). right) Heatmap of all 
significant STAT1 and RelA binding sites that are within 
1 kb of a transcription start site (n  =  4545). (C) 
Binding of RelA to the promoters of the indicated ISGs. 
Sequence reads from anti-RelA ChIP-seq or rabbit-IgG-
control were plotted relative to chromosomal position. 
Genome location of corresponding ISGs is shown 
beneath the track signaling. RelA shows strong and 
specific binding on the promoters of indicated ISGs, 
while the rabbit-IgG, serving as negative control, 
shows no significant binding. (D) In the Huh7 cell-
based mutant ISRE luciferase reporter cells, TNF-α did 
not induce mutant ISRE related luciferase activation as 
measured at 3 different time points (n  =  3 
independent experiments with 2–3 replicates each). 
Data presented as mean ± SD (*P <  0.05; **P <  0.01; 
***P <  0.001; ns, not significant). 
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TNF-α cooperates with IFN-α in ISG induction and antiviral action 
Because of the distinct signaling cascades that finally converge the transcription of antiviral ISGs by 
TNF-α and interferons, we further investigated the combinatory effects of TNF-α with IFN-α on ISG 
induction and antiviral action. Thus, we quantified the expression levels of a list of well-known 
antiviral ISGs in the Huh7 cell line with treatment of TNF-α, IFN-α or a combination thereof. Both 
TNF-α and IFN-α can induce significant up-regulation of tested ISGs, and their combination resulted 
in a strong additive induction of ISGs (Fig. 8A). 
 
Figure 8: TNF-α cooperates with IFN-α in ISG induction and antiviral action. (A) In the Huh7 cells, the 
combination of TNF-α and IFN-α induced a strong additive ISG expression compared with treatment of either 
TNF-α or IFN-α alone as measured by qRT-PCR (n  =  6). (B) In the Huh7 cell-based subgenomic HCV replicon 
model, the combination of TNF-α and IFN-α induced a strong additive anti-HCV effect compared with 
treatment of either TNF-α or IFN-α alone as measured at 3 different time (n  =  3 independent experiments 
with 2 - 3 replicates each). (C) Same as (B) for the Huh7 cell-based subgenomic HEV replicon model. 
 
Consistent with a previous publication [23], our results of ISG antiviral assay (Supplementary 
Figure 7) again highlight the important antiviral role of ISGs. Thus, the cooperation in ISG induction 
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prompted us to test whether an additive antiviral effect can be achieved with the combination of 
TNF-α and IFN-α. Hence, we employed the Huh7 cell line based HCV or HEV replicon luciferase 
reporter as the cell models for the test. As shown in Fig. 8B and 8C, the combination of TNF-α and 
IFN-α resulted in additive antiviral effects in both HCV and HEV replicon models. Thus, TNF-α 
cooperates with IFN-α in ISG induction, explaining their additive antiviral effects against HCV and HEV 
as we observed. 
Discussion 
TNF-α is a cytokine within the TNF superfamily, which acts as a central mediator of inflammation and 
immune regulations. Although TNF-α was first noted for its role in the killing of tumor cells [24], it has 
pleiotropic functions that include the inflammatory response 
and host res istance to pathogens. Indeed, numerous studies  have demonstrated the
 importance of TNF-α in protection against pathogens, including Mycobacterium tuberculosis, 
Cryptococcus neoformans, vesicular stomatitis virus, encephalomyocarditis virus, herpes simplex 
virus, influenza virus and hepatitis B virus [25-29]. Disordered TNF-α regulation may have a significant 
negative role in inflammation and pathogenesis. Based on this, TNF-α antagonists have been proven 
to be highly effective in the treatment of certain inflammatory diseases, such as rheumatoid arthritis 
[30], psoriatic arthritis [31], juvenile rheumatoid arthritis [32], and Crohn’s disease [33]. Several TNF-α 
inhibitors have been approved for the treatment of these inflammatory illnesses by the US Food and 
Drug Administration (FDA). Contradictory, many studies have demonstrated an increased risk of 
opportunistic infections and difficulty in clearing infections once they develop in patients treated 
with TNF-α inhibitors, such as HBV or HCV infection [34-36]. Our experimental results showing that 
clinically used anti-TNF-α inhibitors can totally abrogate the antiviral activity of TNF-α appear to 
support those clinical observations and highlight the primary role of TNF-α in host defense against 
infections. 
As a first line defense, TNF-α and type I interferons are induced by microbial stimuli and 
mediate innate immune responses. Despite the fact that cells at sites of infection are continuously 
exposed to both cytokines, the interactions between TNF-α and interferons remain under 
investigated [37]. Although previous studies have reported that TNF-α interacts with antiviral 
interferon signaling and regulates ISG expression in the setting of different virus infections [8-10], the 
molecular mechanisms behind these interactions have not been delineated. In this study, we 
demonstrated that the activation of NF-κB signaling by TNF-α was able to directly transactivate the 
ISRE motif, resulting in the induction of antiviral ISGs. This whole process is independent of IFN 
production and the canonical JAK-STAT cascade, but relies on TNF-α induced NF-κB activity. NF-κB is 
a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins: RelA (P65), 
RelB, c-Rel, P50 and P52 and the heterodimeric RelA (P65)-P50 complex appear to be the most 
abundant one. The dimers bind to the sequence specific NF-κB response element in the promoter 
region of their target genes to regulate transcription. To our surprise, in silico analysis discovered a 
consensus nucleotide sequence shared by the ISRE motif and NF-κB DNA binding site. ChIP-seq data 
analysis reveals RelA (P65) can directly bind to the promoter region of a large cohort of ISGs. Our 
loss-of-function and mutagenesis assay further confirmed that NF-κB could directly drive ISRE-
controlled gene transcription. Since NF-κB is also the key downstream effector of most Toll-like 
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receptors (TLR), this novel mechanism may also partially explain the antiviral activities of TLR 
agonists in clinic, such as the TLR7 agonists, which are being therapeutically targeted and explored 
for HCV treatment in clinic trial [38]. 
More excitingly, TNF-α not only activates antiviral ISGs transcription, but also cooperates 
with IFN-α, explaining the additive antiviral outcome of their combination. This highlights the 
important facts that different cytokines orchestrate innate immune responses by activating signaling 
cascades to protect against infection efficiently. 
In conclusion, we revealed a novel antiviral mechanism of TNF-α. TNF-α, via the activation of 
NF-κB cascade, can drive the transcription of antiviral ISGs through direct binding of ISREs. This 
antiviral mechanism may provide clues for tackling the high rise of infections caused by TNF-α 
inhibitor treatment in patients. More interestingly, TNF-α also acts cooperatively with IFN-α in 
antiviral ISGs induction to exert additive antiviral effects. These findings not only provide new clues 
for understanding virus-host interactions but also assign a novel function of the canonical NF-κB 
pathway. 
Materials and Methods 
The HCV subgenomic replicon comprised Huh7 cells containing a subgenomic HCV bicistronic 
replicon (1389/NS3-3 V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene were maintained 
with 250 μg/mL G418 (Sigma, Zwijndrecht, the Netherlands). The HEV subgenomic model was based 
on Huh7 cells containing the subgenomic HEV sequence (Kernow-C1 p6/luc) coupled to a Gaussia 
luciferase reporter gene. Lentiviral pLK.O knockdown vectors (Sigma-Aldrich) targeting IRF1, TNFR1, 
RelA were obtained from the Erasmus Biomics Center and produced in HEK293T cells as previously 
described [39]. The use of serum samples from IBD patients was approved by the Medical Ethical 
Committee of the Erasmus Medical Center (Medisch Ethische Toetsings Commissie Erasmus MC), and 
the informed consent was obtained from all subjects. All methods were carried out in accordance 
with the approved guidelines. For more details, see Supplementary Information. 
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Supplementary Materials and Methods 
Reagents 
Recombinant human TNF-α (Peprotech, USA) and human IFN-α (Thermo Scientific, the Netherlands) 
was dissolved in PBS. Stocks of JAK inhibitor 1 (Santa Cruz Biotech, CA) and Bayer-18 (Synkinase, 
China) were dissolved in DMSO with a final concentration of 5 mg/mL. Antibodies phospho-STAT1 
(Tyr701) (58D6, #9167), STAT1 (#9172), RelA (P65) (C22B4, #4764), IRF1 (D5E4), IRF7 (D2A1J), Anti-
rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 conjugate) and Anti-mouse IgG (H+L), F(ab')2 
Fragment (Alexa Fluor® 488 Conjugate) were purchased from Cell Signaling Technology. IRF9 
antibody was obtained from LSBio (Life Span BioSciences, Inc.). β-actin, STAT2 (sc-476), phospho-
STAT2 (Tyr690) were purchased from Santa Cruz Biotechnology; anti-rabbit or anti-mouse IRDye-
conjugated antibodies were used as secondary antibodies for western blotting (Stressgen, Victoria, 
BC, Canada). 
Cell models 
The HCV subgenomic replicon comprised Huh7 cells containing a subgenomic HCV bicistronic 
replicon (1389/NS3-3V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene were maintained 
with 250 μg/mL G418 (Sigma, Zwijndrecht, the Netherlands). The HEV subgenomic model was based 
on Huh7 cells containing the subgenomic HEV sequence (Kernow-C1 p6/luc) coupled to a Gaussia 
luciferase reporter gene. Luciferase normalization cells (LV-PGK-Luc) were generated by transducing 
Huh7 cells with a lentiviral vector expressing the firefly luciferase gene under control of the human 
phosphoglycerate kinase (PGK) promoter. ISRE, NF-κB, AP-1 luciferase reporter cells were generated 
by transducing Huh7 cells with lentiviral vectors expressing the firefly luciferase gene under the 
control of the promoters containing the ISRE, NF-κB, AP-1 motifs, respectively (System Biosciences). 
Gene knockdown or overexpression by lentiviral vectors  
Lentiviral pLKO.1 knockdown vectors (Sigma-Aldrich) targeting IRF1, IRF7, STAT1, TNFR1, RelA (P65) 
were obtained from the Erasmus Biomics Center and produced in HEK293T cells. After a pilot study, 
the shRNA vectors exerting optimal gene knockdown were selected. Stable gene knockdown cells 
were generated after lentiviral vector transduction and puromycin (2 μg/mL; Sigma) selection. IRF1, 
IFI6 and DDX58 lentiviral overexpression vectors were a kind gift from Prof. Charles M. Rice, the 
Rockefeller University [23]. Meanwhile, two control vectors expressing reporter genes Photinus pyralis 
luciferase (Fluc) or Green fluorescent protein (GFP) were also used.  
Measurement of luciferase activity 
For Gaussia luciferase analysis, the activity of secreted luciferase in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs) according to the 
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manufacturer’s instructions. For firefly luciferase, luciferin potassium salt (100 mM; Sigma) was 
added to cells and incubated for 10 min at 37 °C The luciferase activity was quantified with a 
LumiStar Optima luminescence counter (BMG Lab Tech, Offenburg, Germany). 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was synthesized from total RNA 
using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA of all detected genes was amplified for 50 
cycles and quantified with a SYBR-Green-based real-time PCR (Applied Biosystems) according to the 
manufacturer’s instructions. GAPDH and RP2 were considered as reference genes to normalize gene 
expression. All the primer sequences are included in Supplemental Table 2. 
Western Blot Assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT and heated 5 mins at 95 °C, 
followed by loading onto a 10% sodium dodecyl sulfate polyacrylamide gel and separation by 
electrophoresis. After 90 mins running at 120 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride membrane (Invitrogen) for 1.5 hrs with an electric current of 250 mA. 
Subsequently, the membrane was blocked with a mixture of 2.5 mL blocking buffer (Odyssey) and 2.5 
mL phosphate-buffered saline containing 0.05% Tween 20. It was followed by overnight incubation 
with primary antibodies (1: 1 000) at 4 °C. The membrane was washed 3 times followed by 
incubation for 1 h with IRDye-conjugated secondary antibody (1: 5 000). After washing 3 times, 
protein bands were detected with the Odyssey 3.0 Infrared Imaging System. 
Enzyme-linked immunosorbent assay (ELISA) 
Serum samples were collected and stored at -80 °C. TNF-α level was measured by an ELISA kit 
(eBioscience, USA) according to manufacturer’s instructions. The absorbance was measured at 450 
nm in an automatic microplate reader. Results were calculated based on a standard curve. 
Confocal laser electroscope assay 
Huh7 cells were seeded on glass coverslips. After 12 hrs, cells were washed with PBS, fixed in 4% 
PBS-buffered formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 0.05% tween, 
5 g/L skim milk and 1.5 g/L glycine). Samples were incubated with primary antibodies overnight at 4 
°C. Subsequently, samples were incubated with 1:1 000 dilutions of the anti-mouse IgG (H+L), F(ab')2 
Fragment (Alexa Fluor® 488 Conjugate) or anti-rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 
conjugate) secondary antibodies. Nuclei were stained with DAPI (4, 6-diamidino-2-phenylindole; 
Invitrogen). Images were detected using confocal electroscope. 
ChIP-seq data analysis 
ChIP-seq datasets for STAT1 in Gm12878 cells and RelA in the TNFα stimulated Gm12878 cells were 
retrieved from the ENCODE database. ChIP-seq datasets were processed and mapped to hg38 
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reference genome as described [40]. ChIP-seq datasets with multiple replicates were merged. MACS 
1.4.2 was used for peak calling and for the generation of binding profiles [41]. MACS was run with -p 
1e-10, using the mock control of TNF-α stimulated cell as control dataset for both the STAT1 and 
RelA ChIP-seq. Heatmaps were generated based on a unified peak list. If the centers of two binding 
regions reported by MACS were 100 bp or less apart, they were unified to a single binding region. 
Heatmaps were normalized for each individual factor by calculating the RPM based on the sum of all 
reads displayed by the heatmap. RPM was log2 transformed and manhattan clustering was 
performed. The heatmap images were generated in R. The sequencing profiles were generated in the 
IGV browser [42]. 
Construction of mutant ISRE reporter cell line 
Based on the sequence specific ISRE motif, a mutant version of ISRE was designed and synthesized 
(Forward: 5’-
aattcAGTTTCGTCAAGTCTTTCAGTTTCGTCAAGTCTTTCAGTTTCGTCAAGTCTTTCAGTTTCGTCAAGTCTTTa-
3’; Reverse: 5’-
ctagtAAAGACTTGACGAAACTGAAAGACTTGACGAAACTGAAAGACTTGACGAAACTGAAAGACTTGACGAA
ACTg-3’), which shows no consensus sequence with the NF-κB motif. EcoRI and SpeI sites are 
included (shown in italics) to facilitate directional cloning into the pGreenFire Lenti-Reporter vector 
(System Biosciences). The recombinant plasmid was verified by restriction enzyme digestion and DNA 
sequencing. Stable mutant ISRE reporter cells were generated after lentiviral vector transduction and 
puromycin (2 μg/mL; Sigma) selection. 
Statistical analysis 
All results were presented as mean ± SD. Comparisons between groups were performed with Mann-
Whitney test. Differences were considered significant at a P value less than 0.05.  
Ethics Statement 
The use of serum samples from IBD patients was approved by the Medical Ethical Committee of the 
Erasmus Medical Center (Medisch Ethische Toetsings Commissie Erasmus MC). The volunteers or 
patients agreed to participate by written informed consent. 
Supplementary Data 
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Figure S1. TNF-α induced ISRE activation is independent of IRF7. (A) qRT-PCR analysis of successful IRF7 
knockdown by lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. (B) Western blot 
analysis confirmed the successful knockdown of IRF7 by lentiviral shRNA vectors in the Huh7 based ISRE 
luciferase reporter cells. (C) IRF7 knockdown had no significant influence on TNF-α induced ISRE-related 
luciferase activation as measured at 2 different time points (n = 3 independent experiments with 2 - 3 
replicates each). 
 
Figure S2. TNF-α induced ISRE 
activation is independent of 
interferon and the JAK-STAT 
signaling. (A) Illustration of key 
elements in IFN-α induced JAK-STAT 
signaling pathway. (B) The selective 
TYK2 inhibitor, Bayer-18, did not 
abrogate TNF-α induced ISRE-
related luciferase activation (n = 3 
independent experiments with 2- 3 
replicates each). (C) In Huh7 based 
ISRE luciferase cells, TYK2 selective 
inhibitor, Bayer-18, did not exert 
significant effect on IFN-α (1000 
IU/mL) induced ISRE-luciferase activity (left), while JAK inhibitor I (10 μM) abrogated IFN-α (1000 IU/mL) 
induced ISRE luciferase activity as measured at 24, 48 and 72 hrs (n = 3 independent experiments with 2 - 3 
replicates each). (D) JAK inhibitor I exerts no significant influence on TNF-α induced ISG expression as 
measured by qRT-PCR. (n = 4). 
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Figure S3. IFN-α induced ISRE activation depends on the 
JAK-STAT signaling. (A) In Huh7 cells, JAK inhibitor I (10 μM) 
abrogated IFN-α (1000 IU/mL) induced ISG expression as 
measured by qRT-PCR. (B) Confocal microscopy analysis of 
IRF9 localization in Huh7 cells treated with IFN-α or TNF-α. 
IRF9 was induced and translocated to the nucleus upon IFN-
α, but not TNF-α treatment. IRF9 antibody (green). Nuclei 
were visualized by DAPI (blue).  
 
 
 
 
 
 
 
 
 
Figure S4. TNF-α activates ISRE via TNF 
receptor. (A) TNFR1 knockdown blocked 
TNF-α induced ISG expression as measured 
by qRT-PCR (n = 4). (B) In A549 cells, TNF-α 
inhibitor, Humira, abrogated TNF-α induced 
ISG expression as measured by qRT-PCR (n = 
4). (C) Humira decreased serum samples 
(with higher TNF-α levels) induced ISRE-
related luciferase activity. (D) Serum 
samples with higher TNF-α levels inhibited 
HCV-related luciferase activity compared 
with control serum. 
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Figure S5. TNF-α efficiently activate NF-κB signaling pathway. (A) Illustration of key elements in TNF-αinduced 
NF-κB signaling pathway. (B) In the Huh7 cell-based NF-κB or AP1 luciferase reporter cells, TNF-α dose-
dependently induced activation of NF-κB-related luciferase activity, while no significant effect on AP1-related 
luciferase activity as measured at 3 different time points (n = 3 independent experiments with 2 - 3 replicates 
each). 
 
Figure S6. The nucleotide sequence of NF-κB, 
ISRE and the ISRE mutant binding regions.  
Their consensus nucleotides are labeled in red 
color, and the consensus region is marked in a 
rectangular box. The mutated nucleotides are 
shown in purple color. The ISRE (mutant) 
sequencing result is shown in the illustration 
below. 
 
 
 
 
 
 
 
Fig. S7. ISG, e.g. IRF1, IFI6 or DDX58 exerts strong antiviral 
effect against HCV. Huh7 cell based HCV replicon luciferase 
reporter was transduced with integrating lentiviral vectors to 
overexpress ISG, e.g. IRF1, IFI6 or DDX58, showing strong 
antiviral potency against HCV. 
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Abstract 
Interferon-stimulated genes (ISGs) are antiviral effectors that are efficiently induced by interferons 
(IFNs) via the formation of a tripartite transcription factor ISGF3 (IRF9, phosphorylated STAT1 and 
STAT2). However, we found that IFN-independent ISG expression was detectable in immortalized cell 
lines, primary intestinal and liver organoids, and liver tissues. We report that the constitutive 
expression of ISGs was mediated by the unphosphorylated ISGF3 (U-ISGF3) complex, which was 
formed by IRF9 together with unphosphorylated STAT1 and STAT2. Under homeostatic conditions, 
the nuclear localization of endogenous STAT1, STAT2, and IRF9 was observed. Analysis of a 
chromatin immunoprecipitation–sequencing (ChIP-seq) dataset revealed that STAT1 specifically 
bound to the promoters of ISGs even in the absence of IFNs. Knockdown of STAT1, STAT2, or IRF9 by 
RNA interference (RNAi) led to the decreased expression of a range of ISGs in Huh7.5 cells, which was 
confirmed in mouse embryonic fibroblasts (MEFs) from STAT1-/-, STAT2-/-, or IRF9-/- mice. 
Furthermore, decreased ISG expression was accompanied by the increased replication of hepatitis C 
virus (HCV) and hepatitis E virus (HEV). Conversely, simultaneous overexpression of all of the ISGF3 
components, but not any single factor, induced the expression of ISGs and inhibited viral replication. 
However, no phosphorylated STAT1 and STAT2 was detected. Substitution of wild-type STAT1 with a 
phosphorylation-deficient mutant had comparable effect on IFN-independent expression of ISGs or 
antiviral activity, suggesting that ISGF3 works in a phosphorylation-independent manner. These data 
suggest that the U-ISGF3 complex is both necessary and sufficient for constitutive ISG expression and 
antiviral immunity under homeostatic conditions. 
Keywords: U-ISGF3; HCV; HEV; basal ISG; transcription 
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Introduction 
Interferon-stimulated genes (ISGs) are hardwired within genomes and provide a robust first line of 
defense against invading pathogens. Canonically, following pathogen invasion and interferon (IFN) 
stimulation, IFN receptors respond with activation of the Janus kinases JAK1 and TYK2, which in turn 
phosphorylate tyrosine residues in the intracellular tail of the IFN receptors. Subsequently, STAT1 
and STAT2 are phosphorylated, which provokes dimerization and subsequent binding to interferon 
regulatory factor 9 (IRF9) to form the IFN-stimulated gene factor 3 (ISGF3) complex. The ISGF3 
complex translocates into the nucleus, and binds to specific promotor elements denoted as IFN-
stimulated response elements (ISREs), leading to the rapid transcriptional activation of hundreds of 
ISGs. This leads to an effective antiviral state against positive-, negative-, and double-stranded RNA 
viruses, DNA viruses, and intracellular bacteria and parasites [1]. Interestingly, an IFN regulated non-
canonical mechanism of ISG transcription was recently reported. When cells are continuously 
exposed to a low amount of exogenous interferon, unphosphorylated ISGF3 (U-ISGF3), formed by 
interferon induced IRF9 and unphosphorylated STAT1 and STAT2, leads to steady-state increased 
expression of a subset of ISGs [2].  
In the absence of interferon activation, constitutive ISG expression is also critical in 
determining cellular susceptibility to viral infection [3]. Inefficient replication of influenza A virus has 
been reported in human bronchial epithelial cells (BEAS-2B) with a higher expression level of basal 
ISGs, compared with other respiratory epithelial cell lines [4]. Similar observation was reported with 
regard to reovirus replication in cardiac myocytes [5, 6]. Conversely, abnormal regulation of basal ISG 
expression is associated with adverse consequences in patients. Patients with chronic hepatitis C 
virus (HCV) infection who have abnormally high levels of basal ISG expression in the liver are prone 
to poor sustained virologic response (SVR) to pegylated IFN-α and ribavirin therapy [7, 8]. Abnormally 
high expression levels of basal ISGs have been reported to promote tumor growth, and confer 
resistance to chemotherapy and radiotherapy [9, 10]. Thus, the question as to the mechanisms 
maintaining and determining the level of constitutive ISG expression is of utmost importance. 
Here, we report that under homeostatic status, nuclear localization of endogenous STAT1, 
STAT2 and IRF9 were observed in cell lines, 3-D cultured primary intestinal and liver organoids, and 
liver tissues. In the absence of interferons, constitutive ISG expression is mediated by endogenous U-
ISGF3 complex, formed by IRF9, and unphosphorylated STAT1 and STAT2. This process is totally 
independent of IFN production and the upstream elements of IFN signaling, but effectively confers 
resistance of host cells to HCV and HEV infections. Thus, the endogenous U-ISGF3 complex is both 
necessary and sufficient for sustaining constitutive ISG transcription and antiviral immunity in host 
cells under homeostatic condition. 
Results 
Constitutive ISG transcription is independent of IFN production 
The profile of constitutive ISG expression in human liver tissue, 3D-cultured primary human liver and 
intestinal organoids (fig. S1A), and three different cell lines (Huh7.5, Caco2, and A549) was quantified 
by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis. ISG expression 
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was readily detectable in all tested models under homeostatic conditions (Fig. 1, A and B). This 
finding was further confirmed by the quantification of the gene copy numbers of four representative 
ISGs, as normalized to the corresponding plasmid template using a standard curve calculation 
method (Fig. 1C and fig. S1B). 
The classical role of IFN in the induction of ISG expression prompted us to investigate the 
potential involvement of IFN in our system. Thus, we collected conditioned medium from these 
cultured cells (after 48 hours) and added to a transcriptional reporter system that mimics IFN 
response with a luciferase reporter gene that was driven by multiple ISREs (ISRE-Luc). Cell culture 
medium from all three cell lines failed to stimulate any response in the ISRE-luc model(Fig. 1D). 
Consistently, the conditioned medium failed to stimulate ISG expression in Huh7.5 cells (fig. S1C). In 
addition, conditioned culture medium was also used to perform a functional assay on the IFN 
sensitive HCV-replicon model, Huh7.5-HCV-luc; however, we found that the culture media did not 
affect HCV replication (Fig. 1E). JAK1 is the key upstream component that drives the activation of IFN 
signaling. IFN-α-stimulated STAT1 phosphorylation and ISG expression were blocked by a 
pharmacological JAK inhibitor, JAK inhibitor I (fig. S2, A and B). However, JAK inhibitor I did not 
decrease constitutive ISG expression in Huh7.5, Caco2, or A549 cells (Fig. 1F and fig. S2, C and D). 
Together, these data suggest that constitutive ISG expression is independent of IFN production. 
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Figure 1. Cell sustains basal ISG transcription independent of interferon production. (A and B) Total RNA was 
extracted from human liver tissue samples, primary human liver organoids, human intestinal organoids (A), and 
from Huh7.5 cells, A549 cells, and Caco2 cells (B). The relative abundances of mRNAs of the indicated ISGs were 
quantified by qRT-PCR. Human liver organoids, intestinal organoids, Huh7.5 cells, A549 cells, and Caco2 cells 
treated for 24 hours with IFN-α (1000 IU/ml) served as the positive controls for ISG expression. GAPDH was 
used as reference gene. Data are means ± SEM from three independent experiments. (C) The gene copy 
numbers of the four indicated ISGs were quantified relative to the appropriate plasmid templates using a 
standard curve calculation method. Data are means ± SEM from  three independent experiments. (D) Huh7.5-
ISRE-luccells were left untreated or were treated for 24 hours with conditioned medium from Huh7.5, Caco2, 
or A549 cells or with IFN-α (10 IU/ml) as a positive control. ISRE luciferase values were then measured and the 
fold-increase in activity relative to that of untreated cells was determined. Data are means ± SEM from three 
independent experiments. (E) HCV viral replication-related firefly luciferase activity was measured upon the 
treatment of Huh7.5-HCV-luc cells with conditioned medium from Huh7.5, Caco2, or A549 cells. As a positive 
control, the cells were treated with the indicated range of concentrations of IFN-α. Data are means ± SEM from 
three independent experiments. (F) Huh7.5 cells were treated with vehicle (CTR) or with 5 µM JAK inhibitor I 
for 24 hours before being subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. 
Data are means ± SEM of four independent experiments. *P < 0.05; **P < 0.01; ns, not significant. 
STAT1, STAT2, and IRF9 are required for constitutive ISG transcription and 
they constrain HCV and HEV replication 
Upon IFN stimulation, STAT1 is a vital transcription factor to drive ISG transcription. Thus, we first 
examined the role of STAT1 in basal ISG transcription under homeostatic conditions. Because nuclear 
localization is a primary determinant for the transcriptional function of STAT1, we investigated the 
cellular location of endogenous STAT1. We found that the staining of endogenous STAT1 protein in 
both cytoplasm and nucleus was apparent. in human and mouse liver tissue samples as determined 
by immunohistochemistry (IHC) (Fig. 2A). Consistently, the cellular localization of STAT1 was similar 
in primary human liver and intestinal organoids and in three different cell lines (Fig. 2, B to E, fig. S3, 
A and B). To investigate whether STAT1 in the cell nucleus could bind to the promoter regions of 
ISGs, we retrieved genome-wide STAT1 ChIP-seq data (GSE31477) from the ENCODE ChIP-seq 
Experiment Matrix database and Gene Expression Omnibus [11]. The STAT1 ChIP-seq datasets were 
then processed and analyzed. Even without IFN stimulation, STAT1 showed specific binding peaks on 
the promoter regions of a large cohort of ISGs (186 out of 350 ISGs analyzed), including IRF1, IRF9, 
STAT1, and ISG15 (Fig. 2F), whereas rabbit immunoglobulin G (IgG, which was the negative control) 
showed no specific binding peak. 
To further investigate the role of STAT1 in basal ISG expression, Huh7.5 cells were 
transduced with an integrating lentiviral vector expressing STAT1-specific short hairpin RNA (shRNA), 
which resulted in a marked decrease in STAT1 abundance (Fig. 3A). Knockdown of endogenous STAT1 
led to the decreased expression of 13 out of 14 tested ISGs, with inhibitory efficiency ranging from 30 
to 90% (Fig. 3B). In addition, we performed experiments with mouse embryonic fibroblasts (MEFs) 
from wild-type (WT) and STAT1-/- mice to examine the effect of STAT1 on ISG expression (Fig. 3, C and 
D). We found that the abundances of ISG mRNAs were reduced in STAT1-/- MEFs compared to those 
in WT MEFs (Fig. 3E). Furthermore, shRNA mediated STAT1 knockdown increased viral replication of 
HCV (2.2-fold) (Fig. 3F) and HEV (1.7-fold) (Fig. 3G) compared to its shRNA control in Huh7.5-based 
HCV-luc and HEV-luc models. In contrast, over-expression of STAT1 did not substantially affect ISG 
expression or viral replication (Fig. 3, H to J), suggesting that STAT1, although important for such 
responses, does not work alone. 
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Figure 2. A substantial fraction of endogenous STAT1 is localized in the nucleus and binds to ISG promoters 
under homeostatic conditions. (A) Representative immunohistochemical staining analysis of the cellular 
localization of endogenous STAT1 in cells in human (top) and mouse (bottom) liver sections. As a negative 
control (CTR), primary antibody against STAT1 was replaced with PBS containing 0.05% Tween. Images are 
representative of three independent experiments. (B to D) Confocal laser electroscope  analysis of endogenous 
STAT1 localization in human liver organoids (B), human intestinal organoids (C), and Huh7.5 cells (D). STAT1 is 
shown in green in organoids and in red in Huh7.5 cells. Nuclei were visualized by DAPI (blue). As a negative 
control (CTR), primary antibody against STAT1 was replaced with PBS containing 0.05% Tween. Images are 
representative of multiple organoids or cells from three independent experiments. (E) Huh7.5 cell lysates were 
fractionated into cytoplasmic (Cy) and nuclear (Nu) fractions and then were analyzed by Western blotting with 
antibodies against the indicated proteins. Cyclophilin A and Lamin A/C were used as cytosolic and nuclear 
markers, respectively. Western blots are representative of three independent experiments. (F) The ChIP-seq 
dataset for STAT1 (GSE31477) was retrieved from the ENCODE database. Binding profiles of endogenous STAT1 
to the promoter regions of the indicated ISGs. Sequence reads from anti-STAT1 antibody or rabbit-IgG-control 
ChIP-seq data were plotted relative to chromosomal position. The genome locations of the corresponding ISGs 
are shown beneath the track signaling. 
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Next, we examined the involvement of STAT2. Under homeostatic conditions, STAT2 was 
abundantly present in both the cytoplasm and nuclei of human liver tissue, human liver organoids, 
human intestinal organoids, and cell lines (Fig. 4, A to D). Furthermore, knockdown of STAT2 by 
lentiviral shRNA (Fig. 4E) led to the decreased expression of ISGs (10 out of 12 tested ISGs), ranging 
from a 30 to 70% decrease (Fig. 4F). MEFs from STAT2-/- mice (Fig. 4G) had reduced amounts of many 
ISG mRNAs compared to those in WT MEFs (Fig. 4H). ShRNA mediated STAT2 knockdown increased 
replication of HCV (1.5-fold) (Fig. 4I) and HEV (1.6-fold) (Fig. 4J) compared to its shRNA control in 
Huh7.5-based HCV-luc and HEV-luc models. However, overexpression of STAT2 did not affect either 
ISG expression or viral replication (Fig. 4, K to M), mirroring the results obtained from experiments 
with overexpressed STAT1. 
Finally, the role of IRF9 was also investigated. Substantial nuclear localization of IRF9 was 
observed in human and mouse liver tissues (Fig. 5A), human liver organoids (Fig. 5B), human 
intestinal organoids (Fig. 5C), and Huh7.5 cells (Fig. 5D). Knockdown of endogenous IRF9 by lentiviral 
vector based IRF9-specific shRNA (Fig. 5E) resulted in decreased ISG expression in Huh7.5 cells (Fig. 
5F). Consistently, compared with WT MEFs, IRF9-/- MEFs (Fig. 5G) had reduced amounts of ISG 
mRNAs under homeostatic conditions (Fig. 5H). ShRNA mediated IRF9 knockdown  increased 
replication of both HCV (3.8-fold) (Fig. 5I) and HEV (1.8-fold) (Fig. 5J) compared to its shRNA control 
in Huh7.5-based HCV-luc and HEV-luc models. Over-expression of IRF9 in Huh7.5 cells had no effect 
on ISG expression (Fig. 5K). Whereas overexpression of IRF9 in these cells inhibited HCV replication 
(Fig. 5L), it had no effect on HEV replication (Fig. 5M). The idea that the reduced replication of HCV 
was ISG-independent was supported by the observation that over-expression of IRF9 in Caco2 cells 
had no substantial effect on either ISG expression or rotavirus replication (fig. S3, C and D). Together, 
these results suggest that STAT1, STAT2, and IRF9 are all required and likely cooperate to regulate 
the basal expression of ISGs. 
 
Chapter 6 
83 | P a g e  
 
Figure 3. STAT1 is required for sustaining the basal expression of ISGs and constraining viral replication. (A) 
Huh7.5 cells were transduced with lentiviruses expressing control shRNA (shCTR) or three different STAT1-
targeting shRNAs. After the puromycin selection for two weeks, cells were analyzed by Western blotting with 
antibodies against the indicated proteins. Western blots are representative of three independent experiments. 
(B) Huh7.5 cells expressing control shRNA or the indicated STAT1-specific shRNAs were analyzed by qRT-PCR to 
determine the relative abundances of the indicated mRNAs. Data are means ± SEM of four independent 
experiments. (C) WT and STAT1-/- MEFs were analyzed by qRT-PCR to determine the relative abundance of 
STAT1 mRNA. Data are means ± SEM of four independent experiments. (D) WT and STAT1-/- MEFs were 
analyzed by Western blotting with antibodies against the indicated proteins. Western blots are representative 
of three independent experiments. (E) WT and STAT1-/- MEFs were subjected to qRT-PCR analysis of the 
relative abundance of the indicated mRNAs. Data are means ± SEM of three independent experiments. (F)  HCV 
replicon positive Huh7.5 cells were transduced with lentiviruses expressing control or STAT1-specific shRNAs 
before being subjected to a HCV replication–related luciferase activity. Data are means ± SEM of three 
independent experiments. (G) HEV replicon positive Huh7.5 cells were transduced with lentiviruses expressing 
control or STAT1-specific shRNAs before being subjected to a HEV replication–related luciferase activity. Data 
are means ± SEM of three independent experiments. (H) Huh7.5 cells transduced with lentivirus expressing 
control or STAT1-specific shRNA were subjected to qRT-PCR analysis of the relative abundances of the 
indicated mRNAs. Data are means ± SEM of three independent experiments. (I and J) HCV replicon positive (I) 
and HEV replicon positive (J) Huh7.5 cells transduced with control lentivirus or with lentivirus expressing STAT1 
were subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM 
of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
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Figure 4. STAT2 is essential for sustaining the basal expression of ISGs and constraining viral replication. (A) 
Immunohistochemical staining of the cellular localization of endogenous STAT2 in cells from human liver tissue. 
As a negative control, primary antibody against STAT2 was replaced with PBS containing 0.05% Tween. Images 
are representative of three independent experiments. (B to D) Confocal laser electroscope analysis of the 
cellular localization of endogenous STAT2 in human liver organoids (B), human intestinal organoids (C), and 
Huh7.5 cells (D). STAT2 antibody staining is shown in green, whereas nuclei were visualized by DAPI (blue). As a 
negative control, primary antibody against STAT2 was replaced with PBS containing 0.05% Tween. Images are 
representative of multiple organoids or cells from three independent experiments. (E) Huh7.5 cells transduced 
with lentiviruses expressing control shRNA or the indicated STAT2-specific shRNAs were analyzed by Western 
blotting with antibodies against the indicated proteins. Western blots are representative of three independent 
experiments. (F) Huh7.5 cells expressing control shRNA or the indicated STAT2-specific shRNAs were analyzed 
by qRT-PCR to determine the relative abundances of the indicated mRNAs. Data are means ± SEM of four 
independent experiments. (G) WT and STAT2-/- MEFs were analyzed by Western blotting with antibodies 
against the indicated proteins. Western blots are representative of three independent experiments. (H) WT 
and STAT2-/- MEFs were subjected to qRT-PCR analysis of the relative abundance of the indicated mRNAs. Data 
are means ± SEM of three independent experiments. (I and J) HCV replicon positive (I) and HEV replicon 
positive (J) Huh7.5 cells were transduced with lentiviruses expressing control or STAT2-specific shRNAs before 
being subjected to assays of viral replication–related luciferase activity. Data are means ± SEM of three 
independent experiments. (K) Huh7.5 cells transduced with control lentivirus or with lentivirus expressing 
STAT2 were subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means 
± SEM of three independent experiments. (L and M) HCV-positive (L) and HEV-positive (M) Huh7.5 cells 
transduced with control lentivirus or with lentivirus expressing STAT2 were subjected to qRT-PCR analysis of 
the relative abundances of the indicated mRNAs. Data are means ± SEM of three independent experiments. *P 
< 0.05; **P < 0.01; ns, not significant. 
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STAT1, STAT2, and IRF9 function as the U-ISGF3 complex to drive ISG 
expression and exert antiviral effects against HCV and HEV 
Because STAT1, STAT2, and IRF9 alone were all necessary, but not sufficient, to drive constitutive ISG 
expression, we investigated whether these three factors in combination functioned as the ISGF3 
complex independently of activation by exogenous IFN. Thus, we over-expressed STAT1, STAT2, and 
IRF9 in Huh7.5 cells through lentiviral transduction (Fig. 6 A), which led to a substantial antiviral 
effect and induction of ISG expression (Fig. 6, B to D), as compared to the over-expression of any one 
of the three factors alone. These data suggest that the integrity of the ISGF3 complex is necessary for 
these effects. 
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Figure 5. IRF9 is also required for the basal expression of ISGs and for limiting viral replication. (A) 
Immunohistochemical staining of the cellular localization of endogenous IRF9 in cells from human (top) and 
mouse (bottom) liver tissue. As a negative control, primary antibody against IRF9 was replaced with PBS 
containing 0.05% Tween. Images are representative of three independent experiments. (B to D) Confocal laser 
electroscope analysis of the cellular localization of endogenous IRF9 in human liver organoids (B), human 
intestinal organoids (C), and Huh7.5 cells (D). IRF9 antibody staining is shown in green, whereas nuclei were 
visualized by DAPI (blue). As a negative control, primary antibody against IRF9 was replaced with PBS 
containing 0.05% Tween. Images are representative of multiple organoids or cells from three independent 
experiments. (E) Huh7.5 cells transduced with lentiviruses expressing control shRNA or IRF9-specific shRNAs 
were analyzed by Western blotting with antibodies against the indicated proteins. Western blots are 
representative of three independent experiments. (F) Huh7.5 cells expressing control shRNA or IRF9-specific 
shRNAs were analyzed by qRT-PCR to determine the relative abundances of the indicated mRNAs. Data are 
means ± SEM of four independent experiments. (G) WT and IRF9-/- MEFs were analyzed by Western blotting 
with antibodies against the indicated proteins. Western blots are representative of three independent 
experiments. (H) WT and IRF9-/- MEFs were subjected to qRT-PCR analysis of the relative abundance of the 
indicated mRNAs. Data are means ± SEM of three independent experiments. (I and J) HCV-positive (I) and HEV-
positive (J) Huh7.5 cells were transduced with lentiviruses expressing control or IRF9-specific shRNAs before 
being subjected to assays of viral replication–related luciferase activity. Data are means ± SEM of three 
independent experiments. (K) Huh7.5 cells transduced with control lentivirus or with lentivirus expressing IRF9 
were subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM 
of three independent experiments. (L and M) HCV-positive (L) and HEV-positive (M) Huh7.5 cells transduced 
with control lentivirus or with lentivirus expressing IRF9 were subjected to qRT-PCR analysis of the relative 
abundances of the indicated mRNAs. Data are means ± SEM of three independent experiments. *P < 0.05; **P 
< 0.01; ns, not significant. 
 
To rule out any interference by endogenous WT STAT1 or STAT2 (should any be present in 
the cells) and to further confirm the role of ISGF3, we overexpressed STAT1, STAT2, and IRF9 in U3A 
cells (which are STAT1-deficient) and U6A cells (which are STAT2-deficient) (fig. S4, A to D) [12], which 
led to a substantial induction of ISG expression in both cell types (fig. S4, B and D), mirroring the 
results observed in Huh7.5 cells. STAT1 phosphorylated at Tyr701 (pSTAT1-Tyr701) and STAT2 
phosphorylated at Tyr690 (pSTAT2-Tyr690) were undetectable even when either protein was 
overexpressed (Fig. 6A), which suggests that ISGF3 complex occurs through a phosphorylation-
independent mechanism. Indeed, no pSTAT1-Tyr701 or pSTAT2-Tyr690 was detected in either human or 
mouse liver tissue samples by IHC (Fig. 6E and fig. S4E) or in three individual liver tissue samples that 
were examined by Western blotting (Fig. 6F). The same observation was also made by examining 
human liver organoids (Fig. 6G), intestinal organoids (fig. S4, F to H), and Huh7.5 cells (Fig. 6H). 
Furthermore, overexpression of a mutant STAT1 (Y701F-STAT1), which cannot be phosphorylated at 
Tyr701 [13], together with STAT2 and IRF9 in Huh7.5 cells led to a comparable potency of antiviral 
effect and ISG induction (Fig. 6, I to K). This was further confirmed in U3A cells (fig. S4, I and J).  
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In addition to the tyrosine phosphorylation sites in STAT1 and STAT2, phosphorylation of the 
sites Ser708 and Ser727 in STAT1 correlates with ISG expression [14, 15]. However, we were unable to 
detect pSTAT1-Ser727 in either Huh7.5 cells (fig. S4K) or human liver tissue samples (fig. S4L). 
Generally, STAT1 or STAT2 is phosphorylated by specific kinases upon cellular stimulation (for 
example, by IFNs). Furthermore, pSTAT1 and pSTAT2 proteins undergo dephosphorylation. Thus, the 
phosphorylation and dephosphorylation processes are coordinated to maintain the phosphorylation 
states of these proteins to an extent that achieves a balance between their beneficial, antiviral 
actions and their detrimental, proinflammatory effects. Consequently, the inhibition of phosphatases 
would alter this balance, resulting in increased amounts of pSTAT1 and pSTAT2 and to the greater 
induction of ISG expression (fig. S5A) [16]. Thus, we performed experiments with the phosphatase 
inhibitor NSC87877 (which has IC50 values of 0.318 μM for SHP-2, 0.355 μM for 
SHP-1, and 1.691 μM for PTP1B) to specifically inhibit the key phosphatases involved in 
pSTAT1 and pSTAT2 dephosphorylation at both tyrosines and serines [16-18]. However, we found that 
NSC87877 had no effect on basal ISG expression in either Huh7.5 cells or Caco2 cells (Fig. 7A and fig. 
S5B). NSC87877 also had no effect on ISG expression induced by the simultaneous over-expression of 
STAT1, STAT2, and IRF9 (Fig. 7B). Together, these data suggest that STAT1, STAT2, and IRF9 function 
as part of U-ISGF3 to drive ISG expression, which leads to antiviral effects. 
The basal expression of particular ISGs is enhanced in chemotherapy-resistant cancer cells 
and in chronic HCV patients who are resistant to IFN therapy; however, under these conditions, 
pSTAT1 is almost undetectable [2, 19]. Thus, we overexpressed Y701F-STAT1, STAT2, and IRF9 together 
in Huh7.5 cells and examined the basal expression of several ISGs that were previously identified as 
potential makers to predict responsiveness to IFN therapy in patients chronically infected with HCV [7, 
8]. As expected, the expression of all of these ISGs was increased upon overexpression of the 
components of the U-ISGF3 (fig. S5C). Note that IFNs stimulate the expression of antiviral ISGs and of 
negative regulatory ISGs to avoid excessive IFN responses [20]. We found that the expression of four 
of five of these negative regulatory ISGs was also enhanced upon overexpression of U-ISGF3 (fig. 
S5D). 
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Figure 6. U-ISGF3 stimulates the expression of ISGs and constrains viral replication. Huh7.5 cells were 
transduced with control lentivirus (C) or with lentiviruses expressing the indicated proteins before being 
subjected to Western blotting analysis with antibodies against the indicated proteins. As a positive control for 
the detection of pSTAT1 and pSTAT2, Huh7.5 cells were treated with IFN-α for 30min. Western blots are 
representative of three independent experiments. (B and C) HCV-positive (B) and HEV-positive (C) Huh7.5 cells 
were transduced with control lentivirus or with lentiviruses expressing the indicated proteins before being 
subjected to assays of viral replication–related luciferase activity. Data are means ± SEM of three independent 
experiments. (D) Huh7.5 cells were transduced with control lentivirus or with lentiviruses expressing the 
indicated proteins before being subjected to qRT-PCR analysis of the relative abundances of the indicated 
mRNAs. Data are means ± SEM of three independent experiments. (E) Representative immunohistochemical 
analysis of pSTAT1-Tyr701 and pSTAT2-Tyr690 in human liver tissue samples. Neither protein was detected. As 
negative controls (CTR), the primary antibodies were replaced with PBS containing 0.05% Tween. (F) Samples 
from three individual human liver samples were analyzed by Western blotting with antibodies against the 
indicated proteins. As a positive control for pSTAT proteins, Huh7.5 cells were treated with IFN-α for 30 min. 
Western blots are representative of three independent experiments. (G and H) Confocal laser electroscope 
analysis of pSTAT1-Tyr701 (top) and pSTAT2-Tyr690 (bottom) in human liver organoids (G) and Huh7.5 cells (H). 
The pSTAT1 and pSTAT2 proteins are shown in green, whereas nuclei were visualized by DAPI (blue). Human 
liver organoids or Huh7.5 cells treated with IFN-α for 30 min served as the corresponding positive controls. 
Images are representative of multiple organoids or cells from three individual experiments. (I and J) HCV-
positive (I) and HEV-positive (J) Huh7.5 cells transduced with control lentivirus or lentiviruses expressing WT or 
Y701F mutant STAT1 together with STAT2 and IRF9 were subjected to assays of viral replication–related 
luciferase activity. Data are means ± SEM of three independent experiments. (K) Huh7.5 cells transduced with 
control lentivirus or lentiviruses expressing WT or Y701F mutant STAT1 together with STAT2 and IRF9 were 
subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are means ± SEM of 
three independent experiments. *P < 0.05; **P < 0.01; ns, not significant. 
U-ISGF3 drives ISG transcription without stimulating IFN production 
To further dissect whether the U-ISGF3–induced expression of ISGs was independent of IFN 
production, we measured the basal abundances of mRNAs of several IFNs, including IFNA, IFNB, IFNG, 
IL29, and IL28A (fig. S5E). The abundances of IFNA and IFNBmRNAs were not statistically significantly 
increased by the overexpression of STAT1, STAT2, or IRF9 alone or in combination (Fig. 7, C and D), 
whereas the mRNAs encoding IFNG, IL29, and IL28A were undetectable with or without 
overexpression of the U-ISGF3 components (fig. S5E). To further confirm the lack of IFN production, 
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we collected the conditioned medium of these cells (fig. S5F) and performed functional assays. 
Conditioned culture medium from any of the overexpressing Huh7.5 cells was unable to stimulate an 
IFN response in an ISRE reporter assay (fig. 7E). Consistently, treatment of Huh7.5 cells with these 
conditioned media had no effect on ISG expression (fig. S5G). These data suggest that the U-ISGF3–
induced expression of ISGs is IFN-independent. 
U-ISGF3 drives ISG expression independently of the upstream components of 
the IFN signaling pathway 
IFNs are mainly produced by so-called IFN-producing cells (IPCs). In our study, we included three 
types of well-known IPCs, human plasmacytoid dendritic cells (pDCs), myeloid dendritic cells (mDCs), 
and T cells to demonstrate the classical IFN-dependent mechanisms of ISG transcription and antiviral 
action. As expected, these IPCs produced IFNs to activate the JAK-STAT pathway, drive ISG 
transcription, and exert antiviral activity. These effects were specifically blocked by JAK inhibitor I (fig. 
S6). Therefore, upon IFN stimulation, the intact JAK-STAT signaling pathway is a prerequisite for the 
formation of its downstream transcription factor complex, ISGF3, which drives the expression of ISGs 
(fig. S7A). To dissect the involvement of its upstream elements in basal ISG transcription, we knocked 
down either IFN-αR1 or IFN-λR1 in Huh7.5 cells by lentiviral shRNA (Fig. 7F). Efficient knockdown of 
IFN-αR1 or IFN-λR1 had no effect on constitutive ISG expression (Fig. 7G). In addition, knockdown of 
endogenous JAK1 in Huh7.5 cells (Fig. 7, H and I) did not inhibit the constitutive expression of ISGs 
(Fig. 7J). This finding was further confirmed in experiments with Caco2 cells (fig. S7, B to D). 
Conversely, collective overexpression of STAT1, STAT2, and IRF9 by lentiviral transduction in IFN-αR1-, 
IFN-λR1-, or JAK1-knockdown Huh7.5 cells showed comparable ISG induction ability compared with 
control lentiviral vector (Fig. 7K). These results suggest that U-ISGF3 drives the basal expression of 
ISGs independently of the upstream elements of the IFN signaling pathway. 
Discussion  
ISGs are the ultimate antiviral effectors of the IFN signaling. They function either by targeting 
different steps of the viral life cycle or by reinforcing host defense by further activation of ISG 
expression [1, 21]. Classically, upon IFN stimulation, STAT1 and STAT2 are phosphorylated, leading to 
the association with IRF9 to form the transcription factor complex ISGF3. Phosphorylated ISGF3 
translocates into cell nucleus and binds to the promoter regions of ISGs to activate the transcription 
of these hundreds of ISGs. However, when cells are continuously exposed to a low level of 
exogenous interferon, unphosphorylated ISGF3 (U-ISGF3), formed by interferon stimulated IRF9 and 
unphosphorylated STAT1 and STAT2, can also lead to increased expression of a subset of ISGs [2]. 
Importantly, both regulatory mechanisms require the activation by IFN. 
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Figure 7. U-ISGF3 stimulates the expression of ISGs independently of IFN production and the upstream 
elements of the IFN signaling pathway. (A) Huh7.5 cells were left untreated (CTR) or were treated with 5 μΜ 
NSC87877 (phosphatase inhibitor) before the cells were subjected to qRT-PCR analysis of the relative 
abundances of the indicated mRNAs. Data are means ± SEM of three independent experiments. (B to D) 
Huh7.5 cells were transduced with control lentivirus or with lentiviruses expressing STAT1, STAT2, and IRF9, 
individually or in combination, before being treated with vehicle or NSC87877. The cells were then subjected to 
qRT-PCR analysis of the relative abundances of the indicated mRNAs for ISGs (B), IFNA (C), and IFNB (D). Data 
are means ± SEM of three independent experiments. (E) Huh7.5 cells transduced with lentiviruses expressing 
the indicated proteins were cultured for 48 hours before the cell culture medium was collected and used to 
treat an ISRE luciferase reporter cell line. As a positive control, culture medium was collected from cells treated 
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with IFN-α (10 IU/ml). Data are means ± SEM of three independent experiments. (F) Huh7.5 cells transduced 
with lentiviruses expressing control shRNA, IFNAR1-specific shRNA, or IFNLR1-specific shRNA were analyzed by 
qRT-PCR to determine the extent of knockdown of the indicated mRNAs. Data are means ± SEM of three 
independent experiments. (G) Huh7.5 cells transduced with lentiviruses expressing control shRNA, IFNAR1-
specific shRNA, or IFNLR1-specific shRNA were analyzed by qRT-PCR to determine the relative abundances of 
the indicated mRNAs. Data are means ± SEM of three independent experiments. (H and I) Huh7.5 cells 
transduced with lentiviruses expressing control or JAK1-specific shRNAs were analyzed by qRT-PCR to 
determine the extent of knockdown of JAK1 mRNA (H) or by Western blotting with antibodies against the 
indicated proteins (I). Data in (H) are means ± SEM of three independent experiments. Western blots are 
representative of three independent experiments. (J) Huh7.5 cells transduced with lentiviruses expressing 
control or JAK1-specific shRNAs were analyzed by qRT-PCR to determine the relative abundances of the 
indicated mRNAs. Data are means ± SEM of three independent experiments. (K) Huh7.5 cells were transduced 
with lentiviruses expressing control shRNA or shRNAs specific for JAK1, IFNAR, or IFNLR. After the puromycin 
selection, they were not (-) or were (+) transduced with lentiviruses expressing STAT1, STAT2, and IRF9. The 
cells were then subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs. Data are 
means ± SEM of three independent experiments.  *P < 0.05; **P < 0.01; ns, not significant. (L) Illustration of the 
mechanism of basal expression of ISGs under homeostatic conditions. Unphosphorylated STAT1, STAT2, and 
IRF9 shuttle between the cytoplasm and the nucleus. When these three components are present in the 
nucleus, they function as the constitutively active transcription factor complex U-ISGF3 to sustain the basal 
expression of ISGs. The products of these expressed ISGs confer protection to the cell from viral infection. 
 
Classically, IFNs are mainly produced by so-called IFN-producing cells (IPCs) These IPCs 
produced IFNs to activate the JAK-STAT pathway, drive ISG transcription, and exert antiviral activity. 
Huh7.5Huh7.5Here, we highlighted the existence of an IFN-independent mechanism that sustains 
the constitutive expression of IFN-encoding genes. We found that constitutive ISG expression was 
mediated by the endogenous U-ISGF3 complex. This regulatory mechanism was independent of IFN 
production and the upstream elements of IFN signaling, but conferred the cells with resistance 
against viral infections (Fig. 7L). Thus, these data suggest that both IFN-dependent and -independent 
antiviral mechanisms co-exist and work cooperatively.  
As a critical element in determining cellular susceptibility to viral infection, constitutively 
expressed ISGs also determine the rapid response and intensity of cellular antiviral activity. Because 
many ISGs are key components of antiviral pathways, their basal expression is necessary for the 
quick activation of these signaling pathways upon ligand engagement. Taking the JAK-STAT pathway 
as a typical example, because the key components of this cascade are present in the cell under 
homeostatic conditions, the synthesis of new protein components of this pathway in response to 
stimulation with IFN is not required. Therefore, activation of this signaling pathway can rapidly occur, 
resulting in a timely and effective way of controlling invading pathogens. Furthermore, most of the 
necessary components of the JAK-STAT pathway are encoded by ISGs. 
In particular circumstances, deficiency of a single ISG can lead to compromised immunity 
following virus infection. Mice genetically deficient for STAT1, STAT2 or IRF9 developed persistent 
virus infection or even lethal disease in response to virus invasion, including those provoked by 
choriomeningitis virus, respiratory syndrome coronavirus and vesicular stomatitis virus [22-25]. In 
contrast, cells maintaining relatively higher levels of baseline ISGs show stronger resistance against 
virus infection. Nevertheless, the abnormal regulation of constitutive ISG expression is closely 
associated with treatment outcome in cancer or chronic HCV patients. Chronic hepatitis C patients 
with abnormally high levels of ISG expression in the liver at baseline poorly respond to pegylated IFN-
α/ribavirin therapy [7, 8]. In cancer patients, abnormally high expression of ISGs promotes tumor 
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growth, metastasis, and confers resistance to chemotherapy and radiation [9, 10]. Thus, constitutive 
ISGs at requisite levels are vital to prepare the host cells into a “combat ready” or “pre-arming” 
mode, but also determine the treatment responses in particular diseases in patients. In conclusion, 
we have demonstrated that endogenous U-ISGF3 function as the constitutive transcription factor to 
sustain basal ISG transcription, conferring cell resistance against virus infection. In contrast, the 
absence of U-ISGF3 can lead to decreased ISG expression at baseline, being susceptible to virus 
infection.  
Supplementary Materials and Methods 
Study approval 
The animal study was approved by the institutional animal ethics committee (Dier Experimenten 
Commissie). Human intestinal or liver tissues were obtained from patients during surgical resection. 
The patients agreed to participate by written informed consent, and the study was approved by the 
Medical Ethical Committee of the Erasmus Medical Center (Medisch Ethische Toetsings Commissie 
Erasmus MC). 
Reagents 
Human IFN-α (Thermo Scientific) was dissolved in phosphate-buffered saline (PBS) before use. 
Antibody against pSTAT1-Tyr701 (58D6; rabbit monoclonal; #9167) was obtained from Cell Signaling 
Technology. Antibodies against STAT1 (rabbit polyclonal; sc-592), STAT2 (rabbit polyclonal; SC-476), 
pSTAT2-Tyr690 (rabbit polyclonal; sc-21689-R), pSTAT1-Ser727 (rabbit polyclonal; sc-16570-R), ISGF-3γ 
p48 (H-143; rabbit polyclonal; sc-365893), and β-actin were purchased from Santa Cruz 
Biotechnology. Anti-rabbit or anti-mouse IRDye-conjugated secondary antibodies were obtained 
from LI-COR Biosciences. Stocks of JAK inhibitor 1 and NSC87877 (Santa Cruz Biotechnology) were 
dissolved in DMSO at a concentration of 10 mM. 
3-D primary human intestinal or liver organoids models 
Human intestinal crypt isolation and primary human intestinal organoids culture was described 
previously [26]. Human liver cell isolation and primary human liver organoids culture was described 
accordingly [27]. 
Cell models 
Huh7.5 cells (a human hepatoma cell line), Caco2 cells (a human epithelial colorectal 
adenocarcinoma cell line), and A549 cells (a human alveolar basal epithelial cell line) were cultured in 
Dulbecco’s modified Eagle medium (DMEM, Lonza Biowhittaker) complemented with 10% (v/v) fetal 
calf serum (FCS, Hyclone), 100 IU/ml penicillin, and 100 µg/ml streptomycin. Wild-type (WT) MEFs 
and MEFs from STAT1-/- [28] and STAT2-/- [29] mice were generously provided by Prof. Andrea Kröger 
(Helmholtz Centre for Infection Research) and Christian Schindler (Columbia University, NY), 
respectively. IRF9-/- mice and the corresponding WT MEFs [30] [30] were generously provided by K. 
Mossman (McMaster University, Canada). STAT1-deficient (U3A) and STAT2-deficient (U6A) cell lines 
Chapter 6 
93 | P a g e  
were kindly provided by G. R. Stark (Lerner Research Institute). Huh7.5 cells expressing the HCV 
subgenomic replicon containing a subgenomic HCV bicistronic replicon (1389/NS3-3V/LucUbiNeo-ET) 
linked to the firefly luciferase reporter gene were maintained in Dulbecco’s modified Eagle medium 
(DMEM) complemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin and 250 μg/ml G418 (Sigma) [31]. The HEV subgenomic model: Huh7.5 cells containing 
the subgenomic HEV sequence (Kernow-C1 p6/luc) coupled to a Gaussia luciferase reporter gene [32, 
33]. Luciferase normalization cells (Huh7.5-norm) were generated by transducing Huh7.5 cells with a 
lentiviral vector expressing the firefly luciferase gene under the control of the human 
phosphoglycerate kinase (PGK) promoter. For the ISRE reporter model, Huh7.5 cells were transduced 
with a lentiviral transcriptional reporter system that expressed the firefly luciferase gene driven by a 
promoter containing multiple ISRE promoter elements (SBI Systems Biosciences), and luciferase 
activity was used as a reporter of ISRE promoter activation [34, 35]. Human plasmacytoid dendritic cells 
(pDCs), myeloid dendritic cells (mDCs), and T cells were purified from the buffy coats of healthy 
blood donors and were cultured in round-bottom, 96-well plates [36]. Culture medium of these cells 
was harvested after 48 hours and served as conditioned medium for further experiments. For simian 
rotavirus experiments, SA11, a well-characterized and broadly used laboratory strain of the virus, 
was used to inoculate the Caco2 cell line as a rotavirus infection model [26]. 
Gene knockdown or overexpression by lentiviral vectors  
Lentiviral pLKO knockdown vectors (Sigma-Aldrich) expressing shRNAs targeting IFN-αR1, IFN-λR1, 
JAK1, STAT1, STAT2, or IRF9 and their appropriate controls were obtained from the Erasmus Biomics 
Center and were produced in HEK 293T cells. After a pilot study, those shRNA-expressing vectors that 
exerted optimal gene knockdown were selected. These shRNA sequences are listed in table S1. 
Stable gene knockdown cells were generated after lentiviral vector transduction and selection in 
medium containing puromycin (3 μg/ml; Sigma). The pTRIP.CMV.IVSb.ISG.ires.TagRFP–based STAT1, 
STAT2, and IRF9 overexpression lentiviral vectors were a kind gift from C. M. Rice (Rockefeller 
University) [37]. Control vectors expressing green fluorescent protein (GFP) was also used. The pLV-
tetO-CMV-SV40-Puro-LoxP–based lentiviral vectors expressing WT STAT1 or the Y701F-STAT1 mutant 
(which cannot be phosphorylated) were kindly provided by G. R. Stark (Lerner Research Institute) [13]. 
Lentiviral pseudoparticles were generated as described previously [13, 37]. Ultracentrifugation was 
used to achieve high-titer lentiviruses with superior transduction efficiency. 
Measurement of luciferase activity 
For Gaussia luciferase analysis, the activity of secreted luciferase in the cell culture medium was 
measured with the BioLux Gaussia Luciferase Flex Assay Kit (New England Biolabs) according to the 
manufacturer’s instructions. For firefly luciferase assays, luciferin potassium salt (100 mM; Sigma) 
was added to the cells and incubated for 10 min at 37°C. Luciferase activity was then quantified with 
a LumiStar Optima luminescence counter (BMG Lab Tech). 
Quantitative RT-PCR analysis 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke) and quantified with a Nanodrop ND-
1000 spectrophotometer (Wilmington). All RNA samples were adjusted to a concentration of 62.5 
Chapter 6 
94 | P a g e  
ng/μL. RNA (500 ng) was used as template for the generation of complementary DNA (cDNA) with 
the reverse transcription system (TAKARA BIO INC). The cDNA (10 ng/well) of all detected genes was 
amplified for 50 cycles and quantified with a SYBRGreen-based real-time PCR system (Applied 
Biosystems) according to the manufacturer’s instructions. GAPDH was considered as reference gene 
to normalize gene expression. Relative gene expression (based on mRNA abundance) was normalized 
to that of GAPDH using the formula: 2−ΔΔCT (ΔΔCT = ΔCTsample − ΔCTcontrol) [38]. All of the primer 
sequences are included in table S2. 
Quantification of gene copy numbers 
To generate a template with which to quantify ISG copy number under basal conditions, vectors 
containing the corresponding ISG genes were used. A series of dilutions, from 10−2 to 10−10, were 
prepared and then were amplified and quantified by qRT-PCR to generate a standard curve. The 
standard curve was generated by plotting the log of the copy number against the cycle threshold (CT) 
value (fig. S1A). Copy numbers were calculated with the following equation: Copy number 
(molecules/μg) = (1 μg/0.01 μg) × [concentration (ng/μL) × 6.022×1023 (molecules/mol)] / [length of 
amplicon × 640 (g/mol) × 109 (ng/g)]. 
Nuclear extraction and Western blotting analysis 
Nuclear and cytoplasmic proteins were extracted with the nuclear and cytoplasmic protein extraction 
kit (Active Motif) according to the manufacturer’s instructions. All samples were lysed in Laemmli 
sample buffer containing 0.1 M DTT and heated for 5 min at 95°C, which was followed by loading the 
samples onto a 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and separation by 
electrophoresis. After 90 min running at 120 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride (PVDF) membrane (Invitrogen) for 1.5 hours with an electric current of 250 
mA. Subsequently, the membrane was blocked with a mixture of 2.5 ml of blocking buffer (Odyssey) 
and 2.5 ml of PBS containing 0.05% Tween 20. This was followed by overnight incubation with the 
appropriate primary antibody (at a 1:1000 dilution) at 4°C. The membrane was washed three times, 
which was followed by incubation for 1 hour with IRDye-conjugated secondary antibody (1: 5000). 
After the membrane was washed three times, protein bands were detected with the Odyssey 3.0 
Infrared Imaging System. 
IFN production assay 
Huh7.5 cells were seeded into 6-well plates at a density of 10 × 104 cells per well and then were 
transduced with lentiviruses expressing STAT1, STAT2, or IRF9 singly or in combination at 37°C. Forty-
eight hours later, the lentiviral particles were removed and the cells were washed three times with 
PBS. The culture medium was refreshed and the transduced cells were cultured for another 48 hours. 
The culture medium was subsequently collected and added to an ISRE luciferase reporter cell line 
that is sensitive to IFNs. The conditioned medium was also used to treat Huh7.5 cells for 24 hours, 
which was followed by quantification of ISG expression by qRT-PCR analysis. 
Confocal laser electroscope assay 
Chapter 6 
95 | P a g e  
Cells were seeded on glass coverslips. After 12 hours, the cells were washed with PBS, fixed in 4% 
PBS-buffered formalin for 10 min, and blocked with Tween-milk-glycine medium [PBS, 0.05% Tween, 
skim milk (5 g /L), and glycine (1.5 g/L)]. Samples were incubated with primary antibodies overnight 
at 4 °C. The samples were then incubated with anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor 
488 conjugate), or anti-rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 conjugate) secondary 
antibodies (each at a 1:1000 dilution). Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; 
Invitrogen). Images were detected with confocal electroscope (lens: 40 ×, software: ZenLightEdition). 
Immunohistochemistry (IHC) 
Paraffin-embedded liver tissue sections were deparaffinized in xylene, rehydrated in graded alcohols, 
and rinsed once in PBS containing 0.05% Tween. After antigen retrieval, 1.5% H2O2 was used to block 
endogenous peroxidase for 10 min at room temperature. The slides were incubated in 5% milk 
blocking solution, which was followed by overnight incubation with primary antibody at a 1:200 
dilution before the tissue sections were then counterstained with hematoxylin. As a negative control, 
the primary antibody was replaced with PBS containing 0.05% Tween. 
ChIP-seq data analysis 
The ChIP-seq dataset for STAT1 (GSE31477) was retrieved from the ENCODE database. ChIP-seq 
datasets were processed and mapped to the hg19 reference genome as described previously [11]. 
ChIP-seq datasets with multiple replicates were merged. MACS 1.4.2 software was used for peak-
calling and for the generation of binding profiles [39]. If the centers of two binding regions reported by 
MACS were 100 bp or less apart, then they were unified to a single binding region. The sequencing 
profiles were generated in the IGV browser [40]. 
Statistical analysis 
All results were presented as means ± SEM. Comparisons between groups were performed with the 
Mann-Whitney test. Differences were considered to be statistically significant when P < 0.05. 
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Supplementary Figures  
 
Fig. S1. Cells sustain basal ISG expression under homeostatic conditions. (A) Representative microscopy image 
of cultured human primary liver organoids (left) and intestinal organoids (right). (B) Standard curve for 
quantifying ISG genes copy numbers. Plasmids containing the corresponding ISG genes (STAT1, STAT2, IRF9, 
and IFITM1) were used. The plasmids were extracted, followed by a series of dilutions, from 10-2 to 10-10, were 
prepared and then were amplified and quantified by qRT-PCR. Standard curve was generated by plotting the 
cycle threshold (CT) value with regard to the log copy number. (C) With the treatment of Huh7, Caco2, A549 
conditioned medium or IFN-α (10 IU/ml, positive control) for 24 hours, the expression levels of IRF9, IFITM1, 
and ISG15 in Huh7 cells were quantified by qRT-PCR (n = 3 independent experiments). *P < 0.05; **P < 0.01; ns, 
not significant. 
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Fig. S2. Sustained basal ISG expression is independent of IFN production. (A) Representative Western blotting 
analysis (from three experiments) of total STAT1 and pSTAT1 (Tyr701) protein levels under the treatment of 
IFN-α (1000IU/ml), JAK inhibitor I (5uM) or the combination. (B) Huh7.5 cells were treated with IFN-α 
(1000IU/ml), 5 µM JAK inhibitor I or their combination for 24 hours before being subjected to qRT-PCR analysis 
of the relative abundances of the indicated mRNAs. (n = 3 independent experiments). (C) Caco2 cells were 
treated with 5 µM JAK inhibitor I for 24 hours before being subjected to qRT-PCR analysis of the relative 
abundances of the indicated mRNAs (n = 3 independent experiments). (D) Same as (C) for A549 cells (n = 3 
independent experiments). 
 
Fig. S3. STAT1, STAT2, and IRF9 are 
required for constitutive ISG expression.  
(A) A549 and Caco2 cell lysates were 
fractionated into cytoplasmic (Cy) and 
nuclear (Nu) fractions and then were 
analyzed by Western blotting with 
antibodies against the indicated proteins. 
Cyclophilin A and Lamin A/C were used as 
cytosolic and nuclear markers, 
respectively. Western blots are 
representative of three independent 
experiments. (B) Confocal laser 
electroscope analysis of endogenous 
STAT1 localization in Caco2 cells. STAT1 is 
shown in green. Nuclei were visualized by 
DAPI (blue). Images are representative of 
multiple cells from three independent 
experiments.. (C) Caco2 cells transduced 
with control lentivirus or with lentivirus 
expressing IRF9 were subjected to qRT-PCR analysis of the relative abundances of the indicated mRNAs.  (n = 3 
independent experiments). (D) Rotavirus positive Caco2 cells transduced with control lentivirus or with 
lentivirus expressing IRF9 were subjected to qRT-PCR analysis of the relative abundances of the indicated 
mRNAs. (n = 3 independent experiments). *P < 0.05; **P < 0.01; ns, not significant. 
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Fig. S4. The overexpression of U-ISGF3 leads to increased ISG expression. (A) STAT1 mutant cells (U3A) were 
transduced with control lentivirus or with lentivirus expressing STAT1, STAT2 and IRF9 before being subjected 
to Western blotting analysis with antibodies against the indicated proteins. Western blots are representative of 
three independent experiments.Western blotting (B) U3A cells were transduced with control lentivirus or with 
lentiviruses expressing the indicated proteins before being subjected to qRT-PCR analysis of the relative 
abundances of the indicated mRNAs. Data are means ± SEM of three independent experiments. (C) Same as (A) 
for U6A cells. (D) Same as (B) for U6A cells. (E) Representative immunohistochemical analysis of pSTAT1-Tyr701 
in mouse liver tissue samples. As negative control, primary antibody against pSTAT1-Tyr701 was replaced with 
PBS plus Tween 0.05%. (F and G) Confocal laser electroscope analysis (F) and Western blotting analysis (G) of 
pSTAT1-Tyr701 in human intestinal organoids (from three experiments). Human intestinal organoids treated 
with IFN-α for 30 min served as the corresponding positive control. (H) Confocal laser electroscope analysis of 
pSTAT2-Tyr690) in human intestinal organoids. Human intestinal organoids treated with IFN-α for 30 min served 
as the positive control. Images are representative of multiple organoids from three individual experiments. (I) 
RT-PCR confirmed the successful over-expression of STAT1, Y701F-STAT1, STAT2 or IRF9 in U3A cells (n = 3 
independent experiments). (J) In U3A cells, over-expression of Y701F-STAT1 together with STAT2 and IRF9 led 
to a comparable ISG induction compared with its wild type (n = 3 independent experiments). (K) 
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Representative Western blotting analysis (from three experiments) of pSTAT1 (Ser727) in Huh7 cells under the 
homeostatic condition. Huh7 cells treated with IFN-α, IFN-β (100IU/ml, 16 hours) served as positive controls. 
(L) Representative immunohistochemical staining (from three experiments) analysis of pSTAT1 (Ser727) in 
human liver tissue samples from two individuals. Neither of them was detected. As negative control, primary 
antibody against pSTAT1 (Ser727) was replaced with PBS plus Tween 0.05%. *P < 0.05; **P < 0.01; ns, not 
significant. 
 
 
Fig. S5. U-ISGF3 stimulates ISG expression independently of IFN production. (A) The regulation of 
phosphorylation process of STAT1/2 was illustrated. Upon stimulations (e.g. by IFNs), STAT1/2 get 
phosphorylated by specific kinases. Importantly, phosphorylated STAT1/2 undergo dephosphorylation process. 
Thus, the phosphorylation and dephosphorylation process coordinate to maintain the phosphorylation level at 
a balanced state, which balances its beneficial antiviral versus detrimental proinflammatory effects. 
Consequently, the inhibition of phosphatases will alter the balanced state, leading to higher levels of 
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phosphorylated STAT1/2 and a much stronger induction of ISGs. (B) Caco2 cells were left untreated (CTR) or 
were treated with 5 μΜ NSC87877 (phosphatase inhibitor) before the cells were subjected to qRT-PCR analysis 
of the relative abundances of the indicated mRNAs. (n = 3 independent experiments). (C) and (D) Huh7.5 cells 
transduced with control lentivirus or with lentivirus expressing Y701F-STAT1, STAT2 and IRF9 were subjected to 
qRT-PCR analysis of the relative abundances of the indicated mRNAs. (n = 3 independent experiments). (E) The 
basal expression levels of several interferons, including IFNA, IFNB1, IFNG, IL29, IL28A, and the reference gene 
(GAPDH) were evaluated by qRT-PCR. (F) Schematic illustration of the production of conditioned medium 
(supernatant). (G) Huh7.5 cells were treated with conditioned medium from Huh7.5 cells with over-expression 
of STAT1, STAT2, IRF9 or their combination were subjected to qRT-PCR analysis of the relative abundances of 
the indicated mRNAs. IFN-α (10 IU/ml) serves as positive control (n = 3 independent experiments). 
 
Fig. S6. IPCs produce IFNs to activate the JAK-STAT pathway, thus stimulating ISG expression and antiviral 
activity. (A) HEV viral replication-related firefly luciferase activity was measured upon the treatment of 
conditioned medium from pDC, mDC and T cells for 48 hours Data are means ± SEM of two or three replicates 
from three independent experiments. (B) HCV viral replication-related firefly luciferase activity was measured 
at 3 different time points (12 hours, 24 hours and 48 hours) upon the treatment of conditioned medium from 
pDC, mDC and T cells Data are means ± SEM of two or three replicates from three independent experiments. 
(C) ISRE luciferase value was measured at 2 different time points (12 hours and 24 hours) after the treatment 
of conditioned medium from pDC, mDC and T cells Data are means ± SEM of two or three replicates from three 
independent experiments. (D) Huh7.5-ISRE-luc cells were treated with conditioned medium from pDC, mDC 
and T cells without (-) or with  JAK inhibitor I (5 μΜ) for 24 hours ISRE luciferase values were then measured 
and the fold-increase in activity relative to that of untreated cells was determined. Data are means ± SEM of 
two or three replicates from three independent experiments. (E) Representative Western blotting analysis 
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(from three experiments) of total STAT1 and pSTAT1(Tyr701) in Huh7.5 cells treated with conditioned medium 
(from pDC, mDC and T cells). (F) Huh7.5 cells were treated with conditioned medium (from pDC) without or 
with JAK inhibitor I (5 μM) for 24 hours before subjected to qRT-PCR analysis of the relative abundances of the 
indicated mRNAs. (n = 3 independent experiments). (G and H) Same as (F) for conditioned medium from mDC 
(G) and T (H) cells. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
 
Fig. S7. U-ISGF3 stimulates ISG expression independently of upstream elements of the IFN signaling pathway. 
(A) Illustration of type I and III IFN signaling pathways. (B and C) Caco2 cells transduced with lentiviruses 
expressing control or JAK1-specific shRNAs were analyzed by qRT-PCR to determine the extent of knockdown 
of JAK1 mRNA (B) or by Western blotting with antibodies against the indicated proteins (C). Data in (B) are 
means ± SEM of three independent experiments. Western blots are representative of three independent 
experiments. (D) Caco2 cells transduced with lentiviruses expressing control or JAK1-specific shRNAs were 
analyzed by qRT-PCR to determine the relative abundances of the indicated mRNAs. Data are means ± SEM of 
three independent experiments. (n = 3 independent experiments). *P < 0.05; **P < 0.01; ns, not significant. 
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Abstract 
Interferons (IFNs) are broad antiviral cytokines that exert their function by inducing the transcription 
of hundreds of IFN-stimulated genes (ISGs). However, little is known about the antiviral potential of 
these cellular effectors on hepatitis E virus (HEV) infection, the leading cause of acute hepatitis 
globally. In this study, we profiled the antiviral potential of a panel of important human ISGs on HEV 
replication in cell culture models by overexpression of an individual ISG. The mechanism of action of 
the key anti-HEV ISG was further studied. We identified retinoic acid–inducible gene I (RIG-I), 
melanoma differentiation–associated protein 5, and IFN regulatory factor 1 (IRF1) as the key anti-
HEV ISGs. We found that basal expression of RIG-I restricts HEV infection. Pharmacological activation 
of the RIG-I pathway by its natural ligand 5’-triphosphate RNA potently inhibits HEV replication. 
Overexpression of RIG-I activates the transcription of a wide range of ISGs. RIG-I also mediates but 
does not overlap with IFN-a-initiated ISG transcription. Although it is classically recognized that RIG-I 
exerts antiviral activity through the induction of IFN production by IRF3 and IRF7, we reveal an 
IFNindependent antiviral mechanism of RIG-I in combating HEV infection. We found that activation 
of RIG-I stimulates an antiviral response independent of IRF3 and IRF7 and regardless of IFN 
production. However, it is partially through activation of the Janus kinase (JAK)–signal transducer and 
activator of transcription (STAT) cascade of IFN signaling. RIG-I activated two distinct categories of 
ISGs, one class of JAK-STAT-dependent and the other of JAK-STAT-independent, which coordinately 
contribute to the anti-HEV activity. Conclusion: We identified RIG-I as an important anti-HEV ISG that 
can be pharmacologically activated; activation of RIG-I stimulates the cellular innate immunity 
against HEV regardless of IFN production but partially through the JAK-STAT cascade of IFN signaling. 
Keyword: HEV; ISG; Retinoic acid-inducible gene I; JAK-STAT pathway 
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Introduction 
Hepatitis E virus (HEV) infection is the most common cause of acute viral hepatitis worldwide [1]. As a 
single-strand RNA virus, HEV has been divided into 4 genotypes (gt) [1]. Although acute HEV infections 
are mostly self-limiting, gt1 HEV infection during pregnancy may lead to high mortality up to 30% [2]. 
In immunosuppressed patients, such as organ transplant recipients, gt3 HEV infection can cause 
chronic hepatitis [2]. For those chronic patients, monotherapy or the combination of ribavirin or/and 
pegylated Interferon-α (PegIFN-α) have been used as off-label treatment [1]. The observation that 
different populations with different status of their immune system have distinct outcomes of HEV 
infection highlights the importance of studying HEV-host interactions. 
The innate immune response plays an essential role in defending viral infections. Patients 
with genetic deficiencies in the innate immune system are often pro to viral infection and develop 
more severe symptoms [3, 4]. In response to viral infection, host cells produce virus-induced cytokines 
including interferons (IFNs), particularly type I IFN (IFN-α and -β), which have potent antiviral activity 
against a broad spectrum of viruses [5]. Type I IFNs promote an antiviral state in an autocrine or 
paracrine manner by transcriptional induction of hundreds of interferon-stimulated genes (ISGs) [6]. 
However, excessive accumulation of type I IFNs may evoke pathological effects to the organism [7]. 
Recently, emerging studies have described the type I IFNs independent innate antiviral defense [8, 9]. 
These IFN-independent antiviral mechanisms including the production of alternative antiviral 
cytokines (e.g. IFN-λ or interleukin 22) and the basal expression of direct antiviral ISGs [9]. The basal 
expression of these ISGs may be attributed to tonic IFN signaling and this establishes a cell-
autonomous antiviral status of the host, but independent of virus-triggered IFN production. 
Therefore, ISGs play important roles in both IFN-dependent and -independent antiviral mechanisms. 
As the ultimate antiviral effectors, ISGs are transcriptionally induced through the Janus 
kinase/signal transducers and activators of transcription (JAK-STAT) pathway by tonic or exogenous 
IFNs. In previous studies, more than 380 individual human ISGs have been tested for their antiviral 
effects on a wide species of viruses including many important human and animal viruses [10, 11]. 
Surprisingly, only small subsets of ISGs exert antiviral activities against either a specific or broad 
spectrum of viruses. Unexpectedly, a few ISGs even promote the replication of certain viruses [10, 11]. 
Given the fact that IFN-α has anti-HEV activity in vitro and is probably also effective in chronic 
patients [12-14], this strongly suggests that ISGs may play a vital role in IFN-mediated HEV clearance. 
Furthermore, a genome-wide transcriptome profiling has identified the up-regulation of 30 genes in 
blood cells of chronic HEV patients, of which 25 are ISGs [15].  
Because the function of ISGs during HEV infection remains largely elusive, we have profiled 
the effects of a panel of ISGs that are known to have anti- or pro-viral effects on certain viruses [10, 11]. 
We found most of these ISGs only have minor but some have potent anti-HEV effects. Among those 
ISGs, RIG-I is a key member that effectively restricts HEV replication. Furthermore, biological or 
pharmacological activation of RIG-I exerts potent anti-HEV effects. Mechanistically, it robustly 
activates the innate cellular antiviral response, unexpectedly dispensable of IFN production, but 
requiring the key elements of the JAK-STAT signaling. 
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Materials and Methods 
HEV cell culture models 
Multiple cell lines were used for supporting HEV replication, including Huh7.5 cells: a RIG-I defective 
hepatoma cell line that derived from Huh7 cells; A549 cells: a human lung epithelial carcinoma cell 
line that widely used for supporting HEV replication [16]. HepaRG cells: a hepatic cell line which retains 
many characteristics of primary human hepatocytes that also permissive for HEV replication. For the 
full-length HEV model, a plasmid construct containing the full-length HEV genome (Kernow-C1 p6 
clone, GenBank Accession Number: JQ679013) was linearized at a 3’ terminal MluI. Capped HEV viral 
RNA transcripts were generated by the Ambion mMESSAGE mMACHINE® in vitro RNA transcription 
Kit (Thermo Fisher Scientific Life Sciences) [16]. Huh7.5 cells, A549 cells and HepaRG cells were 
electroporated using the Bio-Rad’s electroporation systems (240 V, pulse length 0.5, number 1 and 
cuvette 4 mm) with full-length HEV viral RNA to generate consecutive HEV-infected cell models, 
Huh7.5-p6, A549-p6 and HepaRG-p6. Briefly, cells were collected and washed with 5 mL Opti-MEM 
(Thermo Fisher Scientific Life Sciences) for three times. The cell pellet was resuspended with 100 µL 
Opti-MEM and mixed with 10 µg p6 full-length HEV RNA and then subjected to electroporation. To 
generate the subgenomic (p6-Luc) HEV model, a construct containing subgenomic HEV was also 
used. This plasmid has an HEV sequence in which the 5’ portion of HEV ORF2 was replaced with the 
in-frame Gaussia princeps luciferase reporter gene to generate subgenomic (p6-Luc) [16]. The 
luciferase has a signal sequence that let it secreted into medium, and therefore, measurement of 
secreted luciferase activity represents HEV replication levels. Huh7.5 cells were electroporated as 
described above with HEV subgenomic RNA to generate subgenomic HEV replication model, Huh7.5-
p6-Luc.  
HEV reinfection assays 
Supernatant that contains HEV viral particles were collected from the full-length HEV infectious cells 
(Huh7.5-p6) that cultured for 96 h. The supernatant was filtered by 0.45 μm filter to get rid of dead 
cell and then was centrifuged for 30 min (10 000 rpm) to remove cell debris. Next, 2 h 
ultracentrifugation (22 000 rpm) was used to purify and concentrate HEV virus particles (SW28 rotor; 
Beckman Coulter, Brea CA, USA). Subsequently, the collected pellet was resuspended and was 
diluted to 1 × 107 HEV viral RNA copies/mL and then stored at -80 °C as described previously [17]. For 
HEV infection assay, Huh7.5 and A549 cells were seeded into 12-well plates at a density of 7 × 104 
cells per well. The next day, for each well, 400 µL HEV stock that contains 1 × 107 viral RNA copies/mL 
HEV was incubated with target cells at 37 °C for 6 h. Next, the HEV inoculum was removed and cell 
layers were washed 3 times with 1 mL PBS followed by adding 1 mL fresh medium to each well. For 
6-well plates, cells were seeded at a density of 1.4 × 105 per well. The next day, for each well, target 
cells were incubated with 800 µL HEV stock at 37 °C for 6 h. Then, the HEV inoculum was removed 
and washed as usual and then added 2 mL fresh medium. 
Lentivirus production and transduction assays 
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pTRIP.CMV.IVSb.ISG.ires.TagRFP based ISG overexpression vectors were kind gifts from Prof. Charles 
M. Rice (the Rockefeller University) [10]. Two vectors expressing Photinus pyralis luciferase (Fluc) or 
GFP as reporter genes were used as a control. Lentiviral pseudoparticles were generated in 293T cells 
by co-transfection of ISG expression plasmid (pTRIP.CMV.IVSb.ISG.ires.TagRFP), HIV gag-pol and VSV-
G in a ratio of 1: 0.8: 0.2 as described and lentiviral stocks were stored at -80 °C [10]. For transduction 
assays, cells were seeded into 24-well plates at a density of 5 × 104 cells per well and transduced with 
lentiviral pseudoparticles at 37 °C. pLKO.1 based shRNA lentiviral vectors (Biomics Center in Erasmus 
Medical Center) targeting RIG-I was used to knockdown RIG-I gene expression and scrambled control 
vector (shSCR) was used as a control. Lentiviral pseudoparticles were generated as described 
previously [17]. To obtain stable gene knockdown cell line, cells were transduced with shRNA lentiviral 
particles for 3 days and selected by puromycin (Sigma-Aldrich, Zwijndrecht, the Netherlands) at a 
concentration of 2.5 μg/mL. After selection, optimal knockdown cell lines were chosen. The shRNA 
sequences are listed in Table S1 in Supporting Information. 
Statistical analysis 
GraphPad Prism 5 software was used for data analysis using a Mann-Whitney test. All results were 
presented as mean ± standard errors of the means (SEM). P values of less than 0.05 (single asterisks 
in figures) were considered statistically significant; whereas P values less than 0.01 (double asterisks) 
and 0.001 (triple asterisks) were considered highly significant. Further details are provided in the 
Supporting Information. 
Results 
Identification of antiviral ISGs against HEV replication 
To identify key ISGs that regulate HEV replication, 25 important human ISGs which are known to 
have anti- or pro-viral effects on certain viruses [10] were tested in two Huh7.5 cells based HEV 
models (Huh7.5-p6-Luc and Huh7.5-p6). Huh7.5 is an RIG-I defective hepatoma cell line derived from 
Huh7 cells, which was widely used for supporting viral infections (Supporting Fig. S1A) [18]. These ISGs 
include MAP3K14, IFI44L, RIG-I (also known as DDX58), HPSE, RTP4, NAMPT (also known as PBEF1), 
IRF1, IFITM1, IFITM2, IFITM3, C6orf150 (also known as cGAS), UNC84B (also known as SUN2), IRF2, 
IRF7, IRF9, IFI6, OASL, DDX60, MOV10, TREX1, MDA5 (also known as IFIH1), ADAR, FAM46C, LY6E and 
MCOLN2 [10].  
Ectopic overexpression of each ISG was delivered by a bicistronic lentiviral vector co-
expressing the ISG and a red fluorescent protein (TagRFP). Two vectors that express a Photinus 
pyralis luciferase (Fluc) gene or a green fluorescent protein (GFP) gene were used as controls [10]. The 
successful overexpression of each ISG was confirmed by flow cytometry analysis to measure the 
expression of TagRFP (Supporting Fig. S1B-S1F). Transient transfection was used to overexpression 
ISG when lentiviral stocks failed to achieve high-level transduction [10]. Before profiling on HEV, each 
ISG was first tested for the ability to inhibit HCV replication in Huh7.5 cell-based HCV luciferase 
replicon model [10]. Similar to the previous study, most ISGs inhibit HCV replication to some extent; 
whereas several genes (IRF1, IRF2 and RIG-I) have strong anti-HCV effects (Supporting Fig. S1G). Next, 
all ISGs were tested for their anti-HEV ability in a subgenomic HEV model (Huh7.5-p6-Luc). At 24 h 
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after lentivirus transduction, most genes inhibited HEV-related luciferase activity to some extent (Fig. 
1A). One gene named RIG-I was found to have strong anti-HEV activity at 48 h post transduction (Fig. 
1B). More anti-HEV ISGs were identified 72 h after transduction, including IRF1, MDA5 and RIG-I (Fig. 
1C). These genes could inhibit HEV-related luciferase activity by almost 50% compared to control. To 
further validate the antiviral ability, those ISGs were also tested in the full-length infectious HEV 
model (Huh7.5-p6). A similar inhibition pattern was obtained in this model (Fig. 1D). At 48 h after 
transduction, IRF1, MDA5 and RIG-I potently decreased HEV viral RNA level; whereas most of the 
other genes showed minor effects.  
 
FIG. 1. Identification of ISGs that inhibit HEV 
replication. 
Luciferase activity analysis of HEV-related Gaussia 
luciferase activity in Huh7.5-p6-Luc cells transduced 
with ISG overexpression or Fluc vector for 24 h (A), 48 
h (C) or 72 h (C) (n = 4 independent experiments with 
each of 2 replicates). RLU: relative luciferase unit. (D) 
qRT-PCR analysis of HEV viral RNA level in Huh7.5-p6 
cells transduced with ISG overexpression or Fluc 
vector for 48 h (n = 4). Data were normalized to the 
Fluc control (set as 1) and presented in dot plots. 
 
 
 
 
RIG-I is a key anti-HEV ISG 
Among these three potent anti-HEV ISGs, we have previously demonstrated that IRF1 inhibits HEV 
replication by stimulating antiviral ISG expressions [17]. Both RIG-I and MDA5 are pattern recognition 
receptors (PRRs) that sense viral RNA in the cytoplasm [19]. In this study, we mainly focused on the 
antiviral potential of RIG-I. To validate the anti-HEV activity of RIG-I, we performed additional 
independent experiments in two Huh7.5-based HEV models (Huh7.5-p6 and Huh7.5-p6-Luc). 
Lentiviral transduced RIG-I overexpression was confirmed in Huh7.5-p6 cells by qRT-PCR and 
immunoblotting (Fig. 2A). In both models, RIG-I overexpression inhibited HEV replication to an extent 
similar to a high dose of IFN-α treatment (Fig. 2B). Next, we confirmed the anti-HEV ability of RIG-I in 
different cell models: a human lung epithelial cell line A549 that is widely used for HEV propagation 
and a human hepatic progenitor cell-derived cell line HepaRG. Both of them are capable of 
supporting long-term HEV replication (A549-p6 and HepaRG-p6) [17]. As shown in Fig. 2C and 2D, RIG-I 
overexpression also significantly inhibited HEV replication in both HepaRG and A549 based HEV 
models. 
To further explore the role of basal RIG-I in constraining HEV infection, RNAi approach was 
used to silence RIG-I gene expression. HEV RNA level was significantly increased in RIG-I silenced 
A549 cells (Fig. 2E and 2F). As expected, in RIG-I defective Huh7.5 cells, RIG-I knockdown did not 
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affect HEV infection (Supporting Fig. S2A and S2B) and we indeed observed that RIG-I defected 
Huh7.5 cell are more permissive for supporting HEV infection (Supporting Fig. S2C). These results 
have demonstrated that RIG-I has potent anti-HEV ability and the basal expression of RIG-I plays 
important role in defending HEV infection. 
Pharmacological activation of RIG-I stimulates an antiviral response that 
inhibits HEV replication 
To explore the antiviral response induced by RIG-I pathway, the natural ligand of RIG-I 5’pppRNA was 
used to activate the RIG-I signaling [20]. Different concentrations of RIG-I agonist were used to induce 
an antiviral response in A549 cells, a model with functional RIG-I expression (Supporting Fig. S1A). As 
shown in Fig. 3A, gene expression of type I IFN (IFN-β) 
and type III IFN (IFN-λ) was significantly induced by RIG-I agonist 48 h or 72 h after treatment. 
Concurrently, the expression of many ISGs including STAT1, IFIH1, PKR, TRAIL, RANTES and RIG-I were 
also significantly induced by 5’pppRNA treatment (Fig. 3A). 
Correspondingly, treatment with RIG-I agonist has resulted in a significant reduction of HEV 
replication in A549-p6 cells. With 1000 ng/mL 5’pppRNA treatment, the HEV viral RNA were inhibited 
by 67.8% ± 8.1% (mean ± SEM) (n = 7; P < .01), 90.0% ± 8.6% (n = 6; P < .01) at 48 h and 72 h after 
treatment, respectively (Fig. 3B). Since Huh7.5 cells are RIG-I defected cells (Supporting Fig. S1A), 
RIG-I agonist was unable to induce any antiviral response as expected (Supporting Fig. S2D).  
 
FIG. 2. RIG-I inhibits HEV replication in multiple cell models. qRT-PCR analysis and immunoblot analysis of RIG-
I expression in Huh7.5-p6 cells (A), A549-p6 cells (C) and HepaRG-p6 cells (D) transduced with RIG-I, Fluc vector 
or treated with IFN-α (1000 IU/mL) for 48 h (qRT-PCR: n = 4). (B) Analysis of HEV-related Gaussia luciferase 
activity in Huh7.5-p6-Luc cells transduced with RIG-I, Fluc vector or treated with IFN-α (1000 IU/mL) for 24 h, 
48 h or 72 h (n = 4 independent experiments with each of 3 - 4 replicates) and qRT-PCR analysis of HEV viral 
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RNA level in Huh7.5-p6 cells transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) for 48 h (qRT-PCR: 
n = 8). RLU: relative luciferase unit. qRT-PCR analysis of HEV viral RNA level in A549-p6 cells (C) and HepaRG-p6 
cells (D) transduced with RIG-I, Fluc vector or treated with IFN-α (1000 IU/mL) for 48 h (n = 4). (E) Immunoblot 
analysis of RIG-I expression in A549 cells transduced with lentiviral shRNA vector targeting RIG-I (shRIG-I(1) and 
shRIG-I(2)) or scrambled control (shSCR). Stable RIG-I knockdown or shSCR control A549 cells were infected 
with HEV. RIG-I expression level and HEV viral RNA level (F) were analyzed by qRT-PCR 72 h after HEV infection. 
Data were normalized to the Fluc control (CTR, set as 1, A-D) or to the scrambled control (shSCR, set as 1, F). 
Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. For immunoblot results (A, C, D 
and E), band intensity of each lane was quantified by Odyssey Software. Immunoblot quantification results 
were normalized to β-actin expression and control was set as 1.  
 
 
FIG. 3. 5’pppRNA stimulates an antiviral response that inhibits HEV. A549-p6 cells were transfected with 
various concentrations of 5’pppRNA (10 ng/mL, 100 ng/mL and 1000 ng/mL), IFN gene mRNA levels, ISG mRNA 
levels (A) and HEV viral RNA level (B) were analyzed by real-time qRT-PCR 48 h or 72 h after transfection (A: n = 
3-5; B: n = 6-8). Data were normalized to a control that was transfected with PEI-Mix but without 5’pppRNA at 
each time point (48 h and 72 h, both set as 1), respectively. Data are means ± SEM. *P < 0.05; **P < 0.01; ***P 
< 0.001; NS, not significant. 
To clarify whether the antiviral activity of 5’pppRNA exclusively relies on RIG-I pathway, we 
employed wild-type mouse embryonic fibroblasts (MEF) cells (WT, RIG-I+/+) and RIG-I deficient MEF 
cells (RIG-I−/−). These two MEF cell lines were transfected with different concentrations of 5’pppRNA. 
1000 ng/mL 5’pppRNA treatment induced mouse IFN genes (mouse IFN-β, mIFN-β; mouse IFN-λ, 
mIFN-λ) more than 1000-fold at 24 h after stimulation (Supporting Fig. S3A). In contrast, no IFN gene 
was induced in RIG-I−/− MEF, indicating that this is exclusively dependent on the RIG-I signaling 
(Supporting Fig. S3A). Meanwhile, 5’pppRNA activated the expression of many mouse ISGs, including 
mMX1, mIRF9, mIFIH1, mSTAT1, mIRF1, mPML, mXAF, mIRF7, mISG15 and mRIG-I in RIG-I+/+ MEF 
cells (Supporting Fig. S3A). After 48 h treatment, IFN gene and ISG expression was significantly 
induced by 5’pppRNA, although, to a less extent compared to 24 h after treatment (Supporting Fig. 
S3B). Hence, the anti-HEV activity of 5’pppRNA was specifically via RIG-I. We now demonstrated that 
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pharmacological activation of RIG-I stimulates an antiviral response that inhibits HEV replication 
specifically via RIG-I. 
RIG-I activates the transcription of a wide range of ISGs 
RIG-I has been shown to trigger STAT1 activation and ISG expression [21]. In general, the activation of 
STAT1 leads to the formation and nuclear translocation of IFN-stimulated gene factor 3 (ISGF3). This 
complex further binds to the IFN-stimulated response element (ISRE) motifs in the genome DNA and 
drives the transcription of ISGs. A recent study has reported that RIG-I overexpression stimulates 
ISRE promoter activity [22]. Thus, we employed a transcriptional reporter system that mimics IFN 
response with a reporter luciferase gene that was driven by multiple ISREs (ISRE-Luc). As shown in 
Fig. 4A, RIG-I significantly increased the ISRE-related luciferase activity. The activation of ISRE 
element usually leads to the transcription of ISGs that contain this element in their promoter regions. 
Therefore, we measured gene expression of a wide range of important antiviral ISGs. As shown in Fig. 
4B-4D, RIG-I overexpression stimulated the expression of a large number of ISGs in Huh7.5, A549 and 
HepaRG cells. Interestingly, the ISG expression pattern induced by RIG-I was different from IFN-α 
treatment (Supporting Fig. S4A-S4C). The induction of some important ISGs was further confirmed by 
immunoblotting at protein levels (Fig. 4E and 4F).  
RIG-I mediates IFN-α-induced antiviral ISG transcription 
Gene expression profile analysis in the previous study revealed that 5’pppRNA treatment induced a 
distinct transcriptome compared to IFN-α treatment [20]. Besides, as a nucleic acid sensor, RIG-I is also 
an ISG that can be induced by IFN-α treatment and we already demonstrated that RIG-I activates the 
expression of many ISGs (Fig. 4). Therefore, we hypothesized that RIG-I may reinforce the IFN-α 
initiated ISG induction. We thus investigated the association of RIG-I expression with the response to 
IFN-α treatment. Indeed, in RIG-I overexpressed Huh7.5 cells, IFN-α induced ISG expression was 
significantly enhanced (Fig. 5A). Similarly, IFN-α induced ISG expression was also enhanced in RIG-I 
transduced A549 cells (Fig. 5B).  
To further determine the role of RIG-I in IFN-α-activated cell signaling, the RIG-I knockdown 
A549 cell line and RIG-I deficient MEF cell line (RIG-I-/-) were employed. In A549 cells, RIG-I deficiency 
significantly attenuated the ISG induction ability of IFN-α (Fig. 5C). Consistently, in RIG-I deficient 
MEF cells (RIG-I-/-), the ISG induction ability of mIFN-α (mouse IFN-α) was also significantly reduced 
(Fig. 5D). In contrast, the ISG induction ability of mIFN-α was not affected in IRF3/7-/- or NFκB-/- MEF 
cells (Supporting Fig. S5A and S5B). Taken together, these results demonstrated that RIG-I 
functionally contributes to the antiviral ISG induction ability of IFN-α. 
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FIG. 4. RIG-I activates the transcription of a wide range of ISGs. (A) Analysis of ISRE related firefly luciferase 
activity in Huh7-ISRE-Luc cells transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) for 48 h (n = 3 
independent experiments with each of 1-2 replicates). qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells 
(B), A549-p6 cells (C) and HepaRG-p6 cells (D) transduced with RIG-I or Fluc vector for 48 h (n = 6). Immunoblot 
analysis of ISG protein levels in Huh7.5-p6 cells (E) and A549-p6 cells (F) transduced with RIG-I or Fluc vector for 
48 h or 72 h. Date in (A) were normalized to the untreated Fluc control (CTR, set as 1). Data in (B-D) were 
normalized to the Fluc control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, 
not significant. For immunoblot results (E and F), band intensity of each lane was quantified by Odyssey 
Software. Immunoblot quantification results were normalized to β-actin expression and control was set as 1. 
RIG-I activates the innate anti-HEV immune response dispensable of 
interferon production 
RIG-I is a cytosolic nucleic acid sensor and the binding of viral RNA to RIG-I leads to the activation of 
downstream pathways that eventually triggers IFN gene expression via IRF3 and IRF7 [19]. In turn, the 
secreted IFNs establish antiviral response in infected and surrounding cells by stimulating the 
expression of ISGs. To further study the ISG induction ability of RIG-I pathways, the activator of RIG-I 
5’pppRNA were transfected in IRF3/7 double knockout MEF cells (IRF3/7-/-). Indeed, 5’pppRNA failed 
to induce IFN-β expression in the IRF3/7-/- cells (Fig. 6A). Strikingly, 5’pppRNA is still capable of 
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inducing ISGs in the absent of IRF3/7 and IFN-β expression (Fig. 6B). These results indicate RIG-I could 
also stimulate ISG transcription in IFN- independent manners. Next, we determined the mRNA 
expression levels of IFN genes in RIG-I overexpressed Huh7.5 cell line, a cell line that unable to 
produce any IFNs [23]. We found that the mRNA expression level of IFN genes was very low and no IFN 
gene (IFN-α, -β and -λ) was induced by RIG-I overexpression in Huh7.5-p6 cells (Fig. 6C, Supporting 
Fig. S6A). Furthermore, no IFN gene was up-regulated in HepaRG-p6 cells by RIG-I overexpression 
(Supporting Fig. S6B-S6C). To confirm the lack of IFN production in these RIG-I overexpressed cells, 
conditioned medium (supernatant) from the RIG-I transduced Huh7.5-p6 cells was collected (Fig. 6D). 
Two IFN sensitive assays were performed: an IFN functional assay and an HCV replicon-based 
bioassay. The IFN functional assay was based on a transcriptional reporter system that mimics IFN 
response as used above (Fig. 4A). As shown in Fig. 6E, conditioned medium collected from RIG-I 
overexpressed Huh7.5-p6 cells was not able to induce ISRE activation. Furthermore, this conditioned 
medium did not affect HCV-related luciferase activity (Fig. 6F). Similarly, conditioned medium 
collected from HepaRG cells also failed to activate ISRE-related luciferase activity (Supporting Fig. 
S6D). These results suggest that ectopic overexpression of RIG-I did not trigger IFN expression and 
production. Thus, we demonstrated that RIG-I could activate innate immune response dispensable of 
IFN production. 
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FIG. 5. RIG-I mediates IFN-α-induced antiviral ISG transcription. qRT-PCR analysis of ISG mRNA expression 
levels. Huh7.5 cells were transduced with RIG-I or Fluc vector, at 48 h post-transduction cells were treated with 
IFN-α (1000 IU/mL) for 3 h or 6 h (A) (n = 4). A549 cells were transduced with RIG-I or Fluc vector, at 48 h post- 
transduction cells were treated with IFN-α (1000 IU/mL) for 3 h or 6 h (B) (n = 4). Data in (A and B) were 
normalized to untreated the Fluc control (CTR, set as 1). A549 cells were transduced with lentiviral shRNA 
vectors targeting RIG-I or scrambled control (shSCR). The stable RIG-I knockdown and control A549 cells were 
treated with IFN-α (1000 IU/mL) for 3 h or 6 h (C). ISG mRNA levels were analyzed by qRT-PCR (n = 6). qRT-PCR 
analysis of mouse ISG mRNA levels in WT and RIG-I-/- MEF cells treated with mouse IFN-α (mIFN-α, 1000 IU/mL) 
for 3 h or 6 h (D) (n = 6). Data in (C) were normalized to the untreated scrambled control (shSCR CTR, set as 1). 
Data in (D) were normalized to untreated WT MEF cells (WT CTR, set as 1). Data are means ± SEM. *P < 0.05; 
**P < 0.01; ***P < 0.001; NS, not significant. 
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FIG. 6. RIG-I activates an immune response dispensable of interferon production. WT and IRF3 and IRF7 
double deficient (IRF3/7-/-) mouse embryonic fibroblasts (MEF) cells were transfected with various 
concentrations of 5’pppRNA (100 ng/mL and 1000 ng/mL), mouse IFN-β (mIFN-β) (A) and mouse ISG (B) mRNA 
levels were analyzed by qRT-PCR 24 h after transfection (n = 6). (C) qRT-PCR analysis of IFN gene mRNA levels in 
Huh7.5-p6 cells transduced with RIG-I or Fluc vector for 48 h (n = 4). (D) Production of conditioned medium 
(supernatant). Cells were transduced with RIG-I or GFP (CTR) vector for 72 h and then the cells were washed 5 
times and medium was refreshed. Cells were cultured for another 72 h and supernatant was collected as 
conditioned medium. Analysis of ISRE-related firefly luciferase activity in Huh7-ISRE-Luc cells (E) or HCV-related 
firefly luciferase activity in Huh7.5-ET-Luc cells (F) that treated with conditioned medium from Huh7.5 cells or 
various concentrations of IFN-α for 48 h (n = 3 independent experiments with each of 3 - 4 replicates). Data in 
(A) and (B) were normalized to a control that transfected with PEI-Mix but without 5’pppRNA in each cell line 
(WT and IRF3/7-/-, both set as 1), respectively. Data in (C) was normalized to the Fluc control (CTR, set as 1). 
Data in (E) and (F) were normalized to the untreated GFP control (CTR, set as 1). Data are means ± SEM. *P < 
0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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RIG-I mediated ISG transcription and anti-HEV activity partially through 
activation of JAK-STAT pathway. 
The previous study has demonstrated that RIG-I can augment STAT1 activation, which is a key 
element of JAK-STAT cascade within the IFN pathway [21]. Consistent with these results, we also 
observed that RIG-I overexpression induced the phosphorylation of STAT1 at 701 site in Huh7.5-p6 
cells, which is an indispensable marker of JAK-STAT pathway activation (Fig. 7A).  
To elucidate whether the ISG induction and anti-HEV abilities of RIG-I are through the 
activation of STAT1, we used a JAK inhibitor named CP-690550 (Tofacitinib) to pharmacologically 
block the JAK-STAT pathway. In Huh7.5-p6 cells, RIG-I and IFN-α induced STAT1 phosphorylation 
were totally blocked by CP-690550 (Fig. 7B). Meanwhile, lentiviral-delivered RIG-I overexpression 
was not affected by this inhibitor (Fig. 7B and 7C). Surprisingly, we found that RIG-I-induced ISRE 
activation was not totally diminished by this inhibitor; whereas IFN-α triggered ISRE activation was 
totally blocked (Fig. 7C). These results suggest that RIG-I-induced ISRE activation partially 
independent of its STAT1 phosphorylation ability. Next, we tested the mRNA expression level of 23 
RIG-I inducible ISGs in RIG-I overexpressed Huh7.5-p6 cells treated with JAK inhibitor CP-690550. 
Surprisingly, among these 23 tested RIG-I inducible ISGs, only 10 genes were affected by CP-690550 
treatment, but the others were not affected at all (Fig. 7D and 7E). As a positive control, the 
expression level of all these 23 genes that induced by IFN-α was totally diminished by this inhibitor 
(Supporting Fig. S7A and S7B). Consequently, the anti-HEV ability of RIG-I was only partially blocked 
by CP-690550; whereas the anti-HEV effects of IFN-α were totally abolished (Fig. 7F). To further 
confirm these results, another JAK inhibitor named JAK inhibitor 1 was used to treat RIG-I transduced 
Huh7.5-p6 cells. As expected, similar results were obtained (Supporting Fig. S8). To explore whether 
this is a common mechanism in different cell lines, we also used this JAK inhibitors 1 to treat RIG-I 
overexpressed HepaRG-p6 cells and similar results were obtained (Supporting Fig. S9). 
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FIG. 7. JAK inhibitor CP-690550 partially diminishes RIG-I-induced ISG transcription and anti-HEV activity. (A) 
Immunoblot analysis of p-STAT1 (Tyr701) expression in Huh7.5 cells transduced with RIG-I vector or treated with 
IFN-α (1000 IU/mL) for 48 h or 72 h. (B) Immunoblot analysis of ISG protein levels in Huh7.5 cells transduced 
with RIG-I vector or treated with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h. qRT-PCR analysis of 
RIG-I mRNA level in Huh7.5-p6 cells and analysis of ISRE-related firefly luciferase activity in Huh7-ISRE-Luc cells 
(C) transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h (qRT-
PCR: n = 4; ISRE: n = 3 independent experiments with each of 2 replicates). (D and E) qRT-PCR analysis of ISG 
mRNA levels in Huh7.5 cells transduced with RIG-I vector or treated with CP-690550 (1000 ng/mL) for 48 h (n 
=5-6). (F) Analysis of HEV related Gaussia luciferase activity in Huh7-p6-Luc cells transduced with RIG-I vector 
or treated with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 72 h. (n = 4 independent experiments with 
each of 3 - 4 replicates). For immunoblot results (A and B), band intensity of each lane was quantified by 
Odyssey Software. Immunoblot quantification results were normalized to β-actin expression and control was 
set as 1. Data in (C left panel, D and E) were normalized to the untreated Fluc control (CTR, set as 1). Date in (C 
right panel and F) were normalized to the untreated GFP control (CTR, set as 1). Data are means ± SEM. *P < 
0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
To further confirm the ISG induction ability of RIG-I is not totally dependent on the JAK-STAT 
pathway, we overexpressed RIG-I in STAT1 deficient human (STAT1-/-) fibrosarcoma cells [24]. In 
STAT1-/- cell, RIG-I failed to induce STAT1 phosphorylation (Fig. 8A). A similar ISG induction pattern 
was also observed in RIG-I overexpressed STAT1-/- cells. Some genes such as STAT1, IRF9 and IFI6 can 
only be induced in WT cell but not in STAT1-/- cells by RIG-I, although RIG-I overexpression level was 
similar in both cell lines (Fig. 8B and 8C). Meanwhile, another group includes genes that can be 
activated in both WT and STAT1-/- cells such as IFIT1, RANTES and CXCL10 (Fig. 8D). As a control, IFN-
α induced ISG transcription was totally abolished in STAT1-/- cells (Supporting Fig. S10A). Together, 
these results demonstrated that RIG-I activates ISG transcription and exerts its anti-HEV activity 
partially through the activation of the JAK-STAT pathway. 
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FIG. 8. The ISG induction ability of RIG-I is partially diminished in STAT1 deficient cells. (A) Immunoblot 
analysis of ISG protein levels in WT and STAT1 deficient (STAT1-/-) fibrosarcoma cells transduced with RIG-I 
vector or treated with IFN-α (1000 IU/mL) for 48 h. (B) qRT-PCR analysis of RIG-I mRNA level in WT and STAT1-/- 
cells transduced with RIG-I vector or treated with IFN-α (1000 IU/mL) for 48 h (n =4-5). (C and D) qRT-PCR 
analysis of ISG mRNA levels in WT and STAT1-/- cells transduced with RIG-I or Fluc vector for 48 h (n = 4-5). For 
immunoblot results (A), band intensity of each lane was quantified by Odyssey Software. Immunoblot 
quantification results were normalized to β-actin expression and control was set as 1. Data in (C) were 
normalized to the untreated Fluc control (CTR, set as 1). Date in (D) and (E) were normalized to untreated WT 
and STAT1-/- cells, respectively (both set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, 
not significant. 
Discussion 
Currently, IFNs in particular IFN-α have been approved for treating viral infections including chronic 
hepatitis B (HBV) and C virus (HCV) infections [6]. In some cases, IFN-α has been used as an off-label 
drug to treat chronic HEV infection [12, 25]. In vitro study also showed the inhibition of HEV replication 
by IFN-α treatment [13, 14, 26]. IFN-α exerts its antiviral ability through the induction of ISGs, but how 
these ISGs affect HEV replication are still largely unknown. This study comprehensively profiled the 
antiviral ability of many important human ISGs described previously [10]. We found that most of these 
ISGs showed minor anti-HEV effect. In contrast, several previously reported broad antiviral ISGs 
including MDA5, IRF1 and RIG-I were identified as strong anti-HEV ISGs. Previously, we have 
demonstrated that IRF1 inhibits HEV replication by activating antiviral ISGs [17]. RIG-I is a pattern 
recognition receptor (PRR) and numerous studies have demonstrated that it plays important roles in 
defending a wide spectrum of virus infections such as HCV [10, 20], HBV [27] and influenza virus [28]. Here, 
in this study we comprehensively investigated the antiviral potential of RIG-I and its mechanism-of-
action. 
RIG-I, as a PPR, senses the viral RNA in the cytoplasm during infection. Binding of RIG-I with 
its ligand such as 5’-triphosphorylated RNA activates the downstream signaling pathway through the 
adaptor proteins mitochondrial antiviral signaling protein (MAVS). Classically, the aggregation of 
MAVS in mitochondrial subsequently leads to the production of type I and III IFNs through the 
phosphorylation of IRF3 and IRF7. The produced IFN proteins subsequently activate ISG expression in 
infected and bystander cells to eradicate the virus and prevent further infections. In this study, we 
observed overexpression of RIG-I activated transcription and expression of a wide range of ISGs, and 
many of them are known to have strong antiviral activities [10, 11, 17, 20, 29-32]. 
Although working as a cytosolic nucleic acid sensor that triggers IFN production, RIG-I itself is 
also an ISG regulated by IFN-initiated JAK-STAT cascade. This feedback amplification loop is able to 
enhance the responsiveness of host cells to infection. It has been shown that 5’pppRNA treatment 
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induced a broader transcriptome compared to IFN-α treatment. Consistently, we found that a 
combinatorial action of IFN-α treatment and RIG-I overexpression in ISG induction and anti-HEV 
activity. Conversely, IFN-α induced ISG transcription was attenuated when RIG-I was deleted (Fig. 5). 
These results suggest that RIG-I partially mediates the ISG transcription activity of IFN-α. 
Classically, the main antiviral function of RIG-I is believed via the induction of IFN production 
upon sensing cytosolic viral nucleic acid. However, we found that RIG-I overexpression in our models 
doesn’t induce the production of IFNs, but triggers the transcription of a wide range of genes 
including ISGs, chemokines and cytokines, without the activation of downstream MAVS pathway (Fig. 
4E). In fact, emerging recent studies have proposed additional antiviral mechanisms of RIG-I that are 
partially dependent or independent of IFNs [27, 28, 33]. 
It has been demonstrated that induction of ISGs and antiviral ability by RIG-I activation were 
only partially reduced in the absence of IFN-α/β receptors [20]. Additionally, RIG-I can exert broad 
antiviral activity in the models that have defected IFN signaling [10]. We now observed that in cells 
that lacking of the key downstream components of RIG-I pathway (IRF3 and IRF7), the RIG-I activator 
5’pppRNA is still able to induce ISG expression (Fig. 6A) without activating IFN genes. In line with this, 
we also observed that in Huh7.5 cells (a cell line which could not produce any IFN protein), RIG-I 
overexpression induces ISG transcription and exerts potent anti-HEV activity (Fig. 2). Together with 
recent reports, our observations strongly support that RIG-I can also execute its antiviral action via 
IFN-independent mechanisms. However, these IFN-dispensable actions are diverse and their exact 
mechanisms remain largely elusive. 
Typically, the activation of RIG-I will trigger the activation of IRF3/7 and NF-κB through the 
MAVS antiviral singling.[20, 34] Activation of NF-κB pathway leads to the transcription of many pro-
inflammatory genes including IFN genes. Our previous study also revealed that the NF-κB complex 
can directly bind to ISRE and drives its transcription of some ISGs.[35] Interestingly, many of the pro-
inflammatory genes are regulated by both the NF-κB and JAK-STAT pathways. For instance, the 
transcription of CXCL10 is positively regulated by ISRE and NF-κB during viral infection.[36] It has been 
reported that MEF cells with a defected NF-κB pathway were more sensitive to the antiviral action of 
type I IFN.[37] We also observed that the IFN induced expression of some ISGs was enhanced in NF-κB 
KO MEF cells; whereas the expression of other genes was lower or unaffected (Supporting Fig. S5). 
Furthermore, a subset of RIG-I induced ISGs were unaffected when JAK-STAT pathway was blocked 
(Fig 7E), indicating the involvement of additional regulatory mechanisms. Thus, RIG-I and its down 
downstream pathways form a large complex web. Besides JAK-STAT cascade, other pathways such as 
NF-κB may also involve the regulation of RIG-I mediated ISG induction and antiviral activity.  
A previous study demonstrated that RIG-I overexpression triggers STAT1 activation and ISG 
expression independent of its canonical MAVS pathway [21]. We now confirmed that overexpression 
of RIG-I activated STAT1 phosphorylation at 701 site (Fig. 7A) without the involvement of IFNs. We 
further addressed the contribution of STAT1 phosphorylation to the anti-HEV action of RIG-I. By using 
pharmacological inhibitors to block the JAK-STAT pathway, we demonstrated that RIG-I induced ISG 
transcription and anti-HEV activity is only partially but IFN-α mediated effect are totally dependent 
on this cascade. Furthermore, in a JAK-STAT deficient cell model, only a small proportion of RIG-I 
inducible ISGs were affected upon RIG-I overexpression. We thus classified these RIG-I inducible ISGs 
into two categories. One group, including STAT1, IRF1 and IRF9, is completely dependent on RIG-I-
induced STAT1 phosphorylation. The other group, including IFIT1, IFIH1 and RANTES, is induced 
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independently of JAK-STAT pathway. Of note, both subsets may contribute to the anti-HEV ability of 
RIG-I, since the anti-HEV action of RIG-I was only partially attenuated by blocking JAK-STAT pathway 
(Fig. 7E). Recently, accumulating evidence unrevealed direct antiviral action of RIG-I independent of 
its downstream IFN production effect [27, 28, 33]. However, whether RIG-I has the direct anti-HEV effect 
is still unknown and need further investigation. 
IFN-α and ribavirin have been used as monotherapy or combination for treating chronic HEV 
patients. Ribavirin monotherapy appears effective in many patients but failed in a substantial 
proportion of cases probably due to the development of drug resistance mutations in the viral 
genome [38-40]. IFN-α seems also effective but is associated with organ rejection, since most of the 
chronic HEV patients are immunocompromised organ recipients [41]. It is also well-known that 
excessive exposure to IFNs can result in pathogenesis to the host, and treatment of IFN-α is 
associated with various severe side effects in patients [42]. Therefore, dissecting the antiviral and the 
pathogenic mechanisms is necessary for developing specific antiviral strategies while avoiding 
unnecessary side effects. Our identification of RIG-I as a key anti-HEV ISG and its activation by the 
natural ligand 5’pppRNA exerting potent anti-HEV activity have provided proof-of-concept for 
designing such specific anti-HEV approach. Several RIG-I agonists (ImOl-100, Rigontec; MCT-465, 
Multicell Technologies; SB-9200, Spring Bank Pharmaceuticals) are at various stages of pre-clinical or 
clinical development for treating viral infections [43]. Thus, the possibility of using these RIG-I agonists 
in treating HEV infection deserves further evaluations.  
In conclusion, we have identified RIG-I as a key anti-HEV ISG that inhibit HEV replication. 
Biological or pharmacological activation of the RIG-I pathway potently inhibit HEV replication. We 
further observed ectopic overexpression of RIG-I activated the transcription of many antiviral ISGs to 
establish an anti-HEV status. This is dispensable of IFN production but partially through the activation 
of JAK-STAT cascade. Thus, this study revealed new insights of HEV-host interactions, and provided 
novel avenues for antiviral drug development. 
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glyceraldehyde 3-phosphate dehydrogenase. 
Supplemental Materials and Methods 
Reagents 
Human IFN-α (Thermo Fisher Scientific, Life Sciences, the Netherlands) was dissolved in PBS. Mouse 
IFN-α (mIFN-α) was obtained from Thermo Fisher Scientific (#121001, Life Sciences). CP-690550 
(Tofacitinib) was obtained from Santa Cruz Biotechnology and dissolved in DMSO. JAK inhibitor 1 
(CAS 457081-03-7) was also obtained from Santa Cruz Biotechnology and dissolved in DMSO at a final 
concentration of 5 mg/mL. Dimethyl sulfoxide (DMSO, Sigma, Zwijndrecht, the Netherlands) was 
used as vehicle control at different concentrations. 5’ppp-dsRNA was purchased from InvivoGen 
(#tlrl-3prna, InvivoGen, CA, USA). Phospho-STAT1 (Tyr701) (58D6, Rabbit mAb, #9167), STAT1 (Rabbit 
mAb, #9172), MDA5 (IFIH1) (D74E4, Rabbit mAb, #5321) and IRF7 (D2A1J, Rabbit mAb, #13014) 
antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). MAVS antibody (E-3, 
Mouse mAb, #sc-166583), RIG-I antibody (H-300, Rabbit polyclonal, #sc-98911) and β-actin antibody 
(C-4, Mouse mAb, #sc-47778) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
800CW Goat anti-Rabbit IgG (H + L) or 680RD Goat anti-Mouse IgG (H + L) IRDye®-conjugated 
secondary antibodies were obtained from Li-COR Biosciences (Lincoln, NE, USA). 
Cell culture 
Huh7.5 cells, 293T cells and A549 cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
(Lonza Biowhittaker, Verviers, Belgium) supplemented with 10% (v/v) fetal calf serum (FCS) (Hyclone, 
Lonan, Utah) and antibiotics. HepaRG cell line was maintained in William’s medium (Thermo Fisher 
Scientific Life Sciences) as described previously [17]. Hepatitis C virus (HCV) luciferase replication 
models (ET-Luc) was based Huh7.5 cells coupled with a subgenomic HCV bicistronic replicon 
(I389/NS3-3V/LucUbiNeo-ET). Huh7.5-ET-Luc cells were grown in DMEM with 250 μg/mL G418 
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(Sigma Aldrich, Zwijndrecht, the Netherlands). ISRE (IFN-stimulated response element) activation 
reporter model (Huh7-ISRE-Luc) was based on Huh7 cells that expressing the firefly luciferase 
reporter gene driven by a promoter containing multiple ISRE elements (SBI Systems Biosciences, 
Mountain View, CA). Luciferase activity represents ISRE promoter activation level and this cell line 
was maintained in DMEM with 10% FCS and antibiotics.  
Mouse embryonic fibroblast cells (MEFs) were grown in DMEM with 10% FCS, 0.6 µg/mL 
penicillin, 60 µg/mL streptomycin, 2 mM L-glutamine and 20 mM HEPES as described previously [29]. 
WT and RIG-I-/- MEF cells were generated by Dr. Michael J. Gale (Department of Immunology 
University of Washington). WT, IRF3/7-/- and NFκB-/- MEF cells were generated by Dr. A. Hoffmann 
(Signaling Systems Lab, Los Angeles, CA). All these MEF cells were kindly provided by Dr. Sanna M. 
Mäkelä (National Institute for Health and Welfare Viral Infections Unit, Helsinki, Finland) with the 
permission of Dr. Michael J. Gale and Dr. A. Hoffmann [29]. WT (fTGH) and STAT1 deficient (U3A, 
STAT1-/-) human fibrosarcoma cells were grown in DMEM with 10% FCS and antibiotics. WT and 
STAT1-/- fibrosarcoma cells were kind gifts of Prof. George R. Stark (Lerner Research Institute) [44].  
RNA and DNA transfection 
Polyethylenimine (PEI, Sigma-Aldrich, Zwijndrecht, the Netherlands) was used for transfection of 
5’pppRNA in A549 and MEF cells. Cells were seeded in 96-well plates at a density of 1 × 104 cells per 
well. The next day, the medium was removed and cell layer was washed by Opti-MEM. Different 
concentrations of 5’pppRNA were transfected with PEI in a total volume of 100 µL Opti-MEM. After 5 
h, the medium was changed to normal medium. For lentiviral stocks failed to reach high-level 
transduction efficacy, DNA-transfection-based overexpression approach was used. Briefly, 7 × 104 
Huh7.5 cells were seeded into 24-well plates per well. After cells adhered to the plate, 400 ng 
lentiviral ISG plasmids were transfected with PEI (Sigma-Aldrich, Zwijndrecht, the Netherlands) in a 
total volume of 1 mL Opti-MEM per well. After 5 h, the medium was changed to normal DMEM 
medium that contains 10% FBS.  
Measurement of luciferase activity 
Measurement of secreted Gaussia luciferase activity was conducted by using BioLux® Gaussia 
Luciferase Flex Assay Kit (New England Biolabs, Ipswich, MA, USA) according to the manufacturer’s 
instructions. Luminescence signal was monitored by using a LumiStar Optima luminescence counter 
(BMG Lab Tech, Offenburg, Germany). Measurement of firefly luciferase activity was conducted by 
adding luciferin potassium salt (Sigma-Aldrich, Zwijndrecht, the Netherlands) to cells at a final 
concentration of 0.1 mM. 10 min after incubation, luciferase activity was measured.  
Interferon production bioassay 
10 × 104 cells per well were seeded into 6-well plates. Cells were transduced with control or RIG-I 
lentiviral pseudoparticles at 37 °C as described above. 72 h later, lentiviral particles were removed 
and cell layer was washed 3 times with PBS. Next, the medium wad refreshed and cultured for 
another 72 h to let the produced cytokines secreted into the medium. Subsequently, the supernatant 
(conditioned medium) was collected and then filtered by a 0.45 μm filter. To detect the secreted IFN 
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proteins in conditioned medium, two luciferase reporter models which are extremely sensitive to 
interferon treatments were used. Huh7.5-ET-Luc luciferase model is an HCV replicon which the HCV-
related firefly luciferase activity can be potently inhibited by low concentration of IFN-α treatments. 
Huh7-ISRE-Luc is a luciferase reporter model in which the firefly luciferase gene was driven by a 
promoter containing multiple ISRE elements. In this model, the firefly luciferase activity can be 
potently induced by low concentration of IFN-α treatment. Therefore, these two luciferase models 
can be used to sensitively assess the presence of IFN proteins in the conditioned medium. 
Real-time Quantitative RT-PCR (Real-time qRT-PCR) 
RNA was isolated from cells using the Machery-NucleoSpin RNA II kit (Bioke, Leiden, Netherlands). 
RNA concentration was quantified by a Nanodrop ND-1000 Spectrophotometer (Thermo, DE, USA). 
500 ng RNA was reverse transcribed to cDNA by using Takara cDNA Synthesis Kit with random 
hexamer primers according to manufacturer’s instructions (Takara Bio, Inc., Shiga, Japan). Host gene 
expression and intracellular HEV level were quantified by SYBR-Green-based (Applied Biosystems® 
SYBR® Green PCR Master Mix, Thermo Fisher Scientific Life Sciences) real-time PCR on the 
StepOnePlus™ System (Thermo Fisher Scientific Life Sciences). For all human cell lines, two genes 
GAPDH and RP2 (Human retinitis pigmentosa 2) were used as housekeeping genes and expression 
level of target genes was normalized to GAPDH and RP2 by the 2-ΔΔCT method. For all mouse cell lines, 
one gene mGAPDH was used as housekeeping genes and expression level of target genes was 
normalized to mGAPDH by the 2-ΔΔCT method. Primers sets used for this study were listed in Table S2 
and Table S3 in Supporting Information. 
Quantification of HEV replication 
Huh7.5-p6 and Huh7.5-p6-Luc are two well-established HEV models that could stably support HEV 
replication for a long term. In these two cell models, HEV-related Gaussia luciferase activity and HEV 
viral RNA level were measured over 3 months after electroporation when the HEV replication level 
was stable as described above. Lentivirus transduction and HEV RNA quantification were performed 
2 weeks and 4 weeks after HEV RNA electroporation in A549-p6 and HepaRG-p6 models, 
respectively. WT and RIG-I-/- cells were infected with HEV virus stock as described in reinfection 
assays for 24 h. 3 days after HEV infection, cells were transfected with 5’pppRNA and HEV viral RNA 
was quantified 48 h after transfection. Intracellular HEV viral RNA was isolated from cellular lysates. 
The cells were lysed by using 350 mL RA1 buffer (Bioke, Leiden, The Netherlands) followed by RNA 
isolation as described above. Primer sequences for detecting HEV viral RNA were 5’-
ATCGGCCAGAAGTTGGTTTTTAC-3’ (sense) and 5’-CCGTGGCTATAACTGTGGTCT-3’ (antisense). qRT-
PCR was performed as follows: 10 min at 95 °C, 40 cycles of 15 s at 95 °C, 30 s at 58 °C, and 30 s at 72 
°C. 
Immunoblot analyses 
Whole cell lysates were suspended in SDS sample buffer and heated at 95 °C for 5 min. Proteins were 
separated in 10% sodium dodecyl sulphate-polyacrylamide (SDS-PAGE) gel and were transferred onto 
a PVDF membrane (InvitroGen). Membranes were blocked for 1h at room temperature and then 
Chapter 7 
127 | P a g e  
were probed with primary antibodies overnight at 4 °C. Rabbit anti-p-STAT1 (1: 1000), anti-STAT1 (1: 
1000), anti-IRF7 (1: 1000), anti-MDA5 (1: 1000), anti-RIG-I (1: 1000) antibodies or mouse anti-MAVS 
(1: 1000) and anti-β-actin (1: 1000) were used. Membranes were incubated at room temperature 
with goat anti-rabbit or goat anti-mouse IRDye®-conjugated secondary antibodies (Li-COR 
Biosciences, Lincoln, USA) (1: 5000). β-actin was served as loading control. Antibody signals were 
detected by Odyssey Infrared Imaging System and were visualized by Odyssey 3.0 software. Band 
intensity was quantified by Odyssey Software and normalized to the β-actin signal. The quantification 
result was showed below each band.  
MTT assay 
Cells were seeded in 96-well plates and cell viability was determined by adding 10 mM 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) (Sigma, Zwijndrecht, the Netherlands). 
After 3 h, the medium was replaced with 100 μL of DMSO and was incubated for another 50 min. 
Absorbance was measured by absorbance reader (Bio-Rad, CA, USA) at a wavelength of 490 nm. 
Flow cytometry analysis 
The positive percentage of cells transduced with lentivirus was determined by directly detect TagRFP 
protein expression level. Cells were analyzed on a FACSAria™ flow cytometer (BD Biosciences) 
equipped with a 561-nm laser.  
Supplementary Tables 
Supplementary Table 1. Lentiviral shRNA sequences. 
No. Gene ACCESSIO
N 
Sequences Target 
Sequence 
shRIG-
I(1) 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
NM_0143
14.3 
CCGGCCAGAGAAACTTGCCAGTTATCTCGAGATAA
CTGGCAAGTTTCTCTGGTTTTTTG 
CCAGAGAA
ACTTGCCAG
TTAT 
shRIG-
I(2) 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
NM_0143
14.3 
CCGGCCAGAATTATCCCAACCGATACTCGAGTATCG
GTTGGGATAATTCTGGTTTTTTG 
CCAGAATTA
TCCCAACCG
ATA 
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Supplementary Table 2. Primer sequences for human cells. 
Gene F-Sequences (5’ to 3’) R-Sequences (5’ to 3’) 
ADAR TCCGTCTCCTGTCCAAAGAAGG TTCTTGCTGGGAGCACTCACAC 
CCL3 ACTTTGAGACGAGCAGCCAGTG TTTCTGGACCCACTCCTCACTG 
CCL4 GCTTCCTCGCAACTTTGTGGTAG GGTCATACACGTACTCCTGGAC 
CXCL10 GGTGAGAAGAGATGTCTGAATCC GTCCATCCTTGGAAGCACTGCA 
DDX60 GGTGTTTTCACCAGGGAGTATCG CCAGTTTTGGCGATGAGGAGCA 
GAPDH TGTCCCCACCCCCAATGTATC CTCCGATGCCTGCTTCACTACCTT 
IFI27 CGTCCTCCATAGCAGCCAAGAT ACCCAATGGAGCCCAGGATGAA 
IFI44L TGCACTGAGGCAGATGCTGCG TCATTGCGGCACACCAGTACAG 
IFI6 TGATGAGCTGGTCTGCGATCCT GTAGCCCATCAGGGCACCAATA 
IFIH1(MDA5) GCTGAAGTAGGAGTCAAAGCCC CCACTGTGGTAGCGATAAGCAG 
IFIT1 GCCTTGCTGAAGTGTGGAGGAA ATCCAGGCGATAGGCAGAGATC 
IFIT2 GGAGCAGATTCTGAGGCTTTGC GGATGAGGCTTCCAGACTCCAA 
IFIT3 CCTGGAATGCTTACGGCAAGCT GAGCATCTGAGAGTCTGCCCAA 
IFITM3 CTGGGCTTCATAGCATTCGCCT AGATGTTCAGGCACTTGGCGGT 
IFN-α TGGGCTGTGATCTGCCTCAAAC CAGCCTTTTGGAACTGGTTGCC 
IFN-β1 CTTGGATTCCTACAAAGAAGCAGC TCCTCCTTCTGGAACTGCTGCA 
IFN-λ1 GGAAGACAGGAGAGCTGCAACT AACTGGGAAGGGCTGCCACATT 
IFN-λ2 TCGCTTCTGCTGAAGGACTGCA CCTCCAGAACCTTCAGCGTCAG 
IL-1β CCACAGACCTTCCAGGAGAATG GTGCAGTTCAGTGATCGTACAGG 
IL-32 TCAAAGAGGGCTACCTGGAGAC TCTGTTGCCTCGGCACCGTAAT 
IL-6 AGACAGCCACTCACCTCTTCAG TTCTGCCAGTGCCTCTTTGCTG 
IRF1 GAGGAGGTGAAAGACCAGAGCA TAGCATCTCGGCTGGACTTCGA 
IRF2 TAGAGGTGACCACTGAGAGCGA CTCTTCATCGCTGGGCACACTA 
IRF9 CCACCGAAGTTCCAGGTAACAC AGTCTGCTCCAGCAAGTATCGG 
ISG15 CTCTGAGCATCCTGGTGAGGAA AAGGTCAGCCAGAACAGGTCGT 
JAK1 GAGACAGGTCTCCCACAAACAC GTGGTAAGGACATCGCTTTTCCG 
MX1 GGCTGTTTACCAGACTCCGACA CACAAAGCCTGGCAGCTCTCTA 
NAMPT CTCCACCAGAACCGAAGGCAAT AGGGTTACAAGTTGCTGCCACC 
OASL GTGCCTGAAACAGGACTGTTGC CCTCTGCTCCACTGTCAAGTGG 
PKR GAAGTGGACCTCTACGCTTTGG TGATGCCATCCCGTAGGTCTGT 
PML CCGTCATAGGAAGTGAGGTCTTC GTTTTCGGCATCTGAGTCTTCCG 
RANTES CCTGCTGCTTTGCCTACATTGC ACACACTTGGCGGTTCTTTCGG 
RIG-I CACCTCAGTTGCTGATGAAGGC GTCAGAAGGAAGCACTTGCTACC 
RP2 CCCATTAAACTCCAAGGCAA AAGCTGAGGATGCTCAAAGG 
RSAD2 CCAGTGCAACTACAAATGCGGC CGGTCTTGAAGAAATGGCTCTCC 
STAT1 ATGGCAGTCTGGCGGCTGAATT CCAAACCAGGCTGGCACAATTG 
STAT2 CAGGTCACAGAGTTGCTACAGC CGGTGAACTTGCTGCCAGTCTT 
TRAIL TGGCAACTCCGTCAGCTCGTTA AGCTGCTACTCTCTGAGGACCT 
 
Supplementary Table 3. Primer sequences for mouse cells. 
Gene F-Sequences (5’ to 3’) R-Sequences (5’ to 3’) 
mIFIH1 TGCGGAAGTTGGAGTCAAAGCG TGCGGAAGTTGGAGTCAAAGCG 
mIFN-β AAGAGTTACACTGCCTTTGCCATC CACTGTCTGCTGGTGGAGTTCATC 
mIFN-λ CCAGTGGAAGCAAAGGATTGCC GCACCTCATGTCCTTCTCAAGC 
mIRF1 TCCAAGTCCAGCCGAGACACTA ACTGCTGTGGTCATCAGGTAGG 
mIRF7 CCTCTGCTTTCTAGTGATGCCG CGTAAACACGGTCTTGCTCCTG 
mIRF9 CAACATAGGCGGTGGTGGCAAT GTTGATGCTCCAGGAACACTGG 
mISG15 CATCCTGGTGAGGAACGAAAGG CTCAGCCAGAACTGGTCTTCGT 
mMX1 TGGACATTGCTACCACAGAGGC TGGACATTGCTACCACAGAGGC 
mPML GTCTAAGACCCAACCTGTGGCT CTTCATGGAGCCGACTGTCTGA 
mRIG-I AGCCAAGGATGTCTCCGAGGAA ACACTGAGCACGCTTTGTGGAC 
mSTAT1 GCCTCTCATTGTCACCGAAGAAC TGGCTGACGTTGGAGATCACCA 
mXAF CTGCGCTTCATAGTCCTTTGCC AGGGTGCTGTTGGCTTTCCTTG 
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Supplementary Figures 
 
 
Figure S1. ISG-coupled TagRFP overexpression and the validation of their anti-HCV activities. (A) Sequencing 
analysis of RIG-I mutation in Huh7.5 and A549 cells. The mutation of RIG-I in ORF nt 164 in Huh7.5 cells was 
indicated as red. (B) Flow cytometry analysis of GFP or RFP positive cells in Huh7.5 cells transduced with GFP 
vector at the indicated doses for 48 h. (C-F) Flow cytometry analysis of RFP positive cells in Huh7.5 cells 
transduced with ISG.ires.RFP and Fluc vector at the indicated doses for 48 h. (G) Analysis of HCV related firefly 
luciferase activity in Huh7.5-ET-Luc cells transduced with ISG or GFP vector for 24 h, 48 h or 72 h (n = 4 
independent experiments with each of 2 replicates). RLU: relative luciferase unit. Data in (G) were normalized 
to the GFP control (set as 1) and presented in dot plots. 
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Figure S2. Gene knockdown of RIG-I in Huh7.5 cells does not affect HEV infection and 5’pppRNA does not 
stimulate an antiviral response in this cells. qRT-PCR analysis and immunoblot analysis of RIG-I expression in 
Huh7.5 cells transduced with lentiviral shRNA vectors targeting RIG-I (shRIG-I(1) and shRIG-I(2)) or scrambled 
control (shSCR). (B) Stable RIG-I knockdown or scrambled control (shSCR) Huh7.5 cells were infected with HEV 
and HEV viral RNA level was analyzed by qRT-PCR 72 h after infection. (C) Huh7.5 cells and A549 cells were 
infected with HEV and HEV viral RNA level was analyzed by qRT-PCR 72 h after infection. Date in (A) and (B) 
were normalized to the scrambled control (shSCR, set as 1). Date in (C) were normalized with one 
housekeeping gene RP2 and presented relative to RP2 expression. (D) Huh7.5-p6-Luc cells were transfected 
with various concentrations of 5’pppRNA (10 ng/mL, 100 ng/mL and 1000 ng/mL). HEV related Gaussia 
luciferase activity was analyzed at 24 h, 48 h or 72 h after transfection (n = 2 independent experiments with 
each of 2 - 3 replicates). RLU: relative luciferase unit. Data were normalized to a control that transfected with 
PEI-Mix but without 5’pppRNA at each time point (24 h, 48 h and 72 h, all set as 1), respectively. 
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Figure S3. The antiviral ability of 5’pppRNA is dependent on functional RIG-I signaling. WT (RIG-I+/+) and RIG-I 
deficient (RIG-I-/-) mouse embryonic fibroblasts (MEF) cells were transfected with various concentrations of 
5’pppRNA (10 ng/mL, 100 ng/mL and 1000 ng/mL), mouse IFN genes (mIFN-β and mIFN-λ) and mouse ISGs 
including mMX1, mIRF9, mIFIH1, mSTAT1, mIRF1, mPML, mXAF, mIRF7, mISG15 and mRIG-I mRNA level was 
analyzed by qRT-PCR 24 h (A) or 48 h (B) after transfection (n = 6). Data were normalized to a control that 
transfected with PEI-Mix but without 5’pppRNA at each cell line (RIG-I+/+ and RIG-I-/-, both set as 1), 
respectively. Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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Figure S4. IFN-α activates ISG transcription in different cell lines. qRT-PCR analysis of ISG mRNA levels in 
Huh7.5-p6 cells (A) and A549-p6 cells (C) treated with IFN-α (1000 IU/mL) for 48 h (n = 4). (B) qRT-PCR analysis 
of ISG mRNA levels in Huh7.5-p6 cells transduced with RIG-I or Fluc vector or treated with IFN-α (1000 IU/mL) 
for 48 h (n = 2 - 3). Data were normalized to the untreated Fluc control (CTR, set as 1). Data are means ± SEM. 
*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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Figure S5. The ISG induction ability of mIFN-α is not attenuated in IRF3/7-/- and NFκB-/- cells. qRT-PCR analysis 
of mouse ISG mRNA levels in WT, IRF3/IRF7 double deficient (IRF3/7-/-) or NFκB deficient (NFκB-/-) mouse 
embryonic fibroblasts (MEF) cells treated with mouse IFN-α (mIFN-α, 1000 IU/mL) for 3 h (A) or 6 h (B) (n = 3). 
Data in (A) were normalized to the untreated Fluc control (CTR, set as 1). Data in (B) and (C) were normalized to 
untreated WT MEF cells (WT CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant. 
 
 
 
Figure S6. RIG-I overexpression does not trigger ISG production in HepaRG cells. Plot of qRT-PCR analysis of 
IFN gene expression in Huh7.5-p6 (A) and HepaRG-p6 cells (B) transduced with RIG-I or Fluc (CTR) vector for 48 
h. Rn: Fluorescence signal from the reporter dye normalized to that from the negative control. (C) qRT-PCR 
analysis of IFN gene mRNA levels in HepaRG-p6 cells transduced with RIG-I or Fluc vector for 48 h (n = 4). (D) 
Analysis of ISRE-related firefly luciferase activity in Huh7-ISRE-Luc cells treated with conditioned medium from 
HepaRG cells or IFN-α (100 IU/mL) for 48 h (n = 2 independent experiments with each of 2 - 3 replicates). Data 
in (C) were normalized to the Fluc control (CTR, set as 1). Data in (D) were normalized to the untreated GFP 
control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant.  
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Figure S7. JAK inhibitor CP-690550 totally abolishes IFN-α induced ISG 
transcription. (A) qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells treated 
with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h (n =5-6). (B) MTT 
assay analysis of cell viability in Huh7.5-p6 cells transduced with RIG-I vector or 
treated with IFN-α (1000 IU/mL) or CP-690550 (1000 ng/mL) for 48 h (n = 2 
independent experiments with each of 2 replicates). Data were normalized to the 
untreated control (CTR, set as 1). Data are means ± SEM. 
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Figure S8. JAK inhibitor 1 partially diminishes RIG-I-induced ISG 
transcription and anti-HEV activity. (A) Immunoblot analysis of ISG 
protein levels in Huh7.5 cells-p6 transduced with RIG-I vector or treated 
with IFN-α (1000 IU/mL) or JAK inhibitor 1 (10 µM) for 48 h. qRT-PCR 
analysis of RIG-I mRNA level in Huh7.5-p6 cells (B), analysis of ISRE-
related firefly luciferase activity in Huh7-ISRE-Luc cells (C) and MTT 
assay analysis of cell viability in Huh7.5 cells (D) transduced with RIG-I 
vector or treated with IFN-α (1000 IU/mL) or JAK inhibitor 1 (10 µM) for 
48 h (qRT-PCR: n = 4; ISRE-Luc: n = 3 independent experiments with 
each of 2 replicates; MTT: 2 independent experiments with each of 2 
replicates). (E) qRT-PCR analysis of ISG mRNA levels in Huh7.5-p6 cells treated with IFN-α (1000 
IU/mL) or JAK inhibitor 1 (10 µM) for 48 h (n =3). (F) qRT-PCR analysis of ISG mRNA levels in Huh7.5-
p6 cells transduced with RIG-I vector or treated with JAK inhibitor 1 (10 µM) for 48 h (n = 4). (G) qRT-
PCR analysis of HEV viral RNA level in Huh7.5-p6 cells transduced with RIG-I vector or treated with 
IFN-α (1000 IU/mL) or JAK inhibitor 1 (10 µM) for 48 h (n = 6). For immunoblot results (A), band 
intensity of each lane was quantified by Odyssey Software. Immunoblot quantification results were 
normalized to β-actin expression and control was set as 1. Data in (B, E, F and G) were normalized to 
the untreated Fluc control (CTR, set as 1). Date in (C and D) were normalized to the untreated GFP 
control (CTR, set as 1). Data are means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not 
significant.  
 
 
Figure S9. JAK inhibitor 1 partially diminishes RIG-I-induced ISG transcription 
and anti-HEV activity in HepaRG cells. (A) Immunoblot analysis of RIG-I mRNA 
level in HepaRG-p6 cells transduced with RIG-I vector or treated with IFN-α (1000 
IU/mL) or JAK inhibitor 1 (10 µM) for 48 h. qRT-PCR analysis of ISG mRNA levels 
(B) and HEV viral RNA (C) level in HepaRG-p6 cells transduced with RIG-I vector or 
treated with JAK inhibitor 1 (10 µM) for 48 h. Immunoblot quantification results 
were normalized to β-actin expression and control was set as 1. Data in (B and C) 
were normalized to the untreated Fluc control (CTR, set as 1). Data are means ± 
SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. 
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Figure S10. IFN-α does not induce ISG expression in STAT1 deficient cells. (A) qRT-PCR analysis of ISG mRNA 
levels in WT and STAT1 deficient (STAT1-/-) fibrosarcoma cells treated with IFN-α (1000 IU/mL) for 48 h (n = 4). 
Date were normalized to untreated WT and STAT1-/- cells, respectively (both set as 1). Data are means ± SEM. 
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Dear Editor: We read with great interest the paper by Dao Thi et al1 reporting that sofosbuvir inhibits 
hepatitis E virus (HEV) infection and results in an additive effect when combined with ribavirin in 
vitro. This observation emphasizes the potential of sofosbuvir as an add-on therapy to ribavirin for 
the treatment of HEV infected patients.  
Sofosbuvir is a direct-acting antiviral drug against hepatitis C virus (HCV) by targeting the 
NS5B RNA-dependent RNA polymerase. RNA-dependent RNA polymerase is responsible for initiating 
and catalyzing viral RNA synthesis. Sofosbuvir metabolizes to a pharmacologically active uridine 
analog triphosphate (GS-461203) upon entry into cells. This active form then binds to NS5B and is 
incorporated into the viral RNA, leading to the termination of viral RNA synthesis.2 Because of a high 
curative rate, modest side effect profile, and a temporally reduced therapy, sofosbuvir has achieved 
great success for the treatment of chronic HCV infection. Both HCV and HEV are single-stranded RNA 
virus that have characteristics in common with respect to hepatocyte tropism, life-cycle, and 
requirement of RNA polymerase for replication. Although hepatitis E has evolved into a global health 
issue, there is no proven medication available. The strategy employed by Dao Thi et al to discover 
potential anti-HEV drugs from existing approved antiviral medications is highly relevant and cost 
effective. A successful analogous example of this strategy is the use of lamivudine for the treatment 
of both chronic hepatitis B and human immunodeficiency virus (HIV)/AIDS. Lamivudine is an 
analogue of cytidine. It can inhibit both HIV (type 1 and 2) and hepatitis B virus reverse transcriptase, 
leading to the termination of DNA synthesis, which provides a rational explanation to its clinical 
efficacy.  
Intriguingly, earlier study has documented the high specificity of sofosbuvir for inhibiting HCV. 
It lacks efficacy to a number of HCV-related viruses of the Flaviviridae family, including West Nile 
virus and yellow fever virus. In apparent agreement, no effect of sofosbuvir was observed on 
unrelated viruses including hepatitis B virus, HIV and influenza virus A.3 In fact, HCV and HEV are only 
distantly related. HCV belongs to the genus Hepacivirus within the family Flaviviridae, whereas HEV is 
classified as a member of the genus Orthohepevirus in the Hepeviridae family. It is thus truly 
remarkable that Dao Thi et al now have reported the anti-HEV effects of sofosbuvir in cell culture 
models. With a most sensitive model of a genotype 3 HEV subgenomic replicon, a median inhibition 
concentration of 1.2mmol/L was reported, and an additive anti-HEV effect was observed when 
combined with ribavirin. However, in a widely used genotype 3 replicon with a luciferase reporter 
(p6/luc),4 only approximately 50% of inhibitory effect was observed even with treatment of 10 
mmol/L of sofosbuvir. Strikingly, no antiviral activity was observed in a genotype 1 (Sar55/S17/luc) 
replicon system.  
As a potent HCV polymerase inhibitor, the median effective concentration values of 
sofosbuvir against fulllength replicons of HCV from genotypes 1a, 1b, 2a, 3a, and 4a, and chimeric 1b 
replicons encoding NS5B from genotype 2b, 5a, or 6a have been reported to range from 0.014 to 
0.11 mmol/L. Similarly, we observed a median effective concentration of 0.018 mmol/L against HCV 
replication when using Huh7-based replicon containing a subgenomic HCV bicistronic replicon 
(1389/NS3-3V/LucUbiNeo-ET) linked to the firefly luciferase reporter gene. In contrast, we only 
observed very limited effect of sofosbuvir on HEV (100 mmol/L inhibited luciferase activity by only 
10%) by using the HEV genotype 3 (Kernow-C1, P6) replicon cell model containing a luciferase 
reporter.4  
Chapter 8 
142 | P a g e  
These distinct effects of sofosbuvir on HCV and HEV suggest a rather low affinity toward the 
HEV polymerase, if any exists. We interpret these data that sofosbuvir is likely not a candidate ready 
for the treatment of hepatitis E. Nevertheless, sofosbuvir may represent as a starting point for the 
development of bona fide HEV polymerase inhibitors, but this will require knowledge on the 
crystallographic structure of the HEV polymerase. 
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Abstract  
There is a pressing need for discovering effective antiviral treatment for hepatitis E virus (HEV) 
infection. A recent study reported that sofosbuvir, an anti-hepatitis C virus (HCV) drug that targets its 
RNA-dependent RNA polymerase (RdRp), has potent anti-HEV effect in cell culture. Given the 
important potential clinical implications, this study has comparatively assessed the antiviral efficacy 
of sofosbuvir in both HCV and HEV models. In contrast to HCV, we found that HEV was not sensitive 
to inhibition by sofosbuvir. In coinfection models of HCV and HEV, sofosbuvir markedly inhibited HCV, 
but not HEV. Furthermore, sofosbuvir did not inhibit HEV RdRp activity in vitro. Our study suggests 
that sofosbuvir is likely not valuable in the treatment of HEV or HEV/HCV coinfected patients.  
 
Keywords: Antiviral; Sofosbuvir; Hepatitis E Virus; Hepatitis C Virus 
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Introduction 
Hepatitis E virus (HEV) infection is emerging as a global health issue. HEV genotypes 1 and 2 are 
prevalent in developing countries in which they cause both epidemic and sporadic hepatitis. HEV 
genotypes 3 and 4 are zoonotic viruses which infect both human and animal species.1 HEV infection 
is generally self-limiting and asymptomatic with consequent of low mortality rates. However, in 
immunocompromised patients, such as patients receiving organ transplantation, more than 60% of 
HEV-infected patients will develop chronic disease and quickly progress towards severe liver 
complications such as fibrosis and cirrhosis. Since there are no approved clinical drugs for HEV, the 
management of chronic HEV patients mostly depends on manipulation of immunosuppression drugs, 
either dose-reduction or even withdrawal of these drugs (if possible).2 Moreover, ribavirin, pegylated 
interferon-α, or combination of both drugs have been used as off-label antiviral drugs with varying 
success rate. However, HEV mutations associated with ribavirin treatment failure have been 
reported. 3,4 Therefore, the development of more effective antiviral drugs for HEV is urgently 
required. The search for new anti-HEV drugs based on clinically available antiviral medicine is a 
costeffective and highly relevant approach in the clinical settings. In this context, sofosbuvir (SOF), 
the direct-acting anti-hepatitis C virus (HCV) drug (targeting HCV RdRp; RNA-dependent RNA 
polymerase), has been recently reported to be a potential anti-HEV drug candidate.5 However, we 
believe that the anti-HEV and anti-HCV potency of SOF should be comparatively assessed, before 
proposing its clinical application for treating HEV-infected patients.  
Results and Discussion 
In this study, the potential anti-HEV effect of SOF was investigated in HEV replication models with 
concentrations ranging from 0.01 μΜ to 10 μΜ (Supplementary Figure 1A), which is comparable to 
the previous study.5 In this model, human hepatoma Huh7 cells were transfected with a subgenomic 
construct of HEV coding sequence derived from genotype 1 (Sar55/S17/luc) and genotype 3 (Kernow-
C1, p6-luc), in which the 5’ portion of open reading frame 2 (ORF2) coding sequence was replaced 
with a gene encoding a secreted form of Gaussia luciferase. To normalize for non-specific effects of 
SOF on luciferase signals, Huh7 cells stably expressing a non-secreted firefly luciferase under control 
of the human phosphoglycerate kinase (PGK) promotor (PGK-Luc) was used. In addition, Huh7 cells 
harboring a subgenomic HCV bicistronic replicon (I389/NS3- 3V/LucUbiNeo-ET; Huh7-ET) was used as 
control of anti-HCV activity.6 We demonstrated that SOF significantly reduced and even eliminated 
HCV-driven luciferase activity at 24 and 48 hours of treatments, but did not affect the PGK-driven 
luciferase activity. However, an antiviral effect of SOF was not observed in both HEV genotype 1- and 
genotype 3-based subgenomic replicon either at 24 and 48 hours of treatment (Figure 1A). 
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Figure 1. The antiviral effect of sofosbuvir (SOF) was investigated on various hepatitis E virus (HEV) and 
hepatitis C virus (HCV) models. (A) In the Huh7 cell-based subgenomic HCV replicon, treatment with SOF dose-
dependently decreased and even eliminated HCV replication-related luciferase activity. Although SOF exerted 
no effects on HEV replication in both HEV genotype 1-based and genotype 3-based subgenomic replicon either 
at 24 and 48 hours of treatment. PGK-Luc was used to assess nonspecific effects of SOF on luciferase signals 
(n=3 independent experiments with 2–3 replicates each). (B) SOF strongly inhibited HCV in Huh7 based full-
length JFH1-infectious model, whereas a modest effect on HEV was observed in the full-length p6 infectious 
models after the treatment of SOF at the highest concentration (10 mmol/L) for 48 hours (n=2 independent 
experiments with 2 replicates each). (C) Huh7 cell-based subgenomic HCV replicon was infected with infectious 
HEV p6 particles. SOF exerted no significant anti-HEV effect, while retained its strong effect against HCV 
replication (measured at 48 hours; n=4). (D) Huh7 cells were coinfected with both infectious HEV (p6) and HCV 
(JFH.1) particles. SOF led to the elimination of HCV at a concentration of 1 mmol/L, while exerting no significant 
effect on HEV (measured at 48 hours; n=4). 
 
We further evaluated anti-HEV effect of SOF in the full-length (Kernow-C1, p6) infectious 
models of HEV genotype 3. The infectious HCV model, containing full-length JFH1-derived genome, 
was used as the control of antiviral activity.7 In this model, only a modest effect was observed after 
the treatment of SOF at the highest concentration (10 μM) for 48 hours (Figure 1B). In contrast, SOF 
strongly inhibited HCV in HCV infectious model. At concentration of 1 μM, SOF completely eliminated 
HCV RNA replication (Figure 1B). These results showed the highly specific effect of SOF against HCV 
replication.  
We then examined whether SOF could directly inhibit the activity of HEV RNA-dependent 
RNA polymerase enzyme. An in vitro RdRp assay8 was conducted to evaluate the effect of SOF on 
HEV RdRp activity. Huh7 purified RdRp-Flag was used in the presence of increasing dose of SOF. As 
template, an in vitro transcribed RNA containing 130 bases from 5’-end and 210 bases from 3’-end of 
HEV genotype 1 was employed. Addition of SOF at any of the concentrations tested did not inhibit 
HEV RdRp activity as measured by the level of double stranded RNA intermediate level (680 bases) 
(Supplementary Figure 1B).  
Acute and chronic HEV patients may develop extra-hepatic manifestations such as 
neurological and kidney complications.1 Therefore, we established HEV genotype 3-based infectious 
and replication models in human embryonic kidney epithelial cell line HEK 293T cells and human 
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glioblastoma cell line U-87 MG cells. We then explored the anti-HEV potential of SOF in these cell 
lines. In line with the results observed in Huh7-based HEV replication model, we did not observe any 
effect of SOF on both HEK 293T and U-87 MG based HEV replication models (Supplementary Figure 
1C). Furthermore, in both HEK 293T cell and U-87 MG cell based HEV infectious models, only a 
moderate effect was observed after the treatment of SOF at the highest concentration (10 μM) for 
48 hours (Supplementary Figure 1D). This is consistent with the result in Huh7 based HEV infectious 
model. The similar results we obtained from both hepatic and extra-hepatic cell lines further 
emphasized the highly specific effect of SOF against HCV relative to HEV.  
In clinical settings, coinfection of HCV and HEV could be found.9 To clarify whether SOF could 
inhibit viral replication of both viruses in this specific setting, Huh7-ET cells infected with infectious 
HEV particles (Kernow-C1, p6) were used as an in vitro HCV and HEV coinfection model. Surprisingly, 
SOF lost its modest effect on HEV, while retained its strong antiviral viral effect against HCV 
replication (Figure 2A). This observation was further supported by the coinfection of both infectious 
HEV (Kernow-C1, p6) and HCV particles (JFH.1) in Huh7 cells. In this model, SOF led to the elimination 
of HCV virus at the concentration of 1 μM/mL, while exerting no significant effect on HEV even at the 
concentration of 10 μM (Figure 2B). This results underscored the highly specific anti-viral effect of 
SOF againts HCV.  
Based on evaluation in chronic HCV patients, the geometric mean steady state of SOF 
concentration was 828 ng•hr/mL when coadministered with ribavirin.10 The concentration was much 
lower than the concentration of SOF we used in vitro at which SOF showed modest effect on HEV (10 
μΜ of SOV is equivalent to 5294.5 ng/mL). Therefore, we suggest that SOF is likely not valuable to be 
used in the clinical settings for treating HEV-infected patients. Nevertheless, targeting HEV 
polymerase is a potential strategy to develop new antiviral drugs against HEV.  
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Supplementary Materials and Methods  
Anti-viral Agents  
Sofosbuvir (SOF) was purchased from Selleckchem (Houston, TX). Stocks of SOF were dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 10 mM.  
Cell Culture  
Human hepatoma cell line Huh7, human embryonic kidney epithelial cell line HEK 293T cells, and 
human glioblastoma cell line U-87 MG cells were cultured in Dulbecco’s modified Eagle medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin and 100 
IU/mL streptomycin.  
Stable luciferase expressing cells were generated by transducing naïve Huh7 with a lentiviral vector 
expressing the firefly luciferase gene under control of the human phosphoglycerate kinase (PGK) 
promotor (LV-PGK-Luc). LV-PGK-Luc was used as household luciferase activity for normalization and 
to determine the specific effects on viral replication-related luciferase activity.  
Hepatitis E Virus (HEV) Cell Culture Models 
A plasmid construct containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank Accession 
Number JQ679013) and a construct containing subgenomic HEV sequence coupled with a Gaussia 
luciferase reporter gene (p6-Luc) were used to generate HEV genomic RNA by using the Ambion 
mMESSAGE mMACHINE in vitro RNA transcription Kit (Life Technologies Corporation, Carlsbad, 
CA).1,2 For HEV genotype 1, we used Sar55/S17/luc subgenomic replicons coupled with a Gaussia 
luciferase reporter gene.  
The Huh7 cells, HEK 293T cells, and U-87 MG cells were collected and centrifuged for 5 min, 1500 
rpm, 4 oC. Supernatant was removed and washed with 4 mL Optimem by centrifuging for 5 min, 1500 
rpm, 4 oC. The cell pellet was re-suspended in 100 μL Optimem and mixed with p6 full-length HEV 
RNA or p6-Luc subgenomic RNA. Electroporation was performed to generate infectious or replication 
models, respectively. 
Hepatitis C Virus (HCV) Cell Culture Models  
HCV subgenomic replicon model (Huh7-ET) was based on Huh7 cells containing a subgenomic HCV 
bicistronic replicon (I389/NS3-3V/LucUbiNeo-ET) which contains the non-structural coding sequence 
of HCV and the firefly luciferase gene. Huh7-ET cells were cultured in the presence of 250 μg/mL 
G418 (Sigma).3 As an infectious model, Huh7 cells harboring the full-length JFH-1 derived HCV 
genome was used.4  
Measurement of Luciferase Activity 
To quantify the HEV replication models, the activity of secreted gaussia luciferase in the cell culture 
medium was measured using BioLux Gaussia Luciferase Flex Assay Kit (New England Biolabs, Ipswich, 
MA). Huh7-ET and PGK-Luc firefly luciferase activity was quantified by adding luciferin potassium salt 
(100 mM, Sigma) to the cells and then incubating for 30 minutes at 37 oC. Both gaussia and firefly 
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luciferase activities were quantified with a LumiStar Optima luminescence counter (BMG labTech, 
Offenburg, Germany).  
Quantitative Real-Time Polymerase Chain Reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total RNA 
using a cDNA Synthesis Kit (Takara Bio Inc). The cDNA of HEV, HCV, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), and human retinitis pigmentosa 2 (RP2) were amplified by 50 cycles and 
quantified with a SYBRGreen-based real-time PCR (MJ Research Opticon, Hercules, CA, USA) 
according to the manufacturer’s instructions. GAPDH and RP2 were considered as reference genes to 
normalize gene expression. The qPCR primer sequences listed as follows: HEV-F 5’- 
ATTGGCCAGAAGTTGGTTTTCAC-3’; HEV-R 5’-CCGTGGCTATAATTGTGGTCT-3’; HCV-F 5’- 
GTCTAGCCATGGCGTTAGTATGAG-3’; HCV-R 5’-AGATGTTCAGGCACTTGGCGG-3’; GAPDH-F 5’- 
TGTCCCCACCCCCAATGTATC-3’; GAPDH-R 5’-CTCCGATGCCTGCTTCACTACCTT-3’; RP2-F 5’- 
GTCAGAGACAGAAGAGCAGCGA-3’; RP2-R 5’- GGACACTTCCTTTGTCTGAACTAG-3’  
MTT assays 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was added to 
cells seeded in 96-well plates. The cells was incubated at 37 oC with 5% CO2 for 3 h. The culture 
medium was then removed and 100 μl of DMSO was added to each well. The absorbance of each 
well was read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 nm. All 
measurements were performed in triplicates.  
HEV RNA-dependent RNA-polymerase (RdRp) Assay  
HEV RdRp assay was performed as described previously.5 SOF was added to the reaction mixture at 
the indicated final concentrations (1, 10, 100 μM).  
Statistical Analysis  
Statistical analysis was performed using the nonpaired, nonparametric test (Mann-Whitney test; 
GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values <.05 were considered 
statistically significant. 
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Supplementary figure 1. The antiviral effect of SOF was evaluated on extra-hepatic cell based HEV models. (A) 
The effects of SOF on hepatic and extra-hepatic cell lines were determined by MTT assay. SOF showed 
relatively strong cytotoxicity at the concentration of 100 μΜ. (B) Effect of SOF on HEV RdRp activity in vitro. 
RdRp assay was performed using purified HEV RdRp and a 340 base HEV RNA template. Schematic illustrates 
the position of dsRNA (+,-) and ssRNA. (C) SOF exerted no antiviral effect on both HEK 293T and U-87 MG based 
HEV replication models (n = 3 independent experiments with 2–3 replicates each). (D) In both HEK 293T cell 
and U-87 MG cell based HEV infectious models, a moderate anti-HEV effect was observed after the treatment 
of SOF for 48 hours (n = 2 independent experiments with 2 replicates each). 
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As highlighted by an Editorial in the December, 2016, issue of The Lancet Gastroenterology & 
Hepatology,1 many gaps still exist in our knowledge of hepatitis E virus (HEV). Genotypes 3 and 4 
infections can cause chronic hepatitis, cirrhosis that develops quite rapidly after infection, and extra-
hepatic manifestations such as neurological symptoms and kidney injuries. Ribavirin monotherapy is 
effective for treating chronic HEV and HEV-associated glomerular disease, with sustained virological 
responses (SVRs) of 85–90%. For patients who relapse, retreatment with ribavirin for a longer 
period—eg, 6 months instead of 3 months—achieves viral clearance in some. However, for a few 
patients, ribavirin treatment fails. Mutations in HEV RNA polymerase have been noted before or 
during therapy in patients who relapse. However, the clinical relevance of such mutations in 
treatment failure is uncertain since findings from in-vitro studies show that some of these mutations 
facilitate HEV replication but paradoxically seem to increase ribavirin sensitivity. Effective antiviral 
therapy is therefore needed for HEV-infected patients with ribavirin treatment failure.  
 
 
Figure 1. Both HCV and HEV are single-standard RNA viruses that primary infect the liver and cause hepatitis. 
Both have the RNA-dependent RNA polymerase (RdRp) that is responsible for the replication of the viral 
genome. Sofosbuvir is a potent inhibitor of HCV RdRp that effectively cure chronic hepatitis C patients. It is an 
intriguing question whether sofosbuvir is also an inhibitor of HEV RdRp, and can be used to treat hepatitis E 
patients? (MT, Methyltransferase; Y, Y-domain; Pro, protease; Hel, helicase; RdRp, RNA-dependent RNA 
polymerase).  
 
In-vitro data suggest that sofosbuvir, a direct-acting antiviral (DAA) agent against hepatitis C 
virus (HCV), can inhibit HEV replication and exert an additive effect when combined with ribavirin.2 
Sofosbuvir is a specific and potent inhibitor that targets the HCV NS5B RNA-dependent RNA 
polymerase (Figure 1). Although both HCV and HEV are single-standard RNA viruses requiring RNA 
polymerase for replication, the in-vitro efficacy of sofosbuvir against HEV reported in this study2 is 
modest, even at high concentrations, and varies among diff erent model types of HEV replication or 
infection.2 Findings from another study showed that sofosbuvir was effective at inhibiting HCV 
replication, but was much less efficacious against HEV in cell culture models of both monoinfection 
and HCV–HEV co-infection.3  
van de Walk and colleagues4 reported a case of a patient who had received stem-cell 
transplantation and was infected with HEV, who relapsed after ribavirin cessation. When retreated 
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with ribavirin, no decrease in HEV RNA was noted. Hence, sofosbuvir was added to ribavirin, which 
led to a reduction in HEV viral load. Viral clearance was achieved after two flareups but a relapse 
occurred after treatment cessation.4 In another study,5 a patient who had received a liver 
transplantation and who was chronically co-infected with HCV and HEV was given sofosbuvir and 
daclatasvir (without ribavirin) for 12 weeks. HCV SVR was achieved but no effect was noted on HEV 
viral load or on specific anti-HEV T-cell responses.5  
These in-vitro and in-vivo data suggest that sofosbuvir is unlikely to be the drug of choice for 
patients who do not clear HEV with ribavirin. No data are available for the anti-HEV activity of other 
DAAs that are used to treat HCV; however, it would be unsurprising if they were also ineffective since 
they were specifically designed and optimized for targeting HCV viral proteins. To develop effective 
DAAs for HEV, it is essential to gain more insight into the crystallographic structures of the viral 
proteins, particularly the HEV polymerase. 
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Abstract 
Hepatitis E virus (HEV) infection has emerged as a global health issue; whereas no approved 
medication is available. The nucleoside analogue 2'-C-methylcytidine (2CMC), a viral polymerase 
inhibitor, has been shown to inhibit the infection of a variety of viruses, including hepatitis C virus 
(HCV). Here, we report that 2CMC significantly inhibits the replication of HEV in a subgenomic 
replication and a full-length infectious models. Importantly, long-term treatment with 2CMC did not 
attenuate its antiviral potency, indicating a high barrier to drug resistance development. However, 
the combination of 2CMC with ribavirin, an off-label treatment for HEV, exerts antagonistic effects. 
Our results indicate that 2CMC serves as a potential antiviral drug against HEV infection. 
 
Key words: 2’-C-methylcytidine, hepatitis E virus, replication, antiviral drug, nucleoside analogue 
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Introduction 
Hepatitis E virus (HEV) is a single-stranded, positive-sense RNA virus, and its genome consists of three 
open reading frames (ORFs). ORF1 encodes a polyprotein that has all the nonstructural proteins 
needed for HEV replication. ORF2 encodes the capsid protein of the HEV virion. ORF3 encodes a 
small multifunctional protein with a molecular mass of 13kDa [11]. HEV was initially thought to only 
cause acute infection confined only to developing countries. However, over the last decade, hepatitis 
E cases are frequently reported in developed countries, and have been recognized mainly as 
autochthonous cases rather than an imported disease [11, 12]. Generally, HEV infection is self-
limiting and asymptomatic with a consequence of low mortality rate; whereas it can cause high 
mortality in pregnant women. However, in immunocompromised patients receiving organ 
transplantation, more than 60% of HEV-infected patients will develop chronic disease and quickly 
progress towards severe liver complications such as fibrosis and cirrhosis [20]. Besides hepatitis, this 
virus has been associated with a broad range of extra-hepatic manifestations, in particular renal and 
neurological injuries [14, 21]. Therefore, the development of specific antiviral drugs for HEV infection 
is urgently required.  
Nucleoside analogues have been used in clinic for almost 50 years and represent as 
cornerstones for treating patients with cancer or viral infection. Ribavirin (RBV) has been used as an 
off-label antiviral drug showing high efficacy in many chronic HEV patients, but HEV mutations 
associated with ribavirin treatment failure have been reported [4, 7]. Sofosbuvir (SOF), a potent 
direct-acting agent (DAA) against hepatitis C virus (HCV) [2], has been recently suggested to inhibit 
HEV replication in cell culture and exert an additive effect when combined with ribavirin [4]. 
However, other in vitro and clinical studies have demonstrated that sofosbuvir is not very effective 
against HEV infection [8, 18, 19], suggesting that this drug might not a promising candidate for the 
treatment of chronic HEV patients.  
2'-C-methylcytidine (2CMC) was initially identified as a competitive inhibitor of the HCV RNA-
dependent RNA polymerase (RdRp). Besides HCV, it has been shown to inhibit the replication of a 
variety of other viruses (e.g. dengue virus and norovirus) [13, 15]. It also has been reported to inhibit 
cutthroat trout virus, a non-pathogenic fish virus, which is remarkable similar to HEV [6]. In this study, 
we have demonstrated that 2CMC efficiently inhibit HEV replication, thus serves as a potential 
candidate for anti-HEV drug development. 
Materials and Methods 
Reagents and Antibodies  
2CMC, RBV, Guanosine triphosphate (GTP) and Cytidine 5’-Triphosphate (CTP) were  purchased from 
Sigma-Aldrich, and were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO). The 
HEV-specific antibody was purchased from EMD Millipore (MAB8002). 
HEV Cell Culture Models 
Multiple cell lines were employed in this study, including human hepatoma cell line (Huh7 and 
PLC/PRF/5), human embryonic kidney cell line (HEK293), human primary glioblastoma cell line (U87), 
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human fetal lung fibroblast cell line (MRC5). Huh7 and U87 cell lines were kindly provided by 
Professor Bart Haagmans from Department of Viroscience, Erasmus Medical Center. Human 
embryonic kidney 293 cell line, PLC/PRF/5 and MRC5 were originally obtained from ATCC 
(www.atcc.org). These cells were cultured in Dulbecco’s modified Eagle medium (Lonza Biowhittaker, 
Verviers, Belgium) supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin. For the full-length HEV model, a plasmid construct containing the full-length HEV 
genome (Kernow-C1 p6 clone; GenBank Accession Number JQ679013) was employed to generate 
HEV genomic RNA by using the Ambion mMessage mMachine in vitro RNA transcription Kit (Thermo 
Fisher Scientific Life Sciences) [16]. Huh7, PLC/PRF/5, HEK293, U87 and MRC5 cells were 
electroporated with full-length HEV genome RNA to generate consecutive HEV-infected cell models 
(Huh7-p6, PLC/PRF/5-p6, HEK293-p6, U87-p6 and MRC5-p6). To generate the subgenomic (p6-Luc) 
HEV model, a plasmid construct containing subgenomic HEV was used. This plasmid has an HEV 
sequence in which the 5’ portion of HEV ORF2 was replaced with the in-frame Gaussia princeps 
luciferase reporter gene [16]. Huh7, U87 and HEK293 cells were electroporated with HEV 
subgenomic RNA to generate HEV subgenomic models (Huh7-p6-Luc, U87-p6-Luc, and HEK293-p6-
Luc). To normalize non-specific effects of 2CMC on the luciferase signal, Huh7 cells stably expressing 
a non-secreted firefly luciferase under control of the human phosphoglycerate kinase (PGK) 
promotor (PGK-Luc) were used [18]. In addition, Huh7 cells harboring a subgenomic HCV bicistronic 
replicon (I389/NS3-3V/LucUbiNeo-ET) (Huh7-HCV-Luc) were used as positive control of antiviral 
activity.  
Quantification of HEV Replication 
For Gaussia luciferase, the secreted luciferase activity in the cell culture medium was measured by 
BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). Gaussia luciferase activity was 
quantified with a LumiStar Optima luminescence counter (BMG LabTech, Offenburg, Germany). For 
the full-length infectious models (HEV-p6), intracellular viral RNA was quantified. RNA was isolated 
with a Machery-Nucleo Spin RNA II kit (Bioke, Leiden, The Netherlands) and quantified using a 
Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total RNA using a cDNA 
Synthesis Kit (TAKARA BIO INC). HEV RNA level was quantified with a SYBR Green-based real-time 
PCR (Applied Biosystems® SYBR® Green PCR Master Mix, Life technologies, CA, USA) according to the 
manufacturer's instructions. PCR steps consisted of a 10 min holding stage (95 ℃) followed by 40 
cycles of 15 s at 95 ℃, 30 s at 58 ℃, and 30 s at 72 ℃. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was considered as reference gene to normalize gene expression. Relative gene expression 
was normalized to GAPDH using the formula 2−ΔΔCT (ΔΔCT = ΔCTsample − ΔCTcontrol). The HEV primer 
sequences were as followed: HEV-F 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’; HEV-R 5’-
CCGTGGCTATAATTGTGGTCT-3’; GAPDH-F 5’-TGTCCCCACCCCCAATGTATC-3’; GAPDH-R 
5’CTCCGATGCCTGCTTCACTACCTT-3’. 
MTT assay 
The cells were seeded in 96-well and 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide (MTT) (Sigma) was added to cells. Subsequently, the cells were incubated at 37 ℃ with 5% 
CO2 for 3 h. The culture medium was then removed and 100 μl of DMSO was added to each well. The 
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absorbance of each well was read on the microplate absorbance readers (BIO-RAD) at wavelength of 
490 nm. 
Long-term treatment assay 
For the long-term treatment assay of subgenomic model (Huh7-p6-luc), the cells were seeded into 96 
wells with 5000 cells per well. The cells of CTR or 2CMC treatment groups were passaged and seeded 
with the same cell numbers every 3 days (d), meanwhile maintaining the cell incubated with vehicle 
(non-treatment) or 2CMC (10 µM) respectively throughout the entire incubation period. For the 
long-term treatment assay of infectious model (Huh7-p6), the cells were seeded into 48 wells with 
2×104 cells per well. The cells of CTR or 2CMC treatment groups were passaged and seeded with the 
same cell numbers every 3 days, meanwhile maintaining the cell incubated with vehicle (non-
treatment) or 2CMC (10 µM) respectively throughout the entire incubation period. 
Western blot assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT and heated 5 mins at 95 ℃, 
followed by loading onto a 10 % sodium dodecyl sulfate polyacrylamide gel and separation by 
electrophoresis. After 90 mins running at 120 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride membrane (Invitrogen) for 1.5 h with an electric current of 250 mA. 
Subsequently, the membrane was blocked with a mixture of 2.5 ml blocking buffer (Odyssey) and 2.5 
ml phosphate-buffered saline containing 0.05% Tween 20. It was followed by overnight incubation 
with anti-HEV capsid protein primary antibodies (1:1000) at 4 ℃. The membrane was then washed 3 
times followed by incubation for 1 h with goat anti-mouse IRDye-conjugated secondary antibody (Li-
COR Biosciences, Lincoln, USA) (1:5000). After washing 3 times, protein bands were detected with 
the Odyssey 3.0 Infrared Imaging System. 
IC50 and CC50 calculation  
50% inhibition concentration (IC50) value and 50% cytotoxic concentration (CC50) were calculated 
based on model Y¼Bottom þ (Top-Bottom)/ (1 þ 10^((LogIC50-X)*HillSlope)) by using GraphPad 
Prism 5 software (GraphPad Prism 5; GraphPad Software Inc., La Jolla, CA, USA). 
Statistical Analysis 
Statistical analysis was performed using the nonpaired, nonparametric test with Mann-Whitney test 
and one-way ANOVA with Tukey’s Multiple Comparison post-test (GraphPad Prism version 5.01; 
GraphPad Software). P values <0.05 were considered statistically significant. 
Results 
In this study, the potential anti-HEV effect of 2CMC was investigated in HEV replication models with 
concentrations ranging from 0.1 μΜ to 10 μM. We demonstrated that 2CMC significantly reduced 
HEV-driven luciferase activity, and the anti-HEV activity was even comparable with its anti-HCV effect 
at the concentration of 10 µM (Fig. 1A). IC50 value of 2CMC against HEV replication was 1.64 µM, 
CC50 of 2CMC to Huh7 cells was 111.2 µM and selectivity index (SI, CC50/IC50) was 67.8 (Fig. 1B). 
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The anti-HEV effect of 2CMC was further confirmed in the full-length (Kernow-C1, p6) infectious 
model of HEV genotype 3 by both RT-PCR assay (Fig. 1C) and western blot assay (Fig. 1D). 
 
Figure 1. 2CMC exerts potent 
anti-HEV effect. (A) Huh7-p6-
Luc cells and Huh7-HCV-Luc 
cells were treated with 
indicated concentrations of 
2CMC for 24h, 48h, or 72h, and 
the untreated (CTR) group 
serves as control. Luciferase 
value was measured at 
indicated time points. Data are 
means ± SEM of four 
independent experiments; CTR 
means the non-treatment 
control. *P < 0.05; **P < 0.01; 
***P < 0.001. (B) Huh7-p6-Luc 
cells were treated with 10 μM 
2CMC for 48 h. 50% inhibition 
concentration (IC50) and 50% 
cytotoxic concentration (CC50) 
of 2CMC against HEV 
replication were calculated 
using GraphPad Prism 5 
software. (C) Huh7-p6 cells 
were treated with indicated 
concentrations of 2CMC for 48 
h. RT-PCR analysis of HEV RNA 
or Cell viability analysis were 
performed. Data are means ± 
SEM of four independent 
experiments; CTR means the 
non-treatment control. Abs 490 
means absorption at 490 nm. 
***P < 0.001. (D) Immunoblot analysis of HEV ORF2 protein level in Huh7 cell based HEV infectious cell model 
(Huh7-p6) treated with 2CMC (10 µM) for 48 h. Data are means ± SEM of four independent experiments; CTR 
means the non-treatment control. *P < 0.05. (E) Hepatic and extra-hepatic cells were treated with indicated 
concentrations of 2CMC for 48 h. RT-PCR analysis of HEV RNA was performed. Data are means ± SEM of four 
independent experiments; CTR means the non-treatment control. (F) HEK293T-p6-luc and U87-p6-luc cells 
were treated with indicated concentrations of 2CMC for 48 h and then were subjected to luciferase activity 
analysis. Data are means ± SEM of three independent experiments; CTR means the non-treatment control. *P < 
0.05. (G) Indicated cells were treated with 2CMC for 48 h and then the cells were subjected to cell viability 
analysis using MTT assay. 
 
Since HEV related extra-hepatic manifestations have been reported [12], we extended our 
study to some other hepatic and extra-hepatic cell lines. HEV infectious or replication models were 
established in HEK293, PLC/PRF/5, MRC5 and U87 cells. The anti-HEV potential of 2CMC in these cell 
lines was tested. In line with the results observed in Huh7-based HEV replication and infectious 
models, we observed similar anti-HEV effect of 2CMC in all these cell models without affecting the 
cell viability (Fig. 1E to G).  
Drug resistance is a main factor that limits the effectiveness of the antiviral treatment. To 
characterize 2CMC in this respect, we performed experiments in which both HEV replication and 
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infectious models were constantly exposed to 2CMC (10 μM). Interestingly, 2CMC retained its anti-
HEV activity in both models even after long-term exposure (Fig. 2A and B). Furthermore, the negative 
control retained high levels of luciferase activity after long-term incubation with 2CMC, excluding the 
loss of cell viability during the experimental period (Fig. 2C). Taken together, 2CMC displays a high 
barrier for drug resistance development. 
Figure 2. 2CMC retains anti-
HEV effect in Huh7-p6-luc and 
Huh7-p6 models after long-
term treatment. (A) Treatment 
of 2CMC in the Huh7-p6-luc 
model for 27 days. The cells 
were passaged every 3 days, 
and were incubated with 
vehicle (non-treatment) or 
2CMC (10 μM ) throughout the 
entire period. Data are means 
± SEM of four independent 
experiments; CTR means the 
non-treatment control. (B) 
Treatment of 2CMC in the 
Huh7-p6 model for 15 days. 
The cells were passaged every 
3 days, and were incubated 
with vehicle (non-treatment) 
or 2CMC (10 μM ) throughout 
the entire period. Data are 
means ± SEM of four 
independent experiments. (C) Treatment of 2CMC in the Huh7-p6-luc model for 27 days. The absolute 
luciferase values of Huh7-p6-luc cells are measured at indicated time points. 
Figure 3. Combination of 
CTP and GTP with 2CMC in 
Huh7-p6-luc model (A) and 
Huh7-p6 (B) cell models. 
The cells were treated with 
2CMC, CTP or GTP, alone or 
in combination for 72 h 
before measurement of 
luciferase activity. Data are 
means ± SEM of four to six 
independent experiments. 
*P < 0.05; **P < 0.01; ***P 
< 0.001; ns, not significant. 
 
 
 
 
 
 
Figure 4. 2CMC antagonizes ribavirin in the Huh7-p6-luc model. (A) The Huh7-p6-Luc cells were treated with 
2CMC and ribavirin, alone or in combination, for 72 h before analysis of luciferase activity. Untreated group 
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serves as control. (B) The 
combinatory effect of 2CMC and 
ribavirin on HEV replication was 
analyzed using the mathematical 
model MacSynergy. The three-
dimensional surface plot represents 
the differences (within 95% 
confidence interval) between actual 
experimental effects and theoretical 
additive effects of the combination 
at various concentrations of the two 
compounds. Data are means ± SEM 
of three independent experiments. 
 
 
 
 
Theoretically, 
nucleoside/nucleotide analogs 
serve as potential direct-acting 
antivirals because they bind to 
the viral RNA polymerase active 
site to block viral replication. To evaluate the inhibitory specificity of 2CMC against HEV replication, 
we performed a competition assay employing the substrate cytidine triphosphate (CTP) as an 
analogous competitor of 2CMC. Our results indicated that the CTP dose-dependently reversed the 
inhibitory effects of 2CMC on HEV replication activity. In contrast, guanosine triphosphate (GTP) 
exerted no effect, implying the inhibitory specificity of 2CMC against HEV replication (Fig. 3A and B). 
Another nucleoside analogue, ribavirin, has been used as an off-label treatment for HEV infection in 
clinic. Thus, its combination with 2CMC was tested related to their anti-HEV effects. Interestingly, a 
moderate antagonistic effect (-36.93 µM2 %) was observed, implying a similar antiviral mechanism 
they employed (Fig. 4A and B). 
Discussion 
Nucleoside analogue has been used against a variety of viruses due to its broad spectrum of antiviral 
effects and its high barrier to drug resistance development. Ribavirin, an guanosine analogue, is the  
choice for treating most of the chronic HEV patients. However, treatment failure has been observed 
in some cases. Sofosbuvir, a prodrug of a uridine nucleoside analogue that is very effective against 
HCV, has been recently investigated for its anti-HEV potency. However, debates have been sparked 
regarding its potency against HEV [9, 17]. 2CMC, a cytidine nucleoside analogue, has been shown to 
inhibit the infection of a variety of viruses, including HCV and HIV [5]. In this study, we have 
demonstrated that 2CMC potently inhibits HEV replication in different cell models, even though a 
slight difference between these different cell models (Fig 1A and C). The possible explanation is that 
these models recapitulate the different steps of the HEV life cycle. The full-length infectious clone 
(Huh7-p6) models the entire cycle of HEV infection; whereas the subgenomic model (Huh7-p6-luc) 
only mimics viral replication due to lacking of ORF2 and ORF3.  
Encouragingly, the anti-HEV activity was even comparable with its anti-HCV effect at 
particular concentrations. More importantly, In the long-term treatment experiment, 2CMC displays 
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a high barrier to resistance development. Furthermore , we have extensively demonstrated that it is 
a specific anti-HEV effect, but not due to cytotoxicity. It has been suggested that after absorbed into 
the cells, 2CMC is converted to its 5′-triphosphates (2CMC-CTP) which serves as active molecule that 
compete with natural substrate CTP. Consistently, our results have demonstrated that CTP but not 
GTP reverses the anti-HEV effect of 2CMC, revealing a potential mechanism-of-action of 2CMC 
against HEV. 
Since ribavirin has been widely used to treat chronic HEV patients, a combined therapy of 
ribavirin with 2CMC might be envisaged. To test this, the combinatory effects of both drugs were 
investigated. Unexpectedly, an antagonistic effect was observed. These findings are in agreement 
with the earlier observation of the combinatory effects of ribavirin and 2CMC on HCV and HIV [3].  
Of note, the potential adverse effects of 2CMC should be carefully evaluated in future studies. 
The clinical applications of nucleoside analogues have been limited in some cases due to the off 
target effects. Mitochondrial DNA polymerase is an important off target for many nucleoside 
analogues. It has been reported that the nucleoside analogue containing 2-C-methyl (2-CM) could 
reduce mitochondrial transcription and oxidative phosphorylation, resulting in dysfunction of cell 
metabolism [1, 10]. Therefore, efforts for the future anti-HEV drug development are proposed to 
focus on the design of less toxic agents based on the main chemical structure of 2CMC. 
In conclusion, 2CMC exerts potent anti-HEV effects in well-established cell culture models, 
and serves as a potential backbone for anti-HEV drug design. To achieve better efficacy and less side 
effects, future research is still required for drug optimization based on the chemical structure of 
2CMC. 
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Abstract 
Although hepatitis E has emerged as a global health issue, there is limited knowledge of its infection 
biology and no FDA-approved medication is available. Aiming to investigate the role of protein 
kinases in hepatitis E virus (HEV) infection and to identify potential antiviral targets, we screened a 
library of pharmacological kinase inhibitors in a cell culture model, a subgenomic HEV replicon 
containing luciferase reporter. We identified protein kinase C alpha (PKCα) as an essential cell host 
factor restricting HEV replication. Both specific inhibitor and shRNA-mediated knockdown of PKCα 
enhanced HEV replication. Conversely, over-expression of the activated form of PKCα or treatment 
with its pharmacological activator strongly inhibited HEV replication. Interestingly, upon the 
stimulation by its activator, PKCα efficiently activates its downstream Activator Protein 1 (AP-1) 
pathway, leading to the induction of antiviral interferon-stimulated genes (ISGs). This process is 
independent of the JAK-STAT machinery and interferon production. However, PKCα induced HEV 
inhibition appears independent of the AP1 cascade. The discovery that activated PKCα restricts HEV 
replication reveals new insight of HEV-host interactions and provides new target for antiviral drug 
development.  
 
Keywords: PKCα, hepatitis E virus, PMA, AP-1, ISG 
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Introduction  
Hepatitis E virus (HEV) is one of the most common causes of acute viral hepatitis in the world. 
Although the mortality rate is < 1% among the general population, pregnant women can have a 
fatality rate of up to 30% (1). Additionally, chronic hepatitis E has become a significant clinical 
problem in immunocompromised patients. Up to date, there is still no proven medication available 
and its infection biology is poorly understood. 
Protein kinases are principal components of the machineries that orchestrate immune 
response against diverse pathogenic entities, including viruses, by subsequent stimulation of specific 
signal transduction cascades (2). However, kinase controlled pathways employed by the host cells to 
stimulate antiviral immunity remain largely obscure. Knowledge of such pathways could prove 
exceedingly useful for the rational design of therapeutic avenues against HEV infection. 
Encouragingly, numerous pharmacological kinase inhibitors or activators have been 
developed to target particular kinases. Among those, several are approved drugs in particular for 
treating cancer (3), and many are currently at various stages of preclinical and clinical development. 
These compounds have broad implications for treating various diseases, including cancer, 
inflammation, diabetes and viral infections (4, 5).  
Thus, this study aims to comprehensively profile kinase-mediated cascades in cell–
autonomous antiviral immunity starting from screening a library of pharmacological kinase inhibitors 
in Huh7 based HEV replication cell model. We identified protein kinase C alpha (PKCα) as an 
important anti-HEV mediator. Concurrently, we also revealed a novel function of PKC-Activator 
Protein 1 (AP-1) pathway, serving as a non-canonical pathway to activate transcription of antiviral 
interferon-stimulated genes (ISGs).  
Materials and Methods 
Reagents and Antibodies 
Stocks of phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St Louis, MO) and JAK inhibitor I 
(Santa Cruz Biotech, Santa Cruz, CA) were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St 
Louis, MO) to concentrations of 100 µg/ml and 20 mM, respectively. Antibodies including phospho-
PKCα/β (#9375), phospho-STAT1 (58D6, #9167), c-Fos (9F6, #2250), RelA (C22B4, #4764), Anti-rabbit 
IgG(H+L),F(ab') 2 Fragment (Alexa Fluor 488 conjugate) and Anti-mouse IgG (H+L), F(ab')2 Fragment 
(Alexa Fluor® 488 Conjugate) were purchased from Cell Signaling Technology, the Netherlands. Anti-
rabbit or anti-mouse IRDye-conjugated antibodies were used as secondary antibodies for western 
blotting (Stressgen, Victoria, BC, Canada). 
Viruses and cell culture models 
Hepatocellular carcinoma cells Huh7 were kindly provided by Professor Bart Haagmans from 
Department of Viroscience, Erasmus Medical Center. Human Embryonic Kidney 293 cells were 
originally obtained from ATCC (www.atcc.org). The HEV infectious model (Huh7-P6) was based on 
Huh7 cells containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank Accession Number 
JQ679013) (6). Infectious HEV particles are generated and secreted into cell culture medium, which 
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can be collected and used for secondary infection (7-10). The HEV subgenomic model was based on 
Huh7 cells containing the subgenomic HEV sequence (Kernow-C1 p6/luc) coupled to a Gaussia 
luciferase reporter gene. HEV replication defective model was based on Huh7 cells transfected with 
in vitro transcribed RNA from MluI-linearized plasmids p6-luc-GAD (kindly provided by Suzanne U. 
Emerson). A mutation in the HEV polymerase results in defect of viral replication. ISRE, NF-κB, AP-1 
luciferase reporter cells were generated by transducing Huh7 cells with lentiviral vectors expressing 
the firefly luciferase gene under the control of ISRE, NF-κB, AP-1 promoters, respectively (System 
Biosciences). For simian rotavirus, SA11, a well-characterized and broadly used laboratory strain, was 
used to inoculate the Caco2 cell line as a rotavirus infection model. Murine norovirus 1 (MNV-1) was 
used to infect RAW 264.7 cells as a norovirus infection model (11). The HIV virus production model 
was based on 293T cells transfected with HIV-1 molecular clone pLAI and pRL. The HIV single cycle 
entry model was based on TZM-bl cells infected with HIV clone Plai (12). For influenza virus, 
multicycle replication curves were generated by inoculating A549 cells at a multiplicity of infection 
(MOI) of 0.01 50 percent tissue culture infectious doses (TCID50) of A/Netherlands/246/1978(A/H3N2) 
or A/Netherlands/602/09 (A/H1N1) in duplicate. Supernatants were sampled at 0, 6, 12, 24, 48 and 
72 hours post inoculation, and virus titers in these supernatants were determined by means of end-
point titration in MDCK cells as described previously (13). 
Screen of pharmacological kinase inhibitors 
The kinase inhibitor library used for the screening was made available by the KU Leuven Centre for 
Drug Design & Development (www.cd3.eu). Huh7 cells were seeded in 96-well plates at 7.5 ₓ 103 cells 
per well in 100 μl of DMEM with10% FBS and were incubated at 37°C. After 24 hrs, cell layers were 
washed and transfected with capped p6/luc RNA (100 ng per well [each]) by use of DMRIE-C reagent 
(0.2 μl per well) according to the manufacturer’s instructions. Plates were incubated at 37°C for 4 hrs. 
Afterwards, the transfection medium was removed. Cell layers were washed twice with PBS and 100 
μl of compound (diluted to a final concentration of 100, 20, 4 and 0.8 μM, respectively, in DMEM 
with 10% FBS) was added to each well. For control wells, the compound was omitted. After 
incubation for 3 days, HEV replicon – related Gaussia luciferase values were measured accordingly 
(14). Cell viability (CV) caused by compound-specific side effects were also analyzed after 3 days by 
using the CellTiter 96 AQueous nonradioactive cell proliferation (monotetrazolium salt [MTS]) assay 
(Promega) (15). HEV replicon - related luciferase values were normalized with the following formula: 
Luc (Norm) = (Luc replicon + compound – Luc replicon + control) / (CV replicon + compound – CV replicon + control) 
Gene knockdown or over-expression by lentiviral vectors  
Lentiviral pLKO knockdown vectors (Sigma–Aldrich) targeting PKCα, PKCβ, IRF9, RelA, c-Fos or control 
were obtained from the Erasmus Biomics Center and produced in HEK293T cells as previously 
described (16). After a pilot study, the shRNA vectors exerting optimal gene knockdown were 
selected. These shRNA sequences are listed in Supplementary Table 2. Stable gene knockdown cells 
were generated after lentiviral vector transduction and puromycin (2.5μg/ml; Sigma) selection. 
wtPKCα and caPKCα overexpression lentivral vectors were a kind gift from Dr. Lin from the University 
of Minnesota. To create stable over-expression cell lines, GFP positive cells were sorted by cell sorter 
after lentiviral vectors transduction. 
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Reinfection assays 
Reinfection assay was performed accordingly (17). Supernatant (containing infectious HEV particles) 
was collected from Huh7-P6 HEV model and purified by ultracentrifugation. The supernatant was 
first filtered through 0.45 mm filter followed by centrifugation at 10,000 rpm for 30 min to remove 
cell debris and then 22,000 rpm for 2 hrs to pellet HEV virus (SW 28 rotor). The pellet was suspended 
and diluted to 1 × 107 HEV viral RNA copies/ml. The diluted HEV virus stock was stored at −80°C. For 
HEV infection, cells were seeded into 12-well plates at a density of 7 × 104 cells per well and 
incubated for 24 hrs. Next, cells were incubated with 400 µl HEV stock (1 × 107 viral RNA copies/ml) 
per well at 37°C for 6 hrs. Then, the inoculum was removed, and cell layers were washed 3 times 
with PBS, and 1 ml fresh medium was added to each well.  
Measurement of luciferase activity 
For Gaussia luciferase, the secreted luciferase activity in the cell culture medium was measured by 
BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs). For firefly luciferase, luciferin 
potassium salt (100 mM; Sigma) was added to cells and incubated for 30 min at 37 °C. Both Gaussia 
and firefly luciferase activity was quantified with a LumiStar Optima luminescence counter (BMG 
LabTech, Offenburg, Germany).  
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was synthesized from total RNA 
using a cDNA Synthesis Kit (TAKARA BIO INC). The cDNA of all target genes was amplified for 50 
cycles and quantified with a SYBRGreen-based real-time PCR (Applied Biosystems) according to the 
manufacturer’s instructions. GAPDH was considered as a reference gene to normalize gene 
expression. Relative gene expression was normalized to GAPDH using the formula 2−ΔΔCT (ΔΔCT = 
ΔCTsample − ΔCTcontrol). All the primer sequences are included in Supplementary Table 3. 
Western blot assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT and heated 5 mins at 95 °C, 
followed by loading onto a 10% sodium dodecyl sulfate polyacrylamide gel and separation by 
electrophoresis. After 90 mins running at 120 V, proteins were electrophoretically transferred onto a 
polyvinylidene difluoride membrane (Invitrogen) for 1.5 hrs with an electric current of 250 mA. 
Subsequently, the membrane was blocked with a mixture of 2.5 ml blocking buffer (Odyssey) and 2.5 
ml phosphate-buffered saline containing 0.05% Tween 20. It was followed by overnight incubation 
with primary antibodies (1:1000) at 4 °C. The membrane was washed 3 times followed by incubation 
for 1 hr with IRDye-conjugated secondary antibody (1:5000). After washing 3 times, protein bands 
were detected with the Odyssey 3.0 Infrared Imaging System. 
Confocal laser electroscope assay 
Huh7 cells were seeded on glass coverslips. After 12 hrs, cells were washed with PBS, fixed in 4% 
formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 0.05% tween, 5g/L skim milk 
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and 1.5g/L glycine). Samples were incubated with primary antibodies overnight at 4 °C. Subsequently, 
samples were incubated with 1:1000 dilutions of the anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa 
Fluor® 488 Conjugate) or anti-rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 conjugate) 
secondary antibodies. Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; Invitrogen). 
Images were detected using confocal electroscope. 
Creation of mutant ISRE reporter cell line 
Based on the sequence specific ISRE motif, a mutant version of ISRE was designed and synthesized 
(Forward: 5’-
aattcAGTCACGTCTTCCCTTTCAGTCACGTCTTCCCTTTCAGTCACGTCTTCCCTTTCAGTCACGTCTTCCCTTTa-
3’; Reverse: 5’-
ctagtAAAGGGAAGACGTGACTGAAAGGGAAGACGTGACTGAAAGGGAAGACGTGACTGAAAGGGAAGACG
TGACTg-3’), which shows no consensus sequence with AP-1 motif. EcoRI and SpeI sites are included 
(shown in italics) to facilitate directional cloning into the pGreenFire Lenti-Reporter vector (System 
Biosciences). The recombinant plasmid was verified by restriction enzyme digestion and DNA 
sequencing. Stable mutant ISRE reporter cells were generated after the lentiviral vector transduction 
and puromycin (2.5μg/ml; Sigma) selection. 
C-Fos ChIP-seq data analysis 
The c-Fos ChIP-seq data set with accession number GSM754332 was retrieved from the Gene 
Expression Omnibus. Sequence reads with low complexity that are unlikely to map uniquely to the 
genome were removed from the dataset using prinseq-lite with the dust method with 7 as threshold 
(18, 19). Bases on 5’ and 3’ end of the reads with a quality score below 28 were trimmed also using 
prinseq-lite. Trimmed reads were required to have a minimum length of 20 bases. The remaining 
sequences with a Phred score <70 were mapped to the hg38 reference genome using Bowtie v0.12.7 
(20), where we used a seed length of 36 in which we allowed a maximum of 2 mismatches. If a read 
had multiple alignments, only the best matching read was reported. Duplicated reads were removed. 
MACS v1.4.2 was used for peak calling using default settings. The sequencing profiles of c-Fos were 
created in the IGV browser (21). 
MTT assay 
Cells were seeded in 96-well plates and cultured at 37 °C with 5% CO2 for 24, 48, 72 hrs, respectively. 
Then 10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was added 
to cells and incubated for 4 hrs. Subsequently, medium was removed and 100 μl of DMSO was added 
to each well. The absorbance of each well was read on a microplate absorbance readers (BIO-RAD) at 
a wavelength of 490 nm. All measurements were performed in triplicate. 
Statistical analysis 
All results were presented as mean ± SEM. Comparisons between groups were performed with 
Mann-Whitney test. Differences were considered significant at a P value less than 0.05.  
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Results 
A screening for kinases identifies conventional PKCs as cell-autonomous anti-
HEV elements 
Protein kinases are pivotal mediators of signal transduction and identifying kinases involved in 
biological responses can shed important light on kinase associated virus-host interactions. The lack of 
understanding as to which signal pathways mediate cell-autonomous antiviral immunity against HEV 
thus prompted us to execute a screening of kinase inhibitors with respect to their effects in antiviral 
responses. To this end, we employed a hepatocyte cell line, i.e. Huh7, transfected with a HEV 
replicon luciferase reporter as a platform for the screening of 132 pharmacological kinase inhibitors 
with known specificity profile (14) (Fig. S1A and Table S1). We arbitrarily set the control luciferase 
value to 1 and identified 40 inhibitors (normalized value ≥ 1.2) that increase and 42 compounds 
(normalized value ≤ 0.8) that inhibit luciferase activity in this assay system (Fig. 1A and Table S2). 
Inhibition of luciferase activity might be due to non-specific effects not related to the scientific 
question at hand (e.g. effects on translation or cell survival). Strikingly, stimulation of luciferase 
activity likely relates to the inhibition of signaling elements involved in constraining viral replication 
and hence we concentrated on luciferase enhancing compounds in our search for elements involved 
in antiviral immunity. Go6976, a fairly specific inhibitor of the conventional PKCs (PKCα, PKCβI, PKCβII, 
and PKCγ) (22), has increased HEV luciferase activity. Subsequent western blot analysis for the 
phosphorylation state of PKC isoforms confirmed the inhibition of PKCα and PKCβ by Go6976 in our 
experimental system (Fig.1B). HEV promoting activity of Go6976 was further confirm in two 
independent cell culture models: a subgenomic HEV containing luciferase reporter and a full-length 
HEV infectious cell culture system (Fig. 1C, D and Fig. S1B). Go6976 showed inhibitory effect on host 
cell growth (Fig. S1C), which is expected because of the crucial roles of PKCs in cell physiology. 
Interestingly, Go6976 is also indicated as a potential inhibitor of protein kinase D (PKD), although 
with relatively lower sensitivity compared with PKCα and PKCβ1. Therefore, we also tested the role 
of PKD in Go6976 induced HEV replication. CID 755673, a selective PKD inhibitor (IC50: 0.182 – 
0.227μM) was tested in both HEV cell culture systems. However, CID 755673 showed no significant 
effect on HEV replication (Fig. S1D and E). Therefore, the effect of Go6976 on HEV is likely 
independent of PKD. Collectively, these data demonstrated that conventional PKCs are important 
antiviral elements, at least with respect to HEV infection. 
PKCα is the key anti-HEV isoform 
The observation that conventional PKCs constrain HEV replication raises questions as to the role of 
different PKC isoforms. To dissect the effects of individual PKC isoforms, we silenced the expression 
of PRKCA (the gene coding for PKCα) and PRKCB (that gives rise to PKCβI and PKCβII) in Huh7 cells 
using lentiviral-mediated RNAi. Since PKCγ has been shown to be specifically expressed in neuronal 
tissue (23), we ruled it out for further research. Western blot and qRT-PCR confirmed successful 
down-regulation of PKC isoforms (Fig. 2A and B) at protein and RNA levels. Subsequently, cells were 
inoculated with infectious HEV particles and cellular HEV RNA was quantified by qRT-PCR after 48 hrs. 
Knockdown of PKCα led to a 2.25 ± 0.3 fold (n = 4, p < 0.05) increase of HEV RNA; whereas PKCβ 
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knockdown resulted in no significant effect (Fig. 2C), suggesting that PKCα is the relevant isoform 
here.  
 
Fig 1. Conventional PKCs function as cell-autonomous 
antiviral elements against HEV. (A) Heatmap 
summary of the screening results. The Huh7 cell line 
transfected with a subgenomic HEV luciferase 
reporter replicon was used. Compared to control, 
relative HEV luciferase activity depicted in red to 
green for each inhibitor. Red means that the signal is 
higher than control; whereas green means lower than 
control. See also Table S1. (B) Go6976 (10 µM) 
treatment inhibited phosphorylation of PKCα and 
PKCβ protein levels in Huh7 cells as determined by 
western blot. (C) qRT-PCR analysis of HEV RNA in Huh7 
cells harboring full-length HEV infectious genome. 
Treatment with Go6976 increased cellular HEV RNA (n 
= 3). (D) In the Huh7 cell-based subgenomic HEV 
replicon model, treatment with different doses of 
Go6976 increased HEV replication-related luciferase 
activity. Cells transfected with replicon defective 
control (HEV-luciferase-GAD) RNA were also treated with Go6976 (n = 3 independent experiments with 2 - 3 
replicates each). Data presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P<0.001; ns, not significant). 
 
PKCα maintains its inactive state via an inhibitory region within the effector binding domain 
of the kinase. Its pseudosubstrate site mediates this inhibition by binding to the active site and 
preventing substrate interaction (24). A constitutively active PKCα (caPKCα) is available in which a 
glutamic acid present in this region is substituted for alanine. (Fig. 2D). This form dramatically 
increases effector-independent kinase activity, compared to the wild-type PKCα (wtPKCα) (25). Huh7 
cells were transduced with integrating lentiviral vectors co-expressing GFP and caPKCα or wtPKCα 
(Fig. S1F). Cell cytometry confirmed transgene expression by measuring GFP and positive cells were 
sorted and expanded for further experimentation (Fig. S1G). Huh7 cells expressing caPKCα or wtPKCα 
were inoculated with infectious HEV particles and relative viral RNA level was quantified 48 hrs post-
inoculation. Consistent with PKCα knockdown (Fig. 2C), expression of caPKCα significantly decreased 
HEV RNA by 49% (n = 4, p < 0.05), while wtPKCα over-expression showed no effect on HEV compared 
to control sample (Fig. 2E).  
This promising result prompted us to investigate the potential role of the classical PKC 
pharmacological activator, PMA, also commonly known as 12-O-Tetradecanoylphorbol-13-acetate 
(TPA). PMA, structurally analogous to diacylglycerol, is commonly used to activate PKC. It is also a 
promising drug candidate, currently under a Phase II clinical trial for the treatment of patients with 
relapsed/refractory acute myelogenous leukemia (NCT01009931). As expected, PMA exerted strong 
anti-HEV effects in both HEV subgenomic and full-length infectious models (Fig. 3A, B and Fig. S2A, B); 
while no clear effect on cell growth and viability was observed (Fig. S2C). This result prompted us to 
assess the combined antiviral effect of PMA with the off-label anti-HEV drugs IFN-α or ribavirin (14, 
26, 27). Although PMA and IFN-α showed comparable anti-HEV capacity, they failed to exert further 
combined effect (Fig. 3C and E). The combination of PMA with ribavirin showed strong additive anti-
HEV effect (Fig. 3D and F). These data collectively indicate that activated PKCα plays an important 
role in cell-autonomous anti-HEV immunity. 
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Fig 2. PKCα is the key antiviral isoform against HEV. (A) Western blot analysis of PKCα and PKCβ knockdown 
by lentiviral shRNA vectors. Compared with the control vector transduced cells, the shPKCα clone 53 and 
shPKCβ clone 48 exert potent silencing capability shown at protein levels. Blots depict phosphorylated PKCα, 
PKCβ and β-actin. (B) qRT-PCR analysis of PKCα and PKCβ knockdown by lentiviral shRNA vectors. Compared to 
the control vector transduced cells, the no.53 and 48 clones of shPKCα and PKCβ, respectively, exert a potent 
silencing capability shown at RNA levels (n = 3). (C) Cellular HEV RNA level in PKCα or PKCβ knockdown cells 
was determined by qRT-PCR 48 hrs post-inoculation with HEV particles. Knockdown of PKCα led to a 2.25 ± 0.3 
fold increase of HEV RNA; whereas PKCβ knockdown resulted in no significant increase (n = 4). (D) The change 
in amino acid sequence between wtPKCα and caPKCα is shown in the rectangular frame. (E) qRT-PCR analysis 
of cellular HEV RNA level in CTR, wtPKCα or caPKCα over-expressing cells after inoculation of infectious HEV 
particles for 72 hrs. caPKCα over-expression inhibited HEV RNA by 49%. Data presented as mean ± SEM (*, P < 
0.05; **, P < 0.01; ***, P<0.001; ns, not significant).  
 
Chapter 12 
179 | P a g e  
 
Fig 3. PKC specific activator PMA exerts strong antiviral activity against HEV. (A) In the Huh7 cell-based 
subgenomic HEV replicon model, treatment with different doses of PMA inhibited HEV replication-related 
luciferase activity (n = 3 independent experiments with2 - 3 replicates each). (B) qRT-PCR analysis of HEV RNA 
derived from Huh7 cells harboring the full-length HEV infectious genome. Treatment with PMA (100 ng/ml) for 
48 hrs significantly inhibited cellular HEV RNA by 68% (n = 9). (C) Huh7 cells harboring the full-length HEV 
infectious genome were treated with different doses of IFN-α, PMA or a combination of both for 48 hrs. 
Cellular HEV RNA level was determined by qRT-PCR. PMA and IFN-α showed comparable anti-HEV capacity, but 
they failed to exert further combined effect (n = 4). (D) Same as (C) for ribavirin, PMA or a combination of both. 
The combination of PMA with ribavirin showed strong additive anti-HEV effect (n = 4). (E) The Huh7 cell-based 
subgenomic HEV replicon was treated with PMA, IFN-α or a combination of both. Their combination showed 
no additive effect. Luciferase values were measured at 24, 48 and 72 hrs. (n = 3 independent experiments with 
2 – 3 replicates each). (F) Same as (E) for PMA, ribavirin or a combination of both. Their combination showed 
additive anti-HEV activity. (n = 3 independent experiments with 2 – 3 replicates each). Data presented as mean 
± SEM (*, P < 0.05; **, P < 0.01; ***, P<0.001; ns, not significant). 
PKCα provokes transcriptional activation of ISGs, independent of the IFN-JAK-
STAT pathway 
We extended our study on a list of other viruses (rotavirus, murine norovirus, HIV-1 and influenza 
virus). Although no significant antiviral effects on HIV-1 and influenza virus, PMA significantly 
inhibited rotavirus and murine norovirus 1 infection (Fig. S2B - G). The relative broad antiviral 
efficacy induced by PMA prompted us to investigate its potential link to the function of IFNs, which 
possess broad antiviral effects via efficient induction of ISGs.  
Following interferon stimulation and interferon receptor activation, STAT1 and STAT2 are 
phosphorylated and form heterodimers, which subsequently bind to IRF9 leading to the formation of 
the so-called IFN-stimulated gene factor 3 (ISGF3) complex. ISGF3 translocates to the nucleus and 
binds to the DNA specific sequence motif [5’-CAGTTTCACTTTCC-3’], ISREs, to drive the expression of 
ISGs, which are the ultimate antiviral effectors of the interferon cascade (Fig. 4A) (28). As expected, 
employing a Huh7 stably transfected ISRE-driven luciferase reporter cell line (29), we observed the 
induction of luciferase activity with IFN-α stimulation (Fig. 4A). Surprisingly, forced activation of PKC, 
using the PMA stimulus, also provokes transactivation of ISRE elements (Fig. 4B). Further 
confirmation was obtained by quantification of a panel of well-known antiviral ISGs (Fig. 4C). 
Importantly, when the ISRE reporter cell line was transduced with integrating lentiviral vectors 
expressing shRNA specifically targeting PKCα, β or a control shRNA (shCTR), PKCα silencing resulted in 
a significant decrease of ISRE luciferase activity compared with shCTR control; whereas PKCβ 
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knockdown did not significantly affect ISRE activity (Fig. 4D). These data demonstrate that PMA 
activates PKCα to mediate the transcriptional activity of ISRE, resulting in the induction of antiviral 
ISGs. 
Signal transduction of the IFN-α/β receptor appears kaleidoscopic in that multiple discrete 
signaling cassettes are activated. An important effector is phosphatidylinositol-3OH-kinase (PI3) 
kinase, a major regulator of cellular signaling. Activation of PI3 kinase in turn leads to the activation 
of various effector pathways in different cell types, including 3-phosphoinositide dependent protein 
kinase (PDK), Protein kinase B (PKB), mechanistic target of rapamycin (mTOR) and PKC (Fig. S3B) (30). 
As PI3 kinase signaling and other signaling cassettes downstream of the interferon receptors may 
(in)directly crosstalk with PKCα, we investigated possible effects of IFN-α on PKC activation. As 
determined by western blot, PKC α/β are not activated upon IFNα challenge (1000 IU/ml; Fig. S3C). 
Thus, PKCα activation is not the downstream effect of the IFN receptor. 
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Fig 4. PKCα provokes transcriptional activation of ISGs, independent of IFN-JAK-STAT pathway. (A) In Huh7 
based ISRE luciferase reporter cells, treatment with IFN-α resulted in a dose-dependent induction of ISRE-
related luciferase activity (n = 3 independent experiments with 2 – 3 replicates each). (B) Same as (A) for PMA. 
(C) After PMA (100 ng/ml) treatment, expression profile of 14 different ISGs in Huh7 cells was quantified by 
qRT-PCR. Except for IFI27 and GTBP1, other ISGs were significantly induced (n = 6). (D) Knockdown PKCα by 
lentiviral shRNA vector (No. 48) in Huh7 based ISRE luciferase reporter cells resulted in significant inhibition of 
ISRE-related luciferase activity; while PKCβ knockdown (No. 53) had no significant effect (n = 3 independent 
experiments with 2 – 3 replicates each). (E) qRT-PCR analysis of IFN-α and β1 expression levels in Huh7 cells 
treated with PMA (100 ng/ml) (n = 3). (F) ISRE luciferase activity was measured, after treatment with JAK 
inhibitor I, PMA or a combination of both for 48 and 72 hrs (n = 3 independent experiments with 2 – 3 
replicates each). (G) Phosphorylated STAT1 protein level was detected by western blot, after treatment with 
IFN-α (1000 IU/ml), PMA (100 ng/ml) or a combination of both. (H) Western blot analysis of IRF9 knockdown by 
lentiviral shRNA vectors in the Huh7 based ISRE luciferase reporter cells. Compared to the control vector 
transduced cells, the clone NO.13 of shIRF9 exerts strong silencing capability shown at protein levels. Blots 
depict IRF9 and β-actin. (I) Knockdown of IRF9 in Huh7 based ISRE luciferase reporter cells has no effect on 
PMA induced ISRE-related luciferase activation, as measured at 48 and 72 hrs (n = 3 independent experiments 
with 2 – 3 replicates each). (J) Knockdown of IRF9 in the Huh7 based ISRE luciferase reporter cells blocks IFN-α 
(1 IU/ml) induced ISRE-related luciferase activation, as measured at 48 and 72 hrs (n = 3 independent 
experiments with 2 – 3 replicates each). Date presented as mean ± SD (*, P < 0.05; **, P < 0.01; ***, P<0.001; 
ns, not significant). 
 
To further investigate whether PKCα activation results in direct ISRE activation or whether 
indirect autocrine/paracrine mechanisms are responsible, we investigated possible PMA effects on 
the expression of type I interferons. PMA treatment did not increase IFN-α mRNA but even slightly 
decreased IFN-β1 expression (Fig. 4E). In apparent agreement, incubation with the pan-JAK inhibitor I 
abrogated STAT1 phosphorylation and the induction of ISRE-regulated luciferase activity in Huh7 cells 
even following high dose IFN-α treatment (1000 IU/ml) (Fig. S3D and E), but did not diminish PMA-
induced ISRE activation (Fig. 4F). Furthermore, PMA did not affect STAT1 phosphorylation or IFN-α 
induced STAT1 activation at amino acid 701 (Y701P), which is an indispensable signature of STAT1 
activation (Fig. 4G). We further examined the role of IRF9, a key downstream element antiviral 
effector of the interferon pathway. As expected, PMA-induced ISRE luciferase activity was not 
affected in IRF9 knockdown cells compared to the shCTR control (Fig. 4H and I); whereas IFN-α 
induced activation was clearly impaired (Fig. 4J and S3F). These results collectively indicate that 
PKCα-induced ISRE activation is independent of the classical interferon pathway. 
PKCα mediated ISG transcriptional activation and anti-HEV effect is 
independent of the NF-κB pathway 
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NF-κB signaling is a central pathway involved in cellular innate immune response. PMA can activate 
NF-κB signaling via the phosphorylation of NF-κB/p65 by PKCα (31-33). Thus, we investigated the 
potential involvement of NF-κB pathway. To this end, we used a lentiviral transcriptional reporter 
system expressing the firefly luciferase gene under the control of NF-κB responsive promoter. Huh7 
cells were transduced with the vector to create a stable NF-κB reporter cell line. As expected, 
stimulation with PMA led to the strong activation of NF-κB luciferase activity (Fig. 5A) and thus a role 
of NF-κB signaling cannot be ruled out. Thus, the Huh7 cell line was transduced with integrating 
lentiviral shRNA vectors to silence RelA (P65), an essential subunit of the NF-κB transcription complex, 
resulting in profound down-regulation of RelA expression (Fig. 5B and C). These cells, however, still 
showed ISRE-driven luciferase activation (Fig. 5D). Consistently, PMA induced anti-HEV effect was not 
abrogated in RelA knockdown cells (Fig. 5E). Thus, NF-κB signaling appears not to be involved in PKCα 
mediated ISG transcriptional activation and anti-HEV effect. 
 
Fig 5. PKCα mediated anti-HEV activity is independent of NF-κB signaling. (A) In Huh7 based NF-κB luciferase 
reporter cells, treatment with PMA resulted in a dose-dependent induction of NF-κB related luciferase activity 
(n = 3 independent experiments with 2 – 3 replicates each). (B) Western blot analysis of RelA knockdown by 
lentiviral shRNA vectors in Huh7 cells. Blots depict RelA and β-actin. (C) qRT-PCR analysis of RelA knockdown by 
lentiviral shRNA vectors at RNA level (n = 3). (D) Knockdown of RelA in Huh7 based ISRE luciferase reporter cells 
did not block PMA induced ISRE-related luciferase activation measured at 48 and 72 hrs (n = 3 independent 
experiments with 2 – 3 replicates each). (E) Knockdown of RelA did not block PMA induced anti-HEV activity as 
determined by qRT-PCR 48 hrs post-inoculation with HEV particles (n = 4). Data presented as mean ± SEM (*, P 
< 0.05; **, P < 0.01; ***, P<0.001; ns, not significant). 
PKCα/AP1 represents a non-canonical mechanism of activating ISG 
transcription, but is dispensable for PKCα-mediated anti-HEV activity 
AP-1 signaling is another important pathway involved in cellular innate immune response. PMA can 
also activate AP1 signaling via the activation of PKCα (34, 35). Indeed, PMA stimulation provokes a 
strong induction of c-Fos, an essential subunit of the AP1 transcription complex (Fig. 6A). Accordingly, 
unstimulated cells displayed hardly detectable c-Fos protein, but c-Fos was substantially induced and 
translocated to nucleus following PMA stimulation (Fig. 6B). Convincingly, we also used a lentiviral 
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transcriptional reporter system expressing the firefly luciferase gene under control of an AP-1 
responsive promoter. Huh7 cells were transduced with the vector to create a stable AP-1 reporter 
cell line. As shown in Fig. 6C, stimulation with PMA led to the strong activation of AP-1 luciferase 
activity. Thus, to determine the role of AP-1 activation, Huh7 cells were transduced with integrating 
lentiviral RNAi vectors to silence c-Fos (Fig. 6D and E). Surprisingly, PMA induced ISRE activation was 
abrogated in c-Fos knockdown cells (Fig. 6F). Consistently, the induction of ISGs by PMA was also 
sensitive to c-Fos knockdown (Fig. 6G). Thus, AP-1 appears essential for PKCα-mediated ISRE 
activation. 
Upon signaling activation, the transcription factor, AP-1, can bind to the sequence specific 
palindromic AP-1 site [5’-(A/T)T(G/T)(A/C)(G/C)TCA(G/C/A)-3’] to promote gene transcription (36, 37). 
The puzzling role of AP-1 in the transactivation of the ISRE led us to perform an in silico analysis 
comparing the ISRE motif and the AP-1 DNA binding site and surprisingly revealed a consensus 
sequence of these two motifs (Fig. 6H). We thus hypothesized that AP-1 might bind to this consensus 
sequence within the ISRE motif to drive its transcription. To test this hypothesis, we retrieved 
genome wide c-Fos ChIP-Seq data from GEO database (GSM754332) and analyzed the data set using 
Integrative Genomics Viewer (IGV) (Fig. S4A) (21, 38, 39). Confirming our hypothesis, we found c-Fos 
binding to the promoter regions of a list of ISGs (Fig. S5). To further confirm this notion, we mutated 
the consensus nucleotide sequence within the ISRE motif based on the lentiviral transcriptional 
reporter vector expressing the firefly luciferase gene driven by multiple ISREs, resulting in a mutant 
ISRE luciferase reporter vector that should not be capable of AP-1 binding. (Fig. S4B). Huh7 cells were 
transduced with this vector to create a stable reporter cell line. As expected, PMA failed to activate 
this mutated ISRE (Fig. 6J). Hence, AP-1 is capable of direct transactivation of the ISRE. Surprisingly, 
PMA mediated anti-HEV activity was not abrogated in c-Fos knockdown cells (Fig. 5K), even though 
the ISRE activation and ISG induction was blocked. Thus, AP-1 mediated ISG induction appears not 
essential for PKCα-mediated anti-HEV activity.  
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Fig 6. PKCα/AP1 serves as a non-canonical mechanism to mediate ISG transcription, but is not essential for 
PKCα-mediated anti-HEV activity. (A) Western blot analysis of c-Fos and c-Jun protein levels in Huh7 cells 
treated with PMA (100 ng/ml) for 4, 6 and 8 hrs. PMA stimulation provokes strong induction of c-Fos. (B) 
Confocal microscopy analysis of c-Fos localization in Huh7 cells treated with PMA for 4 hrs. c-Fos was induced 
and translocated to nucleus upon PMA stimulation. c-Fos antibody (green). Nuclei were visualized by DAPI 
(blue). (C) In Huh7 based AP-1 luciferase reporter cells, treatment with PMA resulted in dose-dependent 
induction of AP-1-related luciferase activity (n = 3 independent experiments with 2 – 3 replicates each). (D) 
Western blot analysis of c-Fos knockdown by lentiviral shRNA vectors. Compared to the control vector 
transduced cells, the NO.42 clone of shc-Fos exerts potent silencing capability shown at protein levels. Blots 
depict c-Fos and β-actin. (E) Confocal microscopy analysis confirmed profound down-regulation of c-Fos after 
knockdown by lentiviral shRNA vectors. C-Fos antibody (green). Nuclei were visualized by DAPI (blue). (F) 
Knockdown of c-Fos in Huh7 based ISRE luciferase reporter cells demolished PMA induced ISRE-related 
luciferase activation, as measured at 48 and 72 hrs (n = 3 independent experiments with 2 – 3 replicates each). 
(G) qRT-PCR analysis confirmed that the induction of ISGs by PMA was largely abrogated after c-Fos knockdown 
(n = 3). (H) ISRE and AP-1 sequence specific binding regions. Their consensus nucleotides are labeled in red 
color, and the consensus region is enclosed by the rectangular box. (I) Examples of two ISG genes with c-Fos 
binding to their promoter regions. The normalized binding signals were used as the input data. Binding peak 
detection was performed with PeakSeq v1.01 for identifying and ranking peak regions in ChIP-Seq data analysis. 
The Y axis value represents the binding signaling value; the black bar in the right corner represent the scale (5k 
bp). (J) Huh7 cells carrying the ISRE mutated luciferase reporter showed demolished activation upon PMA 
stimulation, as measured at 48 and 72 hrs (n = 3 independent experiments with 2 – 3 replicates each). (K) 
Knockdown of c-Fos in Huh7 cells did not abrogate PMA induced anti-HEV activity as determined by qRT-PCR 
48 hrs post inoculation with HEV particles (n = 4). Data presented as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, 
P<0.001; ns, not significant). 
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Discussion 
Protein kinases play pivotal roles in regulating immune responses either positively or negatively via 
regulating protein functions, signal transduction or other cellular processes.(40-42). This study 
comprehensively profiled kinase-mediated cascades in cell–autonomous antiviral immunity via 
screening a library of pharmacological kinase inhibitors on Huh7 based HEV replication cell model. 
We identified PKCα as an important antiviral host factor and a targetable host factor for antiviral 
drug development. Both functional over-expression and pharmacological activation showed strong 
and comparable anti-HEV activity compared to IFN-α.  
PMA, as a phorbol ester, binds to the C1 domain in the regulatory region of PKCs to promote their 
activation (43). Although PMA was reported to have a potential tumor-promoting role in 
experimental skin cancer mouse models (44), its anti-cancer activity in fact has been extensively 
investigated in the clinic, including in patients with hematological malignancy, squamous cell 
carcinoma, renal cell carcinoma, ovarian teratocarcinoma, subcutaneous adenocarcinoma and 
prostate cancer (45). Cancer patients often suffer from depressed white blood cell and neutrophil 
counts because of chemotherapeutic drugs. PMA treatment has been shown to increase white blood 
cell and neutrophil counts towards a normal range with only mild and reversible side effects 
observed (46). A Phase I trial of treating hematologic cancer or bone marrow disorder with PMA has 
been successfully conducted at The State University of New Jersey (NCT00004058). The same 
institute is currently pursuing a Phase II trial plus dexamethasone & choline magnesium trisalicylate 
in the treatment of patients with relapsed/refractory acute myelogenous leukemia (NCT01009931). 
An interesting link is that patients with leukemia or other cancers are prone to virus infections, 
including HEV (47-49). The potential clinical prospects of PMA or its derivatives may be of achieving 
“one stone two birds” effects: simultaneously combating cancer and virus. 
An interesting point of this study is the discovery of a new mechanism in transcription of antiviral 
ISGs, although moderately. Classically, ISG induction was known to be initiated predominantly by the 
IFN-JAK-STAT pathway in cell-autonomous defense against viral infection. Upon phosphorylation, 
STAT1 and STAT2 forming a complex with IRF9, this ISGF3 complex translocates to the nucleus and 
binds to the ISRE to drive ISG transcription. Here, we demonstrated that activation of the PKCα/AP-1 
cascade was able to moderately drive ISG transcription as well. This action is independent of IFN 
production and the canonical JAK-STAT machinery. AP-1 is a transcription complex mainly composed 
of c-Jun and c-Fos proteins forming a heterodimers through their leucine-zipper domains. The AP-1 
dimers recognize the sequence specific response elements via the basic domain and regulate target 
genes involved in cell proliferation, differentiation and apoptosis (50). Surprisingly, we observed 
consensus sequence between the ISRE and the AP-1 DNA binding site. Using ChIP-Seq data analysis 
and loss-of-function mutagenesis assays, we firmly demonstrated that AP-1 could directly drive gene 
transcription through binding to the ISRE on the ISG promoter region. Of note, the ISG induction 
effect induced by the PKCα/AP1 pathway is moderate, this may explain its non-essential role for 
PKCα-mediated anti-HEV activity. 
In conclusion, we identified PKCα as an important cell-autonomous antiviral factor against HEV in 
host defense. In addition, we also revealed a non-canonical mechanism in transcriptional activation 
of ISGs, although this is dispensable for PKCα-mediated antiviral activity. These results provide 
valuable antiviral target and shed new insights of virus-host interactions. 
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Supplementary data 
Fig. S1. Conventional PKCs function as cell-
autonomous antiviral elements against HEV. 
(A) Diagram of screening a library of 
pharmacological kinase inhibitors in HEV 
subgenomic replicon. (B) Huh7 cells 
transfected with HEV replication-defective 
control (GAD) RNA were treated for 48 hours 
with Go6976. qRT-PCR analysis showed that 
Go6976 exerted no significant effect on HEV 
replication-defective control (GAD) RNA level. 
(C) MTT assay of Go6976 on Huh7 cell line. (D) 
qRT-PCR analysis of HEV RNA in Huh7 cells 
harboring full-length HEV infectious genome. 
Treatment with PKD inhibitor, CID755673 
exerted no significant effect on cellular HEV 
RNA level (n = 3). (E) In the Huh7 cell-based 
subgenomic HEV replicon model, treatment 
with PKD inhibitor, CID755673 exerted no 
effect on HEV replication-related luciferase 
activity. MTT results of CID755673 on Huh7 
cells were also included. (F) Illustration of 
plasmid map of wtPKCα and caPKCα. (G) Cell 
cytometry sorting result of wtPKCα and 
caPKCα positive cells based on the GFP tag. 
Date presented as mean ± SD (*, P < 0.05; **, 
P < 0.01; ***, P<0.001; ns, not significant). 
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Fig. S2. The PKC specific activator PMA (TPA) exerts relative broad antiviral activity. (A) Huh7 cells transfected 
with HEV replication-defective control (GAD) RNA were treated for 48 hours with PMA. qRT-PCR analysis 
showed that PMA exerted no significant effect on HEV replication-defective control (GAD) RNA level. (B) Huh7 
cells transfected with replicon defective control (HEV-luciferase-GAD) RNA were treatment with PMA. It 
exerted no effect on HEV (GAD) replication-related luciferase activity. (C) MTT assay of PMA on Huh7 cell line. 
PMA exerts no clear cell toxicity. (D) Rotavirus RNA derived from Caco2 cells was detected by qRT-PCR. 
Treatment with PMA (100 ng/ml) for 48 hrs significantly inhibited rotavirus RNA level by 78% (n = 3). (E) 
Treatment with PMA (100 ng/ml) for 48 hrs inhibited murine norovirus 1 RNA level by 31% in RAW264.7 cells 
as determined by qRT-PCR (n = 6). (F) HIV-1 virus production was measured in DNA-transfected 293T cells. 
HEK293T cells were co-transfected with 250 ng HIV-1 molecular clone pLAI and 1 ng of pTK-Renilla. CA-p24 
levels in the culture supernatant and renilla luciferase expression in cells were measured at 2 days post-
transfection. Normalized CA-p24 expression without PMA (only DMSO) was set at 100% (n = 4). (G) Single cycle 
HIV-1 entry assay. The TZM-bl cells were first infected with HIV-1 LAI (225 pg or 2.2 ng CA-p24) for 2 hrs, 
subsequently washed with PBS and then fresh PMA-containing medium was added. Infected cells without PMA 
(only DMSO) were included as control. (n = 2 independent experiments with 4 replicates each). (H) Single cycle 
HIV-1 entry assay. The TZM-bl cells were first pretreated with PMA for 2 hrs and subsequently infected with LAI 
(225 pg or 2.2 ng CA-p24) for an additional 2 hrs. Subsequently fresh PMA-containing medium was added. 
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Infected cells without PMA (only DMSO) were included as control (n = 2 independent experiments with 4 
replicates each). (I) PMA exerts no antiviral effect on influenza virus (A/H3N2 and A/H1N1). A549 cells infected 
with A/H3N2 and A/H1N1 at a multiplex of infectivity of 0.01. Samples were harvested 0, 6, 12, 24, 48 and 72 
hours post infection. Geometric mean titers were calculated from two independent experiments, error bars 
indicate standard deviations. Date presented as mean ± SD (*, P < 0.05; **, P < 0.01; ***, P<0.001; ns, not 
significant). 
 
Fig. S3. PKCα induced ISRE activation is independent of interferon signaling. (A) Illustration of key regulatory 
molecules in the IFN-α induced JAK-STAT signaling pathway. P, phosphorylation. (B) Illustration of key 
regulatory molecules in PI3’K signaling pathway induced by IFN receptors. (C) IFN-α (1000 IU/ml) stimulation 
exerts no effect on phosphorylated PKCα/β proteins as measured at different time points by western blot. (D) 
Western blot analysis of Huh7 cells treated with IFN-α (1000 IU/ml), JAK inhibitor I (10 µM) or combination. 
Incubation with the pan-JAK inhibitor I abrogated STAT1 phosphorylation in Huh7 cells following IFN-α 
treatment. Blots depict phosphorylated STAT1 and β-actin. (E) In Huh7 based ISRE luciferase cells, JAK inhibitor 
I (10 µM) abrogated IFN-α (1000 IU/ml) induced ISRE-related luciferase activity as measured at 24, 48 and 72 
hrs (n = 3 independent experiments with 2 – 3 replicates each). (F) IFN-α induced ISRE luciferase activity was 
partly abolished in IRF9 knockdown cells, compared to the shCTR control as measured at 48 and 72 hrs (n = 3 
independent experiments with 2 – 3 replicates each). All data presented as mean ± SD (*, P < 0.05; **, P < 0.01; 
***, P<0.001; ns, not significant). 
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Fig. S4. PKCα / AP1 serves as a non-canonical mechanism of activating ISG transcription. (A) Integrative 
Genomics Viewer (IGV) analysis of genome wide c-Fos ChIP-Seq data from GEO database (GSM754332). 
Example shown depicts locus on chromosome harboring the genes. Signal tracks record the c-Fos binding 
ability to relevant genes listed below. The positive binding was marked with binding peak based on the 
calculation of signal tracks. (B) The nucleotide sequence of AP-1, ISRE and the ISRE mutant binding regions. 
Their consensus nucleotides are labeled in red color, and the consensus region is marked in a rectangular box. 
The mutated nucleotides are shown in blue color. The ISRE (mutant) sequencing result is shown in the 
illustration below. 
 
 
 
 
 
Fig. S5. Examples of ISG genes with 
c-Fos binding to their promoter 
regions. The normalized binding 
signals were used as the input data. 
Binding peak detection was 
performed with PeakSeq v1.01 for 
identifying and ranking peak regions 
in ChIP-Seq data analysis. The Y axis 
value represents the binding 
signaling value; the black bar in the 
right corner represent the scale 
(5kb). 
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Supplementary Tables 
Table S1 and S2  
http://www.sciencedirect.com/science/article/pii/S0166354216306283?via%3Dihub#appsec1  
Table S3. shRNA sequences  
Name Oligo Sequences 
shPKCα-51 CCGGCTTTGGAGTTTCGGAGCTGATCTCGAGATCAGCTCCGAAACTCCAAAGTTTTT 
shPKCα-52 CCGGCGAGCTATTTCAGTCTATCATCTCGAGATGATAGACTGAAATAGCTCGTTTTT 
shPKCα-53 CCGGCATGGAACTCAGGCAGAAATTCTCGAGAATTTCTGCCTGAGTTCCATGTTTTT 
shPKCβ-47 CCGGCGTCCTTCATTTCTGTCATTCCTCGAGGAATGACAGAAATGAAGGACGTTTTTTG 
shPKCβ-48 CCGGGCCATGAATTTGTCACATTCTCTCGAGAGAATGTGACAAATTCATGGCTTTTTTG 
shPKCβ-49 CCGGGAAACAAAGATGGTTGTATTCCTCGAGGAATACAACCATCTTTGTTTCTTTTTTG 
shPKCβ-50 CCGGGACGACCTGCTTTGATTTAACCTCGAGGTTAAATCAAAGCAGGTCGTCTTTTTTG 
shIRF9-12 CCGGGAGACTTGGTCAGGTACTTTCCTCGAGGAAAGTACCTGACCAAGTCTCTTTTTG 
shIRF9-13 CCGGCTCAGTAGTTGTCCGTGATAACTCGAGTTATCACGGACAACTACTGAGTTTTTG 
shIRF9-14 CCGGTTCAAGGCCTGGGCAATATTTCTCGAGAAATATTGCCCAGGCCTTGAATTTTTG 
shRelA-06 CCGGGCCTTAATAGTAGGGTAAGTTCTCGAGAACTTACCCTACTATTAAGGCTTTTT 
shRelA-07 CCGGCGGATTGAGGAGAAACGTAAACTCGAGTTTACGTTTCTCCTCAATCCGTTTTT 
shRelA-08 CCGGGCAGGCTATCAGTCAGCGCATCTCGAGATGCGCTGACTGATAGCCTGCTTTTT 
shRelA-09 CCGGCACCATCAACTATGATGAGTTCTCGAGAACTCATCATAGTTGATGGTGTTTTT 
shRelA-10 CCGGCCTGAGGCTATAACTCGCCTACTCGAGTAGGCGAGTTATAGCCTCAGGTTTTT 
shc-Fos-37 CCGGGCTGGTAGTTAGTAGCATGTTCTCGAGAACATGCTACTAACTACCAGCTTTTT 
shc-Fos-38 CCGGGCGGAGACAGACCAACTAGAACTCGAGTTCTAGTTGGTCTGTCTCCGCTTTTT 
shc-Fos-39 CCGGCACTGCTTACACGTCTTCCTTCTCGAGAAGGAAGACGTGTAAGCAGTGTTTTT 
shc-Fos-40 CCGGGTGGAACAGTTATCTCCAGAACTCGAGTTCTGGAGATAACTGTTCCACTTTTT 
shc-Fos-42 CCGGGCGGAGACAGACCAACTAGAACTCGAGTTCTAGTTGGTCTGTCTCCGCTTTTTG 
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Table S4. Primer sequences 
Name Oligo Sequences (Forward) Oligo Sequences (Reverse) 
HEV 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’ 5’-CCGTGGCTATAATTGTGGTCT-3’ 
HEV-ORF1 5’-CAAAAAGCCCCGCAACAAGA-3’ 5’-GAGGGTAAGGGGCACAGATG-3’ 
PKCα 5'-GCCTATGGCGTCCTGTTGTATG-3' 5'-GAAACAGCCTCCTTGGACAAGG-3' 
PKCβ 5'-GAGGGACACATCAAGATTGCCG-3' 5'-CACCAATCCACGGACTTCCCAT-3' 
Rotavirus 5'-TGGTTAAACGCAGGATCGGA-3' 5'-AACCTTTCCGCGTCTGGTAG-3' 
IFITM1 5'-GGCTTCATAGCATTCGCCTACTC-3' 5'-AGATGTTCAGGCACTTGGCGGT-3' 
IFITM3 5'-CTGGGCTTCATAGCATTCGCCT-3' 5'-AGATGTTCAGGCACTTGGCGGT-3' 
IFIT2 5'-GGAGCAGATTCTGAGGCTTTGC-3' 5'-GGATGAGGCTTCCAGACTCCAA-3' 
IRF1 5'-GAGGAGGTGAAAGACCAGAGCA-3' 5'-TAGCATCTCGGCTGGACTTCGA-3' 
ISG15 5'-CTCTGAGCATCCTGGTGAGGAA-3' 5'-AAGGTCAGCCAGAACAGGTCGT-3' 
IFI6 5'-TGATGAGCTGGTCTGCGATCCT-3' 5'-GTAGCCCATCAGGGCACCAATA-3' 
IFIT3 5'-CCTGGAATGCTTACGGCAAGCT-3' 5'-GAGCATCTGAGAGTCTGCCCAA-3' 
DDX58 5'-CACCTCAGTTGCTGATGAAGGC-3' 5'-GTCAGAAGGAAGCACTTGCTACC-3' 
PKR 5'-GAAGTGGACCTCTACGCTTTGG-3' 5'-TGATGCCATCCCGTAGGTCTGT-3' 
IFI27 5'-CGTCCTCCATAGCAGCCAAGAT-3' 5'-ACCCAATGGAGCCCAGGATGAA-3' 
IFNα 5'-GACTCCATCTTGGCTGTGA-3' 5'-TGATTTCTGCTCTGACAACCT-3' 
IFNβ1 5'-CTTGGATTCCTACAAAGAAGCAGC-3' 5'-TCCTCCTTCTGGAACTGCTGCA-3' 
SLFN5 TTCTGCTGTGCGGTGTTTGCCA CTGGAGAACCATCTCAGGACAC 
CD74 AAGCCTGTGAGCAAGATGCGCA AGCAGGTGCATCACATGGTCCT 
B2M CCACTGAAAAAGATGAGTATGCCT CCAATCCAAATGCGGCATCTTCA 
GTPBP1 CCTTCATCGACTTGGCTGGTCA CCAGGTGTTCTTTGGTCATCCC 
GAPDH 5’-TGTCCCCACCCCCAATGTATC-3’ 5’-CTCCGATGCCTGCTTCACTACCTT-3’ 
RP2 5’- AAGCTGAGGATGCTCAAAGG-3’ 5’-CCCATTAAACTCCAAGGCAA-3’ 
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Abstract 
Viruses are solely dependent on host cells to propagate, therefore understanding virus-host 
interaction is important for antiviral drug development. Since de novo nucleotide biosynthesis is 
essentially required for both host cell metabolism and viral replication, specific catalytic enzymes of 
these pathways have been explored as potential antiviral targets. In this study, we investigated the 
role of different enzymatic cascades of nucleotides biosynthesis in hepatitis E virus (HEV) replication. 
By profiling various pharmacological inhibitors of nucleotides biosynthesis, we found that targeting 
the early steps of the purine biosynthesis pathway led to enhancement of HEV replication; whereas 
targeting the later step resulted in potent antiviral activity via depletion of purine nucleotide. 
Furthermore, inhibition of pyrimidine pathway resulted in potent anti-HEV activity. Interestingly, all 
these inhibitors with anti-HEV activity concurrently triggered the induction of antiviral interferon-
stimulated genes (ISGs). Although ISGs are commonly induced by interferons via the JAK-STAT 
pathway, their induction by nucleotides synthesis inhibitors is completely independent of this 
classical mechanism. In conclusion, this study revealed an unconventional novel mechanism as to a 
crosstalk between nucleotide biosynthesis pathways and cellular antiviral immunity in constraining 
HEV infection. Targeting particular enzymes in nucleotide biosynthesis represents a viable option for 
antiviral drug development against HEV. 
  
Chapter 13 
198 | P a g e  
Author Summary 
HEV is the most common cause of acute viral hepatitis worldwide and is also associated with chronic 
hepatitis, especially in immunocompromised patients. Although often an acute and self-limiting 
infection in the general population, HEV can cause severe morbidity and mortality in certain patients, 
a problem compounded by the lack of FDA-approved anti-HEV medication available. In this study, we 
have investigated the role of nucleotide synthesis pathway in HEV infection and its potential for 
antiviral drug development. We show that targeting the later but not the early steps of purine 
synthesis pathway exert strong anti-HEV activity. In particular, IMPDH is the most important anti-HEV 
target of this cascade. Importantly, the clinically used IMPDH inhibitors, including mycophenolic acid 
and ribavirin, have potent anti-HEV activity. Furthermore, targeting pyrimidine synthesis pathway 
also exerts potent antiviral activity against HEV. Interestingly, antiviral effects of nucleotide synthesis 
pathway inhibitors appear to depend on medication-induced transcription of antiviral interferon-
stimulated genes. Thus, this study reveals an unconventional novel mechanism as to how nucleotide 
synthesis pathway inhibitors can counteract HEV replication. 
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Introduction 
Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus, which mainly infects the liver. It 
is the most common cause of acute viral hepatitis worldwide. In general, HEV infection is a self-
limiting disease and associated with low mortality, but epidemics of hepatitis E occur periodically 
throughout the developing world, resulting in 70,000 death yearly 1. In western countries, HEV 
primarily affects immunocompromised patients, in particular organ transplant recipients, as well as 
hematopoietic stem cell transplant 2-5. More than 60% of organ recipients infected with HEV develop 
chronic hepatitis with rapid progression to cirrhosis 2. Despite an emerging global health issue, no 
FDA-approved anti-HEV therapy is currently available, only interferon-α, ribavirin or a combination 
have been occasionally used as off-label treatment. Thus, further research aimed at understanding 
its infection biology and developing effective antiviral treatment is urgently required.  
Cellular nucleotides, including purines and pyrimidines, are the basic building blocks that 
form the nucleic acids RNA and DNA. Nucleotides are the fundamental components that are required 
for cell metabolism, such as genome replication. In vivo, nucleotides can be synthesized de novo 
through a series of enzymatic reactions or recycled through salvage pathways. Since viral replication 
heavily relies on the host cells to supply nucleosides, targeting nucleotide biosynthesis pathway thus 
represents an attractive strategy for antiviral drug development. The nucleotide biosynthesis 
pathways have been well-studied for decades 6-8. Numerous compounds have been developed and 
well-characterized to target particular enzymes of this pathway to inhibit viral infections by depletion 
or causing imbalance of nucleotide pools 9-18. Among them, inhibitors of inosine monophosphate 
dehydrogenase (IMPDH), a key enzyme of the purine synthesis pathway, have been successfully used 
in the clinic for decades. These drugs including ribavirin and mycophenolic acid (MPA), used as 
antiviral or immunosuppressive medication respectively, have been demonstrated to have broad 
antiviral activity against a spectrum of viruses, including dengue virus, yellow fever virus (YFV), 
hepatitis B, hepatitis C and hepatitis E virus 14, 15, 18-21. Likewise, Brequinar and Leflunomide, the 
inhibitors of dihydroorotate dehydrogenase (DHODH), an essential enzyme of pyrimidine nucleotide 
synthesis, have been shown to inhibit human polyomavirus type BK (BKV), YFV and dengue virus 12, 22.  
Besides their function as building blocks of genetic material, free nucleotides also play 
important roles in cell signalling. We and others have previously reported the potential interaction of 
nucleotide deprivation and cellular antiviral immune response, such as provoking the expression of 
interferon-stimulated genes (ISGs) 19, 23. Given that the liver is a major site for nucleotide synthesis, 
we comprehensively profiled the role of purine and pyrimidine synthesis pathways in  HEV cell 
culture models, aimed at identifying potential antiviral drug targets and understanding the crosstalk 
with cellular antiviral immunity against HEV infection. 
Materials and Methods  
Reagents  
Guanosine (CAS: 118-00-3), Adenosine (CAS: 58-61-7), Uridine (CAS: 58-96-8), 6-TG (CAS: 154-42-7), 
Lometrexol hydrate (CAS: 106400-81-1), MTX hydrate (CAS: 133073-73-1), FA phosphate (CAS: 
75607-67-9), BQR sodium salt hydrate (MDL: MFCD21363375), LFM (CAS: 75706-12-6) and 6-AU (CAS: 
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461-89-2) were purchased from sigma. 23 IMPDH specific inhibitors were kindly provided by Center 
for Drug Design, University of Minnesota. All the reagents were dissolved in dimethylsulfoxide 
(DMSO). The effects of these de novo nucleotide biosynthesis inhibitors on host cell viability were 
determined by MTT assay (Supplementary Figure 7). Stocks of JAK inhibitor 1 (CAS 457081-03-7, 
Santa Cruz Biotech, CA) was dissolved in DMSO with a final concentration of 5 mg/mL. Stocks of CP-
690550 (Tofacitinib) (Santa Cruz Biotech, CA) were dissolved in DMSO with a final concentration of 
10 mg/mL. 
Cell culture models 
Human hepatoma cell line Huh7 and human embryonic kidney epithelial cell line 293T cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% fetal 
bovine serum, 100IU/mL penicillin and 100IU/mL streptomycin. HEV replication model with 
subgenomic HEV sequence coupled with a Gaussia luciferase reporter gene and HEV infection model 
containing the full-length HEV genome were used in our study. The construction of two models has 
been described previously 18. Besides, Huh7 cells constitutively expressing the firefly luciferase 
reporter gene driven by the human PGK promoter were used as household luciferase activity for 
normalizing nonspecific effects on luciferase Activity 11. Huh7 cells transduced with lentiviral 
transcriptional reporter system expressing the firefly luciferase gene under control of a promoter 
containing multiple ISRE promoter elements (SBI Systems Biosciences, Mountain View, CA) was 
established and luciferase activity represents ISRE promoter activation. 
Quantification of HEV replication and infection 
The details for exanimating HEV replication and infection were described before 18. Briefly, For the 
HEV replication model (p6-Luc), the activity of secreted gaussia luciferase in the cell culture medium 
was measured using BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs), as 
quantification of viral replication, which was normalized by firefly luciferase expression. For full- 
length HEV infectious model, SYBR Green based qRT-PCR was used to quantify the newly formed viral 
genomic RNA after cell lysis and the HEV primer sequences were shown in supplementary Table 2.  
Gene knockdown by lentiviral vector delivered short hairpin RNA (shRNA) 
Lentiviral vectors, targeting PPAT, GART, ATIC, DHODH, were produced in 293T cells as previously 
described 11. To generate stable gene knockdown cells, Huh7 cells were transduced with lentiviral 
vectors. Since the vectors also express a puromycin resistance gene, transduced cells were 
subsequently selected by adding 2.5 μg/ml puromycin (Sigma) in the cell culture medium. After pilot 
study, the shRNA vectors (Supplementary Figure 1 and Supplementary Table 3) exerting optimal gene 
knockdown were selected by qPCR with the corresponding primers shown in supplementary Table 2. 
Meanwhile, shRNA vector expressing Green fluorescent protein (GFP) was used as control (shCTR). 
The amount of HEV were assessed after 3 days of infectious HEV medium post-infecting shGFP cells 
and knockdown cells. For the experiment comparing the activity of compounds between shGFP and 
knockdown cells, infectious HEV cells were directly transduced with lentiviral shRNA vectors and 
selected by puromycin.  
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Statistical analysis  
Statistical analysis was performed using the nonpaired, nonparametric test (Mann–Whitney test; 
GraphPad Prism software). P values less than 0.05 were considered as statistically significant. 
Results 
Exogenous guanosine, but not uridine, stimulates HEV replication  
Purine and pyrimidine nucleotides are the major cellular energy carriers and constitute the defining 
subunits of nucleic acids. Two distinct pathways are responsible for the biosynthesis of these two 
types of nucleotides (Figure 1A and 2A). Their fundamental role in cellular biochemistry raises the 
possibility that modifying flux through nucleotide biosynthesis pathways would profoundly influence 
the course of viral infection. Thus we decided to assess the overall impact of either purine or 
pyrimidine synthesis on HEV infection. A first indication that such effects might exist came from 
experiments in which we arbitrarily increased the purine and pyrimidine content by supplementation 
of exogenous guanosine (Figure 1A) and uridine (Figure 2A) in human hepatoma cell line (Huh7)-
based HEV cell culture models. Guanosine, a purine nucleoside containing guanine attached to a 
ribose, can be converted to guanosine monophosphate (GMP) through purine salvage synthesis 
pathway, subsequently replenishes purine nucleotide pool (Figure 1A). Mechanistically, the cleavage 
of exogenous guanosine was catalysed by purine nucleoside phosphorylase (PNP) to form guanine. In 
the presence of hypoxanthine/guanine phosphoribosyl transferase (HGPRT), guanine was converted 
to GMP by addition of ribose 5-phosphate from phosphoribosyl pyrophosphate (PRPP). 
Supplementation of guanosine dose-dependently enhanced HEV replication-related luciferase 
activity in the subgenomic replicon (p6-Luc) model and increased cellular viral RNA in the full-length 
(p6) infectious model (Figure 1B). Likewise, uridine, which is a pyrimidine nucleoside consisting of 
uracil binding to ribose, commonly presents as uridine monophosphate (UMP) to rescue cells from 
pyrimidine nucleotide depletion (Figure 2A). In contrast, supplementation of exogenous uridine had 
no effect on HEV replication (Figure 2B). Thus interaction between at least some of the pathways 
involved in nucleotide biosynthesis and the HEV infectious process might exist. 
Targeting the catalytic steps leading to the primary purine nucleotide 
synthesis (inosine monophosphate ; IMP), stimulates HEV replication 
Given the clear pro-viral effect of exogenous guanosine, we were encouraged to explore potential 
anti-HEV strategies targeting the different enzymes that are involved in purine nucleotide synthesis. 
De novo purine is mainly synthesized in the liver, which begins with the starting material 5-
phosphoribosyl-1-pyrophosphate, PRPP. The first fully-formed nucleotide IMP is catalyzed through 
ten reactions by six enzymes (Figure 1A). We first selectively targeted three key enzymes of this 
cascade, including amido phosphoribosyltransferase (APRTase), glycinamide ribonucleotide 
trasnformylase (GART) and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase 
(AICARFT) through 6-thioguanine (6-TG), lometrexol and methotrexate (MTX), respectively. 
Somewhat counterintuitively, all three compounds increased HEV replication in both cell culture 
models (Figure 3). To further clarify the role of their targets, lentiviral-mediated RNAi was used for 
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knockdown of these three genes PPAT, GART and ATIC that encode the corresponding enzymes 
APRTase, GART and AICARTF, respectively (Figure 4A). Consistent with the pharmacological results, 
down-regulation of these enzymes enhanced HEV replication (Figure 4B). Furthermore, the pro-viral 
effects of the pharmacological inhibitors were largely absent in a context in which their targets were 
silenced, suggesting that pharmacological effects are not due to off-target effects (Figure 4C).  
 
Figure 1. Exogenous guanosine stimulated HEV replication. (A) Schematic overview of de novo biosynthesis of 
purine nucleotide. PRPP, 5-phosphoribosyl-1-pyrophosphate; PRA, 5-phosphoribosylamine; GAR, glycinamide 
ribonucleotide; FGAR, formyl-GAR; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide. (B) Huh7 cell-
based subgenomic HEV replicons containing the luciferase reporter gene were treated for 24 h, 48 h, and 72 h 
with a dose range of guanosine (n = 4). Data are presented as meansstandard errors of the means (SEM). 
Meanwhile, Huh7 cells with the infectious HEV containing the full-length p6 genome were treated for 48 h with 
a dose range of guanosine (n = 5). Data were normalized to two housekeeping genes (GAPDH and RP2) and are 
presented relative to the control (CTR) (set as 1). Data represent means ± SEM. *, P < 0.05; **, P <0.01; ***, P 
0.001. 
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Figure 2. Exogenous uridine does not affect HEV replication. (A) Schematic overview of de novo biosynthesis 
of pyrimidine nucleotide. (B) Huh7 cell based subgenomic HEV replicon containing the luciferase reporter gene 
was treated for 24 h, 48 h, and 72 h with a dose range of uridine (n = 5). Data are presented as means ±  SEM. 
 
As a bifunctional enzyme, the N-terminal domain of ATIC has AICARFT activity, and the C-
terminal domain has IMP cyclohydrolase (IMPCH) activity. FA, an IMPCH inhibitor, also promoted 
HEV replication but exerted cytotoxicity concurrently (Supplementary Figure 2). Thus these results 
highlight the interaction of nucleotide biosynthesis and the HEV infection process, but also show that 
rational design of therapy aimed at exploiting the nucleotide biosynthesis pathway for treatment of 
HEV is not straightforward. 
IMPDH inhibition counteracts HEV replication by depleting the purine 
nucleotide pool 
As a branching point in purine synthesis, IMP is converted to either AMP or XMP/GMP (Figure 1A). 
IMPDH, an enzyme consisting two isoforms (IMPDH1 and IMPDH2) in human, catalyses the reaction 
of IMP into XMP for further conversion to GMP. We have previously demonstrated that MPA, an 
clinically used immunosuppressant preferentially inhibiting IMPDH2, has anti-HEV activity 18. To 
further explore the potential of targeting this enzyme, a panel of 23 inhibitors were customized 
designed and synthesized with variable affinities in inhibiting IMPDH1 or IMPDH2 (Supplementary 
Table 1). As shown in Figure 5A, HEV replication was inhibited by all of the 23 IMPDH inhibitors at 
concentration of 10 μM measured by luciferase activity. Accordingly, 21 of the 23 inhibitors also 
supressed HEV infection as assessed by full-length HEV genome quantification by qRT-PCR (Figure 5B). 
The anti-HEV activity was also observed at 2 μM of 20 IMPDH inhibitors (Supplementary Figure 3) . 
To further characterize, we selected three representative compounds with anti-HEV activity in both 
models. Similar to ribavirin and MPA, guanosine supplementation abrogated the anti-HEV activity of 
these compounds (Figure 5C), suggesting that depletion of the purine nucleotide pool is responsible 
for their antiviral action. Thus inhibitors with anti-HEV potential exert their action in this respect 
through targeting nucleotide synthesis. 
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Figure 3. Inhibitors of IMP synthesis cascade stimulate HEV replication. The Huh7 cells containing subgenomic 
HEV replicons with luciferase reporter genes were incubated with increasing doses of 6-TG (A), lometrexol (B), 
andMTX(C). The luciferase activity was determined at 24 h, 48 h, and 72 h. Accordingly,Huh7 cells infected with 
full-length HEV were treated with increasing doses of 6-TG (A), lometrexol (B), and MTX (C). The HEV RNA level 
was quantified by qRT-PCR after 48 h. Data were normalized to two housekeeping genes and are presented 
relative to the control (CTR) (set as 1). Data represent means  SEM from five to eight experiments. *, P ﹤0.05; 
**, P ﹤ 0.01; ***, P ﹤ 0.001. 
Targeting pyrimidine biosynthesis inhibit HEV replication 
Even though supplementation of exogenous uridine has no effect on HEV, inhibitors of pyrimidine 
synthesis have been widely reported to inhibit infection of a broad spectrum of other viruses, 
prompting further exploration of the role of pyrimidine biosynthesis in HEV replication. We thus 
selected two catalytic enzymes involved in de novo pyrimidine synthesis for further study. 
Dihydroorotate dehydrogenase (DHODH), which localises to the mitochondria, is a critical enzyme 
that converts dihydroorotate to orotate. Brequinar (BQR) and leflunomide (LFM) are well-known 
clinically tested DHODH inhibitors. Treatment with BQR (10 - 500 nM) results in a significant 
reduction of HEV replication-related luciferase activity in the subgenomic replicon assay system 
(Figure 6A). Concordantly, BQR also dose-dependently inhibits cellular viral RNA in our infectious HEV 
model. Treatment with 500 nM BQR for 48 hours resulted in 78 ± 17% (Mean ± SD, n = 7, P < 0.001) 
inhibition of HEV genomic RNA level (determined by qRT-PCR), compared with the control (Figure 6A). 
Similar results were observed with treatment of LMF (Figure 6B). The specificity of these effects was 
confirmed in experiments in which we examined by lentiviral RNAi-mediated silencing of the cognate 
target of these inhibitors, DHODH. Consistently, knockdown of DHODH inhibited HEV replication and 
abrogated the anti-HEV effect of BQR (Figure 7) and this enzyme does emerges as a relevant target in 
anti-HEV therapy. 
To further identify potential anti-HEV targets, we also examined Orotidine-5’-
monophosphate decarboxylase (ODCase), the downstream enzyme of DHODH that catalyses 
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decarboxylation of OMP to UMP. To this end we employed 6-azauracil (6-AU), a potent inhibitor of 
ODCase. As shown in Figure 6C, HEV replication was dose-dependently inhibited by 6-AU. Conversely, 
supplementation with uridine fully restored the HEV infectious potential despite the presence of BQR, 
LMF or 6-AU (Figure.8). In conjunction, these results show that depletion of pyrimidine nucleotide 
pool is a powerful anti-HEV strategy. 
Inhibitors of purine and pyrimidine synthesis provoke cellular antiviral 
immune responses  through nucleotide depletion 
We previously has demonstrated that the IMPDH inhibitor, MPA, can induce the expression of 
interferon-stimulated genes (ISGs) to combat hepatitis C virus (HCV) infection, although the 
underlying mechanism remained unclear 19. ISGs are the ultimate antiviral effectors and are generally 
assumed to be induced solely through the action of antiviral cytokines, especially interferons. In HEV 
infection models, we observed that MPA as well as other (three selected) IMPDH inhibitors were able 
to induce the expression of a panel of antiviral ISGs (Figure 9A), challenging this dogma. The 
induction of ISGs by IMPDH inhibitors was associated with purine nucleotide depletion, since 
supplementation of guanosine at least partly abrogated the induction of ISGs (Figure 9B). 
 
Figure 4. Silencing of 
enzymes involved in IMP 
synthesis cascade facilitates 
HEV replication. (A) Huh7 
cells were transduced with 
lentiviral shRNAs to stably 
silence the corresponding 
genes for PPAT, GART, and 
ATIC (a set of independent 
shRNA clones targeting each 
gene was used). Huh7 cells 
transduced with lentiviral 
shRNA targeting GFP (shCTR) 
were used as a control. The 
efficiency of gene knockdown 
was analyzed by qRT-PCR. (B) 
Silencing of PPAT, GART, and 
ATIC resulted in significant 
elevation of viral RNA upon 
inoculation of HEV. HEV RNA 
levels were determined 72 h 
after inoculation. (C) Silencing 
of PPAT, GART, and ATIC 
abrogated the pro-HEV 
effects of 6-TG, lometrexol, 
and MTX. Data were 
normalized to that for cells 
without treatment with the 
three compounds (green bar; 
set as 1). All data were normalized to two housekeeping genes and are presented relative to the control (CTR) 
(set as 1) (means ± SEM from four to eight experiments). *, P ﹤ 0.05; **, P ﹤ 0.01; ***, P ﹤ 0.001. 
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In parallel, we also investigated the effects of pyrimidine synthesis inhibitors. We employed 
an interferon response reporter that Huh7 cells are stalely integrated with an interferon-stimulated 
response element (ISRE)-driven luciferase gene that measures ISG transcription upon interferon 
stimulation. BQR potently induces luciferase activity in this reporter assay, and triggers expression of 
a panel of ISGs (Supplementary Figure 4 and Figure 10A). Supplementation of uridine completely 
abrogated these effects on ISG transcription (Figure 10B and Supplementary Figure 4). Similar results 
were also observed with another pyrimidine synthesis inhibitor, 6-AU, targeting ODCase (Figure 10C). 
Thus, both purine and pyrimidine synthesis pathways can interact with cellular antiviral immune 
response, providing a rational explanation as to their antiviral effects.  
 
Figure 5. IMPDH inhibitors potently inhibit HEV replication by depletion of the purine nucleotide pool. (A) 
Huh7 HEV replicon luciferase cells were treated with 23 specific IMPDH inhibitors (10 M) with MPAas a positive 
control. Luciferase activity was quantified at 24 h after treatment (n = 3) (B) Huh7 cells harbouring full-length 
HEV were treated with 23 specific IMPDH inhibitors with MPA as a positive control. HEV RNA levels were 
measured by qRT-PCR at 48 h after treatment (n = 5). (C) Supplementation of guanosine abrogated the anti-
HEV effects of 3 representative IMPDH inhibitors (1346, 1347, and 1348) (n = 5). Ribavirin (RBV) and MPA 
served as positive controls. Data were normalized to two housekeeping genes and are presented relative to the 
control (CTR) (set as 1) (means ± SEM). *, P ﹤ 0.05; **, P ﹤ 0.01; ***, P ﹤ 0.001. 
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Figure 6. Inhibition of pyrimidine nucleotide synthesis suppresses HEV replication. Huh7 cells containing 
subgenomic HEV replicons with luciferase report genes were treated with increasing doses of BQR (A), LFM (B), 
and 6-AU (C). The luciferase activity was determined after 24 h, 48 h, and 72 h. Accordingly, Huh7 cells 
harboring infectious HEV also were treated with increasing doses of BQR (A), LFM (B), and 6-AU (C). HEV RNA 
was quantified by qRT-PCR after 48 h of treatment. Data were normalized to two housekeeping genes and are 
presented relative to the control (CTR) (set as 1). Data represent means ± SEM from four to seven experiments. 
*, P ﹤0.05; **, P  0.01; ***, P ﹤ 0.001. 
 
Figure 7. Anti-HEV activity by BQR can be 
attributed to the inhibition of its target 
DHODH. (A) Huh7 cells were transduced 
with lentiviral shRNA to stably silent DHODH 
(DHODH shRNA+). Huh7 cells transduced 
with lentiviral shRNA targeting GFP were 
used as control (DHODH shRNA-). DHODH 
knockdown was assessed by qRT-PCR (n = 3). 
DHODH knockdown resulted in significant 
inhibition of HEV replication. HEV viral RNA 
were determined 72h after HEV inoculation (n = 6). (B) DHODH knockdown abrogated the anti-HEV effect of 
BQR (n = 7). Data were normalized to cells without BQR treatment (green bar, set as 1 ). All data were 
normalized to two housekeeping genes and presented relative to the control (shCTR) (set as 1) ( mean ± SEM ). 
∗∗P <0.01; ∗∗∗P < 0.001. 
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Figure 8. Uridine reverses the anti-HEV activity 
mediated by pyrimidine inhibition. The Huh7 
subgenomic HEV replicon was incubated with BQR 
(A), LFM (B) and 6-AU (C), supplemented with 
increasing dose of uridine. After 72h, luciferase 
activity was determined. Accordingly, Huh7 cells 
harbouring full-length HEV RNA were treated with 
BQR (A), LFM (B) and 6-AU (C), and supplemented 
with 200 μM uridine. HEV viral RNA was assessed 
by qRT-PCR 48h after treatment. Data were 
normalized to two housekeeping genes and 
presented relative to the control (CTR) (set as 1). 
Data represent mean ± SEM of four to seven 
experiments. ∗P < 0.05; ∗∗P <0.01; ∗∗∗P < 0.001. 
 
 
 
 
 
 
 
The induction of ISGs by nucleotide synthesis inhibitors is independent of the 
JAK-STAT machinery 
Classically, ISGs are thought only to be induced by interferons through activation of the JAK-STAT 
pathway. Briefly, the binding of interferons to their receptors leads to activation of Janus activated 
kinase 1 (JAK1), resulting in tyrosine phosphorylation of downstream substrates, including signal 
transducer and activator of transcription 1 (STAT1) and STAT2. The complex of STAT1–STAT2–IRF9 
(IFN-regulatory factor 9) enters nucleus and binds to the IFN-stimulated response elements (ISRE) 
motifs in the target gene, subsequently regulating ISG transcription and thus mediating the innate 
anti-viral immune response. 
To assess whether the induction of ISGs by nucleotide synthesis inhibitors also occurs via this 
classical pathway, we blocked JAK-STAT cascade by employing the pharmacological JAK inhibitors, 
JAK inhibitor 1 or CP-690550, which were conceivably identified to impair the expression ISGs 
triggered by IFN-α (Supplementary Figure 5). Surprisingly, the induction of ISGs as well as the anti-
HEV effects of these inhibitors were not affected (Figure 11). These results revealed that targeting 
nucleotide synthesis provokes ISG induction via a non-canonical mechanism that is independent of 
the classical interferon signalling.  
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Figure 9. Inhibition of 
IMPDH stimulates ISG 
expression through purine 
nucleotide deprivation. (A) 
Huh7 cells infected HEV 
were treated with MPA or 3 
other IMPDH inhibitors 
(1346, 1347 and 1348). The 
expression of a panel of ISGs 
were determined by qRT-
PCR after 48h treatment. 
Data were normalized to 
basal ISG expression without 
treatment (grey bar, set as 1). 
(B) Supplementation of 
guanosine abrogated the 
induction of ISGs by IMPDH 
inhibitors. The expression of 
ISGs were determined by 
qRT-PCR 48h after treatment. 
Data were normalized to 
basal ISG expression without 
treatment (purple bar, set as 
1). All data were normalized 
to two housekeeping genes 
and represent mean ± SEM 
of four experiments. 
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Figure 10. Inhibition of pyrimidine synthesis stimulates ISG expression through pyrimidine nucleotide 
depletion. (A) Huh7 cells infected with HEV were treated with BQR or 6-AU. After 48h, the expression of a 
panel of ISGs were determined by qRT-PCR. Data were normalized to basal ISG expression without treatment 
(grey bar, set as 1). (B) Supplementation of uridine completely abrogated the induction of ISGs by BQR (B) or 6-
AU (C).The expression of ISGs were determined by qRT-PCR at 48h after treatment. Data were normalized to 
basal ISG expression without treatment (purple bar, set as 1). All data were normalized to two housekeeping 
genes and represent mean ± SEM of five experiments. ∗P < 0.05; ∗∗P <0.01. 
Discussion 
Nucleotides are key components involved in host cell metabolism and virus infection. Most of the 
inhibitors targeting de novo nucleotide biosynthesis have been well-characterized by many studies 
and their efficacy in inhibiting nucleotide synthesis have been thoroughly demonstrated 16, 17, 24-31. 
Based on that, we profiled and established the effects and mechanism-of-action of inhibiting de novo 
nucleotides biosynthesis on HEV replication. Unexpectedly, targeting the early steps of the purine 
nucleotide synthesis pathway (before the primary purine IMP formed) leads to enhancement of HEV 
replication, whereas targeting later steps (IMPDH enzyme) results in potent antiviral activity against 
HEV, an effect apparently relating to purine nucleotide depletion. Inhibition of pyrimidine nucleotide 
synthesis pathway also inhibits HEV replication. Mechanistically, these effects are related to an 
unconventional interaction with cell-autonomous antiviral immunity dependent  on very strong 
induction of antiviral ISGs.  
It is counterintuitive that targeting the upstream enzymes of the purine pathway (before IMP 
formed) by pharmacological inhibitors facilitates HEV replication, but the specificity became evident 
from silencing genes encoding the enzymes involved. Supplementation with exogenous purine 
nucleotides (adenosine or guanosine) in culture medium in presence of these purine synthesis 
inhibitors were not capable of abrogating the stimulation of HEV replication, suggesting these pro-
viral effects may only partly relate to the nucleotide synthesis pathway (Supplementary Figure 6A-C). 
It is worth noting that targeting the early stage of purine synthesis result in depletion of ATP and/or 
GTP pool. Cellular energy metabolism mediated by ATP might be important for the host cells to 
defend virus infection 32, 33. Therefore, insufficient ATP level might facilitate HEV infection by escaping 
from host cellular immunity. However, how the ATP levels regulate virus infection deserves further 
investigation. Similarly, a previous study reported pro-viral activity by nucleotides biosynthesis 
inhibitors, LFM and FK778, in hepatitis B virus model, although these two compounds are generally 
antiviral against other viruses 17. Thus, the question whether the pro-HEV effects of targeting the 
early steps of the purine pathway are specific to this virus or a general phenomenon in virus biology 
remains unanswered.  
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Figure 11. ISGs induction and the anti-
HEV activity triggered by nucleotide 
synthesis inhibitors are independent 
of the JAK-STAT signalling pathway. 
The induction of ISGs (A, C) and the 
anti-HEV effects (B,D) by MPA were 
quantified in presence or absence of 
JAK inhibitor 1 (A, B)/CP-690550 (CP) 
(C, D); The induction of ISGs were 
normalized to basal ISG expression 
without MPA treatment (purple bar, 
set as 1). The relative HEV RNA levels 
were normalized to cells without 
treatment of MPA (set as 1). Similarly, 
the induction of ISGs (E, G) and the 
anti-HEV effects (F, H) mediated by 
BQR were quantified in presence or 
absence of JAK inhibitor 1 (E, F)/CP (G, 
H). The induction of ISGs were 
normalized to basal ISG expression 
without BQR treatment (purple bar, 
set as 1). The relative HEV RNA levels 
were normalized to cells without BQR 
treatment (set as 1). Data were 
normalized to two housekeeping 
genes and represent mean ± SEM of 
three to four experiments. 
 
 
 
 
 
 
 
IMPDH, as a target for antiviral drug development for a broad spectrum of viruses, has been 
widely investigated. We previously have demonstrated that the IMPDH inhibitors ribavirin and MPA 
inhibit HEV replication in vitro 18, 20. This study further validated this notion by showing the anti-HEV 
potential of 23 specifically designed IMPDH inhibitors. The efficacy of 23 IMPDH inhibitors on HEV 
infection were consistent but with variable degree, which might be due to the different ability and 
variable affinities in inhibiting IMPDH1 and IMPDH2. As a competitive IMPDH inhibitor, ribavirin has 
been used in the clinic to treat chronic hepatitis C for decades. However, ribavirin monotherapy 
hardly has detectable effect on HCV viral load reduction 34, but only when combined with IFN-α, it 
doubles the response rate, compared with IFN-α alone 35. In contrast, ribavirin monotherapy as off-
label treatment appears very effective for treating chronic HEV infection in that viral clearance was 
observed in the majority of the patients as reported by a recent large retrospective multicentre study 
36, although prospective randomized trials are still required to confirm the findings. Of note that in 
addition to IMPDH inhibition, ribavirin also possesses pleiotropic biological properties, including 
immunomodulation, inhibition of gene translation, and interaction with viral RNA-dependent RNA 
polymerase (RdRp) and mutation of virus 37-39. Thus, the exact anti-HEV mechanism by ribavirin 
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remains to be further elucidated, but the present study provides evidence that answer may lie in its 
relation to nucleotide biosynthesis.  
As a non-competitive IMPDH inhibitor, MPA has been used as an immunosuppressant to 
prevent allograft rejection following organ transplantation 40. Despite of the opposing effects of 
inhibitors targeting early or later steps of purine synthesis cascade on HEV, we demonstrated that 
the anti-HEV action of MPA was independent of those early step enzymes (Supplementary Figure 6D) 
Interestingly, clinical evidence appears to support our experimental observation that the use of 
immunosuppressive treatments containing mycophenolate mofetil (the pro-drug of MPA) may lead 
to more frequent HEV clearance in heart transplant recipients 41. Nevertheless, because of limited 
patient number, it is still not sufficient to draw solid conclusion regarding the in vivo effect of MPA. A 
recent cohort study reported the anti-HEV activity by ribavirin was not affected by MPA in patients, 
but they didn’t analyse the direct effect of MPA on HEV infection 42.  
The three inhibitors used in our study interfering pyrimidine synthesis have been described in 
many previous studies 16, 29-31. Adding to the previous knowledge that pyrimidine synthesis inhibitors, 
such as BQR and LFM, have broad antiviral activity against a spectrum of viruses 16, 23, 43, we now 
report their potent anti-HEV activity. Both BQR and LFM are immunosuppressive agents, although 
whether the mechanism of action is solely via pyrimidine inhibition remains controversially unclear 
44-46. The efficacy of BQR against graft rejection has been extensively investigated in preclinical 
models 47-49; whereas LFM has been proposed as off-label immunosuppressive therapy in bone 
marrow 11 and renal 50 transplantation. In addition, DHODH inhibitors have been explored to treat 
various other diseases, including malaria, autoimmune and inflammatory diseases, cancer, 
rheumatoid arthritis and psoriasis 51-55. Given the bifunctional effects of antiviral and 
immunosuppressive of BQR and LFM, these regimens may hold the potential to treat HEV-infected 
organ recipients.  
Interestingly, nucleotide synthesis interacts with cellular antiviral immune responses. Here 
we demonstrated a direct effect of depletion of nucleotide pools on the transcription of antiviral ISGs. 
ISGs are ultimate antiviral effectors that are thought to be induced by interferons only. Although 
hundreds of ISGS have been identified, recent functional studies of individual ISG have surprisingly 
found out that only a small subset of ISGs actually have potent or broad antiviral activities, which 
include IRF1, DDX58 and IRF7 56, 57. It is these antiviral ISGs that are induced in our HEV models upon 
treatment with nucleotide synthesis inhibitors. Consistently, previous studies in HCV models 
reported that induction of IRF1 or IRF7 was associated with the antiviral activity of MPA 19 or 
ribavirin58, respectively. Furthermore, the antiviral activity of inhibitors of pyrimidine biosynthesis 
against measles virus, chikungunya virus and West Nile virus was also associated with the induction 
of ISGs 23.  
For now the mechanistic details as to inhibitors of nucleotide biosynthesis can induce ISGs 
remain obscure. Classically, transcription of ISGs is initiated from the binding of interferons to their 
receptors, which subsequently drives the activation of JAK-STAT cascade 56. Inhibition of JAK1 to 
phosphorylate STAT1, the key event of interferon signalling transduction, often results in complete 
blockage of antiviral interferon responses 59. However, exceptions also exist in that ISGs can be 
induced in the absence of JAK1 or STAT1 activation 60, 61. Here, we found that induction of ISGs and 
the anti-HEV effects by nucleotide synthesis inhibitors are independent of the classical JAK-STAT 
cascade, suggesting the involvement of a non-canonical mechanism that is independent of 
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interferons and identification of these mechanisms should have substantial value for our 
understanding of antiviral immunity.  
In conclusion, selectively targeting host enzymes involved in de novo nucleotide biosynthesis 
potently inhibits HEV replication. Furthermore, nucleotide biosynthesis pathways interact with 
cellular immune response that all the pharmacological inhibitors exerting anti-HEV activity are 
capable of triggering antiviral ISG transcription. Thus, targeting nucleotide biosynthesis represents a 
viable option for antiviral drug development against HEV.  
Supplementary Materials  
Supplementary Table 1. Information of 23 specific IMPDH inhibitors 
 
Inhibitory constant (Ki) on IMPDH1 and IMPDH2 of 23 specific IMPDH inhibitors. First 3 compounds in the table 
are insoluble in DMSO. Other compounds are soluble in DMSO. Compounds 1406 and 1407 do not inhibit 
IMPDH but if converted in the cell into their corresponding NAD analogues should show some inhibition of the 
enzymes. Ki of 1410-L-ABC, 1406 and 1407 was not determined (ND). Chemical structures of the IMPDH 
inhibitors will be published somewhere else. 
Supplementary Table 2. Primer sequences 
Gene Sequences 5’ to 3’ (Forward) Sequences 5’ to 3’ (Reverse) 
HEV ATTGGCCAGAAGTTGGTTTTCAC CCGTGGCTATAATTGTGGTCT 
DDX58 CACCTCAGTTGCTGATGAAGGC GTCAGAAGGAAGCACTTGCTACC 
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ISG15 CTCTGAGCATCCTGGTGAGGAA AAGGTCAGCCAGAACAGGTCGT 
STAT1 ATGGCAGTCTGGCGGCTGAATT CCAAACCAGGCTGGCACAATTG 
IFI27 CGTCCTCCATAGCAGCCAAGAT ACCCAATGGAGCCCAGGATGAA 
IRF1 GAGGAGGTGAAAGACCAGAGCA TAGCATCTCGGCTGGACTTCGA 
IRF9 CCACCGAAGTTCCAGGTAACAC AGTCTGCTCCAGCAAGTATCGG 
IFIT1 GCCTTGCTGAAGTGTGGAGGAA ATCCAGGCGATAGGCAGAGATC 
IFIT2 GGAGCAGATTCTGAGGCTTTGC GGATGAGGCTTCCAGACTCCAA 
IFI6 TGATGAGCTGGTCTGCGATCCT GTAGCCCATCAGGGCACCAATA 
IRF7 CCACGCTATACCATCTACCTGG GCTGCTATCCAGGGAAGACACA 
CXCL10 GGTGAGAAGAGATGTCTGAATCC GTCCATCCTTGGAAGCACTGCA 
MX1 GGCTGTTTACCAGACTCCGACA CACAAAGCCTGGCAGCTCTCTA 
APRT GCGATTGAAGCACCTGTGGATG CGGTTTTTACACAGCACCTCCAC 
GART GCACATCTCTGCCTGTTTGGCT CATGGAACACCTCCAGTCCTAG 
ATIC CCGAGAGTAAGGACACCTCCTT GGCATCTGAGATACGCCTTTGC 
DHODH GAGGACATTGCCAGTGTGGTCA TTCCCACTCAGCCCTCCTGTTT 
Supplementary Table 3. shRNA sequences 
Gene Sequences 
PPAT (3) CCGGCCCTTCGTTGTTGAAACACTTCTCGAGAAGTGTTTCAACAACGAAGGGTTTTTG 
GART (1) CCGGGCCCAGGAGTTTGACTTACAACTCGAGTTGTAAGTCAAACTCCTGGGCTTTTTG 
GART (2) CCGGGCACAGTCTCATCATGTCAAACTCGAGTTTGACATGATGAGACTGTGCTTTTTG 
GART (3) CCGGCCCTAACTGTTGTCATGGCAACTCGAGTTGCCATGACAACAGTTAGGGTTTTTG 
ATIC (1) CCGGGCCTTGACAATACTTTCCAAACTCGAGTTTGGAAAGTATTGTCAAGGCTTTTTG 
ATIC (2) CCGGGCAATCTCTATCCCTTTGTAACTCGAGTTACAAAGGGATAGAGATTGCTTTTTG 
ATIC (3) CCGGGCTGGAATCCTAGCTCGTAATCTCGAGATTACGAGCTAGGATTCCAGCTTTTTG 
DHODH (5) CCGGGTGAGAGTTCTGGGCCATAAACTCGAGTTTATGGCCCAGAACTCTCACTTTTT 
 
 
Figure S1. Gene knockdown of PPAT and DHODH with different shRNA lentiviral vectors. Huh7 cells were 
transduced with lentiviral shRNAs targeting at PPAT (A) and DHODH (B) using a set of 5 different independent 
shRNA preparations for each gene knockdown. Huh7 cells transduced with lentiviral shRNA targeting GFP 
(shCTR) were used as control. The efficiency of knockdown of the 2 genes were analysed by qRT-PCR using 
specific primers. Data were normalized to GAPDH and presented relative to control (set as 1).  
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Figure S2. Fludarabine enhances HEV replication. (A) Huh7 cell-based subgenomic HEV replicon containing the 
luciferase reporter gene were treated for 24h, 48h and 72h with a dose-range of FA. Data presented as mean ± 
SEM. Meanwhile, Huh7 cells with the infectious HEV containing the full-length p6 genome were treated for 48h 
with a dose-range of FA. Data were normalized to GAPDH and presented relative to results from untreated cells 
(set as 1). (B) Huh7 cells were incubated with dose-range of FA. After 72h, MTT assay was performed to 
determine cytotoxicity of FA.  
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Figure S3. 2 μM IMPDH inhibitors moderately inhibit HEV replication. Huh7 HEV replicon luciferase cells were 
treated with 23 specific IMPDH inhibitors (2μM) with MPA as a positive control. Luciferase activity was 
quantified at 24h after treatment (n = 3). 
 
Chapter 13 
216 | P a g e  
 
Figure S4. BQR stimulates ISRE transcription through pyrimidine depletion. Huh7-ISRE-Luc cells were 
incubated with BQR (B) in presence or absence of Uridine (U). ISRE promoter-related firefly luciferase activity 
was quantified 72h after culture. 
 
 
Figure S5. JAK inhibitors diminish IFNα stimulated ISG expression. (A) Huh7 cells infected with HEV were 
incubated with IFNα in presence or absence of Jak inhibitor 1. After 48h, the expression of ISGs were assessed 
by qRT-PCR. (B) Same experiment was performed with another JAK inhibitor, CP-690550 (CP). Data were 
normalized to basal ISG expression without IFNα treatment (purple bar, set as 1). All data were normalized to 
two housekeeping genes and experiments were performed two to five times. 
 
Figure S6. Inhibition of IMP synthesis enhanced HEV replication independent of purine depletion and does 
not affect the anti-HEV activity of MPA. Huh7 cells infected HEV were treated with 6-TG (A), lometrexol (B) 
and MTX (C), respectively, in the presence or absence of guanosine (G)/adenosine (A). The HEV RNA was 
assessed by qRT-PCR 48h after treatment. (D) Huh7 cells infected HEV were treated with 6-TG, lometrexol and 
MTX, respectively, in the presence or absence of MPA. The HEV RNA was assessed by qRT-PCR 48h after 
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treatment. Data were normalized to two housekeeping genes and presented relative to the control (CTR) (set 
as 1). Experiments were performed two to five times.  
 
Figure S7. The effects of nucleotide synthesis inhibitors on Huh7 cells viability. Huh7 cells were incubated 
with a dose-range of 6-TG, lometrexol, MTX, BQR, LFM or 6-AU for 72h treatment. Huh-7 cells were incubated 
with 23 IMPDH inhibitors at 10 μM for 48h. MTT assay was performed to determine cytotoxicity of these 
compounds.  
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Abstract 
The outcomes of hepatitis E virus (HEV) infection are diverse, ranging from asymptomatic carrier, 
self-limiting acute infection, fulminant hepatitis to persistent infection. This is closely associated with 
the immunological status of the host. This study aims to understand the innate cellular immunity as 
the first-line defense mechanisms in response to HEV infection. Phosphorylation of STAT1, a hallmark 
of the activation of antiviral interferon (IFN) response, was observed in the liver tissues of majority of 
HEV infected patients, but not in the liver of uninfected individuals. In cultured cell lines and primary 
liver organoids, we found that HEV RNA genome potently induced IFN production and antiviral 
response. This mechanism is conserved among different HEV strains, including genotype 1, 3 and 7 as 
tested. Interestingly, the single-stranded HEV RNA (ssRNA) is sufficient to trigger the antiviral 
response, without requirement of viral RNA synthesis and the generation of RNA replicative form or 
replicative intermediate. Surprisingly, the m7G cap and poly A tail are not required, although both are 
the key features of HEV genome. Mechanistically, this antiviral response occurs in a RIG-I-, MDA5-, 
MAVS- and β-catenin-independent, but IRF3 and IRF7-dependent manner. Furthermore, the integrity 
of the JAK-STAT pathway is essentially required. In conclusion, HEV infection elicits an active IFN-
related antiviral response in vitro and in patients. It is triggered by the viral RNA and mediated by 
IRF3/7 and the JAK-STAT cascade. These findings have revealed new insights on HEV-host 
interactions and provided the basis for understanding the pathogenesis and outcome of HEV 
infection. 
 
Keywords: hepatitis E virus; viral RNA; interferon; IRF3/7; JAK-STAT 
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Introduction 
Over the last decade, hepatitis E virus (HEV) infection has emerged as a global health issue. It is one 
of the most common causes of acute viral hepatitis in the world. Although the infection is generally 
self-limiting, severe complications and high mortality rates have been reported in special 
populations, including pregnant women, immunocompromised patients, or patients with pre-existing 
liver disease (1-3). HEV outbreaks periodically occur throughout the resource limited countries 
including the large ongoing outbreak in Niger, resulting in heavy clinical burden with high mortality 
rate in pregnant women (4, 5). Unfortunately, there is no FDA-approved medication available and its 
infection biology is poorly understood. 
Virus infections universally evoke active interactions between the virus and host. Host cells 
are equipped with mechanisms that rapidly detect and respond to virus invasion. These defense 
mechanisms largely rely on receptors that monitor the cytosol for the presence of atypical nucleic 
acids from the virus. DExD/H-box RNA helicases of the RIG-I like receptor (RLR) family have been 
identified as essential intracellular sensors of RNA viruses. Two of the RLR family members, retinoic 
acid-inducible gene-I protein (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) are 
ubiquitously expressed, which enable the detection of viral infection in almost all cell types. Upon 
the detection of viral RNA ligand, RIG-I or MDA5 interacts with a mitochondrion-anchored adaptor 
protein, MAVS, to initiate downstream signaling that eventually leads to the transcription and 
production of interferons (IFNs). Once secreted, IFNs create a state of antiviral alertness by inducing 
the expression of hundreds of IFN-stimulated genes (ISGs). RIG-I has been reported to be essential 
for IFN production in the setting of Newcastle disease virus, vesicular stomatitis virus, influenza, and 
Japanese encephalitis virus infections (6, 7). IFN production is impaired in MDA5 deficient cells 
infected with Picornaviridae, murine norovirus 1 and the murine hepatitis virus (8-10). Some viruses 
such as West Nile virus and Dengue virus are recognized by both RIG-I and MDA5 (11, 12). Other 
intricate viral RNA sensor systems outside the RLR family have also been implicated in eliciting IFN 
response to virus infection, including DDX3 (13), DHX9 (14), DDX1-DDX21-DHX36 complex (15), NLR 
NOD2 (nucleotide-binding oligomerization domain 2) (16) and LRRFIP1 (17). It is believed that these 
intricate RNA sensors act independently or cooperatively to mediate innate immune response upon 
virus invasion. 
HEV is a single-stranded positive-sense RNA virus within the family of Hepeviridae. The 
genome contains short 5′- and 3′-noncoding regions (NCRs), 5′-m7G cap, 3′-poly A tail and three open 
reading frames (ORF1, ORF2 and ORF3) (18). In patients, in particular in case of acute infection with 
severe hepatitis, active virus-host interactions is likely the cause of pathogenesis but also the process 
of combating the infection (19). In this study, we found the phosphorylation of STAT1 (Y701), a 
hallmark of IFN-related antiviral response, in the liver of HEV infected patients. Since viral nucleic 
acid is the main pathogen-associated molecular patterns (PAMPs) recognized by host innate immune 
system, we delivered in vitro generated HEV genomic RNA into host cells to investigate the host 
response. Consistently, HEV RNA potently induce IFN production and antiviral response in both cell 
lines and 3D cultured primary liver organoids. Surprisingly, the single-stranded HEV RNA (ssRNA) is 
sufficient to trigger the host response. This occurs in a RIG-I-, MDA5-, MAVS- and β-catenin-
independent, but IRF3 and IRF7-dependent manner. Importantly, the integrity of the JAK-STAT 
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cascade is required for the antiviral response triggered by HEV. These results have provided novel 
insights into HEV-host interactions.  
Results 
Activation of STAT1 phosphorylation in the liver of HEV infected patients 
To investigate whether HEV infection activates host antiviral response in patients, the expression of 
phosphorylated STAT1 (Y701), a hallmark of IFN-related antiviral response, was stained in the liver 
biopsies (Fig.1A). The staining of HEV viral protein ORF2 and phosphorylated STAT1 (P-STAT1) was 
scored independently based on the proportion of positive cells (Fig.1B). Up to 89% of HEV infected 
patients showed a positive staining of phosphorylated STAT1 in the liver; whereas no staining was 
observed in the liver tissues from uninfected individuals (Fig.1C and Table S1). These results indicated 
that HEV infection elicits an active IFN-related antiviral responses in patients.  
HEV genomic RNA potently induces antiviral IFN response 
Upon HEV invasion, HEV-derived components, like viral capsid protein or viral genomic RNA can be 
sensed as “non-itself” by host innate immunity. Therefore, the potential role of HEV protein ORF2 
and ORF3 in IFN response was evaluated firstly. HEK293 cells were transfected with control, ORF2 or 
ORF3-expressing vectors. The expression of ORF2 or ORF3 protein (sFig. 1A and B) has no significant 
effect on IFN expression as well as the subsequent ISG induction (sFig.1C and D). To further 
investigate whether any functional IFNs are produced, we collected the conditioned medium from 
the transfected cells (supernatant) (sFig.1E) and performed an ISRE-based IFN reporter assay, and a 
highly IFN-sensitive HCV-replicon based bioassay. Consistently, no IFN production was detected in 
both models (sFig. 1F and G). 
We next examined whether HEV viral RNA is the trigger of host innate immune response. In 
vitro generated HEV genomic RNA was used to efficiently deliver into host cells. Upon transfection of 
genotype 3 (Gt3) HEV RNA (Kernow-C1, P6) into the human liver hepatoma Huh7.5 cells (named 
Huh7.5-P6), the viral protein ORF2 was subsequently detected by immunofluorescent assay (sFig.2A). 
The anti-HEV effects of IFN-α and ribavirin were confirmed in these cells (sFig.2B). After inoculation 
with conditioned cell culture medium derived from Huh7.5-P6 cells, viral protein was also detected in 
HEK293 cells (sFig.2C). Therefore, Gt3 HEV RNA generated in vitro is functional to initiate the 
essential steps of HEV life cycle. 
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Figure 1. Immunohistochemistry showed the positive staining of P-STAT1 in liver tissues of HEV patients. (A) 
Representative staining of HEV and P-STAT1 in liver tissue of HEV patients or negative control individuals. (B) 
Representative staining indicating variable levels of HEV and P-STAT1 on liver tissues. (C) The distribution of 
HEV and P-STAT1 score among liver tissues. 
 
Importantly, transfection of Gt3 HEV RNA strongly induced IFN response in an dose-
dependent manner; while no response was observed in the negative controls, transfection of a GFP 
vector or cellular RNA. Specifically, the expression of IFNβ (type I IFN), IFNλ1 and IFNλ2 (type III IFN) 
was strongly induced (Fig. 2A), although no significant change in the levels of IFNα (type I IFN) and 
IFNγ (type II IFN) (sFig.2D). To examine whether functional IFNs are produced, we collected the 
conditioned medium from the transfected cells (supernatant) (sFig.1E) and performed an ISRE-based 
IFN reporter assay, and a highly IFN-sensitive HCV-replicon based bioassay. As shown in Fig. 2B, 
supernatant from HEK293 cells transfected with Gt3 HEV RNA strongly induced ISRE coupled 
luciferase activity. Consistently, HCV replicon-related luciferase activity was decreased upon the 
same treatment (Fig. 2C). Since Interferon-stimulated genes (ISGs) are the downstream antiviral 
effectors of IFN signaling, thus a list of well-known antiviral ISGs were quantified. The expression 
levels of these ISGs were significantly up-regulated upon transfection of Gt3 HEV RNA (Fig. 2D). 
Correspondingly, HEV replicon-related luciferase activity was decreased in HEK293 cells (Fig. 2E). In 
addition, HEV induced IFN response was further confirmed by the employment of in vitro generated 
genotype 1 (Gt1) HEV and dromedary camel hepatitis E virus (DcHEV; Gt7) (20) (Fig. 2F – I, sFig. 2F). 
Therefore, in HEK293 cells, HEV could potently induce antiviral IFN response upon viral RNA entry 
into the cytoplasm.  
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HEV infection was reported to cause both hepatic and extra-hepatic manifestations, thus we 
extended our study to hepatic cell lines (Huh7.5 and HepaRG) as well as other extra-hepatic cell line 
(U87, a neural cell line). Consistently, transfection of HEV RNA led to strong IFN production and IFN 
response in Huh7.5 (sFig.3), HepaRG (Fig. 3A and B) and U87 cells (Fig. 3C - E). Recently, three 
dimensional (3-D) cultured primary liver organoids have emerged as innovative models for studying 
liver physiology and pathology. They contain various types of cells and recapitulate most if not all 
aspects of in vivo liver tissue architecture (21). We further validated that transfection of HEV RNA 
lead to strong IFN expression and subsequent ISG induction in primary liver organoids cultured from 
mouse or human liver tissues (Fig. 3F - J).  
HEV RNA triggered host response is independent of the m7G cap and poly A 
tail 
HEV genome is a ∼ 7.2 kb single stranded RNA with 5’ terminal capped (m7G cap) and 3’ terminal 
polyadenylated (Fig. 4A). The m7G cap is essential for the HEV infectivity both in vivo and in vitro (22, 
23). The poly A tail is crucial for viral RNA dependent RNA polymerase (RDRP) binding to the 3’ UTR 
(24). Since host cells specifically recognize certain features of the viral nucleic acids, we investigated 
whether m7G cap and poly A tail are required for HEV triggered IFN response. Thus, Gt3 HEV RNA 
lacking m7G cap or poly A tail were generated in vitro and transfected in both HEK293 and Huh7.5 
cells. Interestingly, compared with the wild type form, HEV RNA lacking of m7G cap or poly A tail 
retains a comparable potency to induce IFN response (Fig.4B and C, sFig.4A - C). These data indicated 
that HEV triggers IFN response independent of m7G cap and poly A tail. 
The single-stranded HEV RNA (ssRNA) is sufficient to trigger the antiviral 
response 
Upon transfection of HEV RNA genome, the virus replicates and produces different RNA species 
including ssRNA, viral RNA replicative form (double-stranded RNA, dsRNA) and replicative 
intermediate. To clarify whether IFN response induced by HEV depend on viral RNA replication and 
which specific RNA species is involved, two mutant forms of Gt3 HEV RNA (G1634R, G1634K) (Fig. 4A) 
were transcribed in vitro. These two mutant forms have comparable ribavirin sensitivity to the wild 
type HEV but possessed an enhanced replication fitness in vitro (25, 26). However, they exerted 
comparable activity in inducing IFN response in both HEK293 and Huh7.5 cells when compared with 
the wild type form (Fig.4D and E, sFig.5A - D). These results imply that the replication of HEV RNA 
may not be important in this process. To confirm this notion, a replication defective Gt3 HEV replicon 
(GAD) carrying an alanine substitution in the polymerase active site was used (27, 28). Consistently, 
compared with wild type form, transfection of Gt3 HEV replicon (GAD) RNA induced strong and 
comparable IFN response in both HEK293 and Huh7.5 cells (Fig.4F and G, sFig.5E - G). More 
convincingly, the IFN induction ability of Gt3 HEV replicon (GAD) was also confirmed in other 2-D 
cultured cell models (e.g. HepaRG and U87) (Fig.5A - E) as well as 3-D mouse and human primary 
liver organoids (Fig.5F - H). Collectively, these results indicate that HEV ssRNA is the specific RNA 
species involved in triggering IFN response, and this process is independent of viral replication. 
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Figure 2. Transfection of HEV RNA potently induces IFN production and IFN response in HEK293 cells. HEK293 
cells were transfected with control (transfection reagent only, CTR), GFP-vector (plasmid, GFP-V), cellular RNA 
or Gt3 HEV RNA. The expression levels of indicated IFNs (A) and ISGs (D) were quantified at 48h.p.t. by qRT-PCR 
(n = 4). (B) ISRE luciferase value was measured (at 48h) after the treatment of conditioned medium from 
HEK293 cells transfected with CTR, GFP-V, cellular RNA or Gt3 HEV RNA (n = 6). (C) HCV viral replication-related 
firefly luciferase activity was measured after the treatment of conditioned medium from HEK293 cells 
transfected with CTR, GFP-V or Gt3 HEV RNA (n = 4). (E) HEV viral replication-related firefly luciferase activity 
was measured after the transfection of CTR, GFP-V or Gt3 HEV RNA in HEK293-P6-luc cells (n = 4). HEK293 cells 
were transfected with CTR, Gt1 HEV RNA (F) or DcHEV RNA (H). The expression levels of indicated IFNs and ISGs 
were quantified at 48h.p.t. by qRT-PCR (n = 4). HCV viral replication-related firefly luciferase activity was 
measured after the treatment of conditioned medium from HEK293 cells transfected with Gt1 HEV RNA (G) or 
DcHEV RNA (I). (n = 4). 
It is independent of RIG-I and MDA5  
Pattern recognition receptors (PRRs) are the primary sensors detecting viral RNA and subsequently 
activate antiviral IFN response. They are generally categorized into two major classes depending on 
their subcellular location, membrane-bound PRRs (e.g. Toll-like receptors) and intracellular PRRs (e.g. 
RIG-I-like receptors) (29). Membrane-bound PRRs are predominantly expressed in immune cells, such 
as macrophages and dendritic cells. Intracellular PRRs are ubiquitously expressed. Our previous study 
have demonstrated that overexpression of the intracellular PRRs, MDA5 or RIG-I exerts anti-HEV 
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effects (30). Therefore, we investigated whether these two molecules mediate HEV RNA triggered 
IFN response.  
Interestingly, overexpression of MDA5 triggered IFN production and subsequent IFN 
response in both HEK293 and Huh7.5 cells (sFig.6A - L). A similar response was observed in HEK293 
cells upon the overexpression of RIG-1 (sFig.7A - F), but Huh7.5 cells are defective of RIG-I (30). 
Consistently, the transfection of 5’-ppp RNA, a specific RIG-I agonist, was unable to induce any IFN 
responses in Huh7.5 cells (sFig.8A-C). Thus, the fact that HEV triggers IFN response in Huh7.5 cells 
upon the transfection of viral RNA (sFig. 2C - H) indicates a RIG-I-independent mechanism. To further 
confirm this notion, wild type (WT) and RIG-I knockout (RIG-I-/-) mouse embryonic fibroblasts (MEF) 
was employed. The efficient knockout of RIG-I was confirmed by both 5’-ppp RNA transfection assay 
and western blot assay (sFig.8D and E). Transfection of Gt3 HEV RNA strongly induced IFNβ and 
representative ISG expression in RIG-I-/- MEF cells (Fig.6A and B, left and right panels). In addition, 
the conditioned medium was collected from RIG-I-/- MEF cells transfected with Gt3 HEV RNA. 
Incubation of conditioned medium efficiently induced STAT1 phosphorylation, a key feature of IFN 
signaling pathway activation. Collectively, HEV initiates IFN production and IFN response 
independent of RIG-I. 
Next, we examined the involvement of MDA5. The efficient knockout of MDA5 (MDA5-/-) 
was confirmed by western blot assay (sFig. 8F). Strikingly, transfection of HEV RNA in MDA5-/- MEF 
cells can also strongly induce IFN production and IFN response (Fig.6C), indicating a MDA5 - 
independent mechanism. Some viruses such as West Nile virus and Dengue virus are recognized by 
both MDA5 and RIG-I to initiate IFN response (11, 12). This forced us to clarify whether HEV induced 
IFN response require both MDA5 and RIG-I. Therefore, HEV RNA was transfected in RIG-I and MDA5 
double knockout (RIG-I and MDA5-/-) MEF cells (sFig.8E and F). However, IFN production and IFN 
response were still efficiently initiated (Fig.6D). On the contrary, transfection of a commonly used 
RIG-I/MDA5 agonist, poly (I;C) only induced IFNβ and ISGs expression in WT, while not RIG-I and 
MDA5-/- MEF cells (sFig.8G). Thus, HEV RNA triggered IFN response is independent of both MDA5 
and RIG-I. 
HEV RNA triggered antiviral response is independent of MAVS and β-catenin, 
but requiring IRF3 and IRF7 
In addition to RIG-I and MDA5, other proteins have been implicated in cytosolic sensing of viral RNA 
to trigger IFN response. They include DDX3 (13), DHX9 (14), DDX1-DDX21-DHX36 complex (15), and 
NLR NOD2 (nucleotide-binding oligomerization domain 2) (16). Importantly, similar with RIG-I and 
MDA5, these proteins are thought to sense viral RNA and induce IFN expression in a MAVS-
dependent manner. Surprisingly, in MAVS knock out (MAVS-/-) MEFs, IFN response was strongly 
induced after the transfection of HEV RNA (Fig.6E). Notably, the cytosolic nucleic acid sensor LRRFIP1 
has been reported to sense DNA and RNA viruses, thus mediating IFN response via a MAVS-
independent, but β-catenin-dependent pathway (17). Therefore, the involvement of β-catenin was 
investigated by employing β-catenin-/- MEF cells (sFig.8H). Remarkably, the transfection of HEV RNA 
initiated strong IFN response in β-catenin-/- MEF cells (sFig. 8I). These results indicated that HEV RNA 
is most likely recognized by a currently undefined or unknown cytosolic nucleic acid sensor to 
activate antiviral IFN response via MAVS- and β-catenin-independent mechanisms. 
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Figure 3. Transfection of HEV RNA induces antiviral response in both 2-D and 3-D cell culture models. (A) 
HepaRG cells were transfected with CTR, GFP-V or Gt3 HEV RNA (200 ng / well) in 96-well plates. The 
expression levels of indicated IFNs and ISGs were quantified at 48h.p.t. by qRT-PCR (n = 4). (B) ISRE luciferase 
value was measured after the treatment of conditioned medium from HepaRG cells transfected with CTR, GFP-
V or Gt3 HEV RNA (n = 5). (C) and (D) Same as (A) for U87 cells. (E) Same as (B) for U87 conditioned medium 
measured at 24h. Representative microscopy image of 3-D cultured mouse (F) and human (H) primary liver 
organoids. (G) After the transfection of Gt3 HEV RNA in mouse liver organoids, the expression levels of IFNβ 
and indicated ISGs were quantified at 48h.p.t. by qRT-PCR (n = 4). (I) Same as (G) for human liver organoids (n = 
4). (H) Same as (B) for human liver organoids (n = 5).  
 
Given the essential role of two transcription factors, IRF3 and IRF7, in the production of IFNs, 
we investigated whether these two factors are required. Transfection of HEV RNA failed to stimulate 
any IFNβ and ISG expression in IRF3 and IRF7 knock out MEFs (Fig.6F, left and right panel). 
Correspondingly, incubation of conditioned medium (supernatant, IRF3 and IRF7-/- MEFs transfected 
with HEV RNA) has no effect on STAT1 phosphorylation (Fig.6F,middle panel). Therefore, HEV induces 
IFN responses in an IRF3 and IRF7-dependent manner. Since HEV ssRNA is the specific RNA species 
involved in IFN responses, the replication defective Gt3 HEV replicon (GAD) RNA was tested as well. 
Consistent with its wild type, Gt3 HEV replicon (GAD) RNA induces IFN response in a RIG-I-, MDA5-, 
MAVS- and β-catenin-independent, but IRF3 and IRF7-dependent manner (Fig.7A - F, sFig.8J). 
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Figure 4. HEV ssRNA is sufficient to trigger IFN response, while independent of viral RNA m7G cap and poly A 
tail. (A) The illustration of HEV RNA genome (MT, Methyltransferase; Y, Y-domain; Pro, protease; Hel, helicase; 
RdRp, RNA-dependent RNA polymerase). (B) HEK293 cells were transfected with CTR, wild type (WT), no m7G 
cap or no poly A tail Gt3 HEV RNA (200ng / well) in 96-well plates. The expression levels of indicated IFNs and 
ISGs were quantified at 48h.p.t. by qRT-PCR (n = 3). (C) HEV viral replication-related firefly luciferase activity 
was measured after the same transfection indicated in (B) in HEK293-P6-luc cells (n = 4). (D) HEK293 cells were 
transfected with CTR, WT, 1634R mutant or 1634K mutant Gt3 HEV RNA (200ng / well) in 96-well plates. The 
expression levels of indicated IFNs and ISGs were quantified at 48h.p.t. by qRT-PCR (n = 3). (E) ISRE luciferase 
value was measured after the treatment of conditioned medium from HEK293 cells transfected with CTR, WT, 
1634R mutant or 1634K mutant Gt3 HEV RNA (n = 4). HEK293 cells were transfected with CTR, WT or 
replication defective Gt3 HEV replicon (GAD) RNA (n = 4). The expression levels of indicated IFNs (F) and ISGs 
(G) were quantified at 48h.p.t. by qRT-PCR. 
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Figure 5. HEV ssRNA triggers IFN response in both 2-D and 3-D cell culture models. (A) HepaRG cells were 
transfected with Gt3 HEV replicon (GAD) RNA (200ng / well) in 96-well plates. The expression levels of 
indicated IFNs and ISGs were quantified at 48h.p.t. by qRT-PCR (n = 4). (B) ISRE luciferase value was measured 
after the treatment of conditioned medium from HepaRG cells transfected with Gt3 HEV replicon (GAD) RNA (n 
= 5). (C) and (D) Same as (A) for U87 cells. (E) Same as (B) for conditioned medium from U87 cells. (F) Same as 
(A) for mouse liver organoids (n = 4). (G) Same as (A) for human liver organoids (n = 4). (H) Same as (B) for 
human liver organoids (n = 5).  
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Figure 6. HEV triggers IFN response in a RIG-I-, MDA5- and MAVS-independent but IRF3/IRF7-dependent 
manner. The transfection of Gt3 HEV RNA (200ng / well) was performed in WT (A), RIG-I-/- (B), MDA5-/- (C), 
RIG-I and MDA5-/- (D), MAVS-/- (E) and IRF3/IRF7-/- (F) MEFs in 96-well plates. The levels of IFNβ (red line) and 
the relative intracellular HEV RNA (blue line) were quantified at 48h.p.t. by qRT-PCR (n = 4) (left panel). The 
MEF cells were treated with conditioned medium collected from indicated cells for 24h. The protein levels of 
total and phosphorylated (Y701) STAT1 were detected by WB (middle panel). The expression levels of 
representative ISGs (ISG15 and IFIT1) were quantified at 48h.p.t. by qRT-PCR (n = 4) (right panel). 
 
Figure 7. HEV ssRNA triggers IFN response in a MAVS-independent but IRF3/IRF7-dependent manner. The 
transfection of WT or Gt3 HEV replicon (GAD) RNA was performed in WT (A), RIG-I-/- (B), MDA5-/- (C), RIG-I and 
MDA5-/- (D), MAVS-/- (E) and IRF3/IRF7-/- (F) MEFs. The levels of IFNβ and the indicated ISGs were quantified 
at 48h.p.t. by qRT-PCR (n = 4). 
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The integrity of the JAK-STAT cascade is essential for the antiviral response 
Upon IFN production, the thus-released IFN molecules bind to cell-surface receptors and initiate 
signal transduction prominently via the Janus kinase/signal transducer and activator of transcription 
(JAK–STAT) pathway. This activates the transcription of hundreds of ISGs that are the effectors of 
cell-autonomous antiviral defense (31). The transfection of HEV RNA in U3A cells (which are STAT1-
deficient) or U6A cells (which are STAT2-deficient) achieved much lower expression levels of ISGs 
compared with their wild type (Fig. 8A). Strikingly, the expression of IFNs was also largely demolished 
(Fig. 8B). This was further supported by the use of JAK inhibitor I, a pharmacological JAK inhibitor to 
block JAK–STAT signal transduction (sFig.8K). JAK inhibitor I sufficiently blocked HEV RNA induced ISG 
and IFN expression in both HEK293 and Huh7.5 cells (Fig.8C - I). Therefore, the integrity of JAK–STAT 
pathway is essential for HEV induced IFN response and (in turn) IFN production. 
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Figure 8. The integrity of JAK–STAT pathway is essential for HEV induced antiviral response. 
Gt3 HEV RNA was transfected in WT, U3A (STAT1 deficient) and U6A (STAT2 deficient) cells. The levels of ISGs 
(A) and IFNs (B) were quantified at 48h.p.t. by qRT-PCR (n = 4). Gt3 HEV RNA was transfected in HEK293 cells 
with or without JAK inhibitor I (10μm). The levels of ISGs (C) and IFNs (D) were quantified at 48h.p.t. by qRT-
PCR (n = 4).(E) Same as (C) for Huh7.5 cells. (F) Same as (D) for Huh7.5 cells. (G) HCV viral replication-related 
firefly luciferase activity was measured after the treatment of conditioned medium from HEK293 cells 
transfected with Gt3 HEV RNA with or without JAK inhibitor I (n = 4). (H) ISRE luciferase value was measured 
after the treatment of conditioned medium from Huh7.5 cells transfected with Gt3 HEV RNA with or without 
JAK inhibitor I (n = 4). (I) Same as (G) for Huh7.5 cells. 
 
Discussion 
The innate immune system is a major host defense machinery triggered by viral infections. One 
prominent characteristic is the rapid and efficient detection of invading pathogens through 
recognition of the PAMPs by host PRRs. After specific ligand recognition, host PRRs initiate distinct 
signaling transduction that lead to the production and secretion of IFNs. IFNs transcriptionally 
stimulate hundreds of ISGs via the JAK–STAT pathway, thus creating an antiviral state. IFNs in 
particular IFN-α have been approved for treating viral infections in clinic for decades, including 
chronic hepatitis B (HBV) and C virus (HCV) infections. IFN-α has also been used as an off-label drug 
to treat chronic HEV infection (2). Therefore, identifying the cellular innate immune response during 
virus infection has attracted much attention in recent years. In this study, we found that HEV 
infection could elicit an active IFN-related antiviral responses in most patients. Mechanistically, we 
found that HEV RNA could potently induce IFN production and antiviral response upon entry into the 
cytoplasm. This observation was captured in two dimensional culture of hepatic and extra-hepatic 
cell lines as well as three dimensional culture of mouse and human primary liver organoids.  
HEV genome is a positive-stranded RNA with 5’ terminal capped (m7G cap) and 3’ terminal 
polyadenylated. The m7G cap structure was critical for efficient infectivity in cell culture models (23). 
Furthermore, the intrahepatic inoculation of uncapped transcripts failed to initiate HEV infection in 
chimpanzees even followed for 20 weeks (22). The 3’ end of HEV genome could bind specifically to 
the viral RdRp, directing the synthesis of complementary-strand RNA (24). However, these key 
features are not essential for HEV triggered IFN response.  
After HEV RNA genome entering into host cells, viral replication was initiated. Therefore, 
different viral RNA species are produced and co-exist, including ssRNA, dsRNA and replicative 
intermediate. With respect to different viruses, host PRRs recognize different specific PAMPs to 
initiate IFN productions. For most viruses, like dengue virus, Japanese encephalitis virus or 
picornavirus, viral replicative form (dsRNA) serves as an IFN inducer (8, 32). However, for some 
viruses, like respiratory syncytial virus and influenza A virus, ssRNA could induce IFN production (16, 
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29). In our study, we found that HEV ssRNA is sufficient in inducing IFN response, independent of 
viral replication. This suggests that host cells are capable to immediately sense HEV invasion before 
the starting of viral replication. 
In the cytosol, RLR helicase subfamily (e.g. RIG-I and MDA5) serve as essential immune 
sensors to detect viral nucleic acids. Upon ligand binding and recognition, RIG-I and MDA5 undergo 
conformational changes that activate the signaling partner MAVS on the mitochondrial and 
peroxisomal membranes. MAVS can signal to downstream signaling pathways by activating the 
serine/threonine-protein kinase IKK and TBK-1 kinases, leading to the induction of IFNs. In our study, 
overexpression of either RIG-I or MDA5 could efficiently initiate IFN production and subsequent IFN 
response in particular cell lines. In addition to RLRs, other RNA sensor-related pathways have been 
implicated in the IFN response to viruses. They include DDX3 (13), DHX9 (14), DDX1-DDX21-DHX36 
complex (15), NLR NOD2 (nucleotide-binding oligomerization domain 2) (16) and LRRFIP1-β-catenin 
pathways (17). With respect to the fact that host cells may encounter a wide variety of intracellular 
virus infections, these diversified RNA sensors may act both independently and/or cooperatively with 
the classical RLRs to more efficiently mediate antiviral response. Strikingly, we found that HEV ssRNA 
induced IFN response is largely independent of the classical RLRs as well as the other RNA sensing 
pathways as mentioned. However, it is via an IRF3- and IRF7-dependent manner, which is consistent 
with the essential role of these two transcription factors in IFN production. Therefore, our present 
study strongly indicates that HEV RNA is likely recognized by a undefined or unknown cytosolic RNA-
sensing systems, which deserves further investigation. An unbiased biochemical screen or a genome-
wide CRISPR-based screen represents the state-of-art tools to identify and investigate 
uncharacterized host factors possessing PRRs function. 
IFN-mediated innate immune response forms a first line of cell-autonomous defense against 
pathogens. IFN activates the JAK–STAT pathway, leading to the induction of a wide array of ISGs. 
Functionally, they are divided into three groups: antiviral effector, negative regulator and positive 
regulator. ISGs, such as MX1 and ISG15, are antiviral effectors. They control infection by directly 
targeting pathways and functions essential for pathogen life cycles. some ISGs (e.g. SOCS, USP18) are 
negative regulators. They help resolve the IFN–induced state and return to cellular homeostasis. 
ISGs, including RIG-I, MDA5, IRFs and STAT1/2, serve as positive regulators to reinforce IFN response. 
In our study, when the integrity of JAK–STAT pathway was compromised, the expression levels of 
ISGs induced by HEV were largely blocked. They include antiviral effector (e.g. MX1, ISG15) as well as 
positive regulators (e.g. RIG-I and MDA5) (Fig. 7). This in turn lead to the attenuation of IFN 
expression and production. Therefore, the integrity of JAK-STAT cascade is essentially required for 
HEV-triggered antiviral IFN response. 
Our findings that the host cells can rapidly recognize the income HEV genomic ssRNA and 
evolve potent antiviral response may explain the asymptomatic infection in the general population. A 
subset of patients with acute hepatitis eventually clear the infection through active virus-host 
interactions, although pregnant women bear high risk to develop fulminant hepatitis with mortality 
rate reaching up to 25% (18). In immunocompromised patients, chronic infection has been widely 
reported, which is conceivably attributed to compromised innate and adaptive immunity (33, 34). 
Consistently, a recent study have reported that persistent HEV infection in cell culture does not 
activate type I IFN, although companied by a type III IFN response (35). In our study, we found that 
HEV RNA activates both type I and III IFN responses, resulting in potent antiviral effects, which more 
Chapter 14 
237 | P a g e  
likely reflected the infection phase with active virus-host interactions in HEV patients. Of note, other 
elements of the virus, in particular the HEV viral proteins, are also capable of modulating antiviral 
response (36-39), thus collectively determine the eventual infection course and clinical outcome. 
In summary, we have demonstrated that HEV infection elicit an active antiviral interferon 
response triggered by the viral genome. The incoming genomic ssRNA is the specific viral RNA species 
to trigger the response. This occurs in a RLRs-, MAVS- and β-catenin- independent, but IRF3 and IRF7-
dependent manner. Important, the integrity of JAK-STAT pathway is required for the host antiviral 
response. These findings have revealed new insights on HEV-host interactions and may provide new 
avenues for antiviral drug development.  
Materials and Methods 
Patient materials 
Eighteen liver biopsies from patients (2010 – 2017) diagnosed of acute or chronic hepatitis E were 
retrieved at Beijing 302 hospital, China. The use of patient materials was approved by the medical 
ethical committee of Beijing 302 hospital. The expression of P-STAT1 (Y701) was stained. Five liver 
biopsies from hepatic hemangioma patients were collected as negative control. These patient 
information was shown in Table S1. 
Immunohistochemistry (IHC) staining 
Immunohistochemistry staining of HEV ORF2 viral protein or P-STAT1 (Y701) was performed to 
validate HEV infection and visualize phosphorylated-STAT1. In detail, the liver biopsies were fixed in 
10% formalin for 1.5 h at room temperature, processed for paraffin embedding, and sectioned at a 
thickness of 4 μm. The sections were deparaffinized in xylene and rehydrated through graded 
ethanol treatment, followed by high pressure in citrate buffer (pH 6.0) for 3 min for antigen retrieval. 
Then they were blocked with 3% H2O2 in TBS for 15 min and further blocked with goat serum for 1 
hour. The sections were incubated with anti-HEV ORF2 viral protein (Millipore,1:600) or anti-P-STAT1 
(Cell signaling,1:800) monoclonal antibody overnight at 4 °C, and incubated with goat anti-
mouse/rabbit secondary antibody (ZSGB-BIO,KIT-5030) for 15 min at 37°C. Subsequently, the 
sections were developed with diaminobenzidine (DAB) (ZSGB-BIO, ZLI-9018), followed by 
counterstaining hematoxylin. Immunostained sections were scanned using Leica DFC400 digital 
camera and Leica Application Suite software (Leica Microsystems). 
Plasmids and Reagents 
The plasmids constructs containing the full-length Gt1 HEV genome (Sar55/S17, GenBank Accession 
Number: AF444002 ), Gt3 HEV genome (Kernow-C1 P6 clone, GenBank Accession Number: 
JQ679013) and HEV replication defective genome (GAD) were kindly provided by Suzanne U. 
Emerson (National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
Bethesda, MD). The plasmid containing the full-length dromedary camel HEV genome (GenBank 
Accession: KJ496144) was kindly provided by Tian-Cheng Li (National Institute of Infectious Diseases, 
Japan). The plasmids constructs containing the full-length HEV genome (Kernow-C1 P6 clone) with 
1634R or 1634K mutations were generated accordingly (25). Plasmid pLVX-ORF2-IRES-zsGrenn1 was 
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kindly provided by Alexander Ploss (Princeton University) (40). Plasmid pEGFP-C1-ORF3 was 
constructed in our lab. pTRIP.CMV.IVSb.ISG.ires.TagRFP based RIG-I and MDA5 expression vectors 
were a kind gift from Prof. Charles M. Rice, the Rockefeller University (41). Human IFN-α (Thermo 
Fisher Scientific, Life Sciences, the Netherlands) was dissolved in PBS. 5’ppp-dsRNA was purchased 
from InvivoGen (#tlrl-3prna, InvivoGen, CA, USA). FuGENE® HD Transfection reagent (E2311) was 
purchased from Promega, USA. Stocks of JAK inhibitor I was dissolved in DMSO at a concentration of 
10 mM. Antibodies including phospho-STAT1 (58D6, #9167), RIG-I (D14G6, #3743), MDA5 (D74E4, 
#5321), β-catenin (6B3, #9582), anti-rabbit IgG(H+L),F(ab') 2 Fragment (Alexa Fluor 488 conjugate) 
and anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) were purchased from Cell 
Signaling Technology, the Netherlands. Hepatitis E Monoclonal Antibody was purchased from EMD 
Millipore Corporation, USA. Anti-rabbit or anti-mouse IRDye-conjugated antibodies were used as 
secondary antibodies for western blotting (Stressgen, Victoria, BC, Canada). 
Additional procedures are described in detail in Supplementary Materials and Methods. 
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Supplementary data 
Supplementary Materials and Methods 
Cell culture models 
Human hepatoma cells Huh7.5 were kindly provided by Professor Bart Haagmans from Department 
of Viroscience, Erasmus Medical Center. STAT1-deficient (U3A) and STAT2-deficient (U6A) cell lines 
were kindly provided by G. R. Stark (Lerner Research Institute). Human liver progenitor cell line 
HepaRG was purchased from Thermofisher Scientific. Human embryonic kidney 293 cells (HEK293), h 
human glioblastoma cells U87 were originally obtained from ATCC (www.atcc.org). Huh7.5, HEK293 
and U87 cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Lonza Biowhittaker, 
Verviers, Belgium) supplemented with 10% (v/v) fetal calf serum (FCS) (Hyclone, Lonan, Utah) and 
antibiotics. HepaRG cell line was maintained in William’s medium (Thermo Fisher Scientific Life 
Sciences) as described previously (1). The HEV replicon model was based on Huh7.5 (Huh7.5-P6-luc) 
or HEK293 (HEK293-P6-luc) cells containing the subgenomic HEV sequence (Kernow-C1 p6/luc) 
coupled to a Gaussia luciferase reporter gene. ISRE luciferase reporter cells were generated by 
transducing Huh7.5 cells with lentiviral vectors expressing the firefly luciferase gene under the 
control of ISRE promoter (2). The HCV subgenomic replicon comprised Huh7.5 cells containing a 
subgenomic HCV bicistronic replicon (1389/NS3-3V/LucUbiNeo-ET) linked to the firefly luciferase 
reporter gene were maintained with 250 μg/ml G418 (Sigma, Zwijndrecht, the Netherlands). MEF 
cells (WT, RIG-I-/-, MDA5-/-, RIG-I and MDA5-/-, MAVS-/-, IRF3/7-/-) were kindly provided by Dr. 
Sanna M. Mäkelä (National Institute for Health and Welfare Viral Infections Unit, Helsinki, Finland). 
β-catenin knockout MEF cells were kindly provided by Prof. Konrad Basler (University of Zürich). 
Mouse or human liver cell isolation and primary liver organoids culture were described accordingly 
(3). 
Measurement of luciferase activity 
For Gaussia luciferase analysis, the activity of secreted luciferase in the cell culture medium was 
measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs) according to the 
manufacturer’s instructions. For firefly luciferase, luciferin potassium salt (100 mM; Sigma) was 
added to cells and incubated for 20 min at 37 °C The luciferase activity was quantified with a 
LumiStar Optima luminescence counter (BMG Lab Tech, Offenburg, Germany). 
Quantitative real-time polymerase chain reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). All RNA samples were adjusted to the 
concentration of 62.5ng/μl. 500 ng of RNA was used as template for cDNA preparation with the 
reverse transcription system(TAKARA BIO INC). The cDNA (10ng/well) of all detected genes was 
amplified for 50 cycles and quantified with a SYBRGreen-based real-time PCR (Applied Biosystems) 
according to the manufacturer’s instructions. GAPDH was considered as reference genes to 
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normalize gene expression. Relative gene expressions were normalized to GAPDH using the formula 
2−ΔΔCT (ΔΔCT = ΔCTsample − ΔCTcontrol). All the primer sequences are included in Table S2 and S3. 
In Vitro RNA Synthesis 
Capped viral RNA was in vitro transcribed from linearized plasmid DNA with the Ambion mMESSAGE 
mMACHINE® in vitro RNA transcription Kit (Thermo Fisher Scientific Life Sciences). Un-capped viral 
RNA was in vitro generated by NEB T7 High Yield RNA Synthesis Kit (E2040S). Nucleic acid 
concentrations were determined by spectroscopy (Nanodrop ND-1000; Thermo Fischer Scientific, 
Waltham, MA). 
Transfection assay 
FuGENE® HD Transfection Reagent was used for transfection assays. Cells were seeded in 96-well 
plates at a density of 1 × 104 cells per well. After 24h, the medium was removed and cell layer was 
washed by Opti-MEM. Different concentrations of RNA or plasmid constructs were transfected with 
FuGENE® HD Transfection Reagent in a total volume of 100 µL Opti-MEM according to the protocol. 
After 6 h, the medium was changed back to normal medium.  
Interferon production assay  
10 × 104 cells per well were seeded into 6-well plates. Cells were transfected with corresponding RNA 
or plasmid constructs as described above. 6h later, medium was removed and cell layer was washed 
3 times. Then, the medium wad refreshed and cultured for another 48 h to let the produced 
cytokines secreted into the medium. Subsequently, the supernatant (conditioned medium) was 
collected. To detect the secreted IFN proteins in conditioned medium, two luciferase reporter 
models (Huh7.5-HCV-luc and Huh7.5-ISRE-luc, described above) were used, which are extremely 
sensitive to interferon treatments.  
Confocal laser electroscope assay 
Cells were seeded on glass coverslips. After 12 hours, cells were washed with PBS, fixed in 4% PBS-
buffered formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 0.05% tween, 5g/L 
skim milk and 1.5g/L glycine). Samples were incubated with primary antibodies overnight at 4 °C. 
Subsequently, samples were incubated with 1:1000 dilutions of the anti-mouse IgG (H+L), F(ab')2 
Fragment (Alexa Fluor® 488 Conjugate) or anti-rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 
conjugate) secondary antibodies. Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; 
Invitrogen). Images were detected using confocal electroscope. 
Statistical analysis 
All results were presented as mean ± SEM. Data analysis were performed with Mann-Whitney test. 
Differences were considered significant at a p-value less than 0.05 (single asterisks in figures). 
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sFig.1 Expression of HEV viral protein ORF2 and ORF3 failed to elicit IFN production and antiviral responses. 
(A) Western blot analysis of HEK 293 cells transfected with control or ORF2- expressing plasmid. (B) Western 
blot analysis of HEK 293 cells transfected with control, GFP or GFP-ORF3- expressing plasmid. (C) HEK293 cells 
were transfected with control or ORF2- expressing plasmid. The expression levels of indicated IFNs and ISGs 
were quantified at 48h.p.t. by qRT-PCR (n = 4). (D) Same as (C) for ORF3 protein. (E) Schematic illustration of 
the production of conditioned medium (supernatant). (F) ISRE luciferase value (left) and HCV viral replication-
related firefly luciferase activity (right) were measured after the treatment of conditioned medium from 
HEK293 cells transfected with CTR or ORF2- expressing plasmid (n = 4). (G) Same as (F) for ORF3. 
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sFig 2. HEV RNA generated in vitro is functional to initiate the essential steps of HEV life cycle. (A) Confocal 
microscopy was used to detect HEV viral protein ORF2 in Huh7.5 cells transfected with CTR or Gt3 HEV RNA. 
ORF2 antibody (green). Nuclei were visualized by DAPI (blue). (B) Huh7.5 cells transfected with Gt3 HEV RNA 
were treated with IFNα (1000 IU/ml) or ribavirin (100 μm) for 48h. The intracellular HEV RNA level was 
quantified by qRT-PCR (n = 4). (C) HEK293 cells were inoculated with conditioned medium from Huh7.5 cells 
transfected with CTR or Gt3 HEV RNA. Confocal microscopy was used for the detection of HEV viral protein 
ORF2 in HEK293 cells. ORF2 antibody (green). Nuclei were visualized by DAPI (blue). (D) HEK293 cells were 
transfected with CTR, GFP-V or Gt3 HEV RNA. The expression levels of indicated IFNs were quantified at 
48h.p.t. by qRT-PCR (ND, not detected; n = 3). (E) Phylogenetic tree of HEV complete genome sequences. Three 
representative HEV strains (GenBank Accession Number: AF444002, JQ679013, KJ496144) employed in this 
study were indicated. 
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sFig.3. Transfection of HEV RNA induces IFN production and antiviral responses. Huh7.5 cells were 
transfected with CTR, GFP-V, cellular RNA or Gt3 HEV RNA. The expression levels of indicated IFNs (A and B) 
and ISGs (C) were quantified at 48h.p.t. by qRT-PCR (n = 3). (D) ISRE luciferase value was measured (at 48h) 
after the treatment of conditioned medium from Huh7.5 cells transfected with CTR, GFP-V, cellular RNA or Gt3 
HEV RNA (n = 6). (E) HCV viral replication-related firefly luciferase activity was measured after the treatment of 
conditioned medium from Huh7.5 cells transfected with CTR, GFP-V or Gt3 HEV RNA (n = 4). (F) HEV viral 
replication-related firefly luciferase activity was measured after the transfection of CTR, GFP-V or Gt3 HEV RNA 
in Huh7.5-P6-luc cells (n = 4). 
 
sFig.4. HEV RNA triggers antiviral responses independent of m7G cap and poly A tail. Huh7.5 cells were 
transfected with CTR, wild type (WT), no m7G cap or no poly A tail Gt3 HEV RNA (200ng / well) in 96-well plates. 
The expression levels of indicated IFNs (A) and ISGs (B) were quantified at 48h.p.t. by qRT-PCR (n = 3). (C) ISRE 
luciferase value was measured after the treatment of conditioned medium from Huh7.5 cells transfected with 
CTR, wild type (WT), no m7G cap or no poly A tail Gt3 HEV RNA (n = 4).  
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sFig.5. HEV RNA triggers antiviral responses independent of viral replication. (A) HEV viral replication-related 
firefly luciferase activity was measured after the transfection of CTR, WT, 1634R mutant or 1634K mutant Gt3 
HEV RNA in HEK293-P6-luc cells (n = 4). Huh7.5 cells were transfected with CTR, WT, 1634R mutant or 1634K 
mutant Gt3 HEV RNA. The expression levels of indicated IFNs (B) and ISGs (C) were quantified at 48h.p.t. by 
qRT-PCR (n = 3). (D) ISRE luciferase value was measured after the treatment of conditioned medium from 
Huh7.5 cells transfected with CTR, WT, 1634R mutant or 1634K mutant Gt3 HEV RNA (n = 4). (E) HEV viral 
replication-related firefly luciferase activity was measured after the transfection of Gt3 HEV WT or replicon 
defective (GAD) RNA in HEK293-P6-luc cells (n = 4). Huh7.5 cells were transfected with CTR, WT or replication 
defective (GAD) Gt3 HEV RNA (n = 3). The expression levels of indicated IFNs (F) and ISGs (G) were quantified at 
48h.p.t. by qRT-PCR. 
 
sFig.6. The overexpression of MDA5 potently induces IFN production and antiviral responses in both HEK293 
and Huh7.5 cells. HEK293 cells were transfected with MDA5-expression plasmid (200ng / well) in 96 well-
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plates. The expression levels of MDA5 (A), IFNs (B) and ISGs (C) were quantified at 48h.p.t. by qRT-PCR (n = 3). 
(D) HEV viral replication-related firefly luciferase activity was measured after the transfection of MDA5-
expression plasmid in HEK293-P6-luc cells (n = 4). (E) ISRE luciferase value was measured after the treatment of 
conditioned medium from HEK293 cells transfected with MDA5-expression plasmid (n = 4). (F) HCV viral 
replication-related firefly luciferase activity was measured after the same treatment indicated in (E) (n = 4). 
Huh7.5 cells were transfected with MDA5-expression plasmid. The expression levels of MDA5 (G), IFNs (H) and 
ISGs (I) were quantified at 48h.p.t. by qRT-PCR (n = 3). (J) Same as (D) for MDA5 in Huh7.5-P6-luc (n = 4). (K) 
Same as (E) for conditioned medium from Huh7.5 cells transfected with MDA5 (n = 4). (L) Same as (F) for 
conditioned medium from Huh7.5 cells transfected with MDA5 (n = 4). 
 
sFig.7. The overexpression of RIG-I potently induces IFN production and antiviral responses in HEK293 cells. 
HEK293 cells were transfected with RIG-I-expression plasmid (200ng / well) in 96-well plates. The expression 
levels of MDA5 (A), IFNs (B) and ISGs (C) were quantified at 48h.p.t. by qRT-PCR (n = 3). (D) HEV viral 
replication-related firefly luciferase activity was measured after the transfection of RIG-I -expression plasmid in 
HEK293-P6-luc cells (n = 4). (E) ISRE luciferase value was measured after the treatment of conditioned medium 
from HEK293 cells transfected with RIG-I-expression plasmid (n = 4). (F) HCV viral replication-related firefly 
luciferase activity was measured after the same treatment indicated in (E) (n = 4).  
 
Chapter 14 
247 | P a g e  
 
sFig.8. HEV ssRNA triggers IFN response in a MAVS- and β-catenin-independent but IRF3 and IRF7-dependent 
manner. (A) ISRE luciferase value was measured after the transfection of 5’pppRNA in Huh7.5-ISRE-luc cells (n = 
5). (B) HEV viral replication-related firefly luciferase activity was measured after the transfection of 5’pppRNA 
in Huh7.5-P6-luc cells (n = 4). (C) Huh7.5 cells were transfected with 5’pppRNA. The expression levels of 
representative IFN and ISG were quantified at 48h.p.t. by qRT-PCR (n = 3). (D) MEF WT or RIG-I-/- cells were 
transfected with 5’pppRNA. The expression levels of indicated IFNs and ISGs were quantified at 48h.p.t. by qRT-
PCR (n = 3). (E) The RIG-I protein level was detected in WT, RIG-I-/-, RIG-I and MDA5-/- MEF cells by western 
blot analysis. (F) Same as (E) for the detection of MDA5 protein. (G) The transfection of Poly (I:C) was 
performed in WT or RIG-I and MDA5-/- MEF cells. The expression levels of IFNβ and the representative ISGs 
were quantified at 48h.p.t. by qRT-PCR (n = 4). (H) The β-catenin protein level was detected in WT and β-
catenin-/- MEF cells (I) The transfection of Gt3 HEV RNA (200ng / well) was performed in β-catenin-/- MEF cells 
in 96-well plates. The expression levels of IFNβ (left panel) and the representative ISGs (ISG15 and IFIT1) (right 
panel) were quantified at 48h.p.t. by qRT-PCR (n = 3). Conditioned medium was collected from β-catenin-/- 
MEF cells transfected with CTR or Gt3 HEV RNA. The MEF cells were treated with the corresponding 
conditioned medium for 24h. The expression levels of total and phosphorylated (Y701) STAT1 proteins were 
measured by western blot (middle panel). (J) The transfection of WT or Gt3 HEV replicon (GAD) RNA was 
performed in β-catenin-/- MEF cells. The levels of IFNβ and the indicated ISGs were quantified at 48h.p.t. by 
qRT-PCR (n = 3). (K) Conditioned medium was collected from HEK293 cells transfected with Gt3 HEV RNA with 
or without JAK inhibitor I. Then the corresponding conditioned medium was added in HEK293 cells for 24h. The 
expression levels of total and phosphorylated (Y701) STAT1 proteins were measured by western blot. 
  
Chapter 14 
248 | P a g e  
Table S1. Patient information 
HE
V 
pa
tie
nt
s 
patient 
number 
Gender Age diagnosis HEV-
IgG 
HEV-
IgM 
HEV 
staining 
P-STAT1 
(Y701) staining 
1 Female 38  acute non-icteric HEV - + 1-5% 1-5% 
2 Female 58 acute icteric HEV weak 
+ 
- 5-10% 1-5% 
3 Male 42 acute icteric HEV - + 5-10% 1-5% 
4 Male 24 acute icteric HEV + + 5-10% 1-5% 
5 Male 20 acute icteric HEV + - 10-15% 10-15% 
6 Male 38 acute icteric HEV weak 
+ 
+ 10-15% 1-5% 
7 Female 58 acute icteric HEV + + 0% 1-5% 
8 Male 58 acute icteric HEV - weak 
+ 
1-5% 0% 
9 Male 1,5 acute HEV - + 1-5% 1-5% 
10 Male 3 acute HEV - + 0% 1-5% 
11 Female 61 acute icteric HEV + + 1-5% 1-5% 
12 Male 55 acute HEV + weak 
+ 
10-15% 1-5% 
13 Male 35 HEV + - 5-10% 5-10% 
14 Male 19 HEV + - 1-5% 10-15% 
15 Female 66 acute HEV + - 1-5% 5-10% 
16 Male 52 HEV + - 10-15% 5-10% 
17 Male 11 acute non-icteric HEV + + 5-10% 0% 
18 Male  36 chronic HEV  + + 10-15% 1-5% 
N
eg
at
iv
e 
co
nt
ro
ls
 
19 Female 40 hepatic hemangioma - - 0% 0% 
20 Female 44 hepatic hemangioma - - 0% 0% 
21 Male 49 hepatic hemangioma - - 0% 0% 
22 Female 48 hepatic hemangioma - - 0% 0% 
23 Female 43 hepatic hemangioma - - 0% 0% 
+, postive. -, negative. 
Table S2. qRT-PCR primer sequences (human) 
Gene  F-Sequences (5’ - 3’) R-Sequences (5’ - 3’) 
IFNα GACTCCATCTTGGCTGTGA TGATTTCTGCTCTGACAACCT 
IFNβ CTTGGATTCCTACAAAGAAGCAGC TCCTCCTTCTGGAACTGCTGCA 
IFNγ GAGTGTGGAGACCATCAAGGAAG TGCTTTGCGTTGGACATTCAAGTC 
IFNλ1 GGAAGACAGGAGAGCTGCAACT AACTGGGAAGGGCTGCCACATT 
IFNλ2 TCGCTTCTGCTGAAGGACTGCA CCTCCAGAACCTTCAGCGTCAG 
IFI6 TGATGAGCTGGTCTGCGATCCT GTAGCCCATCAGGGCACCAATA 
DDX58 CACCTCAGTTGCTGATGAAGGC GTCAGAAGGAAGCACTTGCTACC 
MX1 GGCTGTTTACCAGACTCCGACA CACAAAGCCTGGCAGCTCTCTA 
ISG15 CTCTGAGCATCCTGGTGAGGAA AAGGTCAGCCAGAACAGGTCGT 
IFITM1 GGCTTCATAGCATTCGCCTACTC AGATGTTCAGGCACTTGGCGGT 
IFIT2 GGAGCAGATTCTGAGGCTTTGC GGATGAGGCTTCCAGACTCCAA 
IFIH1 GCTGAAGTAGGAGTCAAAGCCC CCACTGTGGTAGCGATAAGCAG 
IRF1 GAGGAGGTGAAAGACCAGAGCA TAGCATCTCGGCTGGACTTCGA 
GAPDH TGTCCCCACCCCCAATGTATC CTCCGATGCCTGCTTCACTACCTT 
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Table S3. qRT-PCR primer sequences (mouse) 
Gene F-Sequences (5’ - 3’) R-Sequences (5’ - 3’) 
IFNβ AAGAGTTACACTGCCTTTGCCATC CACTGTCTGCTGGTGGAGTTCATC 
ISG15 CATCCTGGTGAGGAACGAAAGG CTCAGCCAGAACTGGTCTTCGT 
IFIT1 TACAGGCTGGAGTGTGCTGAGA CTCCACTTTCAGAGCCTTCGCA 
IFI16 CCAGTCACCAATACTCCACAGC CTCTGAGTGGAGAACAGCACCT 
MX1 TGGACATTGCTACCACAGAGGC TTGCCTTCAGCACCTCTGTCCA 
OAS1b CTGTGCTGACCTCAGAGAAGTC TGCCCTTGAGTGTGGTGCCTTT 
DDX60 CGCAAGCCAGACAGTCCTACAA AAACATCGCCCTGTCTCACGGA 
GAPDH CATCACTGCCACCCAGAAGACTG ATGCCAGTGAGCTTCCCGTTCAG 
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Abstract 
Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis globally, but the 
mechanisms by which it corrupts hepatocyte cellular machinery to facilitate its replication remain 
only partially understood. STAT3 is a vital transcription factor centrally involved in cell signaling 
pathways to exert diverse cellular responses. Here, we demonstrate that HEV potently activates 
STAT3 phosphorylation in the liver of hepatitis E patients and in cell cultures. This corresponded to a 
concomitant increase in STAT3-related transcriptional activity. Mechanistically, HEV-mediated STAT3 
activation is independent of classical humoral IL-6 and interferon signaling but involves hijacking of 
Janus kinases (JAKs) and Src kinases via the active viral infection. Importantly, genetic or 
pharmacological inhibition of STAT3 activation constrained HEV replication. Conversely, over-
expression of the activated form of STAT3 increased HEV replication. In conclusion, our results 
revealed a previously undescribed function of STAT3 as a pro-HEV host factor. HEV-induced STAT3 
phosphorylation in turn create a favorable environment to facilitate HEV replication. Therefore, 
STAT3 serves as a promising target for the development of antivirals against HEV . 
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Introduction 
Hepatitis E virus (HEV) is the most common causes of acute viral hepatitis around the world. It yearly 
causes around 20 million infections, resulting in around 3 million illnesses and 70,000 deaths 
worldwide. Epidemics of hepatitis E occur periodically throughout the developing world, resulting in 
fulminant hepatitis and high mortality in pregnant women (1, 2). In developed countries, persistent 
HEV infection is also emerging in immunocompromised patients (3, 4). However, there is no FDA-
approved medication available. The fundamental and translational research related to virus-host 
interaction remains largely elusive. 
HEV is a single-stranded non-enveloped virus particle. Its genome encodes three viral 
proteins. ORF1 is a multifunctional nonstructural protein, ORF2 is the viral capsid protein, and ORF3 
is a small protein involved in virus secretion (5). Like most viruses, HEV is obligate intracellular 
parasite that needs to corrupt the host cell machinery to accomplish their life-cycle. However, for 
HEV, knowledge about host factors needed for virus life cycle is largely unknown. This hampers the 
development of effective anti-HEV therapy. 
The signal transducer and activator of transcription (STAT) family members are transcription 
factors that play crucial roles in mediating signaling in virtually all cytokine pathways. They become 
activated through tyrosine phosphorylation typically via cytokine receptor associated kinases, the 
Janus kinase (JAK) (6). Of all the STAT members, STAT3 is known to exert diverse cellular responses 
that are highly dependent on cell types and different physiological settings (7). STAT3 is activated by 
phosphorylation at tyrosine 705 in its C-terminal domain and more than 40 different ligands are 
known to cause STAT3 activation, including interleukin (IL)-6, IL-10, leukemia inhibitory factor, 
interferons (IFNs). Upon activation, phosphorylated STAT3 undergoes homodimerization and nucleus 
translocation, binding to specific DNA response elements in the promoter regions of target genes 
and regulating their transcription (8). As a vital host protein, STAT3 was reported to play a key role in 
regulating host immune and inflammatory responses (9). Its role in viral infection appears to be 
complex. It serves as a proviral factor in some viral infections and antiviral factor in others (6) (10, 11). 
Correspondingly, STAT3 is either positively or negatively regulated in a range of viral infections 
depending on the specific virus involved. All these facts highlight the significant role of STAT3 in the 
complex interplay between viruses and their hosts.  
In this study, we found that STAT3 was activated by HEV infection in the liver of hepatitis E 
patients and in cell cultures. Functionally, STAT3 activation following HEV infection appears an 
essential step in viral replication. Hence pharmacological inhibition of STAT3 activation constitutes an 
important novel target to combat the HEV infection. 
Results 
HEV potently activates STAT3 phosphorylation in the liver of HEV patients 
and in cultured cell lines 
To investigate a possible relationship between STAT3 and HEV, the expression of phosphorylated 
STAT3 (Y705) was detected in paraffin-embedded liver tissues from 21 HEV patients (Fig.1A). The 
staining of HEV and P-STAT3 were scored independently based on the proportion of positive cells 
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(Fig.1B). Up to 86% of HEV infected patients showed a positive staining of P-STAT3; while no staining 
was observed in five negative controls (Fig.1C). This result indicates that HEV infection induces STAT3 
activation in patients.  
 
Figure 1. HEV potently activates STAT3 phosphorylation in the liver of HEV patients and in cultured cell lines. 
(A) Representative staining of HEV or P-STAT3 in liver tissue of HEV patients or negative control individuals. 
HEV mainly localized within cytoplasm, while P-STAT3 in cell nucleus. (B) Representative staining indicated 
variable levels of HEV and P-STAT3. The proportion of positive cells were scored from 0% - 15%. (C) The 
distribution of HEV and P-STAT3 score among all liver tissues tested. (D) Huh7.5 cells infected with HEV or 
treated with IFN-α (1000IU/ml, 30min) were analyzed with indicated antibodies. HEV infection specifically 
activates STAT3 phosphorylation at site Y705, while no effect on the protein level of total STAT3 . IFN-α served 
as a positive control. (E) Confocal laser electroscope analysis of the cellular localization of P-STAT3 and HEV in 
mock or HEV infected Huh7.5 cells. HEV mainly located in cytoplasm, while HEV-induced P-STAT3 mainly in cell 
nucleus. (F) Western blotting analysis of P-STAT3 in mock or HEV infected HEK293 cells. (G) Mock or HEV 
infected HEK293 cells were transiently transfected with STAT3-luc and TK-Renilla (used to normalize the 
transfection efficiency). The luciferase activity was determined 48 hours post-transfection. HEV infection 
significantly increased STAT3 promoter-related transcriptional activity.  
This interesting observation from HEV patients encouraged us to further investigate in cell 
culture models. Consistently, the inoculation of HEV activated STAT3 phosphorylation in hepatic cell 
line, i.e. Huh7.5 (Fig. 1D and E). The level of P-STAT3 induced by HEV is robust, which is even 
comparable to that elicited by a high dose of IFN alpha (IFN-α, 1000IU/ml) treatment (served as a 
positive control). On the contrary, uninfected Huh7.5 cells did not show any detectable P-STAT3. Of 
note, HEV infection did not alter the protein level of total STAT3, suggesting a specific effect on 
STAT3 phosphorylation rather than a general effects on gene transcription. The clinical observations 
that HEV infection causes both hepatic and extra-hepatic manifestations prompts us to extend our 
study to extra-hepatic cell line, i.e. HEK293. Consistently, HEV could also induce STAT3 
phosphorylation in HEK293 cells (Fig. 1F), indicating a general mechanism in HEV infection. Based on 
the fact that STAT3 is a transcriptional factor, its transcriptional activity was also measured upon HEV 
infection. HEV significantly increased STAT3-related transcriptional activity, correlating with the 
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activation of STAT3 phosphorylation (Fig. 1G). Collectively, these in vivo and in vitro results 
demonstrate that HEV potently activates STAT3 phosphorylation. 
Active viral infection determines STAT3 activation  
The activation of STAT3 by HEV infection could be caused by incoming virions, viral replication 
products or active virus infection. To test the possible involvement of HEV viral replication in STAT3 
activation, the status of P-STAT3 was detected in the HEV subgenomic replicon model. This model 
was based on Huh7.5 cells containing the subgenomic HEV sequence (ORF1 region,Kernow-C1, P6-luc) 
coupled to a Gaussia luciferase reporter gene. Although active HEV replication was confirmed by the 
measurement of replication-related luciferase value (Fig. 2A), no detectable P-STAT3 was observed 
(Fig. 2B). Two vectors encoding the corresponding viral proteins (ORF2 or ORF3) were transfected, 
respectively. This strategy resulted in substantial expression of the relevant viral proteins, but failed 
to elicit the phosphorylation of STAT3 (Fig. 2C and D). Levels of P-STAT3, however, showed positive 
correlation with the levels of HEV (Fig. 2E), while same amounts of UV-inactivated virus failed to 
induce STAT3 activation (Fig. 2F). Thus, active HEV infection results in enhanced phosphorylation of 
STAT3. 
 
Figure 2. Active HEV infection determines STAT3 activation. (A) The HEV subgenomic replicon model was 
based on Huh7.5 cells containing the subgenomic HEV sequence (ORF1 region,Kernow-C1, P6-luc) coupled to a 
Gaussia luciferase reporter gene. The luciferase activity was measured 48 hours post-transfection. (B) The 
status of P-STAT3 was detected in Huh7.5 cells (CTR) or HEV subgenomic replicon model. Huh7.5 cells infected 
with HEV served as a positive control. (C) HEK 293 cells were transfected with plasmid pLVX-ORF2-IRES-
zsGrenn1. HEV ORF2 protein exerted no effect on STAT3 activation. Cells infected with HEV served as a positive 
control. (D) Same as (C) for the transfection of plasmid pEGFP-C1-ORF3. HEV ORF3 protein exerted no effect on 
STAT3 activation. Cells infected with HEV served as a positive control. (E) Western blotting analysis of Huh7.5 
cells infected with different doses of HEV. The levels of P-STAT3 positively correlate with the replication levels 
of HEV. (F) Huh7.5 cells were inoculated with the same dose of UV-inactivated or infectious HEV particles. 
Western blotting analysis indicated that only the infectious HEV could induce STAT3 activation. 
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Figure 3. HEV induced STAT3 activation occurs independent of IL-6 and IFNs signaling. (A) Huh7.5 cells were 
treated with IL-6 (40 ng/ml), IFN-γ (100 ng/ml) and IFN-λ1 (100 ng/ml) for 30 min. The levels of P-STAT3 were 
analyzed by western blotting. (B) The expression levels of IFNAR1, IFNLR1, IFNGR1, IL6R and IL10R in Huh7.5 
cells were analyzed by qRT-PCR. All receptors except IL-10 receptor are expressed in Huh7.5 cells. (C) Huh7.5 
cells were transduced with lentiviruses expressing control shRNA (CTR) or two IL-6 receptor –targeting shRNAs. 
qRT-PCR analysis confirmed the efficient knockdown of IL-6 receptor. (D) CTR or IL-6 receptor knockdown cells 
were infected with HEV. Western blotting analysis showed that HEV induced comparable levels of P-STAT3 in 
IL-6 receptor knockdown cells compared with their controls. (E) Same as (C) for the knockdown of IFNAR1 or 
IFNLR1. (F) Same as (D) for IFNAR1 or IFNLR1 knockdown. (G) Same as (C) for the knockdown of IFNGR1. (H) 
Same as (D) for IFNGR1 knockdown. 
HEV induced STAT3 activation occurs independent of humoral IL-6 and IFN 
signaling 
Depending on cell types and different physiological settings, multiple ligands, including IL-6, IL-10 and 
IFNs, are known to trigger STAT3 activation. In our model system, IFN-α,IL-6, IFN-γ and IFN-λ1 are 
capable of inducing STAT3 phosphorylation (Fig. 3A). Therefore, to dissect whether HEV induced 
STAT3 activation depends on IL or IFN related signaling, the expression status of their corresponding 
receptors were detected. All the receptors except IL-10 receptor can be easily detected (Fig. 3B), thus 
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potential HEV-provoked production of these humoral factors constitutes a possible mechanism to 
mediate HEV associated STAT3 activation. However, lentiviral-based shRNA-mediated knock down of 
either the IL-6 receptor (Fig. 3C), the IFNAR1, the IFNLR1 (Fig. 3E) or the IFNGR1 (Fig. 3G) does not 
influence the capacity of HEV to induce STAT3 activation (Fig. 3D, F and H). Therefore, HEV induced 
STAT3 activation is independent of production of humoral cytokines by the infected cells. 
HEV highjacks JAKs and Src to induce STAT3 activation 
JAKs (JAK1, JAK2, JAK3 and Tyk2) are cytoplasmic tyrosine protein kinases. Upon signal transduction, 
STATs are thought to become phosphorylated by JAKs on a tyrosine residue near the C terminus that 
is conserved in all STAT family members (8). Therefore, the JAK kinases might be the primary 
candidates to mediate HEV induced STAT3 activation. Although HEV infection provoked no 
substantial effect on the levels of phosphorylated and total JAKs (Fig. 4A), HEV-mediated STAT3 
activation is impaired by the pharmacological JAK inhibitor, JAK inhibitor I (Fig. 4B and C) as well as 
other JAK inhibitors (AG490, CP690,550 and Bay-18; Fig. 4D-G). Similarly, STAT3 phosphorylation 
status can also be controlled by Src family protein kinases (12). While HEV infection exerts no major 
effect on Src levels and phosphorylation status, inhibition of Src substantially impacts HEV-
dependent STAT3 activation (Fig. 4H). In contrast, however, inhibition of the bona-fide STAT3 
activators FGF receptor family does not impact HEV mediated STAT3 activation (Fig. 4I) (13, 14). 
Collectively, HEV infection corrupts JAK and Src kinases to mediate STAT3 phosphorylation. 
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Figure 4. HEV highjacks JAKs and Src to induce STAT3 activation. (A) Western blotting analysis of mock or HEV 
infected Huh7.5 cells with indicated antibodies. HEV infection exerted no significant effect on the 
phosphorylated and total levels of JAK kinases. (B) Huh7.5 cells were treated with IFN-α (1000IU/ml) or the 
combination with JAK inhibitor I (5μm). Western blotting analysis showed that JAK inhibitor I abrogated IFN-α 
induced STAT3 phosphorylation. (C) Same as (B) for HEV infection. (D) Same as (B) for JAK inhibitors AG490 and 
CP 690,550. (E) Same as (C) for JAK inhibitors AG490 and CP 690,550. (F) Same as (B) for JAK inhibitor, Bay-18. 
(G) Same as (C) for JAK inhibitor, Bay-18. (H) Same as (A) for detection of the phosphorylated and un-
phosphorylated Src kinases. (I) Huh7.5 cells infected with HEV were treated with control, FGF inhibitor (10μm) 
or Src inhibitor I (10μm). Western blotting analysis showed that Src inhibitor I decreased HEV induced STAT3 
phosphorylation, while FGF inhibitor has no significant effect. 
Upon signaling transduction, STATs gets phosphorylated by specific kinases. Meanwhile, P-
STATs undergoes dephosphorylation process by specific phosphatase. Thus, the level of P-STAT3 is 
coordinately determined by phosphorylation and dephosphorylation process (sFig. 1A). Hence it is 
possible that HEV-induced STAT3 activation occurs via blocking the expression of STAT3-related 
phosphatases. Seven out of twelve STAT3-related phosphatases can be detected in our model system 
(sFig. 1B). However, HEV infection exerts no significant effects on the levels of phosphatases 
measured either by qRT-PCR or western blotting assays (sFig. 1C and D).  
STAT3 is essential for efficient HEV replication 
To evaluate the importance of STAT3 activation for the HEV infectious process, wild type, STAT3 
knockout (STAT3-/-) and STAT3 constitutively activated (STAT3-C) mouse embryonic fibroblasts (MEF) 
cells were used. HEV replication is decreased in STAT3-/- cells compared with its wild type. 
Conversely, STAT3-C cells display increased virus replication (Fig. 5A). Therefore, STAT3 serves as a 
proviral host factor to facilitate HEV replication.  
IFN-α induces a wide spectrum of anti-viral mediators, the so-called interferon–stimulated 
genes (ISGs) via the JAK-STAT pathway (15). STAT1 and STAT2 are well characterized to counteract 
viral infection through upregulation of ISG expression. Even though STAT3 is also activated by IFN-α, 
its role in antiviral ISG induction is controversial. Some studies indicated that STAT3 negatively 
regulates the type I IFN-mediated antiviral response, while a positive regulatory effect has also been 
reported (16-18). Hence it is possible that STAT3-mediated stimulation of HEV replication involves 
the IFN pathway. However, this notion was not supported when constitutive expression of IFN-α, 
IFN-β and representative ISGs were studied in wild type and STAT3-/- cells (Fig. 5B and C). In addition, 
STAT3-/- cells are comparable to STAT3 proficient controls with respect to the levels of 
phosphorylated STAT1, phosphorylated STAT2 and ISGs following IFN-α treatment (Fig. 5D and E). 
Therefore, STAT3 is a proviral host factor for HEV, functionally independent of IFN pathway.  
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Figure 5. HEV serves as a proviral host factor to promote HEV replication, independent of IFN pathway. (A) 
Wild type (WT), STAT3 knockout (STAT3-/-) and STAT3 constitutively activated (STAT3-C) MEFs were infected 
with HEV for 48 hours. qRT-PCR analysis indicated that HEV replication was inhibited in STAT3-/- cells 
compared with its wild type. Conversely, virus replication was increased in STAT3-C cells. (B) and (C) qRT-PCT 
analysis of the constitutive expression levels of IFN-α, IFN-β and the representative ISGs in WT and STAT3-/- 
MEFs. STAT3 knockout exerted no significant effect on the expression levels of IFN-α, IFN-β and representative 
ISGs. (D) WT and STAT3-/- MEFs were treated with IFN-α (1000IU/ml, 15 min). The protein levels of P-
STAT1(Y701), total STAT1, P-STAT2(Y690), P-STAT3 (Y705) and STAT3 were analyzed by western blotting. (E) WT 
and STAT3-/- MEFs were treated with IFN-α (1000IU/ml, 15 min). The expression levels of indicated ISGs were 
analyzed by qRT-PCR.  
Pharmacological blockage of STAT3 activation constrains HEV replication 
Finally, we evaluated the therapeutic potential of targeting STAT3 for combating HEV infection. We 
investigated the commercially available STAT3 inhibitor, S3I-201, on HEV infection. S3I-201 
specifically blocks STAT3 phosphorylation induced by IFN-α or HEV (Fig. 6A). Importantly, S31-201 
leads to significant inhibition of HEV replication in our HEV subgenomic model (P6-luc), while no 
significant cell toxicity is observed at the indicated concentrations (Fig. 5C). Of note, the anti-HEV 
effect of S3I-201 at the concentration of 20 μm is comparable to that of treatment with IFN-α. 
Consistent with these observations, the anti-HEV effect of the inhibitor was also observed in three 
different human hepatic cell lines (Huh7.5, HepaRG and PLC/PRF/5) and two extra-hepatic cell lines 
(HEK293 and MRC5). harboring full-length HEV genome (Fig. 6C and D). Therefore, pharmacological 
blockage of STAT3 activation represents a novel strategy for constraining HEV replication.  
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Figure 6. Pharmacological blockage of STAT3 activation constrains HEV replication. (A) Huh7.5 cells were 
treated with IFN-α (1000IU/ml), infected with HEV or the combination with STAT3 inhibitor, S3I-201 (20 μm). 
Western blotting analysis showed that S3I-201 decreased IFN-α or HEV induced STAT3 phosphorylation. (B) 
HEV subgenomic replicon model (Huh7.5-P6-luc) were treated with control or S3I-201 for 48 hours. S3I-201 
significantly inhibited HEV-related luciferase activity, while no significant cytotoxicity was observed. IFN-α 
served as a positive control. (C) and (D) Five HEV infectious cell models (named Huh7.5-P6, PLC/PRF/5-P6, 
HepaRG-P6, MRC5-P6 and HEK293-P6) were treated with control or S3I-201(20 μm) for 48 hours. qRT-PCR 
analysis indicated that S3I-201 significantly inhibited HEV replication in all five different cell models. 
IFN-α and ribavirin have been used as off-label treatment for chronic HEV infection. 
Mycophenolic acid (MPA), an immunosuppressive medication used in the clinic for decades, has 
been demonstrated to exert potent antiviral effect against HEV (19). To evaluate any potential 
combinatory anti-HEV effect for STAT3 inhibitor and these three drugs, MacSynergy 2 combination 
analysis was performed (20). The combination of S3I-201 with IFN-α, ribavirin or MPA showed no 
significant antagonistic or synergistic effect with respect to their anti-HEV ability (sFig. 2A-C).  
Discussion 
HEV infection is emerging as a global health issue. HEV outbreaks periodically occur throughout the 
resource limited countries, resulting in heavy health burden with high mortality rate in pregnant 
women (1). In industrialized regions, persistent infection has also been frequently reported in 
immunocompromised patients (3). However, the optimal treatment for HEV infection remains to be 
defined. HEV relies on host machinery to accomplish its full life-cycle, including entry, viral replication 
and egress. However, the studies related to the identification of host factors that regulate the HEV 
life cycle are limited.  
STAT3 is a vital transcription factor, with clear links to the acute phase response, chronic 
inflammation, autoimmunity, metabolism and cancer progression (21). The highly pleiotropic nature 
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of STAT3 signaling suggests that its impact on virus replication will be multifactorial and complex. 
Indeed, both pro- and antiviral roles of STAT3 have been reported (6). In this study, we find that HEV 
infection elicit phosphorylation and activation of STAT3 in patients and in vitro cell culture models. 
This in turn created a favorable environment to facilitate HEV replication. Since STAT3 has been 
studied extensively as a transcription factor, it is plausible that the up-regulation of STAT3-
dependent target genes would assist in creating a cellular environment to facilitate HEV replication. 
However, little is known about the proviral potential of these STAT3 target genes and this evidently 
requires future investigation. Alternatively, STAT3 itself may interact directly with viral proteins to 
enhance HEV replication. As expression of viral proteins does not impact STAT3 activation, this 
indicates an indirect relationship between STAT3 and HEV. Furthermore, STAT3 may regulate the 
host antiviral responses. STAT3 has been reported to act either as a positive or negative regulator of 
type I IFN responses, thus influencing ISGs (16-18). However, our results indicated that the pro-HEV 
effect of STAT3 is independent of IFN pathway. Thus we feel that expression of specific STAT3-
dependent genes is the most likely explanation for our finding that STAT3 is essential for HEV 
replication, and identification of these STAT3 target genes constitutes an urgent task for future 
research. 
Activated STAT3 has been reported to positively regulate microtubules stabilization (22). The 
microtubule network could be utilized as the transport system to facilitate virus replication and the 
release of mature virus (23, 24). Therefore, it might be interesting to investigate the possible 
involvement of microtubules in HEV replication. Recently, the finding that STAT3 also localizes to 
mitochondria has opened a new area to discover its functions (25, 26). Mitochondrial STAT3 serves 
as a regulator of the electron transport chain (ETC) and mitochondrial production of ATP and reactive 
oxygen species (ROS) (27, 28), which may be conceivable linked to the HEV infectious process. Based 
on the fact that STAT3 is a multi-functional regulator, it is likely that STAT3 may exert its pro-HEV 
effect in a multifaceted manner.  
Constitutive STAT3 activation has been associated with malignant transformation. A large 
number of studies have been undertaken for the investigation of STAT3 as a cancer drug target, and 
several pharmacological inhibitors are at various stages of preclinical and clinical development (29). 
Interestingly, chronic HEV infection has been recently reported to be associated with the 
development of liver cancer (30). Therefore, the future clinical use of STAT3 inhibitors as anti-cancer 
drug will provide as an off-label therapy against HEV infection. 
Materials and Methods 
Additional procedures are described in detail in SI Materials and Methods. 
Reagents and antibodies 
Stocks of JAK inhibitor I (Santa Cruz Biotech, Santa Cruz, CA, 20), CP690550 (tofacitinib) and AG490 
(Santa Cruz Biotech, Santa Cruz, CA), Bayer-18 (Synkinase, China) were dissolved in dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) to concentration of 10 mg/ml. FGF Receptor Tyrosine 
Kinase Inhibitor and Src Kinase Inhibitor I (Merck Chemicals BV) were dissolved in DMSO to 
concentration of 10 mM. STAT3 Inhibitor VI, S3I-201 (Santa Cruz Biotech, Santa Cruz, CA) were 
dissolved in DMSO to concentration of 20 mM. phospho-STAT1(Y701) (58D6, #9167), phospho-STAT3 
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(Y705) (D3A7, #9145), STAT3 (79D7, #4904), Anti-rabbit IgG(H+L),F(ab') 2 Fragment (Alexa Fluor 488 
conjugate) and Anti-mouse IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) antibodies were 
purchased from Cell Signaling Technology. STAT1 (rabbit polyclonal; sc-592), phosphor-STAT2 (Y690) 
(rabbit polyclonal; sc-21689-R) and β-actin were purchased from Santa Cruz Biotechnology. Hepatitis 
E Monoclonal Antibody (ORF2) was purchased from EMD Millipore Corporation, USA. 
Patient materials 
Twenty-one liver biopsies from patients (2010 – 2017) diagnosed of acute or chronic hepatitis E were 
retrieved at Beijing 302 hospital, China. The use of patient materials was approved by the medical 
ethical committee of Beijing 302 hospital. The expression of P-STAT3 (Y705) was stained. Five liver 
biopsies from hepatic hemangioma patients were collected as negative control. These patient 
information was shown in Table S1. 
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Supporting Information 
SI Materials and Methods 
Cell culture models and plasmids 
Human hepatoma cells Huh7.5 were kindly provided by Professor Bart Haagmans from Department 
of Viroscience, Erasmus Medical Center. Human embryonic kidney 293 cells (HEK293) were originally 
obtained from ATCC (www.atcc.org). Huh7.5 and HEK293 cells were grown in Dulbecco’s modified 
Eagle medium (DMEM) (Lonza Biowhittaker, Verviers, Belgium) supplemented with 10% (v/v) fetal 
calf serum (FCS) (Hyclone, Lonan, Utah) and antibiotics. ). The HEV subgenomic model was based on 
Huh7.5 cells containing the subgenomic HEV sequence (Kernow-C1, P6-luc) coupled to a Gaussia 
luciferase reporter gene. HEV-infected cell models (named Huh7.5-P6, PLC/PRF/5-P6, HepaRG-P6, 
MRC5-P6 and HEK293-P6), electroporated with full-length HEV genome RNA were generated as 
described (1, 2). MEF cells (WT, STAT3-/- and STAT3-C) were kindly provided by Annalisa Camporeale 
(University of Turin) (3, 4). Plasmid STAT3-Luc was kindly provided by Michael R. Beard (University of 
Adelaide). Plasmid pLVX-ORF2-IRES-zsGrenn1 was kindly provided by Alexander Ploss (Princeton 
University) (5). Plasmid pEGFP-C1-ORF3 was constructed in our lab. 
Immunohistochemistry (IHC) staining 
Immunohistochemistry staining of HEV ORF2 viral protein or P-STAT3 (Y705) was performed to 
validate HEV infection and visualize phosphorylated-STAT3. In detail, the liver biopsies were fixed in 
10% formalin for 1.5 h at room temperature, processed for paraffin embedding, and sectioned at a 
thickness of 4 μm. The sections were deparaffinized in xylene and rehydrated through graded 
ethanol treatment, followed by high pressure in citrate buffer (pH 6.0) for 3 min for antigen retrieval. 
Then they were blocked with 3% H2O2 in TBS for 15 min and further blocked with goat serum for 1 
hour. The sections were then incubated with anti-HEV ORF2 viral protein (Millipore,1:600) or anti-P-
STAT3 (Cell signaling,1:800) monoclonal antibody overnight at 4 °C, and incubated with goat anti-
mouse/rabbit secondary antibody (ZSGB-BIO,KIT-5030) for 15 min at 37°C. Subsequently, the 
sections were developed in diaminobenzidine (DAB) (ZSGB-BIO, ZLI-9018), followed by 
counterstaining hematoxylin. Immunostained sections were scanned using Leica DFC400 digital 
camera and Leica Application Suite software (Leica Microsystems). 
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Gene knockdown by lentiviral vectors 
Lentiviral pLKO knockdown vectors (Sigma–Aldrich) targeting IL6R, IFNAR1, IFNGR1, IFNLR1 or 
control were obtained from the Erasmus Biomics Center and produced in HEK293T cells as previously 
described (6). After a pilot study, the shRNA vectors exerting optimal gene knockdown were selected. 
These shRNA sequences are listed in Table S2. Stable gene knockdown cells were generated after 
lentiviral vector transduction and puromycin (4 μg/ml; Sigma) selection. 
Measurement of luciferase activity 
For HEV (ORF1)-related Gaussia luciferase analysis, the activity of secreted luciferase in the cell 
culture medium was measured by BioLux® Gaussia Luciferase Flex Assay Kit (New England Biolabs) 
according to the manufacturer’s instructions. STAT3 promoter elements related luciferase activity 
(STAT3-luc) was measured using the Luciferase Assay System (Promega, Madison, WI). Data were 
normalized for the transfection efficiency by using the Dual Luciferase Reporter Assay system 
(Promega) according to the manufacturer's instructions. The luciferase activity was quantified with a 
LumiStar Optima luminescence counter (BMG Lab Tech, Offenburg, Germany). 
Quantitative real-time polymerase chain reaction 
RNA was isolated using a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). All RNA samples were adjusted to the 
concentration of 62.5ng/μl. 500 ng of RNA was used as template for cDNA preparation with the 
reverse transcription system(TAKARA BIO INC). The cDNA (10ng/well) of all detected genes was 
amplified for 50 cycles and quantified with a SYBRGreen-based real-time PCR (Applied Biosystems) 
according to the manufacturer’s instructions. GAPDH was used as a reference gene for normalizing 
gene expression. Relative gene expressions were normalized to GAPDH using the formula 2−ΔΔCT 
(ΔΔCT = ΔCTsample − ΔCTcontrol). All the primer sequences are included in Table S3. 
Transfection assay 
FuGENE® HD Transfection Reagent was used for transfection assays. Cells were seeded in 96-well 
plates at a density of 1 × 104 cells per well. After 24h, the medium was removed and cell layer was 
washed by Opti-MEM. Plasmid constructs were transfected with FuGENE® HD Transfection Reagent 
in a total volume of 100 µL Opti-MEM according to the protocols. After 6 h, the medium was changed 
back to routine medium.  
Confocal laser electroscope assay 
Cells were seeded on glass coverslips. After 12 hours, cells were washed with PBS, fixed in 4% PBS-
buffered formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 0.05% tween, 5g/L 
skim milk and 1.5g/L glycine). Samples were incubated with primary antibodies overnight at 4 °C. 
Subsequently, samples were incubated with 1:1000 dilutions of the anti-mouse IgG (H+L), F(ab')2 
Fragment (Alexa Fluor® 488 Conjugate) or anti-rabbit IgG(H+L), F(ab') 2 Fragment (Alexa Fluor 488 
conjugate) secondary antibodies. Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; 
Invitrogen). Images were detected using confocal electroscope. 
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HEV infection assay 
HEV inoculation and infection assay was performed according to previously described protocols (7). 
Infectious HEV particles were collected from Huh7-P6 HEV model and purified by ultracentrifugation. 
The supernatant was first filtered through 0.45 mm filter followed by centrifugation at 10,000 rpm 
for 30 min to remove cell debris and then 22,000 rpm for 2 h to pellet HEV virus (SW 28 rotor). The 
pellet was suspended with DMEM and diluted to 1 × 107 HEV viral RNA copies/ml. The diluted HEV 
virus stock was stored at −80 °C. For HEV infection, cells were seeded into 12-well plates at a density 
of 7 × 104 cells per well and incubated for 24 h. Next, cells were incubated with 400 μl of the HEV 
stock (1 × 107 viral RNA copies/ml) per well at 37 °C for 3 days. Then, the inoculum was removed, and 
cell layers were washed three times with PBS. 
Western blot assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M DTT and heated for 5 min at 
95 °C, followed by loading onto a 10% sodium dodecyl sulfate polyacrylamide gel and separation by 
electrophoresis. After 90 min running at 120 V, proteins were transferred onto a polyvinylidene 
difluoride membrane (Invitrogen) for 1.5 h with an electric current of 250mA. Subsequently, the 
membrane was blocked with a mixture of 2.5 ml blocking buffer (Odyssey) and 2.5 ml phosphate-
buffered saline containing 0.05% Tween 20. This was followed by overnight incubation with primary 
antibodies (1:1000) at 4 °C. The membrane was washed 3 times followed by incubation with IRDye-
conjugated secondary antibody (1:5000). After washing 3 times, protein bands were detected with 
the Odyssey 3.0 Infrared Imaging System. 
Statistical analysis 
All results were presented as mean ± SEM. Data analysis were performed with Mann-Whitney test. 
Differences were considered significant at a p-value less than 0.05 (single asterisks in figures), P 
values less than 0.01 (double asterisks) and 0.001 (triple asterisks) were considered highly significant. 
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sFig. 1. HEV infection results in no significant effects on the levels of phosphatase. (A) The regulation of 
phosphorylation process of STAT3 was illustrated. Upon signaling transduction, STAT3 gets phosphorylated by 
specific kinases. Meanwhile, phosphorylated STAT3 undergoes dephosphorylation process by specific 
phosphatase. Thus, the phosphorylation and dephosphorylation process coordinate to maintain the 
phosphorylation level at a balanced state. Consequently, the inhibition of phosphatases will alter the balanced 
state, leading to higher levels of phosphorylated STAT3. (B) The expression levels of indicated phosphatases in 
Huh7.5 cells were analyzed by qRT-PCR. (C) qRT-PCR analysis of indicated phosphatases in Huh7.5 cells infected 
with HEV or controls. HEV infection exerted no significant effect on the expression levels of phosphatases. (D) 
Western blotting analysis of mock or HEV infected Huh7.5 cells with PTP1B antibody (H-135, sc-14021, Santa 
Cruz Biotechnology). HEV infection exerted no significant effect on the levels of PTP1B. 
 
sFig. 2. The combination of STAT3 inhibitor S3I-201 with IFN-α, ribavirin or MPA results in no antagonistic or 
synergistic effect against HEV. The combinatory anti-HEV effects of two drugs were analyzed using the 
mathematical model MacSynergyII. The three-dimensional surface plot represents the differences (within 95% 
confidence interval) between actual experimental effects and theoretical additive effects of the combination at 
various concentrations (n = 5). The antiviral effects of S3I-201 in combination with IFN-α (A), ribavirin (B) or 
MPA (C) was analyzed by the MacSynergyII model. 
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Table S1. Patient information 
HE
V 
pa
tie
nt
s 
patient 
No. 
Gender Age diagnosis HEV-IgG HEV-IgM HEV 
staining 
P-STAT3 
staining 
1 Female 38  acute non-icteric HEV - + 1-5% 1-5% 
2 Female 58 acute icteric HEV weak + - 5-10% 1-5% 
3 Male 42 acute icteric HEV - + 5-10% 1-5% 
4 Male 24 acute icteric HEV + + 5-10% 1-5% 
5 Male 20 acute icteric HEV + - 10-15% 10-15% 
6 Male 5 acute non-icteric HEV - + 1-5% 1-5% 
7 Male 38 acute icteric HEV weak + + 10-15% 0% 
8 Female 58 acute icteric HEV + + 0% 0% 
9 Male 58 acute icteric HEV - weak + 1-5% 1-5% 
10 Male 1,5 acute HEV - + 1-5% 1-5% 
11 Female 67 acute HEV + - 5-10% 1-5% 
12 Male 3 acute HEV - + 0% 1-5% 
13 Female 61 acute icteric HEV + + 1-5% 1-5% 
14 Male 40 acute icteric HEV - + 5-10% 1-5% 
15 Male 55 acute HEV + weak + 10-15% 1-5% 
16 Male 35 HEV + - 5-10% 10-15% 
17 Male 19 HEV + - 1-5% 1-5% 
18 Female 66 acute HEV + - 1-5% 1-5% 
19 Male 52 HEV + - 10-15% 5-10% 
20 Male 11 acute non-icteric HEV + + 5-10% 0% 
21 Male  36 chronic HEV  + + 10-15% 5-10% 
N
eg
at
iv
e 
co
nt
ro
ls
 
22 Female 40 hepatic hemangioma - - 0% 0% 
23 Female 44 hepatic hemangioma - - 0% 0% 
24 Male 49 hepatic hemangioma - - 0% 0% 
25 Female 48 hepatic hemangioma - - 0% 0% 
26 Female 43 hepatic hemangioma - - 0% 0% 
+, postive. -, negative. 
Table S2. qRT-PCR primer sequences (human)  
Gene  F-Sequences (5’ - 3’) R-Sequences (5’ - 3’) 
IFNAR1 CGCCTGTGATCCAGGATTATCC TGGTGTGTGCTCTGGCTTTCAC 
IFNLR1 CAGCAAGTTCTCTAAGCCCACC GTCATTCACGGACTCTGGTCTG 
IFNGR1 AGTGCTTAGCCTGGTATTCATCTG GGCTGGTATGACGTGATGAGTG 
IL6R GACTGTGCACTTGCTGGTGGAT ACTTCCTCACCAAGAGCACAGC 
IL10R GCCGAAAGAAGCTACCCAGTGT GGTCCAAGTTCTTCAGCTCTGG 
HEV(P6) ATCGGCCAGAAGTTGGTTTTTAC CCGTGGCTATAACTGTGGTCT 
GAPDH TGTCCCCACCCCCAATGTATC CTCCGATGCCTGCTTCACTACCTT 
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Table S3. qRT-PCR primer sequences (mouse)  
Gene F-Sequences (5’ - 3’) R-Sequences (5’ - 3’) 
IFNα-F GGATGTGACCTTCCTCAGACTC ACCTTCTCCTGCGGGAATCCAA 
IFNβ-F AAGAGTTACACTGCCTTTGCCATC CACTGTCTGCTGGTGGAGTTCATC 
IFIT1-F TACAGGCTGGAGTGTGCTGAGA CTCCACTTTCAGAGCCTTCGCA 
MX1-F TGGACATTGCTACCACAGAGGC TTGCCTTCAGCACCTCTGTCCA 
DDX58-F AGCCAAGGATGTCTCCGAGGAA ACACTGAGCACGCTTTGTGGAC 
IFIH1-F TGCGGAAGTTGGAGTCAAAGCG CACCGTCGTAGCGATAAGCAGA 
IRF9-F CAACATAGGCGGTGGTGGCAAT GTTGATGCTCCAGGAACACTGG 
GAPDH-F CATCACTGCCACCCAGAAGACTG ATGCCAGTGAGCTTCCCGTTCAG 
Table S4. Lentiviral shRNA sequences 
Name Oligo Sequences (5’ - 3’) 
IL6R kd No.01 CCGGCTCTGGAAACTATTCATGCTACTCGAGTAGCATGAATAGTTTCCAGAGTTTTTG 
IL6R kd No.02 CCGGAGCCCTTATGACATCAGCAATCTCGAGATTGCTGATGTCATAAGGGCTTTTTTG 
IFNAR1 kd No.01 CCGGGCCAAGATTCAGGAAATTATTCTCGAGAATAATTTCCTGAATCTTGGCTTTTTG 
IFNAR1 kd No.02 CCGGCCTTAGTGATTCATTCCATATCTCGAGATATGGAATGAATCACTAAGGTTTTTG 
IFNLR1 kd No.01 CCGGCCAACAGACAAGATGGAAGAACTCGAGTTCTTCCATCTTGTCTGTTGGTTTTTG 
IFNLR1 kd No.02 CCGGACACGTTCAGTGTCCCGAAATCTCGAGATTTCGGGACACTGAACGTGTTTTTTG 
IFNGR1 kd No.01 CCGGGCCTATGCAAAGTCAGAAGAACTCGAGTTCTTCTGACTTTGCATAGGCTTTTTG 
IFNGR1 kd No.02 CCGGCGGAAGTGAGATCCAGTATAACTCGAGTTATACTGGATCTCACTTCCGTTTTTG 
IFNGR1 kd No.03 CCGGCCACCTCCTTTGGTTATGATACTCGAGTATCATAACCAAAGGAGGTGGTTTTTG 
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Hepatitis E virus (HEV) infection is the most common cause of acute hepatitis worldwide. Epidemics 
of hepatitis E occur periodically throughout the developing world. High mortality rate occurs in 
specific populations, in particular in pregnant women (1). In Chapter 2, I comprehensively reviewed 
the global burden of HEV outbreak. HEV outbreaks were mainly reported from Asian and African 
countries, and only a few from European and American countries. India represents the country with 
the highest number of reported HEV outbreaks. HEV genotypes 1 and 2 were responsible for most of 
the large outbreaks in developing countries. During the outbreaks in developing countries, a 
significantly higher case fatality rate was observed in pregnant women. The control measures mainly 
depend upon improvement of sanitation and hygiene. This study highlights that HEV is a continuous 
global health problem. Unfortunately, there is no effective prevention or treatment available in this 
setting, besides supportive care. Remarkably, chronic hepatitis E is emerging in developed countries, 
specifically in immunocompromised patients. Of note, chronic HEV infection could result in rapid 
progression to liver fibrosis and cirrhosis in organ transplant recipients, which is an important cause 
of graft loss and patient death. Although hepatitis E was discovered in early 1980s, not enough 
attention was paid to its clinical burden. Besides supportive care and off-label treatment for some 
cases, there is still no proven anti-HEV medication available. Fundamental and translational research 
has fallen far behind, when compared to the research on other hepatitis viruses. Therefore, there is 
an urgent need for the development of novel antivirals, which ideally should act on distinct 
mechanisms to maximize the antiviral effect, a strategy that has proven essential for successful 
control of other viruses, like HIV. 
The role of interferon-stimulated genes in combating HEV infection 
The interferon (IFN)-mediated cellular response is thought to be the first line of antiviral defense. IFN 
exerts its antiviral function by inducing the expression of the so-called IFN-stimulated genes (ISGs) (2, 
3). There is accumulating data to indicate that host cells have evolved complex but elaborate systems 
to defend against virus infection, and that the pathways involved are not limited to the well-
described action of IFNs. Recently, the existence of an antiviral pathway that acts before the 
production of IFNs was reported (4). Upon infection, a subset of NF-kB-inducible genes (e.g. CXCL9 
and CXCL10) were induced apparently before IFNs were produced in the viral infection process, and 
these genes may thus be part of an auxiliary system combating viral disease. CXCL9 and CXCL10 were 
found to recruit neutrophils to exert their antiviral activity. Since some specific ISGs possess direct 
antiviral activity, ISGs expressed at a basal level can exert cell-autonomous antiviral activity, 
independent of virus-induced IFN production (4). 
In Part I Chapter 3, I comprehensively reviewed the canonical and non-canonical regulation 
mechanisms of ISG transcription. I highlighted the non-canonical regulation of ISG expression that 
involved some unique pathways or complex, such as non-canonical ISGF3 complex, STAT5-CrkL 
complex and nucleotide synthesis pathway. This finding apparently expands our understanding of 
the regulation of ISG at transcriptional leve and shows that these mechanisms are more complex as 
thought but may also provide clues for the development of antiviral strategies. In Chapter 4, I 
discussed the IFN-independent antiviral mechanisms of some ISGs. Many important antiviral ISGs 
have the ability to activate or amplify ISG transcription apparently independent of IFN production. 
Some ISGs which are believed to exert antiviral function via induction of IFN production also have 
direct antiviral abilities. This is still a largely unexplored area in need of further investigation. Besides 
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IFN-α, TNF-α (Tumor Necrosis Factor-alpha) is also an important antiviral cytokine and its 
downstream NF-κB pathway plays essential roles in regulating the expression of inflammatory 
cytokines. In Chapter 5, I investigated the antiviral ability of TNF-α and its role in regulating ISG 
transcription (5). I first demonstrated that TNF-α exerts potent antiviral ability against HEV and HCV. I 
ruled out the possibility that TNF-α induces ISG expression through the production of IFN or JAK-
STAT signaling. I found the TNF-α activates ISG transcription via its canonical downstream pathway, 
NF-κB. NF-κB protein complex, serving as an important transcription factor, directly binds to the 
promoter region of many ISGs. I further found that TNF-α cooperated with IFN-α in ISG induction and 
antiviral action against HCV and HEV.  
Even without the presence of IFNs, many ISGs are constitutive expressed, which enable host 
cell to mount a rapid and direct response to viral infection. However, how host cells maintains ISGs 
expression at basal level is still not clear. In Chapter 6, I reported that the unphosphorylated ISGF3 
(U-ISGF3) complex, which is constituted out of IRF9 together with unphosphorylated STAT1 and 
STAT2, drives the constitutive expression of ISGs under homeostatic conditions (6). Deletion of any 
element of this U-ISGF3 complex leads to the decreased expression of ISGs and increased viral 
replication. Conversely, the overexpression of these three proteins, not any one of them alone, 
increased ISG expression and inhibited viral replication. These results expand our knowledge on the 
regulation of ISG transcription. In Chapter 7, using a lentivirus-based experimental strategy, I profiled 
a cohort of human ISGs for their anti-HEV ability. RIG-I, MDA5 and IRF1 were identified as potent 
anti-HEV ISGs.I focused on RIG-I for further mechanistic study. RIG-I is a pattern recognition receptor 
(PRR) that mainly recognizes viral RNAs (7-9). Interestingly, I found that RIG-I is involved in IFN 
induced ISG transcription. The absence of RIG-I will attenuate IFN-initiated ISG expression while its 
overexpression appears to enhance ISG expression. It is generally believed that RIG-I exerts its 
antiviral action by the induction of IFN production. However, I found that RIG-I exerts its anti-HEV 
activity independent of IFN production. The overexpression of RIG-I activated the phosphorylation of 
STAT1 and the induction of ISGs without triggering IFN production.  
Collectively, all these canonical and non-canonical mechanisms coordinately regulate the vast 
host antiviral web that is centered around the ISGs. With regards to the adverse effects of IFNs, ISG-
based antiviral strategies could be the next promising frontier in drug development for controlling 
hepatitis E. Several ISGs have been identified to exert potent anti-HEV effect in our study. Based on 
the fact that ISGs encompass hundreds members, a comprehensive study to characterize individual 
ISGs with respect to their anti-HEV specificity is highly demanded. These data are invaluable for the 
development of ISG-based specific antivirals against HEV.  
Direct-acting antiviral (DAA) agents against hepatitis E 
A variety of nucleoside analogues have been widely used to treat viral infections due to their potent 
antiviral effects and high barrier to drug resistance development. Ribavirin, an guanosine analogue, is 
the drug of choice for treating most chronic HEV patients. Ribavirin monotherapy is effective for 
treating chronic HEV with sustained virological responses (SVRs) of 85–90% (10-12). However, for a 
few patients, ribavirin treatment fails (13, 14). Effective antiviral therapy is therefore needed for 
HEV-infected patients with ribavirin treatment failure. One study indicated that sofosbuvir, a direct-
acting antiviral (DAA) agent against hepatitis C virus (HCV), can inhibit HEV replication and exert an 
additive effect when combined with ribavirin (15). Sofosbuvir is a specific and potent inhibitor that 
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targets the HCV NS5B RNA-dependent RNA polymerase. In Part II Chapter 8, I found that the in-vitro 
efficacy of sofosbuvir against HEV is modest even at high concentrations (16). In Chapter 9, I showed 
that sofosbuvir was effective at inhibiting HCV replication, but was much less efficacious against HEV 
in cell culture models of both monoinfection and HCV–HEV co-infection (16). In Chapter 10, I 
reviewed in-vitro and in-vivo data and concluded that sofosbuvir is unlikely to be the drug of choice 
for patients who do not clear HEV under ribavirin therapy (17). To develop effective DAAs for HEV, it 
is essential to gain more insight into the crystallographic structures of the viral proteins, particularly 
the HEV polymerase.  
For HEV infection, antiviral is needed only for a subpopulation or limited number of patients, 
and pharmaceutical companies have no interest in therapeutic development, despite the necessity 
and urgency. Therefore, the discovery of potential anti-HEV candidates from pre-clinical or clinical 
used antiviral drugs represent an cost-effective but unconventional paths. The nucleoside analogue 
2'-C-methylcytidine (2CMC), a viral polymerase inhibitor, has been shown to inhibit the infection of a 
variety of viruses (18, 19). In Chapter 11, I found that 2CMC significantly inhibits the replication of 
HEV. This result indicated that 2CMC constitutes a potential antiviral drug for the treatment of HEV 
infection(20). Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is another antiviral drug, 
which selectively inhibits the RNA-dependent RNA polymerase of influenza virus (21). In addition to 
its anti-influenza activity, favipiravir also blocks the replication of many other RNA viruses. Therefore, 
it is also worthwhile to investigate the effect of favipiravir on HEV. With its direct mechanism of 
action and broad spectrum of antiviral activity, favipiravir may represent another promising drug 
candidate for HEV. 
HEV-host interactions: the path to novel antiviral strategies 
Viruses heavily rely on the host to complete their life-cycle. In turn, the human body possesses a 
powerful immune system to sense and defend against viral infections. Gaining insight how HEV 
triggers host antiviral defense and how the virus interferes with these mechanisms is essential for 
the development of new therapeutic approaches. Protein kinases are principal components of the 
machineries that orchestrate immune response against diverse pathogens. To comprehensively 
profile kinase-mediated cascades in cell–autonomous antiviral immunity, in Part III Chapter 12, I 
screened a library of pharmacological kinase inhibitors in Huh7.5 based HEV replication cell model. I 
identified protein kinase C alpha (PKCα) as an important cell host factor restricting HEV replication 
(22). In fact, except PKCα, several other kinases have also been identified either promoting or 
inhibiting HEV replication, (e.g. CDK, AKT). These kinases also represent good candidates to study the 
interaction between host kinome and HEV. 
Since de novo nucleotide biosynthesis is essentially required for both host cell metabolism 
and viral replication, specific catalytic enzymes of these pathways have been explored as potential 
antiviral targets. In Chapter 13, I investigated the role of different enzymatic cascades of nucleotides 
biosynthesis in hepatitis E virus (HEV) replication. I found that targeting the early steps of the purine 
biosynthesis pathway led to enhancement of HEV replication; whereas targeting the later step 
resulted in potent antiviral activity. Interestingly, all these inhibitors with anti-HEV activity 
concurrently triggered the induction of ISGs. This study highlighted a crosstalk between nucleotide 
biosynthesis pathways and cellular antiviral immunity in constraining HEV infection (23). However, 
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the mechanism as to the inhibition of nucleotide biosynthesis can induce ISGs are still unknown. This 
also represents a non-canonical regulation of ISGs needing further investigation. 
The outcomes of hepatitis E virus (HEV) infection are closely associated with the 
immunological status of the host. To understand the innate cellular response to HEV infection, in 
Chapter 14, I studied the phosphorylation of STAT1 (Y701), a hallmark of IFN-related antiviral 
response, in the liver of HEV infected patients. Maybe not surprisingly, I found that HEV RNA potently 
induces IFN production and antiviral response in both cell lines and 3D cultured primary liver 
organoids. Single-stranded HEV RNA (ssRNA) was sufficient to trigger this host response. This occurs 
in a RIG-I-, MDA5-, MAVS- and β-catenin-independent, but IRF3 and IRF7-dependent manner. Our 
result indicates that HEV RNA is likely recognized by an undefined or unknown cytosolic RNA-sensing 
systems. Until now, only limited numbers of intracellular RNA sensors are described, a 
comprehensive study to further explore undiscovered sensors will definitely facilitate the studies in 
this field.  
Viruses heavily rely on the host to supply biochemical materials, and use essential cellular 
machineries of the host to complete their life-cycle. However, the knowledge related to host factors 
that impact the HEV life cycle are quite limited. In Chapter 15, the phosphorylation of STAT3 (Y705) 
was assessed in a cohort of HEV infected patients using paraffin embedded liver tissue. Consistent 
with the results obtained (which suggested that STAT3 activation is linked to HEV infection), the 
inoculation of model systems with HEV resulted in STAT3 phosphorylation in different in vitro cell 
lines. STAT3 activation occurs in a HEV replication dependent manner via the kinase activity of Janus 
kinases (JAKs) and Src kinase. Functional studies indicated that HEV-dependent STAT3 
phosphorylation in turn created a favorable environment to facilitate HEV replication. Interestingly, 
constitutive STAT3 activation has been associated with malignant transformation. A large number of 
studies have been undertaken for the investigation of STAT3 as a cancer drug target, and several 
pharmacological inhibitors are at various stages of preclinical or clinical development (24). 
Interestingly, chronic HEV infection has been recently reported to be associated with the 
development of liver cancer (25). Therefore, the future clinical use of STAT3 inhibitors as anti-cancer 
drug will provide as an off-label therapy against HEV infection.  
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Final Remarks 
• The ISGs network represents a complex butrobust and effective system defining the state of 
host anti-pathogen defense, which are not restricted to the well-described action of IFNs. 
Profiling individual ISGs with respect to their antiviral effects against HEV is highly called for. 
This knowledge is highly relevant for guiding the development of novel therapies that 
promote the clearance of HEV infection, but avoiding autoimmune diseases and toxic effects 
to the host.  
• For HEV infection, antiviral therapy is needed only for a limited number of patients. 
Therefore, the discovery of potential anti-HEV candidates from pre-clinical or clinical used 
antiviral drugs represent a cost-effective but likely only to improve care for a restricted 
number of cases and thus such therapies shall remain unconventional in nature. 
• Viruses heavily rely on the host to complete their life-cycle. In turn, the human body has 
evolved a powerful immune system to defend against viral infections. Gaining insight how 
HEV triggers host antiviral defence and how the virus interferes with these mechanisms will 
not resolve the clinical burden immediately. However, such fundamental knowledges will 
prove essential for exploiting the full potential of current anti-HEV therapy, as well as the 
development of new therapeutic approaches.  
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Dutch Summary 
Nederlandse samenvatting voor niet ingewijden 
Het HEV (hepatitis E virus) is één van de voornaamste oorzaken van het ontstaan van virale hepatitis. 
Normalitair btreedt het HEV de bloedbaan via het maag-darm kanaal en infecteert het de lever waar 
het zich uitstekend vermenigvuldigen in de lever. Het beloop van een typische HEV-infectie wordt 
gekenmerkt door een aantal fases: van subklinisch, naar acuut en uiteindelijk naar fulminant. 
Hepatitis E wordt  in steeds grotere mate gezien als een “public health concern” en in dit proefschrift 
voer ik ook een analyse uit in welke mate deze visie terecht is.  Deze wordt beschreven in hoofdstuk 
2 en is ook gepubliceerd (Hakim MS, Wang W, Bramer WM, Geng J, Huang F, de Man RA, 
Peppelenbosch MP, Pan Q. The global burden of hepatitis E outbreaks: a systematic review. Liver Int. 
2017 Jan;37(1):19-31).  Ik concludeer in dit hoofdstuk dat alhoewel een mortaliteit van 0.2 tot 1.0 % 
in verhouding tot andere ziekten klein lijkt, deze bij zwangeren in het laatste trimester van de  
zwangerschap kan oplopen tot zo’n 20-25%. Ook zijn er substantiële zorgen met betrekking tor het 
risico van juist dit virus voor immuun-gecompromitteerde individuen en dan specifiek 
orgaantransplantatie-patiënten.  HEV is dus inderdaad een groot probleem en ik richt me in mijn 
proefschrift dan ook verder met name op het verder begrijpen van de biologie die de interactie 
tussen men en virus onderligt alsmede op het exploreren van nieuwe therapeutische opties. Het 
proefschrift is daartoe verdeeld in drie delen, waarbij het eerste deel de moleculaire biologie van de 
afweer tegen HEV exploreert, het tweede deel de interactie van de moleculaire virale machinerie 
met potentiële geneesmiddelen onderzoekt en in het derde deel zich concentreert op de interactie 
van virussen met de gastheer en de mogelijkheden die daar liggen om tot nieuwe therapie te komen. 
Helaas is er dan wel heel wat literatuur over de mechanismen waarmee het lichaam zichzelf 
verdedigt tegen HEV infectie, maar is deze is goed samengevat noch afdoende geanalyseerd. Om 
deze deficiëntie te repareren voer ik in hoofdstuk 3 en hoofdstuk 4 een systematisch 
literatuuronderzoek uit, waar ik mij met name concentreer op de interferonen (inflammatoire 
hormonen belangrijk bij de virale afweer) alsook de zogenaamde ISGs (genproducten die van het 
DNA worden afgeschreven volgend op stimulatie van cellen door interferonen en die de uiteindelijke 
antivirale werking uitvoeren). Deze analyse vormt de basis van experimentele studies in de daarop 
volgende hoofdstukken en werd gepubliceerd in twee artikelen (Wang W, Xu L, Su J, Peppelenbosch 
MP, Pan Q. Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. Trends Microbiol. 
2017 Jul;25(7):573-584 & Xu L, Wang W, Peppelenbosch MP, Pan Q. Noncanonical Antiviral 
Mechanisms of ISGs: Dispensability of Inducible Interferons. Trends Immunol. 2017 Jan;38(1):1-2). 
Met name op de mechanismen die leiden tot productie van antivirale genproducten heb ik 
vervolgens onderzocht. Het is welbekend dat het antivirale hormoon interferon de productie van 
dergelijke genproducten stimuleert en wel door het activeren van een zogenaamde STAT 
transcriptiefactor die direct aan de receptor voor interferon bindt, vervolgens gefosforileerd en 
geactiveerd wordt en dan in de kern aan promotor van de betrokken genproducten bindt en door 
het rekruteren van de transcriptionele machinerie naar deze promotoren de transcriptie van deze 
genen in gang zet. In praktijk zal echter bij virale infectie interferonen hun werking doen in de 
aanwezigheid van andere genproducten. Met name het inflammatoire hormoon TNF-alpha zal ook 
aanwezig zijn. In het vierde hoofdstuk ontrafel in de details van de resulterende interactie en laat 
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zien dat met name het activeren van zogenaamde NF-kappaB transcriptiefactoren door TNF een 
belangrijk synergistisch signaal dat samen met de interferon-afhankelijke signalen de transcriptie van 
de betrokken genen aanjaagt. Ook deze data zijn reeds gepubliceerd (Wang W, Xu L, Brandsma JH, 
Wang Y, Hakim MS, Zhou X, Yin Y, Fuhler GM, van der Laan LJ, van der Woude CJ, Sprengers D, 
Metselaar HJ, Smits R, Poot RA, Peppelenbosch MP, Pan Q. Convergent Transcription of Interferon-
stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV. Sci Rep. 2016 
May 6;6:25482). 
Dergelijke interacties laten onverlet dat zelfs in de afwezigheid van inflammatoire hormonen cellen 
al substantiële antivirale mechanismen kunnen activeren. In het vijfde hoofdstuk kijk ik hoe deze t 
eerste beschermingslinie tegen virale infectie in elkaar steekt. In stel vast dat ook zonder stimulatie 
en dus ook zonder fosforilatie de betrokken transcriptiefactoren al aan het DNA kunnen binden en 
transcriptionele machinerie kunnen rekruteren. Dit is in aanzienlijke tegenspraak met het dogma in 
de gedachten over de organisatie van deze verdediging en deze data werden dan ook gepubliceerd in 
een wetenschappelijk tijdschrift dat een duidelijke zichtbaarheid in het veld heeft (Wang W, Yin Y, Xu 
L, Su J, Huang F, Wang Y, Boor PPC, Chen K, Wang W, Cao W, Zhou X, LiuP, van der Laan LJW, 
Kwekkeboom J, Peppelenbosch MP, Pan Q. Unphosphorylated ISGF3 drives constitutive expression of 
interferon-stimulated genes to protect against viral infections. Sci Signal. 2017 Apr 25;10(476). Het 
betrokken mechanisme, dat dus ook belangrijk is in de afwezigheid van het anti-virale 
interferonhormoon werd verder uitgediept in hoofdstuk 7. Hier bleek dat met name het antivirale 
genproduct RIG-I een belangrijke effector vervult. Ook deze data kon ik een tijdschrift dat een grote 
zichtbaarheid geniet publiceren (Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, de Man RA, van der Laan 
LJW, Huang F, Kamar N, Peppelenbosch MP, Pan Q. RIG-I is a key antiviral interferon-stimulated gene 
against hepatitis E virus regardless of interferon production. Hepatology. 2017 Jun;65(6):1823-1839). 
Nu ik meer inzicht had gekregen in moleculaire mechanismen die het lichaam gebruikt om zich te 
verdedigen tegen HEV infectie, besloot ik uit te zoeken hoe afweer tegen HEV ondersteunt kan 
worden antivirale therapie. Dit vormt het tweede deel van dit proefschrift. 
In eerste instantie onderzoek ik hierbij in welke het virale polymerase (een eiwit gecodeerd door het 
virale genoom dat essentieel is voor de vermenigvuldiging van het genetisch materiaal van het virus) 
een bruikbaar doelwit vorm voor dergelijke farmacologische therapie, een analyse die ik opgenomen 
heb in dit proefschrift in hoofdstuk 8 maar die ik ook wereldkundig heb gemaakt middels een 
publicatie in wederom een vooraanstaand tijdschrift in mijn vakgebied (Wang W, Peppelenbosch MP, 
Pan Q. Targeting Viral Polymerase for Treating Hepatitis E Infection: How Far Are We? 
Gastroenterology. 2016 Jun;150(7):1690). In hoofdstuk 9 ga ik dan in op het vermogen van 
Sofosbuvir om hepatitis E te bestrijden. Deze medicatie heeft een sterk effect op het hepatitis C virus 
en zou daarom ook een goede optie kunnen zijn bij de behandeling van hepatitis E. Ik laat echter zien 
dat de gevoeligheid van hepatitis C virus en HEV voor dit middel sterk verschillend is. Dit 
teleurstellend en daarom ook klinisch belangrijk effect werd wederom gepubliceerd in een 
gezichtsbepalend tijdschrift in mijn vakgebied (Wang W, Hakim MS, Nair VP, de Ruiter PE, Huang F, 
Sprengers D, Van Der Laan LJ, Peppelenbosch MP, Surjit M, Pan Q. Distinct Antiviral Potency of 
Sofosbuvir Against Hepatitis C and E Viruses. Gastroenterology. 2016 Dec;151(6):1251-1253). Op 
zoek naar een oplossing testte ik een andere medicatie, in casu het nucleoside-analoog (een namaak 
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DNA-base die de polymerase van het virus kan foppen en dus zo mogelijk de vermenigvuldiging van 
genetisch materiaal van het virus stoppen). Dit middel bleek inderdaad het virus te remmen. Echter, 
tegelijkertijd bleek het ook de werking van de enige medicatie met in ieder geval enige bewezen 
effectiviteit tegen HEV (ribavarine) te verstoren, waardoor de netto opbrengst van behandeling van 
hepatitis E met nucleoside analogen  tegen valt en dus andere mogelijkheden onderzocht moesten 
worden. De betreffende experimenten en hun overkoepelende analyse staan beschreven in 
hoofdstuk 10 en hoofdstuk 11. Ook deze data werden gepubliceerd in de wetenschappelijke 
literatuur (Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W. Nucleoside analogue 2'-C-
methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. Arch Virol. 2017 Jun 16 
& Kamar N, Wang W, Dalton HR, Pan Q. Direct-acting antiviral therapy for hepatitis E virus? Lancet 
Gastroenterol Hepatol. 2017 Mar;2(3):154-155). 
Nieuwe strategieën met betrekking tot de behandeling van hepatitis E kunnen heel wel ontwikkeld 
worden uit vergrootte kennis van de gastheercel met het HEV. Ik analyseer daarom in hoofdstuk 12 
de rol van zogenaamde kinasen (een verzamelnaam voor een groep enzymen die een fosfaatgroep 
kan aanbrengen op een ander eiwit of een ander molecuul (fosforylering), terwijl een fosfatase een 
dergelijke groep kan verwijderen (defosforylering). Vaak wordt door zo'n fosforylering of 
defosforylering het doeleiwit geactiveerd of gedeactiveerd. Deze schakelfunctie kan zo chemische 
reacties in de cel aansturen en vormt een belangrijke factor in de cel-interne signaaltransductie) en 
stel vast dat het zogenaamde proteïne kinase C een sleutelfunctie vervuld bij het opwekken van 
cellulaire reacties in de gastheercel. Ook deze data werden gepresenteerd aan de wetenschappelijke 
gemeenschap middels een publicatie (Wang W, Wang Y, Debing Y, Zhou X, Yin Y, Xu L, Herrera 
Carrillo E, Brandsma JH, Poot RA, Berkhout B, Neyts J, Peppelenbosch MP, Pan Q. Biological or 
pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral 
Res. 2017 Apr;140:1-12). Hoe cellulaire biochemie en cel-autonome immuniteit dan samen het 
natuurlijk beloop van een HEV infectie kunnen verklaren wordt dan verder uitgezocht in hoofdstuk 
13 en is ook gepubliceerd in een wetenschappelijk tijdschrift (Wang Y, Wang W, Xu L, Zhou X, 
Shokrollahi E, Felczak K, van der Laan LJ, Pankiewicz KW, Sprengers D, Raat NJ, Metselaar HJ, 
Peppelenbosch MP, Pan Q. Cross Talk between Nucleotide Synthesis Pathways with Cellular 
Immunity in Constraining Hepatitis E Virus Replication. Antimicrob Agents Chemother. 2016 Apr 
22;60(5):2834-48).1. Een volgend hoofdstuk 14 exploreert dan welke elementen uit het genoom 
van HEV precies de cel-autonome antivirale immuniteit oproepen. Dit hoofdstuk is momenteel onder 
review bij het tijdschrift “Hepatology”. Het laatste experimenteel hoofdstuk karakteriseert de rol van 
STAT3 in de HEV replicatie. Heel spectaculair toont de kandidaat aan dat STAT3 een onmisbare co-
factor is voor virale vermenigvuldiging. Een manuscript gebaseerd op deze data wordt nu klaar 
gemaakt om voor publicatie te worden aangeboden. Een overkoepelende samenvattende discussie is 
ook opgenomen in dit proefschrift. 
Samen hoop ik met dit werk een wezenlijke bijdrage te hebben geleverd aan het begrijpen van de 
biologie van de interactie tussen levercel en het HEV en ook aanzetten te hebben gegeven voor 
nieuwe rationele behandeling van hepatitis E. 
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